# CONTENTS

<table>
<thead>
<tr>
<th>Category</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>CROI FOUNDATION</td>
<td>2</td>
</tr>
<tr>
<td>IAS—USA</td>
<td>3</td>
</tr>
<tr>
<td>CROI 2023 SCIENTIFIC PROGRAM COMMITTEE</td>
<td>4</td>
</tr>
<tr>
<td>Scientific Program Committee</td>
<td>4</td>
</tr>
<tr>
<td>Community Liaison Subcommittee</td>
<td>6</td>
</tr>
<tr>
<td>EXTERNAL REVIEWERS</td>
<td>7</td>
</tr>
<tr>
<td>CONTINUING MEDICAL EDUCATION</td>
<td>10</td>
</tr>
<tr>
<td>GENERAL CONFERENCE INFORMATION</td>
<td>12</td>
</tr>
<tr>
<td>Overview</td>
<td>12</td>
</tr>
<tr>
<td>Funding and Grant Support</td>
<td>12</td>
</tr>
<tr>
<td>Affiliated and Proximate Activities</td>
<td>12</td>
</tr>
<tr>
<td>Conference Badges</td>
<td>13</td>
</tr>
<tr>
<td>Conference Etiquette</td>
<td>13</td>
</tr>
<tr>
<td>HEALTH AND SAFETY</td>
<td>13</td>
</tr>
<tr>
<td>COVID-19 Policies</td>
<td>13</td>
</tr>
<tr>
<td>Americans with Disabilities Act</td>
<td>14</td>
</tr>
<tr>
<td>Emergency Services</td>
<td>14</td>
</tr>
<tr>
<td>TECHNOLOGY AND CONNECTIVITY</td>
<td>15</td>
</tr>
<tr>
<td>Wi-Fi Access at the Conference</td>
<td>15</td>
</tr>
<tr>
<td>Conference Platform</td>
<td>15</td>
</tr>
<tr>
<td>Website</td>
<td>15</td>
</tr>
<tr>
<td>Webcasts</td>
<td>15</td>
</tr>
<tr>
<td>ABSTRACT PROCESS</td>
<td>16</td>
</tr>
<tr>
<td>Abstracts Related to Study Populations</td>
<td>17</td>
</tr>
<tr>
<td>PRECONFERENCE SESSIONS</td>
<td>18</td>
</tr>
<tr>
<td>OPENING SESSION, PLENARIES, AND SYMPOSIA BY DAY</td>
<td>22</td>
</tr>
<tr>
<td>ORAL ABSTRACT SESSIONS AND THEMED DISCUSSIONS BY DAY</td>
<td>33</td>
</tr>
<tr>
<td>POSTER SESSIONS BY DAY</td>
<td>58</td>
</tr>
<tr>
<td>POSTER SESSIONS BY CATEGORY</td>
<td>153</td>
</tr>
<tr>
<td>INDEX OF PRESENTERS</td>
<td>158</td>
</tr>
<tr>
<td>SCHOLARSHIP AWARDEE INFORMATION</td>
<td>165</td>
</tr>
<tr>
<td>CONFERENCE SERVICES</td>
<td>166</td>
</tr>
<tr>
<td>CONFERENCE SCHEDULE</td>
<td>Foldout</td>
</tr>
<tr>
<td>CONVENTION CENTER FLOOR PLANS</td>
<td>Foldout</td>
</tr>
</tbody>
</table>
The CROI Foundation is a 501(c)(3) not-for-profit professional organization that operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the annual Conference on Retroviruses and Opportunistic Infections (CROI).

Roles and Responsibilities of the CROI Foundation Volunteer Board of Directors

- Works closely with the CROI Program Committee (CROI PC) and the CROI Organizer to accomplish the mission of CROI
- Approves nominations for members of the CROI PC and the CROI PC Chair and Vice Chairs
- Ensures that the CROI PC is responsible for the scientific program content of CROI
- Enters into and oversees the partner agreement with the CROI Organizer
- Has the sole and absolute discretion to veto any policies, procedures, or actions taken or proposed that would pose a substantial risk of preventing the Foundation at any time from qualifying or continuing to qualify as a 501(c)(3) organization or that might cause the loss of such qualification
- Oversees the long-term financial and administrative integrity of CROI

CROI Foundation Board of Directors

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Institution</th>
<th>City</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constance A. Benson, MD</td>
<td>President</td>
<td>University of California San Diego</td>
<td>San Diego</td>
<td>CA, United States</td>
</tr>
<tr>
<td>John M. Coffin, PhD</td>
<td>Secretary-Treasurer</td>
<td>Tufts University</td>
<td>Boston</td>
<td>MA, United States</td>
</tr>
<tr>
<td>Elaine J. Abrams, MD</td>
<td></td>
<td>Columbia University</td>
<td>New York</td>
<td>NY, United States</td>
</tr>
<tr>
<td>Susan P. Buchbinder, MD</td>
<td></td>
<td>San Francisco Department of Public Health</td>
<td>San Francisco</td>
<td>CA, United States</td>
</tr>
<tr>
<td>Judith S. Currier, MD, MSc</td>
<td></td>
<td>University of California Los Angeles</td>
<td>Los Angeles</td>
<td>CA, United States</td>
</tr>
<tr>
<td>Diane V. Havlir, MD</td>
<td></td>
<td>University of California San Francisco</td>
<td>San Francisco</td>
<td>CA, United States</td>
</tr>
<tr>
<td>Sharon L. Hillier, PhD</td>
<td></td>
<td>University of Pittsburgh</td>
<td>Pittsburgh</td>
<td>PA, United States</td>
</tr>
<tr>
<td>James A. Hoxie, MD</td>
<td></td>
<td>University of Pennsylvania</td>
<td>Philadelphia</td>
<td>PA, United States</td>
</tr>
<tr>
<td>Richard A. Koup, MD</td>
<td></td>
<td>Vaccine Research Center within NIAID</td>
<td>Bethesda</td>
<td>MD, United States</td>
</tr>
<tr>
<td>John W. Mellors, MD</td>
<td></td>
<td>University of Pittsburgh</td>
<td>Pittsburgh</td>
<td>PA, United States</td>
</tr>
<tr>
<td>Landon Myer, MD, PhD</td>
<td></td>
<td>University of Cape Town</td>
<td>Cape Town</td>
<td>South Africa</td>
</tr>
<tr>
<td>Robert T. Schooley, MD</td>
<td></td>
<td>University of California San Diego</td>
<td>San Diego</td>
<td>CA, United States</td>
</tr>
</tbody>
</table>
IAS–USA

The International Antiviral (formerly AIDS)–USA (IAS–USA) serves as the Conference Organizer for the planning and organization of CROI in partnership with the CROI Foundation and Program Committee. The IAS–USA is a 501(c)(3) tax-exempt, not-for-profit organization guided by a volunteer board of directors. The mission of the IAS–USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV or other viral infections and their associated health conditions through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

To access primary educational and informational programs sponsored by the IAS–USA, please visit www.iasusa.org for:

- Live CME courses, CME webinars, and dialogues available for signup
- Archived webcasts of CME courses and webinars
- Topics in Antiviral Medicine, including the annual CROI review
- Practice guidelines
CROI 2023 SCIENTIFIC PROGRAM COMMITTEE

The CROI Scientific Program Committee (PC) is a team of experts in their given field who volunteer to organize the scientific program for CROI. Members are selected based on their area of scientific expertise and their commitment to the mission of the conference. Initial terms are up to 3 years; subsequent terms are based on previous participation and interest level. Members are nominated by the PC and approved by the CROI Foundation Board of Directors. The PC members are responsible for identifying topics and speakers that will ensure innovative programming; strategic planning; abstract review and program development; and organizing, conducting, or convening workshops, symposia, and special sessions.

Scientific Program Committee

James A. Hoxie, MD
CROI 2023 Chair
University of Pennsylvania
Philadelphia, PA, United States

Diane V. Havlir, MD
CROI 2023 Vice Chair
University of California
San Francisco
San Francisco, CA, United States

Landon Myer, MD, PhD
CROI 2023 Vice Chair
University of Cape Town
Cape Town, South Africa

Elaine J. Abrams, MD
Columbia University
New York, NY, United States

Adaora Adimora, MD
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States

Susan P. Buchbinder, MD
San Francisco Department of Public Health
San Francisco, CA, United States

Connie L. Celum, MD, MPH
University of Washington
Seattle, WA, United States

Richard E. Chaisson, MD
The John Hopkins University
Baltimore, MD, United States

Nicholas Chomont, PhD
Université de Montréal
Montreal, Canada

John M. Coffin, PhD
Tufts University
Boston, MA, United States

Katharine J. Bar, MD
University of Pennsylvania
Philadelphia, PA, United States

Ruanne Barnabas, MD, PhD
Massachusetts General Hospital
Boston, MA, United States

Constance A. Benson, MD
University of California San Diego
San Diego, CA, United States
Community Liaison Subcommittee

The Community Liaison Subcommittee is a group of community educators and advocates that provides feedback to the PC about the content and structure of the scientific program in general and specifically related to scientific topics of interest to the HIV/AIDS-affected community.

Dawn Averitt
The Well Project
South Strafford, VT, United States

Ntando Yola
Desmond Tutu HIV Foundation
Cape Town, South Africa

Jim Pickett
AVAC
Chicago, IL, United States
EXTERNAL REVIEWERS
We gratefully acknowledge the contributions of the following, who, in addition to the scientific program committee members, served as volunteer external reviewers of abstract submissions for CROI 2023.

K. Rivet Amico, PhD
University of Michigan School of Public Health
Ann Arbor, MI, United States

Blossom Damania, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States

Peter L. Anderson, PharmD
University of Colorado Anschutz Medical Campus
Aurora, CO, United States

Kevin M. De Cock, MD
Center for Disease Control and Prevention
Nairobi, Kenya

Georg Behrens, MD, PhD
Medizinische Hochschule Hannover
Hannover, Germany

Kelly E. Dooley, MD, PhD
Vanderbilt University
Nashville, TN, United States

Marta Boffito, MD, PhD
Chelsea and Westminster Hospital
London, United Kingdom

Kristine Erlandson, MD
University of Colorado Anschutz Medical Campus
Aurora, CO, United States

Bruce Brew, MBBS, DMedSci, Dsc
St. Vincent’s Hospital
Sydney, Australia

David Evans, PhD
University of Wisconsin Madison Madison, WI, United States

Todd T. Brown, MD, PhD
The John Hopkins University
Baltimore, MD, United States

Paul Farrell, PhD
Imperial College London
London, United Kingdom

David Burger, PharmD
Radboud University Medical Center
Nijmegen, Netherlands

Matthew Feinstein, MD, MSc
Northwestern University
Chicago, IL, United States

Maria J. Buzon, PhD
Vall d’Hebron Research Institute
Barcelona, Spain

William Fischer, MD
University of North Carolina at Chapel Hill
Chapel Hill, NC, United States

Carol Camlin, PhD
University of California San Francisco
San Francisco, CA, United States

Courtney Fletcher, PharmD
University of Nebraska Medical Center
Omaha, NE, United States

Corey Casper, MD, MPH
Access to Advanced Health Institute
Seattle, WA, United States

Charles Flexner, MD
The John Hopkins University
Baltimore, MD, United States

Ellen Chadwick, MD
Northwestern University
Chicago, IL, United States

Patricia Flynn, MD
St. Jude Children’s Research Hospital
Memphis, TN, United States

David B. Clifford, MD
Washington University in St. Louis
St. Louis, MO, United States

Nathan Ford, MPH, DSc, PhD
World Health Organization
Geneva, Switzerland

Elizabeth Connick, MD
University of Arizona
Tucson, AZ, United States

John Frater, MD
University of Oxford
Headington, United Kingdom
Sari L. Reisner, DSc
Brigham and Women’s Hospital
Boston, MA, United States

Robert H. Remien, PhD
Columbia University
New York, NY, United States

Erie Robertson, PhD
University of Pennsylvania
Philadelphia, PA, United States

Michael Saag, MD
University of Alabama at Birmingham
Birmingham, AL, United States

Thomas Schulz, MD
Hannover Medical School
Hannover, Germany

Kenneth Sherman, MD, PhD
University of Cincinnati
Cincinnati, OH, United States

Euphemia Sibanda, PhD
Centre for Sexual Health and HIV/AIDS Research Zimbabwe
Harare, Zimbabwe

Viviana Simon, MD, PhD
Icahn Schol of Medicine at Mount Sinai
New York, NY, United States

Lynda Stranix-Chibanda, MBChB
University of Zimbabwe
Harare, Zimbabwe

Patrick S. Sullivan, PhD
Emory University
Atlanta, GA, United States

Susan Swindells, MBBS
University of Nebraska Medical Center
Omaha, NE, United States

Alexandra Trkola, PhD
University of Zurich
Zurich, Switzerland

Alice Tseng, PharmD
University Health Network
Toronto, Canada

Heidi van Rooyen, PhD
Human Sciences Research Council
Johannesburg, South Africa

Gert van Zyl, MD, PhD
Stellenbosch University
Stellenbosch, South Africa

Timothy Wilkin, MD
Weill Cornell Medicine
New York, NY, United States

Alan Winston, MD
Imperial College London
London, United Kingdom

David Wyles, MD
Denver Health Medical Center
Denver, CO, United States

Robert Yarchoan, MD
National Cancer Institute
Bethesda, MD, United States

Markella V. Zanni, MD
Harvard Medical School
Boston, MA, United States
CONTINUING MEDICAL EDUCATION

Accreditation Statement
The International Antiviral Society—USA (IAS—USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The IAS—USA designates this live activity for a maximum of 17.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives
After participating in CROI 2023, participants will be able to describe the following as they relate to research in HIV, hepatitis viruses, SARS-CoV-2, mpox, and other viral infections and their related conditions:

• Describe basic science research advances
• List the most recent findings from clinical trials and the implications of these data for state-of-the-art treatment strategies
• Describe current epidemiologic data on the prevalence of infection, transmission, treatment, and linkage to and retention in care in populations worldwide; the implications of these data for public health program planning; and current advances in biobehavioral prevention.

Statement of Need
Since HIV was identified, the scientific response to the global pandemic has been a coordinated effort among basic researchers, clinical investigators, health care providers, epidemiologists, and community leaders to move information and potential treatment options from research to clinical trials and out to affected communities as quickly as possible. CROI was founded in 1993, by researchers working in the field of HIV/AIDS and its complications, as a science-focused forum for exchanging current research findings among their international peers. CROI continues to focus on scientific exchange, providing an environment in which basic science researchers, translational researchers, clinical investigators, epidemiologists, and public health experts meet to present and discuss the latest research into different facets of HIV and its complications, as well as selected other emerging infections, such as Covid-19 and mpox.

CME Credit Information
Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for their participation in CROI. CME credits can be claimed for premeeting workshops, opening session lectures, plenary lectures, symposia, meet the luminary sessions, and selected special sessions. CME credits cannot be claimed for oral abstract sessions, themed discussion sessions, certain special sessions, or poster sessions. For physician attendees certified by the American Board of Internal Medicine (ABIM), Maintenance of Certification (MOC) points are available for participation in CROI. Other researchers, practitioners, and attendees can receive a Certificate of Participation verifying their attendance, as required by the American Medical Association (AMA).
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.25 MOC points in the ABIM MOC program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Claiming CME Credits, ABIM MOC Points, or a Certificate of Participation
During the conference, links to the daily and final evaluations will be available on the CROI website. Detailed instructions will be provided. You will need the email address that you used to register for this conference and your reference number (on your badge) to access this page. To obtain CME credits, ABIM MOC points, or a Certificate of Participation for CROI, all final evaluations and claim forms must be submitted by April 28, 2023. Once the final evaluation and posttest are submitted, your certificate will be uploaded to your CROI profile on the CROI or IAS—USA website.

To determine the number CME credits, ABIM MOC points, or hours of participation that can be claimed, calculate time spent attending the conference activities, including premeeting workshops, opening session lectures, plenary lectures, selected special sessions, and symposia. For example, if you attended 2 plenary talks (8:30 to 9:30 AM), and a symposium (4:00 to 5:30 PM), you would have a total of 2.5 hours to apply toward CME credits or ABIM MOC points (if applicable) for that day. At the end of CROI, please add the total hours you attended.

A CME/ABIM MOC hour worksheet can be found on the CROI website.

Disclosure of Financial Relationships
In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS—USA requires all persons with control of content (eg, the Scientific Program Committee, Community Liaison Subcommittee, invited speakers, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The information is intended to make the audience aware of speaker and contributor financial relationships with ineligible companies, enabling the audience members to form their own judgments about such associations.

Each author, contributor, or person in control of content in the CME activity is required to complete this financial relationship disclosure declaration. In accordance with IAS—USA policy, the IAS—USA will identify and mitigate ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information will also be included at the beginning of each presentation.

Drug and Product Disclaimer
This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
GENERAL CONFERENCE INFORMATION

Overview
CROI was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI is the preeminent HIV research meeting in the world and includes up to 4000 HIV research and care leaders internationally. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research.

Funding and Grant Support
CROI seeks grants from commercial (ineligible) companies, particularly from companies with competing products. These companies have no input or control over the selection of faculty or the content of the CME portions of the program or abstract review and selection processes. This support is used to cover some of the costs of the conference venue, audiovisual services, and other conference expenses. CROI 2023 received grant support commitments from the following:

PLATINUM LEVEL SUPPORT
Gilead Sciences, Inc.
Merck & Co, Inc
ViiV Healthcare

GOLD LEVEL SUPPORT
Janssen Therapeutics

BRONZE LEVEL SUPPORT
Hologic, Inc.
Theratechnologies, Inc.

Additional support received after the printing of this program book will be announced during the Conference.

Affiliated and Proximate Activities Policies
The goal of CROI is to promote meaningful and high-level interchange of scientific ideas to find better ways to prevent and treat HIV and AIDS and to one day see HIV and other viral infections, including hepatitis viruses, SARS-CoV-2, and mpox virus eradicated. In keeping with this goal, certain organizations (commercial companies and their agents, not-for-profit groups, research study groups, government agencies, etc) have been approved to host Affiliated or Proximate Activities occurring outside CROI sessions times. Affiliated or Proximate Activities are not sponsored by, endorsed by, or supported by the IAS–USA, the CROI Foundation, or CROI 2023. An Affiliated and Proximate Activity is any activity, event, or meeting held at any time from 3 days before (Thursday, February 16) through 2 days after (Friday, February 24) CROI 2023, and targeted toward or including any registrants of CROI.

If an activity is found to have violated the Guidelines for Affiliated or Proximate Activities, the sponsoring organization, the supporting organization, and the organizer of the meeting may be prohibited from holding an Affiliated or Proximate Activity at future CROI conferences and may have their current registration revoked. Noncompliance may be subject to fines and could negatively impact the registration and attendance of anyone attending an unapproved activity.

In the spirit of CROI and the goal of promoting scientific collaboration among colleagues, if you are invited to or are attending a meeting or activity that you feel
may not have been approved by CROI, please contact an IAS–USA staff member in the IAS–USA office.

Conference Badges
Badge pickup is available at the registration lobby; please bring government-issued photo identification that clearly shows your name. The CROI badge must be worn at all times during the conference in order to gain entry to all official meeting activities, including the poster sessions. Attendees will not be admitted into the meeting spaces without their CROI badge. **THE CROI BADGE MAY ONLY BE USED BY THE PERSON NAMED ON THE BADGE AND CANNOT BE TRANSFERRED OR SHARED WITH OTHERS. USING ANOTHER INDIVIDUAL’S BADGE OR GIVING YOUR BADGE TO SOMEONE ELSE TO GAIN ACCESS TO THE CONFERENCE IS STRICTLY PROHIBITED AND IS A VIOLATION OF CROI POLICIES.**

DO NOT LOSE YOUR BADGE. Payment equivalent to the full registration fee will be required to replace a lost badge.

Conference Etiquette
Please ensure all mobile devices are turned off or set on SILENT mode in session rooms. In consideration for the work of the presenters at CROI and the CROI copyright policy, attendees may not photograph posters, record parts of talks, or post data without the presenter’s consent.

Out of respect for the presenters and conference attendees, children are not permitted in meeting rooms, including the poster halls.

**HEALTH AND SAFETY**

**COVID-19 Policies**
For the health and safety of CROI attendees, staff, and surrounding communities, all attendees must be appropriately vaccinated. **All conference participants must wear a high-quality mask at all times (eg, N95, KN95, or KF94) while in the meeting rooms and other public spaces in the convention center. Please be conscious of physical distancing and airflow when lowering your mask to eat or drink.**

Per the World Health Organization, a fully vaccinated individual is 2 weeks or more post-initial vaccination series and may also receive a recommended booster dose after 4 to 6 months. Per the Center for Disease Control guidelines, you are up to date when you have completed a COVID-19 vaccine primary series and gotten the most recent booster dose recommended for you by the CDC.

- If you have completed your primary series — but are not yet eligible for a booster — you are considered up to date.
- If you become ill with COVID-19 after you received all vaccine doses recommended for you, you are also considered up to date. You do not need to be revaccinated or receive an additional booster.

All on-site conference attendees must verify their vaccination status with conference organizers, prior to departing for the CROI Conference via the CROI 2023 CrowdPass Site, provided in preconference communication. Visit the information desk at registration for any questions.

To accommodate any attendee who does not meet the vaccine requirement we will convert your registration to virtual attendee via the Conference Platform.
Rapid antigen tests are available on a first-come, first-served basis. Additional rapid tests are available at area pharmacies, or via a local COVID-19 testing site (see above). Contact CROIinfo@iasusa.org if you have concerns about your ability to present your abstract due to illness.

CROI conference organizers will continue to monitor the World Health Organization’s recommendations pertaining to COVID-19 and adapt these guidelines accordingly.

**Americans With Disabilities Act**

CROI endeavors to comply fully with the legal requirements of the Americans with Disabilities Act (ADA). If you require assistance on-site during the conference, please visit the Conference Information desk in the registration area.

**Emergency Services**

In the event of an emergency, please notify CROI staff, or contact the Seattle Convention Center Security by dialing 4748 on a convention center phone or by calling +1 (206) 219-4748, available 24 hours daily. You may also use one of the red phones in the elevator lobbies for an automatic connection to security. Emergency Medical Services are located on Level 2, near Flex C. If a medical emergency occurs while you are at the Seattle Convention Center, please contact Convention Center security directly. The Convention Center requests that guests do not contact 911 directly, when possible.
TECHNOLOGY AND CONNECTIVITY SERVICES

WiFi Access at the Conference
Complimentary WiFi access is provided at the Seattle Convention Center. Network information is as follows:

Network name: CROI2023

The WiFi password will change daily to prevent devices from automatically connecting to the network. Limiting the number of concurrent devices will help maximize the internet speeds for those devices actively in use. The password for each day of the conference is listed below and is case sensitive.

Saturday password: 2023saturday
Sunday password: 2023sunday
Monday password: 2023monday
Tuesday password: 2023tuesday
Wednesday password: 2023wednesday

If you are having a problem with WiFi access, please contact an IAS-USA staff member.

CONFERENCE PLATFORM

The CROI 2023 Conference Platform has many features to enhance your conference experience, including to:

• View abstracts
• Find information about speakers and other CROI attendees
• Create a personal calendar of the sessions you plan to attend
• Receive the latest changes to the CROI program
• View electronic posters
• Submit questions to live streamed presentations

To access the Conference Platform, select the appropriate platform option below and log in using the email you used to register for CROI and your registration ID.

To view sessions off-site and participate in session chat, Q & A, and polling, log in to the virtual platform: https://CROI2023.e-attend.com

To participate in Q & A and polling in-person, log in to the in-person platform: https://CROIonsite.e-attend.com

Website
For additional information about the conference and to access electronic materials, please visit the website at www.CROIconference.org.

The final Abstract eBook (flip book and PDF versions) will be available for public download following the conference. Abstracts from CROI 2020 can be viewed and downloaded in the searchable database during the conference. Abstracts and electronic posters from CROI 2014 to 2022 are available at www.CROIconference.org/abstracts/search-abstracts/

Webcasts
Plenary lectures, symposia, oral abstract sessions, and themed discussions will be available as webcasts within 24 hours of the end of the relevant session. Webcasts are also available as streaming videos for the Apple iPad and iPhone. Visit www.CROIconference.org or www.CROIwebcasts.org to access the CROI webcasts.
ABSTRACT PROCESS

Abstract Content
Author names, institutions, titles, and abstracts in the CROI Program and Information Guide, Abstract eBook, Mobile App, and other materials are presented largely as submitted by the submitting author. The submitting author is responsible for ensuring that all coauthors have reviewed and approved the abstract before submission and for providing complete, including email addresses. **THE SUBMITTING AUTHOR MUST ENSURE THAT THE EMAIL ADDRESSES OF ALL LISTED AUTHORS IN THEIR SUBMISSION ARE CORRECT** for authors to receive important information regarding dispositions, presentation details, registration and housing information, and other CROI-related announcements.

Special Notes on Abstract Content
Presentations from randomized trials and cohorts should follow the International Committee of Medical Journal Editors (ICMJE) guidelines, including reporting of study designs, (eg, prospective, observational, randomized, double-blind, STROBE, CONSORT, or others), statistical methods, and outcomes by demographic variables.

Appropriate information and correct terminology should be used regarding sex and gender. For human clinical or epidemiologic studies, sex-stratified results should be provided, who was included in the study (or if the study includes only a single population). Appropriate terminology such as cisgender (people whose gender match the sex assigned at birth) or transgender (people whose gender does not match the sex assigned at birth) should be used. Both sex and gender data should be provided in the presentation. Presentations of preclinical data including use of cell lines and animal studies should include the sex of the animals or the sex of the source of the cell lines. If data are not available on sex and gender, this should be identified as a limitation in your presentation.

Out of respect for their contributions to our scientific advances, avoid calling study volunteers “subjects.” The preferred terms are study “participants” or “volunteers.”

Presenting Author Responsibilities
The presenting author is responsible for presenting the abstract at the conference and must be present at the poster during the entire session. **Submitting authors are responsible for ensuring that all coauthors have reviewed and approved the abstract contents before submission.**

Embargo Policies and Social Media
All research presented at CROI 2023 is embargoed until the conclusion of the study’s presentation at the conference. For example, if a study is presented from 2:15 PM to 2:30 PM, as part of a session that begins at 2:00 PM and ends at 3:00 PM, the embargo on that study lifts at 2:30 PM. Embargoes on poster presentations lift at the beginning of the session in which the poster is presented.

If a study to be presented at CROI 2023 is included in an official CROI press conference that takes place before the scheduled presentation of the study, the embargo on that study lifts at the conclusion of the press conference panel in which the study is featured.

No public dissemination of research information from the conference is permitted prior to the lifting of the conference embargo. CROI embargo policies apply to any public dissemination of research information presented at the conference, including electronic publications (eg, blogs), or social media (eg, Twitter, Instagram, Facebook, etc). Individuals or organizations that violate the conference embargo policy may have their conference credentials revoked and may forfeit the opportunity to participate in future conferences.
Abstract Review Process
The PC and a panel of volunteer external reviewers reviewed more than 1500 submitted abstracts. Each abstract was reviewed by 5 to 10 reviewers selected for each abstract category based upon their individual expertise.

Abstracts were reviewed for the quality and originality of the work and were scored numerically. All reviewers were instructed to abstain from scoring any abstract on which they are an author or coauthor, have a financial or personal conflict of interest, or do not have the appropriate expertise to evaluate.

Scores for each abstract were averaged and the standard deviation was calculated to assess variability. If variability was high, outlier scores were discussed. Abstracts were accepted for oral presentations, for poster presentations, or rejected. Late-breaking abstract reviews included an assessment of the late-breaking nature of the work (distinct from a late submission, as they must meet a high threshold of scientific merit).

For more information, including common reasons for abstract rejection, visit the Abstract Guidelines page of www.CROIconference.org

Statistics for Abstracts
Abstract and Presentation Statistics for CROI 2023

<table>
<thead>
<tr>
<th>Description</th>
<th>Number</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Abstracts Submitted</td>
<td></td>
<td>1051</td>
</tr>
<tr>
<td>General Abstracts Accepted</td>
<td></td>
<td>658</td>
</tr>
<tr>
<td>Late-Breaking HIV, SARS-CoV-2, or mpox Abstracts Submitted</td>
<td></td>
<td>558</td>
</tr>
<tr>
<td>Late-Breaking HIV, SARS-CoV-2, or mpox Abstracts Accepted</td>
<td></td>
<td>347</td>
</tr>
<tr>
<td>Total Abstracts Submitted</td>
<td></td>
<td>1609</td>
</tr>
<tr>
<td>Total Abstracts Accepted</td>
<td></td>
<td>1005</td>
</tr>
<tr>
<td>Oral Abstract Presentations</td>
<td></td>
<td>115</td>
</tr>
<tr>
<td>Themed Discussion Presentations*</td>
<td></td>
<td>56</td>
</tr>
<tr>
<td>Poster Presentations</td>
<td></td>
<td>834</td>
</tr>
<tr>
<td>Total Scientific Abstract Presentations</td>
<td></td>
<td>1005</td>
</tr>
</tbody>
</table>

*Abstracts accepted a for presentation as a themed discussion are also presented as a poster

Accepted Abstracts on Emerging Infections or Special Populations **

<table>
<thead>
<tr>
<th>Description</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2</td>
<td>228</td>
</tr>
<tr>
<td>Mpox</td>
<td>61</td>
</tr>
<tr>
<td>Adolescents</td>
<td>76</td>
</tr>
<tr>
<td>Men who have sex with men (MSM)</td>
<td>152</td>
</tr>
<tr>
<td>People who inject drugs (PWID)</td>
<td>51</td>
</tr>
<tr>
<td>Transgender men or women</td>
<td>55</td>
</tr>
<tr>
<td>Women or girls</td>
<td>155</td>
</tr>
</tbody>
</table>

**As reported by the abstract submitter. Studies may include more than 1 special population (eg Adolescents and Transgender Men or Women)
PRECONFERENCE SESSIONS
SUNDAY, FEBRUARY 19, 2023

Workshop 01 SCOTT M. HAMMER WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES
Flex A (Level 2) 8:30 AM - 12:30 PM

Objectives: At the completion of the session, participants will be able to:
• Understand fundamental aspects of HIV virology and relevant immunology, including emerging understandings of host-pathogen interactions
• Identify recent advances in HIV prevention and treatment
• Gain new understanding of the experiences of people with HIV

Target Audience: This session is directed to new investigators and trainees (eg, postdoctoral fellows, physician fellows, undergraduate students, and graduate students). Attendance is mandatory for all scholarship recipients, but the workshop is open to all CROI attendees.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for fewer than 3 years.

Moderators
Nicolas Chomont, Université de Montréal, Montreal, QC, Canada
Serena Spudich, Yale University, New Haven, CT, USA

OVERVIEW SCOTT M. HAMMER WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES UPDATE ON HIV VIROLOGY

ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-CoV-2
Stuart J. D. Neil, King’s College London, London, United Kingdom

ADVANCES IN HIV AND SARS-CoV-2 IMMUNOLOGY
Guido Silvestri, Emory University, Atlanta, GA, USA

ADVANCING RESEARCH: THE POWER OF COMMUNITY ENGAGEMENT
Dawn Averitt, The Well Project, Women’s Research Initiative on HIV/AIDS, South Strafford, VT, USA

ADVANCES IN HIV TREATMENT STRATEGIES
Monica Gandhi, University of California San Francisco, San Francisco, CA, USA

ADVANCES IN BIOMEDICAL PREVENTION OF HIV
Raphael J. Landovitz, University of California Los Angeles, Los Angeles, CA, USA

ADVANCES IN HIV CURE
John W. Mellors, University of Pittsburgh, Pittsburgh, PA, USA
A CALL TO ACTION FOR NEW INVESTIGATORS: OPPORTUNITIES IN RESEARCH AND PUBLIC HEALTH

Rochelle Walensky, Centers for Disease Control and Prevention, Atlanta, GA, USA

SUNDAY, FEBRUARY 19, 2023

Workshop-02 FRONTIERS IN LABORATORY TECHNOLOGIES

Ballroom 2 (Level 5) 1:30 PM - 3:30 PM

Objectives: At the completion of the session, participants will be able to:
• Describe distinct techniques for single cell analyses, transcriptomics, and imaging, including strengths and limitations
• Describe how deep learning can be applied to characterize protein dynamics

Target Audience: This session is directed to scientists, clinicians, stakeholders, students, and members of the community at large, who are interested in understanding the impact of novel laboratory technologies.

Level of Knowledge: It is assumed that the participants are familiar with the main technologic and data analysis approaches used in research.

Moderators
Katharine Bar, University of Pennsylvania, Philadelphia, PA, USA
Frank Kirchhoff, Ulm University Medical Center, Ulm, Baden-Wurttemberg, Germany

2 SINGLE-CELL ANALYSIS OF THE RNA, PROTEIN, AND GLYCAN FEATURES OF HIV-INFECTED CELLS

Nadia R. Roan, Gladstone Institutes, San Francisco, CA, USA

3 SINGLE-CELL MULTIOMIC ANALYSES OF THE HIV RESERVOIR

Michael R. Betts, University of Pennsylvania, Philadelphia, PA, USA

4 SINGLE-CELL MULTIOMICS AND EXPANSION DYNAMICS OF HIV RESERVOIR OVER SPACE AND TIME

Ya-Chi Ho, Yale University, New Haven, CT, USA

5 NOVEL APPROACHES TO CHARACTERIZING IMMUNE RECOGNITION

Michael Birnbaum, Massachusetts Institute of Technology, Cambridge, MA, USA
SUNDAY, FEBRUARY 19, 2023

Workshop-03 CASE-BASED LIVER WORKSHOP

Flex A (Level 2) 1:30 PM - 3:30 PM

Objectives: At the completion of the session, participants will be able to:
- Identify etiologies and diagnostic tests for children with severe viral hepatitis
- Describe strategies for the prevention of hepatitis B transmission
- Describe the burden of disease and the current treatment strategies for hepatitis D in people with HIV

Target Audience: This session is directed towards physicians and researchers interested in obtaining a contemporary understanding of key issues in viral hepatitis and liver disease in people living with and without HIV infection.

Level of Knowledge: It is assumed that the participants are familiar with the major viral causes of hepatitis and other key issues related to liver disease in people living with and without HIV infection.

Moderators
Debika Bhattacharya, University of California Los Angeles, Los Angeles, CA, USA
Christoph Boesecke, Bonn University Hospital, Bonn, Nordrhein-Westfalen, Germany

6  FULMINANT HEPATITIS IN CHILDREN

Luz Helena Gutierrez Sanchez, University of Alabama at Birmingham, Birmingham, AL, USA

7  HBV PREVENTION: NEWER VACCINES AND THE BOUNDARIES OF HBV PROTECTION

H. Nina Kim, University of Washington, Seattle, WA, USA

8  HEPATITIS DELTA INFECTION AMONG PERSONS WITH HIV

Charles Béguelin, University of Bern, Bern, Switzerland
SUNDAY, FEBRUARY 19, 2023

Workshop-04 CLINICAL TRIAL DESIGN AND ANALYSIS

Preconference Session • Sunday

Ballroom 3 (Level 5)  1:30 PM - 3:30 PM

Objectives: At the completion of the session, participants will be able to:
• Describe some key lessons we have learned from platform trials
• List some of the major types of modeling studies and how to interpret results from these studies
• Identify some of the central reasons why it is important to include behavioral and social science in clinical trials

Target Audience: This session is directed to clinicians and scientists who are interested in designing or interpreting clinical and epidemiologic studies.

Level of Knowledge: It is assumed that participants are familiar with the basic design of randomized and observational clinical trials and epidemiologic studies of HIV, SARS-CoV-2, or mpox.

Moderators

Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA
Richard Chaisson, The Johns Hopkins University, Baltimore, MD, USA

9  ADAPTIVE PLATFORM TRIALS: EXPERIENCE FROM THE COVID-19 PANDEMIC

Michael D. Hughes, Harvard TH Chan School of Public Health, Boston, Massachusetts, MA, USA

10  UNPACKING MODELING STUDIES

Viviane D. Lima, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada

11  SOCIAL AND BEHAVIORAL SCIENCE: THE MISSING INGREDIENT TO SUCCESSFUL CLINICAL TRIALS

Heidi van Rooyen, Human Sciences Research Council, Cape Town, Western Cape, South Africa
OPENING SESSION, PLENARIES, AND SYMPOSIA BY DAY
SUNDAY, FEBRUARY 19, 2023

OPENING-01 OPENING SESSION
Flex C (Level 2)  5:00 PM - 7:20 PM

WELCOME FROM THE CROI 2023 CHAIR
James Hoxie, University of Pennsylvania, Philadelphia, PA, USA

12  MODELING THE DYNAMICS OF HIV INFECTION:
    ESTABLISHING PARADIGMS FOR TREATMENT AND CURE
Alan S. Perelson, Los Alamos National Laboratory, Los Alamos, NM, USA

INTRODUCTION OF THE N’GALY-MANN LECTURE
Diane V. Havlir, University of California San Francisco, San Francisco, CA, USA

13  HIV AND GLOBAL HEALTH IN A PANDEMIC ERA
Kevin M. De Cock, Centers for Disease Control and Prevention (former), Nairobi, Kenya

INTRODUCTION OF THE MARTIN DELANEY PRESENTATION
Dawn Averitt, The Well Project, Women’s Research Initiative on HIV/AIDS, South Strafford, VT, USA

14  COMMUNITY AND ADVOCATES ARE EQUAL PARTNERS IN
    RESEARCH AND DEVELOPMENT
Yvette A. Raphael, Advocacy for Prevention of HIV and AIDS, Midrand, Gauteng, South Africa

CROI AT 30: PROGRESS IN HIV THROUGH THE LENS OF CROI

INTRODUCTION OF DR ANTHONY FAUCI
Robert T. Schooley, University of California San Diego, San Diego, CA, USA

CROI: A 30-YEAR CHRONICLE OF HIV/AIDS RESEARCH PROGRESS
Anthony S. Fauci, Former Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Washington, DC
MONDAY, FEBRUARY 20, 2023

PLENARY-01 MONDAY PLENARY SESSION

Flex C (Level 2) 8:30 AM - 9:30 AM

CROI PROGRAM COMMITTEE CHAIR WELCOME TO MONDAY

15

20 YEARS OF PEPFAR: LOOKING BACK, STRIDING FORWARD

John Nkengasong, US Department of State, Washington, DC, USA

16

THE PATH TO HEPATITIS B CURE

Anna S. Lok, University of Michigan, Ann Arbor, MI, USA

Symposium-01 VIRAL ORIGINS AND EVOLUTION OF HIV AND SARS-CoV-2

Ballroom 2 (Level 5) 4:00 PM - 5:30 PM

Objectives: At the completion of the session, participants will be able to:
- Understand conditions for virus zoonosis and spread in a new host
- Identify factors that influence virus spread and evolution in specific populations
- Identify tools used for global virus surveillance and information obtained from sequencing data

Target Audience: This session is directed towards physicians and researchers interested in obtaining a contemporary understanding of key issues in viral evolution of HIV and SARS-CoV-2

Level of Knowledge: It is assumed that participants are familiar with the basic virology of HIV and SARS-CoV-2.

Moderators

Theodora Hatziioannou, The Rockefeller University, New York, NY, USA
Julie M. Overbaugh, University of Washington, Seattle, WA, USA

17

ORIGINS OF HIV-1 AND SARS-CoV-2

Michael Worobey, University of Arizona, Tucson, AZ, USA

18

FROM PROMISE TO REALIZATION: SEQUENCING AND SURVEILLANCE FROM HIV-1 TO SARS-CoV-2

Emma B. Hodcroft, University of Bern, Basel, Basel-Stadt, Switzerland

19

ANTIBODY DRIVEN EVOLUTION OF HIV-1 AND SARS-CoV-2

Paul Bieniasz, The Rockefeller University, New York, NY, USA
MONDAY, FEBRUARY 20, 2023

Symposium-02 FROM ROCKET SCIENCE TO REALITY: MONITORING ANTIRETROVIRALS AND ADHERENCE

Objectives: At the completion of the session, participants will be able to:
• Identify the strengths and weaknesses of current adherence measures; identify new adherence measures currently in development
• Describe current digital technologies for supporting patient adherence
• Identify what might be most useful in HIV treatment and prevention with advanced adherence forgiveness of current ARV therapies, list adherence implementation considerations in low and middle income countries

Target Audience: This session is directed to physicians and researchers interested in strategies for monitoring and improving antiretroviral therapy adherence.

Level of Knowledge: It is assumed that participants are familiar with the basic understanding of monitoring and improving antiretroviral therapy adherence.

Moderators
K. Rivet Amico, University of Michigan, Ann Arbor, MI, USA
Alice Tseng, University Health Network, Toronto, ON, Canada

20 THE LANDSCAPE OF ADHERENCE TESTING
Peter L. Anderson, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

21 DIGITAL TECHNOLOGIES FOR SUPPORTING ADHERENCE
Lisa Hightow-Weidman, Florida State University, Pittsboro, NC, USA

22 CONSIDERATIONS FOR MEASURING ADHERENCE WITH LA/ED THERAPIES IN LOW- AND MIDDLE-INCOME COUNTRIES
Catherine Orrell, Desmond Tutu Health Foundation, Cape Town, Western Cape, South Africa

Symposium-03 DELIVERING ON THE SUCCESS OF INJECTABLE PrEP

Objectives: At the completion of the session, participants will be able to:
• Describe the current state of evidence for long-acting injectable cabotegravir across at-risk populations, including current guidelines for use
• Describe the barriers and data gaps that threaten the population-level impact of novel HIV PrEP strategies
• Identify actions that can mitigate or eliminate disparities in benefit of novel HIV PrEP strategies in key populations

Target Audience: This session is directed to physicians and researchers interested in injectable modalities for the delivery of preexposure prophylaxis.

Level of Knowledge: It is assumed that participants are familiar with contemporary modalities for the delivery of preexposure prophylaxis.
Opening Session, Plenaries, and Symposia by Day

23 FROM EFFICACY TO EFFECTIVENESS: CATALYZING ROLLOUT OF LONG ACTING PrEP

Nyaradzo M. Mgodi, University of Zimbabwe, Harare, Harare, Zimbabwe

24 AVOIDING DISPARITIES: NOT MAKING THE SAME MISTAKE AGAIN

LaRon Nelson, Yale University, New Haven, CT, USA

25 LA PrEP: WHAT WE KNOW AND WHAT WE STILL NEED TO KNOW

Sunil S. Solomon, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Moderators

Raphael J. Landovitz, University of California Los Angeles, Los Angeles, CA, USA

Christina Psaros, Massachusetts General Hospital, Boston, MA, USA
TUESDAY, FEBRUARY 21, 2023

Plenary-02 TUESDAY PLENARY SESSION

Flex C (Level 2)  8:30 AM - 9:30 AM

CROI PROGRAM COMMITTEE VICE CHAIR WELCOME TO TUESDAY

Landon Myer, University of Cape Town, Cape Town, Western Cape, South Africa

26 HIV RESERVOIRS: OBSTACLES TO A CURE

Janet M. Siliciano, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

27 RESTRICTIONS ON REPRODUCTIVE RIGHTS AND THEIR IMPACT ON PEOPLE LIVING WITH HIV

Denise J. Jamieson, Emory University, Decatur, GA, USA

Symposium-04 PEDIATRIC HIV CURE

Ballroom 2 (Level 5)  4:00 PM - 5:30 PM

Objectives:
At the completion of the session, participants will be able to:
• List contemporary approaches to research in pediatric cure of HIV
• Describe the progress in clinical trials of HIV prevention and cure

Target Audience: This session is directed to adult and pediatric HIV clinicians and clinical investigators as well as trainees in these areas.

Level of Knowledge: It is assumed that the participants are familiar with antiretroviral regimens commonly used for HIV treatment and prevention.

Moderator
Deborah Persaud, The Johns Hopkins University, Baltimore, MD, USA

28 APPROACHES TO PEDIATRIC CURE

Philip J.R. Goulder, University of Oxford, Oxford, United Kingdom

29 NONHUMAN PRIMATE STUDIES OF PEDIATRIC CURE INTERVENTIONS

Ann Chahroudi, Emory Vaccine Center, Atlanta, GA, USA

30 PROGRESS IN CLINICAL TRIALS OF PEDIATRIC HIV CURE

Roger Shapiro, Harvard University, Boston, MA, USA
**Symposium-05 COVID-19: WHERE ARE WE NOW?**

**Flex A (Level 2)**

**4:00 PM - 5:30 PM**

**Objectives:** At the completion of the session, participants will be able to:

- Identify the strengths and weaknesses of current adherence measures, and describe existing and next generation approaches to outpatient antiviral and immune-based (monoclonal antibody) treatment for mild to moderate COVID-19 disease and the impact of treatment on attendant complications of SARS-CoV-2 infection.
- Identify key features of the biology and pathogenesis of SARS-CoV-2 viral rebound in the setting of acute infection and antiviral treatment.
- Describe emerging syndromes associated with Long COVID and emerging data about its pathogenesis, treatment, and prognosis

**Target Audience:** This session is directed towards physicians and researchers interested in obtaining a contemporary understanding of the state of the COVID-19 pandemic.

**Level of Knowledge:** It is assumed that participants are familiar with the basic understanding of COVID-19 epidemiology.

**Moderators**

- Brenda E. Crabtree-Ramirez, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Distrito Federal, Mexico
- Irini Sereti, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA

31  **FUTURE DIRECTIONS IN OUTPATIENT THERAPY FOR MILD TO MODERATE COVID-19**

Kara W. Chew, University of California Los Angeles, Los Angeles, CA, USA

32  **VIRAL REBOUND DURING AND AFTER SARS-CoV-2 TREATMENT**

Jonathan Z. Li, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, USA

33  **WHAT WE KNOW NOW ABOUT LONG COVID SYNDROMES**

Michael J. Peluso, University of California San Francisco, San Francisco, CA, USA

---

**Symposium-06 GETTING PrEPped (AND PEPped) FOR SEX: FROM HIV TO STIs TO MPox**

**Ballroom 1 (Level 5)**

**4:00 PM - 5:30 PM**

**Objectives:** At the completion of the session, participants will be able to:

- List strategies for incorporating HIV PEP/PrEP into clinical practice
- Describe different strategies for prevention of STIs in adults and adolescents
- Identify methods for prevention of mpox pre- and post-exposure

---

CROI 2023 27
Target Audience: This session is directed to physicians interested in applying preventative strategies for HIV, sexually transmitted infections, and mpox in practice.

Level of Knowledge: It is assumed that participants are familiar with the contemporary strategies for preventing HIV, sexually transmitted infections, and mpox.

Moderators

Bridget G. Haire, Kirby Institute, Sydney, New South Wales, Australia
Maryam Shahmanesh, Africa Health Research Institute, Durban, KwaZulu-Natal, South Africa

34 IMPLEMENTING THE PrEP AND PEP TOOLKIT

Colleen Kelley, Emory University School of Medicine, Atlanta, GA, USA

35 PREVENTION OF STIs IN ADULTS AND ADOLESCENTS A SEXUAL REPRODUCTIVE HEALTH PERSPECTIVE

James Kiarie, World Health Organization, Geneva, Geneve, Switzerland

36 MPOX PREVENTION

Jade Ghosn, University of Paris Cité Department: Infectious Diseases, Bichat hospital, Paris, Ile-de-France, France

SPECIAL SESSION-1 RESULTS FROM THE MOSAICO HIV VACCINE TRIAL AND FUTURE DIRECTIONS FOR HIV VACCINES

Flex A (Level 2) 5:40 PM - 6:00 PM

Moderators

Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA

OVERVIEW OF THE MOSAICO HIV VACCINE TRIAL

Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA

HIV VACCINE DEVELOPMENT POST-MOSAICO

Lawrence Corey, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
WEDNESDAY FEBRUARY 22, 2023

PLENARY-03 WEDNESDAY PLENARY SESSION
Flex C (Level 2)
8:30 AM - 9:30 AM

CROI PROGRAM COMMITTEE VICE CHAIR WELCOME TO WEDNESDAY
Diane V. Havlir, University of California San Francisco, San Francisco, California, USA

37  HOW THE HUSH COMPLEX PROTECTS YOUR GENOME FROM RNA-DERIVED RETROELEMENTS
Paul J. Lehner, Cambridge University, Cambridge, England, United Kingdom

38  THE SCIENCE OF AGING: LESSONS FOR HIV
George A. Kuchel, University of Connecticut, Farmington, CT, USA

SPECIAL SESSION-2 SPECIAL SESSION ON THE MPOX VIRUS OUTBREAK
Ballroom 1 (Level 5)
12:15 PM - 1:15 PM

Moderators
Diane V. Havlir, University of California San Francisco, San Francisco, California, USA
Robert Schooley, University of California San Diego, San Diego, CA, USA

39  STAGE THE SETTING: THE EPIDEMIOLOGY OF THE MPOX VIRUS
John Brooks, Centers for Disease Control and Prevention, Atlanta, GA, USA

40  MOLECULAR PATHOGENESIS AND THERAPEUTIC TARGETS FOR MPOX VIRUS
Stuart N. Isaacs, University of Pennsylvania, Philadelphia, PA, USA

41  IMMUNOLOGY AND VACCINOLOGY PERSPECTIVES FOR MPOX VIRUS
Sharon Frey, Saint Louis University, St. Louis, MO, USA
SYMPOSIUM-07 THE VIRUSES THEY ARE A CHANGING: HOW THE IMMUNE SYSTEM Responds

Ballroom 3 (Level 5)  4:00 PM - 5:30 PM

Objectives: At the completion of the session, participants will be able to:

• Describe how the presence of antibodies against a given epitope may affect the response to that epitope during vaccination
• Describe how B cells respond to new viral variants of SARS-CoV2 during infection and vaccination
• Describe how HIV and SARS-CoV-2 serum antibody responses adapt to virus variation

Target Audience: This session is directed to physicians and researchers interested in obtaining a contemporary understanding of the how the immune system responds to virus variation.

Level of Knowledge: It is assumed that participants are familiar with the basic understanding of immune responses to virus variation.

Moderators
Shelly Krebs, Walter Reed Army Research Institute, Silver Spring, MD, USA
George K. Lewis, University of Maryland School of Medicine Baltimore, Baltimore, MD, USA

42 EFFECT OF NEW VIRAL VARIANTS ON NEUTRALIZING ANTIBODY POTENCY AND BREADTH

Penny L. Moore, University of the Witwatersrand, Johannesburg, Gauteng, South Africa

43 MEMORY B CELL RESPONSES TO NEW VIRUS VARIANTS: RELEVANCE TO THE CONCEPT OF ORIGINAL ANTIGENIC SIN

Marion Pepper, University of Washington, Seattle, WA, USA

44 EPITOPE MASKING DURING A RECALL RESPONSE: IMPLICATIONS FOR COVID AND HIV VACCINES

Facundo Batista, Harvard University, Cambridge, MA, USA
SYMPOSIUM-08 CASE-BASED DISCUSSION OF CARDIO-METABOLIC COMPLICATIONS OF HIV AND CONSEQUENCES FOR MANAGEMENT
Ballroom 1 (Level 5)  4:00 PM - 5:30 PM

Objectives: At the completion of the session, participants will be able to:

- Describe implications of cardiovascular disease in patients with HIV infection
- Describe implications of patients with HIV experiencing weight gain or obesity
- Describe implications of NASH and nonalcoholic fatty liver disease (NAFLD) in patients with HIV infection

Target Audience: This session is directed towards clinical care providers and researchers with an interest in cardiometabolic complications of HIV and its treatment, including potential management implications.

Level of Knowledge: It is assumed that the participants are familiar with the management of HIV and cardiometabolic comorbidities associated with HIV.

Moderators
Georg Behrens, Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
Vidya Mave, Center for Infectious Diseases, Pune, Maharashtra, India

SESSION FORMAT: This case-based and interactive session will provide an up-to-date overview of the pathogenesis, prevention, and treatment of cardiovascular disease and heart failure in HIV medicine.

Panelists
Pam S. Douglas, Duke University School of Medicine, Durham, NC, USA
Ntobeko Ntsui, University of Cape Town, Cape Town, South Africa
Donal O’Shea, University College Dublin, Dublin, Ireland
Giada Sebastiani, McGill University, Montreal, QC, Canada

SYMPOSIUM-09 SCIENCE COMMUNICATION IN THE AGE OF MISINFORMATION
Ballroom 2 (Level 5)  4:00 PM - 5:30 PM

Objectives: At the completion of the session, participants will be able to:

- Describe the history and current state of traditional media, social media and internet-based health information, misinformation, and disinformation
- Evaluate approaches to proactively address health literacy, vaccine uptake, and health communications
- Design effective communications to proactively address vaccine hesitancy
Target Audience: This session is directed to physicians and researchers interested in the communication of information to audiences with and without a training in science.

Level of Knowledge: It is assumed that participants are familiar with the contemporary issues in SARS-CoV-2, mpox, HIV, and related conditions.

Moderators

Jonathan Mermin, Centers for Disease Control and Prevention, Atlanta, GA, USA
Jon Cohen, Science, Cardiff By The Sea, CA, USA

46 COUNTERING VACCINE AND HEALTH MIS AND DISINFORMATION: AN EVIDENCE-BASED APPROACH

Scott C. Ratzan, City University of New York, Princeton, NJ, USA

47 WHAT CAN I DO? THE CHALLENGE OF HEALTH MISINFORMATION ONLINE

Emily Vraga, University of Minnesota, Minneapolis, MN, USA

48 WHAT'S FUELING THE SPREAD OF MISINFORMATION: LOOKING BEYOND FAKE FACTS

Heidi J. Larson, London School of Hygiene & Tropical Medicine, Brussels, Brussels Hoofdstedelijk Gewest, Belgium
MONDAY FEBRUARY 20, 2023

ORAL ABSTRACTS AND THEMED DISCUSSIONS BY DAY

Oral Abstract Session-01 VIROLOGY/PATHOGENESIS
Ballroom 2 (Level 5)  10:00 AM - 12:00 PM

Moderators

Stuart Neil, King’s College London, London, United Kingdom
Molly Ohainle, University of California Berkeley, Berkeley, CA, USA

100  LENACAPAVIR INHIBITS VIRION MATURATION BY BLOCKING FORMATION OF CAPSID PENTAMERS

Szu-Wei Huang, Lorenzo Briganti, Guochao Wei, Arun Annamalai, Stephanie Bester, Nikoloz Shkriabai, Mamuka Kvaratskhelia

101  INHIBITION OF NEUTRAL SPHINGOMYELINASE 2 BLOCKS HIV-1 MATURATION

Abdul Waheed, Yanan Zhu, Seung-Wan Yoo, Ferri Soheilian, Eva Agostino, Lwar Naing, Pragney Deme, Yun Song, Peijun Zhang, Barbara S Slusher, Norman Haughey, Eric O. Freed

102  INVESTIGATING THE ROLE OF CAPSID STABILITY IN INNATE IMMUNE SENSING OF HIV-1 CORES

Jenna E. Eschbach, Sebila B. Kutluay

103  MUTATIONS OUTSIDE INTEGRASE LEAD TO HIGH-LEVEL RESISTANCE TO DOLUTEGRAVIR

Yuta Hikichi, Jennifer L. Groebner, Ann Wiegand, John W. Mellors, Mary F. Kearney, Eric O. Freed

104  MX2 ANTIVIRAL SPECIFICITY IS AFFECTED BY GTPase ACTIVITY AND CAPSID-CypA INTERACTIONS

Bailey Layish, Haley Flick, Ram Goli, Mariah Cashbaugh, Robert Z Zhang, Melissa Kane

105  HOST CELL GLYCOSYLATION DIFFERENTIALLY AFFECTS CCR5- AND CXCR4-TROPIC HIV-1 INFECTION

Hannah L. Itell, Julie M. Overbaugh

106  THE FRACTION OF CELLS WITH UNSPLICED HIV RNA IS NOT ASSOCIATED WITH PLASMA VIREMIA

Adam A. Capoferri, Ann Wiegand, Francis Hong, Jana Jacobs, Jonathan Spindler, Andrew Musick, Michael J. Bale, Wei Shao, Michele D. Sobolewski, Anthony Cillo, Rebecca Hoh, Steven G. Deeks, John M. Coffin, John W. Mellors, Mary F. Kearney

107  HUMAN ANTI-ACE2 MONOCLONAL ANTIBODIES AS PAN-SARBEVIRUS PROPHYLACTIC AGENTS

Fengwen Zhang, Jesse Jenkins, Renan de Carvalho, Sandra Nakandakari-Higa, Teresia Chen, Morgan Abernathy, Elisabeth Nyakatura, Ivo Lorenz, H.-Heinrich Hoffmann, Charles Rice, Gabriel Victora, Christopher Barnes, Theodora Hatzioannou, Paul D. Bieniasz
108  11:32  SARS-CoV-2 VARIANTS EVOLVED CONVERGENT STRATEGIES TO REMODEL THE HOST RESPONSE

Oral Abstract Session-02 TB AND HEPATITIS
Ballroom 1 (Level 5)  10:00 AM - 12:00 PM

Moderators
Constance A. Benson, University of California San Diego, San Diego, CA, USA
David Wyles, Denver Health Medical Center, Denver, CO, USA

109  10:05  SimpliciTb RESULTS AND HEPATIC SAFETY OF PRETOMANID REGIMENS +/- PYRAZINAMIDE
Marika Eristavi, Ebrahim Variava, Fredrick Haraka, Margareth Pretti Dalcolmo, Harriet Mayan-Janza, Morounfolu Olugbosi, Mengchun Li, Leandra Lombard, Muge Cevik, Lindsay Thompson, Derek Sloan, Mel Spigelman, Jerry Nedelman, Maria Beumont, Eugene Sun

110  10:13  STANDARD VS DOUBLE DOSE Dolutegravir in HIV-ASSOCIATED TUBERCULOSIS: WEEK 48 RESULTS
Rulan Griesel, Ying Zhao, Bryony Simmons, Zaayid Omar, Andrew Hill, Graeme Meintjes, Gary Maartens

111  10:21  INCREASED TB PREVENTIVE THERAPY COVERAGE WITH INTEGRATED COMMUNITY-BASED IPT AND ART
Adrienne E. Shapiro, Adam Szpiro, Kombi Sausi, Nisika Sithole, Olivier Koole, Meighan Krows, Torin Schaafisma, Maryam Shahmanesh, Heidi van Rooyen, Connie Celum, Alastair van Heerden, Ruanne Barnabas
Research Group: DO ART Study Team

112  10:29  RCT of Economic Incentives for Reduced Alcohol Use and INH Adherence Among PWH
Gabriel Chamie, Judith A. Hahn, Allen Kekibiina, Nnaka Ememionyu, Brian Beesiga, Karno Marson, Robin Fatch, Sara Lodi, Julian Adong, Harsha Thirumurthy, Michael McDonell, Monica Gandhi, Kendall Bryant, Moses Kamya, Winnie Muyindike

113  11:00  Efficacy and Safety of 8-WK Tuberculosis Treatment Regimens in the TRUNCATE-TB Trial
Nicholas Paton, Christopher Cousins, Qingshu Lu, Rajesh Moorakonda, Celina Suresh, Erina Burhan, Vincent Balanag, Christine Sekaggya-Wiltshire, Anchalee Avihingsan, Rihot Sarin, Angela Crook
Research Group: The TRUNCATE-TB trial team

114  11:08  PanACEA Sudocu Combination Dose-Finding Trial Shows SUTEZOLID IS A SAFE OXAZOLIDINONE
115 11:16 cccDNA SILENCING AND LIMITED DECAY OF INFECTED CELLS IN HIV-HBV (HBeAg-) DURING NUCs
Chloe L. Thio, Maraake Taddesse, Yasmeen S. Saad, Kristina Zambo, Tanner Grudda, Mark S. Sulkowski, Richard K. Sterling, Hyon Hwang, Ashwin Balagopal

116 11:24 PREDICTORS OF HEPATITIS B RESPONSE IN PEOPLE WITH HIV/HBV COINFECTION
Anchalee Avihingsanon, Chee L. Leong, Chien-Ching Hung, Ellen Koenig, Man-Po Lee, Khuanchai Supparatpinyo, Fujie Zhang, Hongyuan Wang, Hal Martin, Jason Hindman, Jared M. Baeten, Sasisopin Kiertiburanakul

117 11:32 PAGE-B SCORE TO ESTIMATE THE HEPATOCELLULAR CARCINOMA RISK IN PEOPLE WITH HIV AND HBV
Bernard Surial, Adria Ramirez Mena, Marie Roumet, Andreas Limacher, Colette Smit, Olivier Leleux, Amanda Mocroft, Marc van der Valk, Fabrice Bonnet, Lars Peters, Juergen K. Rockstroh, Huldrych F. Gunthard, AnnaLisa Berzigotti, Andri Rauch, Gilles Wandelner
Research Group: Swiss HIV Cohort Study, EuroSIDA, ATHENA and Aquitaine

Oral Abstract Session-03 HIV AND STI PREVENTION: NEW TOOLS AND APPROACHES
Flex C (Level 2) 10:00 AM - 12:00 PM

Moderators
Adaora Adimora, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Renee Heffron, University of Alabama at Birmingham, Birmingham, AL, USA

118 10:05 MUCOSAL PHARMACOLOGY OF DOXYCYCLINE FOR BACTERIAL STI PREVENTION IN MEN AND WOMEN
Richard Haaland, Jeffrey Fountain, Chuong Dinh, Tiancheng Edwards, Amy Martin, Deborah Omoeyege, Christopher Conway-Washington, Colleen Kelley, Walid Heneine

119 10:13 ANRS 174 DOXYVAC: AN OPEN-LABEL RANDOMIZED TRIAL TO PREVENT STIs IN MSM ON PrEP
Jean-Michel Molina, Beatrice Bercot, Lambert Assoumou, Algarte-Genin Michele, Emma Rubenstein, Gilles Pialoux, Christine Katlama, Laure Surgers, Cecile Bebear, Nicolas Dupin, Jean-Paul Viard, Juliette Pavie, Claudine Duivivier, Jade Ghosn, Dominique Costagliola
Research Group: ANRS 174 Doxyvac Group

120 10:21 DOXYPEP & ANTIMICROBIAL RESISTANCE IN N. GONORRHOEAE, COMMENSAL NEISSERIA, & S. AUREUS
Anne F. Luetkemeyer, Deborah Donnell, Julia C. Dombrowski, Stephanie Cohen, Cole Grabow, Clare Brown, Cheryl Malinksi, Sharon K. Martens, Alison Cohee, Veronica Viar, Phong Pham, Susan P. Buchbinder, Diane V. Havlin, Connie Celum, Olusegun O. Soge
Research Group: DoxyPEP Study Team
121
10:29
DOXYCYCLINE POSTEXPOSURE PROPHYLAXIS FOR PREVENTION OF STIs AMONG CISGENDER WOMEN
Jenell Stewart, Kevin Oware, Deborah Donnell, Lauren R. Violette, Josephine Odoyo, Caitlin W. Scoville, Oussegou O. Soje, Victor Omollo, Felix Mogaka, Fredricka A. Sesay, R. Scott McClelland, Elizabeth A. Bukusi, Jared M. Baeten
Research Group: the dPEP Kenya Study Team

122
11:00
POTENTIAL IMPACT AND EFFICIENCY OF DOXY-PEP AMONG PEOPLE WITH OR AT RISK OF HIV
Michael W. Traeger, Kenneth H. Mayer, Douglas S. Krakower, Sy Gitin, Samuel Jeness, Julia L. Marcus

123
11:08
CLUSTER RANDOMISED TRIAL OF RISK-DIFFERENTIATED CARE FOR FEMALE SEX WORKERS: AMETHIST

124
11:16
RANDOMIZED TRIAL OF COMMUNITY HEALTH WORKER DELIVERED DYNAMIC CHOICE HIV PREVENTION
Elijah Kakande, James Ayieko, Helen Sunday, Edith Biira, Marilyn Nyabutí, George Agengo, Jane Kabami, Gabriel Chamie, James Peng, Melanie Bacon, Moses Kamya, Diane V. Havlíř, Maya Petersen, Laura Balzer
Research Group: SEARCH Study Team

125
11:24
CLUSTER RANDOMIZED TRIAL OF INTEGRATED HIV AND SEXUAL & REPRODUCTIVE HEALTH SERVICES
Rashida Ferrand, Ethel Daunya, Chido Dziva Chikwari, Tsitsi Bandason, Sarah Bernays, Katharina Kranzer, Constance Mackworth-Young, Constancia Mavodza, Owen Mugurungi, Victoria Simms, Mandikudza Tembo, Richard Hayes
Research Group: CHIEDZA Trial Group

Oral Abstract Session-04 INSIGHTS INTO PREVENTION AND TREATMENT OF HIV IN WOMEN AND CHILDREN
10:00 AM - 12:00 PM
Moderators
Jennifer Jao, Northwestern University, Chicago, IL, USA
John Kinuthia, Kenyatta National Hospital, Nairobi, Kenya

126
10:05
RECENT HIV INFECTION SURVEILLANCE IN BREASTFEEDING WOMEN IN MALAWI: JUL 2019-JUL 2022
Davie D. Chalira, Bridget Miller, Danielle Payne, Melissa Arons, Alinune N. Kabaghe, Joe Theu, Romance Thawi, Reno Stephens, Ireen Namakhoma, Joseph Njala, Alexandra Ernst, Gabrielle O'Malley, Kerry A. Thomson, Nellie Wandonda-Kabondo

127
10:13
DELIVER: A SAFETY STUDY OF A DAPIVIRINE VAGINAL RING AND ORAL PrEP DURING PREGNANCY
Katherine E. Bunge, Jennifer Balkus, Felix Mhlanga, Ashley Mayo, Lee Fairlie, Clemensia Nakabiito, Luis Gadama, Catherine Chappell, Nyaradzo M. Mgodi, Jeanna Piper, Nahida Chakhtoura, Daniel szydlo, Barbra Richardson, Sharon L. Hillier
Research Group: MTN-042 DELIVER Study Team

128
10:21
RANDOMIZED TRIAL OF DYNAMIC CHOICE HIV PREVENTION IN ANTE/POSTNATAL CARE CLINICS
Jane Kabami, Catherine Koss, Helen Sunday, Edith Biira, Marilyn Nyabuti, Laura Balzer, Shalika Gupta, Gabriel Chamie, James Ayieko, Elijah Kakande, Melanie Bacon, Diane V. Havlíř, Moses Kamya, Maya Petersen
Research Group: SEARCH Study Team
Oral Abstracts and Themed Discussions by Day

Monday 10:29

129  
**Oral Abstracts and Themed Discussions by Day**

**Continuing Medical Education**

Late-Breaking New Investigator Scholarship Nonauthor Presenter

10:29

129  **MATERNAL POINT-OF-CARE VIRAL LOAD AT DELIVERY IMPACTS INFANT ARV PROPHYLAXIS REGIMEN**


**Research Group:** LIFE Study consortium

---

130  **MULTICOMPONENT INTERVENTION IMPROVES VIRAL SUPPRESSION FOR PREGNANT/POSTPARTUM WOMEN**

Jane Kabami, Laura Balzer, Faith Kagoya, Jaffer Okiring, Joanita Nangendo, Elizabeth Arinitwe, Stella Kabageni, Michael Ayebare, Anne Katahoire, Philippa Musoke, Moses Kamya

---

131  **IMPROVED STRATEGY TO PREVENT HIV POSTNATAL TRANSMISSION: A RANDOMIZED TRIAL**

Chipepo Kankasa, Anaïs Mennecier, Souleymane Tassambedo, Catherine Chunda-Liyoka, Leticia Sakana, Morgana D’Ottavi, Melany Tonga, Dramane Kania, Jean-Pierre Moles, Mwiya Mwiya, Paulin Fao, David Rutagwera, Thorkild Tylleskår, Nicolas Nagot, Philippe Van de Perre

**Research Group:** ANRS 12397 PROMISE-EPI Study group

---

132  **BIRTH POINT-OF-CARE TEST & TREAT REDUCES EARLY MORTALITY AMONG HIV INFECTED INFANTS**


**Research Group:** LIFE Study Consortium

---

133  **POSTMORTEM CHARACTERIZATION OF HIV-ASSOCIATED UNDER-5 DEATHS IN FOUR CHAMPS SITES**

Inacio Mandomando, Dickens Onyango, Zachary Madewell, Kurt Vyas, Sana Mahtab, Portia Mutevedzi, Victor Akelo, Dianna Blau, Tacilta Helena Francisco Nhampossa, Ikechukwu Ogbruatu, Carrie Cain, Cynthia Whitney, Beth Tippett Barr, Quique Bassat

---

134  **SARS-Cov-2 IN CHILDREN & ADOLESCENTS LIVING WITH HIV IN EUROPE & SOUTH AFRICA**

Charlotte Jackson, Siobhan Crichton, Alasdair Bamford, Arantxa Berzosa, Kimberly Gilmour, Tessa Goetghhebuer, Sarah May Johnson, Ali Judd, Antoni Noguera, Marthe Le Prevost, Vana Spoulou, Kate Sturgeon, Alla Volokha, Heather J Zar, Intira Jeannie Collins

**Research Group:** EPPICC (European Pregnancy and Paediatric Infections Cohort Collaboration)

---

**Themed Discussion-01 HIV AND THE MICROBIOME: NEW THEMES**

**Flex C (Level 2)**

**1:30 PM - 2:30 PM**

**Moderator**

Ronald G. Collman, University of Pennsylvania, Philadelphia, PA, USA

1:35

**CHANGES IN GUT MICROBIOTA PROFILE IN PWHIV WHO SWITCH FROM EFV/FTC/TDF TO BIC/FTC/TAF**

Sandra Pinto-Cardoso, Monserrat Chávez-Torres, Adriana Aguilar, Santiago Ávila-Ríos

---

**CME Continuing Medical Education**

**Late-Breaking**

**New Investigator Scholarship**

**Nonauthor Presenter**

CROI 2023 37

Oral Abstracts and Themed Discussions by Day • Monday
Oral Abstracts and Themed Discussions by Day

**CROI 2023**

### Oral Abstracts and Themed Discussions by Day

**Monday**

- **Continuing Medical Education**
- **Late-Breaking**
- **New Investigator Scholarship**
- **Nonauthor Presenter**

#### Oral Abstracts

1. **The Effects of CD4+ Lymphopenia on the Human Skin Microbiome**
   - Irini Sereti, Jungmin Han, Andrea Lisco, Julia A. Segre, Heidi H. Kong
   - **250**

2. **Commensal Bacteria Within the Family Lachnospiraceae Robustly Inhibit HIV Infection**
   - **251**

3. **Bacterial Dysbiosis Persists in Women Living with HIV-1 After ART-Treatment**
   - Katherine M. Bricker, Andrea Lisco, Alessandra Borgogno, Maura Manion, Andrew Redd, Frances Galindo, Sarah Kalibbala, Aggrey Anok, Stephen Tomusange, Steven J. Reynolds, Marc Noguera Julian, Irini Sereti
   - **252**

#### Themed Discussions

**Themed Discussion-02 STEATOHEPATITIS: SEX DIFFERENCES AND OTHER RISK FACTORS**

**Ballroom 2 (Level 5)**

**1:30 PM - 2:30 PM**

- **Moderator**
  - Susanna Naggie, Duke University, Durham, NC, USA

1. **Prevalence and Factors Associated with NAFLD in People with HIV**
   - Louise E. van Eekeren, Marc J.T. Blaauw, Nadira Vadaq, Vasiliki Matzaraki, Wilhelm A.J.W. Vos, Albert L. Groenendijk, Adriana Navas, Gert Weijers, Mike van der Kolk, Andre J.A.M. van der Ven, Quirijn De Mast, Leo Joosten, Eric Tjwa
   - **609**

2. **Liver Steatosis and Fibrosis in Women with HIV by Integrase Inhibitor Use**
   - **610**

3. **Sex Differences in the Association of HIV with Metabolic-Fatty Liver Disease**
   - Dana Kablawi, Thierry Fotsing Tadjo, Jovana Milic, Wesal Elgretli, Claudia Gieoe, Bertrand Lebouché, Antonio Cascio, Giovanni Guaraldi, Giovanni Mazzola, Giada Sebastiani
   - **611**

4. **NAFLD and Its Combination with NASH Predict DM Development in People with HIV**
   - Win Min Han, Tanakorn Apornpong, Jedsadakorn Bonrungrisrap, Thanathip Wichiangsan, Hay Mar Su Lwin, Sivaporn Gatechompol, Sasiwimol Ubolyam, Stephen J. Kerr, Anchalee Avihingsanon
   - **612**

**Research Group:** 2000HIV

**Group:** CME

**Continuing Medical Education**

**LB** Late-Breaking

**NIS** New Investigator Scholarship

**NP** Nonauthor Presenter
Oral Abstracts and Themed Discussions by Day

**Themed Discussion-03 PREDICTORS OF TB TREATMENT OUTCOMES**

**Ballroom 1 (Level 5)**
1:30 PM - 2:30 PM

**Moderator**
Amita Gupta, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

1:35  **TB OUTCOMES IN PEOPLE LIVING WITH HIV: AN INTEGRATIVE DATA ANALYSIS OF PHASE 3 TRIALS**
Rob van Wijk, Vincent Chang, Marjorie Imperial, Patrick Phillips, Susan Swindells, Richard Chaïsson, Payam Nahid, Rodney Dawson, Ian Sanne, Ziyaad Waja, Susan Dormann, Ekaterina Kurbatova, Rada Savic

**Research Group:** Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team

1:40  **PREDICTORS OF POOR OUTCOMES IN PATIENTS WITH TUBERCULOSIS SYMPTOMS AT HIV DIAGNOSIS**

1:45  **TREATMENT OUTCOMES OF PERSONS WITH DSTB ON A MEDICATION MONITOR AND ADHERENCE SUPPORT**
Salome Charalambous, Noriah Maraba, Lauren Jennings, Kavindhran Velen, Piotr Hippner, Israel Rabothata, Rachel Mukora, Stembridge Mpemba, Lihle Mchunu, Dolphina Cogill, Pren Naidoo, Catherine Orrell, Katherine Fielding

**Themed Discussion-04 UNDERSTANDING MORTALITY IN PEOPLE WITH HIV**

**Ballroom 3 (Level 5)**
1:30 PM - 2:30 PM

**Moderator**
Maureen Syowai, ICAP at Columbia University, Nairobi, Nairobi Area, Kenya

1:35  **TRENDS IN MORTALITY IN PEOPLE LIVING WITH HIV IN AN INTERNATIONAL COHORT (RESPOND)**
Erich Tusch

**Research Group:** The RESPOND Study Group

1:40  **PROPORTION OF DEATHS OCCURRING OUTSIDE OF HEALTH FACILITIES ATTRIBUTABLE TO HIV/AIDS**
Newton L. Kalata, Alinune N. Kabaghe, George Mtonga, Emmanuel Mkambankhani, Masauo Musa, Amos Nyaka, Kondwani Nkanaunena, Verita Buie, Ramesh Sethi, Rodrick Langwe, Kelsey Mirkovic, Nellie Wandonda-Kabondo

1:45  **MEASURING EXCESS MORTALITY ASSOCIATED WITH HIV: ESTIMATES FROM THE PHIA PROJECT**
Shannon M. Farley, Giles Reid, Katharine Yuengling, Connor Wright, George Bello, James M. Juma, Stephane Helleringer, Jessica Justman

1:50  **ONE-YEAR MORTALITY OF PEOPLE WITH HIV AFTER INTENSIVE CARE UNIT ADMISSION**
Nicholas Bakewell, Caroline Sabin, Tanmay Kanitkar, Maggie Symonds, Oshani Dissanyake, Stephanie Rimmer, Amit Adlakha, Marc Lipman, Sanjay Bhagani, Banwari Agarwal, Robert Miller

**CME** Continuing Medical Education
**PB** Late-Breaking
**NIS** New Investigator Scholarship
**NP** Nonauthor Presenter
40 | CROI 2023

**Oral Abstracts and Themed Discussions by Day**

**875**
**REGISTRY LINKAGE IMPROVES SURVIVAL ESTIMATION AMONG PEOPLE WITH HIV IN LATIN AMERICA**
Gabriela Carriquiry, Yanink Caro-Vega, Paula Luz, Ahra Kim, Karu Jayathilake, Eduardo Gotuzzo, Lara E. Coelho, Antonio G. Pacheco, Claudia M. Cortes, Regina Succi, Lorena Guerrero-Torres, Bryan E. Shepherd, Stephany Duda, **Peter F. Rebeiro Research Group**: Caribbean, Central and South America network for HIV epidemiology (CCASAnet)

**Themed Discussion-05 NEW INSIGHTS THROUGH RECENCY TESTING**

**Flex A (Level 2)**

**1:30 PM - 2:30 PM**

**Moderator**
George W. Rutherford, *University of California San Francisco, San Francisco, CA, USA*

**847**
**HOTSPOTS OF RECENT HIV INFECTIONS AMONG ADULT PEOPLE LIVING WITH HIV IN NIGERIA**
Amobi A. Onovo, Pamela Gado, Angela Agweye, Abiye Kalaiwo, Ughwerogheny Omo-Emmanuel, Konrad Bradley, Kristina Bishop, Helina Meri, Rachel Goldstein

**848**
**PROGRAMMATIC IMPLICATIONS OF NATIONAL RECENT HIV INFECTION SURVEILLANCE IN CAMBODIA**
Vichea Ouk, Sovannarith Samreth, Bora Ngaau, Bunthoeun Eng, Rommel Bain, Chhaily Hy, Alexandra Ernst, George W. Rutherford, Chunfu Yang, Vanthy Ly, **Amitabh B Suthar**, Rachel Albalak

**849**
**AN ANALYSIS OF HIV RECENT INFECTION SURVEILLANCE DATA AMONG YOUNG PEOPLE IN MALAWI**
Alinune N. Kabaghe, **Reno Stephens**, Danielle Payne, Joe Theu, Misheck Luhanga, Davie D. Chalira, Melissa Arons, Gabrielle O'Malley, Kerry A. Thomson, Mtemwa Nyangulu, Trudy Dobb's, Vedapuri Shanmugam, Rose Nyirenda, Pragna Patel, Nellie Wandonda-Kabondo

**850**
**HIV RECENT INFECTION IN SEXUAL AND GENDER MINORITIES IN BRAZIL AND PERU: IMPREP STUDY**
Thiago S. Torres, Sylvia L. M. Teixeira, Brenda Hoagland, Kelika A. Konda, Monica Derrick, Juan V. Guanira, Marcos Benedetti, Sandro Nazer, Silver K. Vargas, Cristina Pimenta, Beatriz Grinsztejn, Celia Landmann Szwarcwald, Carlos Caceres, Valdilea Veloso

**851**
**HIV TIME-SPACE ALERTS AMONG PWID AND MSM IN THE UNITED STATES: 2018-2021**
Camden J. Hallmark, Laurie Linley, Agha Ajmal, Olivia O. Russell, Mary Plaster, Sheryl B. Lyss, Nivedha Panneer, Rashida Hassan, Anne Marie France, Alexandra M. Oster
TUESDAY FEBRUARY 21, 2023

Oral Abstract Session-05 HIV RESERVOIRS AND CURE STRATEGIES
Ballroom 1 (Level 5)  10:00 AM - 12:00 PM

Moderators

Katharine J. Bar, University of Pennsylvania, Philadelphia, PA, USA
Linos Vandekerckhove, HIV Cure Research Center, Ghent University, Ghent, Vlaanderen, Belgium

135  SINGLE-CELL PROTEOGENOMIC PROFILING OF HIV-1 RESERVOIR CELLS
10:05  NIS

136  THE IMPACT OF 3BNC117, 10-1074, AND LEFITOLIMOD ON HIV-1 PERSISTENCE: THE TITAN TRIAL
10:13

137  VIRAL AND HOST MEDIATORS OF PERSISTENT LOW-LEVEL VIREMIA
10:21  NIS
Abbas Mohammadi, Behzad Etemad, Xin Zhang, Yijia Li, Steven G. Deeks, Michael M. Lederman, Sigal Yawetz, Daniel Kuritzkes, Mathias Lichterfeld, Athé Tsibris, Mary Carrington, zabrina Brumme, Joseph R. Castillo, Mathias Lichterfeld

138  PROVIRUSES IN SELF-REACTIVE CD4+ T CELLS ARE A COMMON SOURCE OF RESIDUAL HIV VIREMIA
10:29  NIS

139  EX VIVO HIV DNA INTEGRATION IN STAT3 DRIVES T CELL PERSISTENCE AND OVERGROWTH
11:00  NIS
Michael Rist, Machika Kaku, Michael Freeman, John M. Coffin

140  THERAPEUTIC VACCINATION OF SHIV-INFECTED, ART-SUPPRESSED INFANT RHESUS MACAQUES
11:08  NIS

141  VIRAL RESERVOIR LANDSCAPE OF CHILDREN WITH HIV IN BOTSWANA TREATED WITH DUAL bNAbS
11:16  NIS
Aischa Niesar, Xiaodong Lian, Renee Hua, Gbolahan Ajibola, Molly Pretorious Holme, Kenneth Maswabi, Sikhulile Moyo, Nyaladze C. Maphorisa, Terence Mohammed, Maureen Mosethli, Kathleen M. Powis, Daniel Kuritzkes, Roger L. Shapiro, Mathias Lichterfeld

142  SINGLE-CELL EPIGENETIC, TRANSCRIPTIONAL, AND PROTEIN STATES OF HIV RESERVOIR
11:24  LB
Yulong Wei, Timothy C. Davenport, Jack Collora, Katherine H. Ma, Delia Pinto-Santini, Javier Lama, Ricardo Alfaro, Ann Duerr, Ya-Chi Ho
143 ANTI-IL-10/PD-1 IMMUNE MEDITATED CONTROL OF VIRAL REBOUND IN SIV INFECTED MACAQUES  
11:32  
Susan Pereira Ribeiro, Zachary Strongin, Felipe Ten Caten, Khader Gheime, Mohamed Abdel Halekem, Timothy N. Hoang, Kevin Nguyen, Justin Harper, Luca Micci, Jeffrey D. Lifson, Bonnie Howell, Daniel Gorman, Daria J. Hazuda, Mirko Paiardini, Rafic P. Sekaly

Oral Abstract Session-06 CONSTERNATION ABOUT COMPLICATIONS  
Flex A (Level 2)  
10:00 AM - 12:00 PM

Moderators
Judith S. Currier, University of California Los Angeles, Los Angeles, CA, USA
Roger Bedimo, University of Texas Southwestern, Dallas, TX, USA

144 EFFECTS OF EPLERENONE ON MYOCARDIAL PERFUSION AND FUNCTION: THE MIRACLE HIV STUDY  
10:05  
Suman Srinivasa, Allie Walpert, Theresa Thomas, Daniel Huck, Michael Jerosch-Herold, Sabeel Islam, Hang Lee, Gregory Robbins, Tricia H. Burdo, Christopher DeFilippi, Carolyn Dunderdale, Raymond Kwong, Marcelo DiCarli, Gail Adler, Steven K. Grinspoon

145 DEPRESSION AND ANXIETY ASSOCIATED WITH INCIDENT TYPE I AND II MI AMONG PWH  
10:13  
Emily P. Hyle, Elizabeth Humes, Shibani Mukerji, Sally B. Coburn, Heidi Crane, Svetlana Eden, Kelly Gebo, Maile Karris, Raynell Lang, Vincent C. Marconi, Richard Moore, Sonia Napravnik, Leah H. Rubin, Virginia Triant, Keri Althoff  
Research Group: North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA

146 WEIGHT AND METABOLIC CHANGES WITH CABOTEGRAVIR+RILPIVIRINE LONG-ACTING OR BICTEGRAVIR  
10:21  
Darrell H. S. Tan, Andrea Antinori, Beng Eu, Maria José Galindo, Clifford Kinder, Donna Sweet, Cornelius N. Van Dam, Kenneth Sutton, Denise Sutherland-Phillips, Alessandro Berni, Feifan Zhang, William R. Spreen, Harmony P. Garges, Parul Patel, Ronald D’Amico

147 A LOSS OF ERA ATTENUATES DTG-MEDIATED DISRUPTION OF THERMOGENESIS IN BROWN ADIPOCYTES  
10:29  
Fikrak Jung, Sunghee Jin, Becky Tu-Sekine, Frederick Anoyke-Danso, Todd T. Brown, Sangwon Kim

148 MICROBIOTA-DERIVED METABOLITES ARE POWERFUL BIOMARKERS FOR ANAL CANCER PREVENTION  
11:00  
Sergio Serrano-Villar, Camilla Tincati, Sajan C Raju, Johan Sebastian Saenz Medina, Elena Moreno, Rafael Bargiela, Alfonso Cabello, Elena Sendagorta, José A. Pérez-Molina, Johaness Roskund, Laura Fernández-López, Amaparo de Benito, Marius Troise, Jana Seifert, Manuel Ferrer

149 IMPACT OF INTEGRASE INHIBITORS ON CARDIOVASCULAR EVENTS IN PERSONS STARTING ART  
11:08  
Bernard Surial, Frédérique Chammartin, José Damas, Alexandre Calmy, David Haerry, Marcel Stöckle, Patrick Schmid, Enos Bernasconi, Philip Tarr, Huldrych F. Günthard, Gilles Wandeler, Andri Rauch  
Research Group: Swiss HIV Cohort Study

150 HIV-RELATED KAPOSI SARCOMA IN EAST AFRICA: CONTEMPORARY UPDATE ON STAGE AND SURVIVAL  
11:16  
Helen Byakwaga, Aggrey Semeere, Miriam Laker-Oketta, Megan Wenger, Elyne Rotich, Charles Kasoz, Winnie Munydieke, Philippa Kadama-Makanga, Sigrid Collier, Hilda Muwando, Toby Maurer, Esther Freeman, Samson Kiprono, Andrew Kambugu, Jeffrey Martin
NEW RECOMMENDATIONS FOR INFANT FEEDING AND PREVENTION OF PEDIATRIC HIV INFECTION IN THE US: WHAT AND WHY NOW?

Moderator: Elaine Abrams, Columbia University, New York, NY, USA
Presenter: Judy Levison, Baylor College of Medicine, Houston TX, USA

Oral Abstract Session-07 GLOBAL EPIDEMIOLOGY OF HIV
Ballroom 2 (Level 5) 10:00 AM - 12:00 PM

Moderators
Connie Celum, University of Washington, Seattle, WA, USA
Andrew Mujugira, Makerere University, Auburn, WA, USA

151 PHYLODYNAMICS OF HIV-1 VARIANT ACROSS POLAND AND UKRAINE
10:05
Karol Serwin, Miłosz Parczewski, Kaja Scheibe, Bogusz Aksak-Wąs, Piotr Żąbek, Iwona Celniań, Monika Bociąga-Jasik, Adam Witor, Szymczak Aleksandra, Paweł Jakubowski, Antoine Chaillon

152 TIME TO KEY MILESTONES IN THE HIV INDEX TESTING/CONTACT TRACING PATHWAY IN INDIA
10:13
Parthasarathy Mugundu Ramien, Padum Narayan, Shruti H. Mehta, Ajay Enugu, Allison M. McFall, Devanga Ashok, Anthony Reddy, Jade Bell, Viswanathan Arumugam, Maria Salvat Ballester, Sunil S. Solomon, Aditya Singh

153 ASSISTED PARTNER SERVICES FOR PWID TO IDENTIFY PARTNERS LIVING WITH HIV & HCV
10:21

154 HIV INCIDENCE DIFFERENCES MEASURED BY SERIAL CROSS-SECTIONAL TESTING: HPTN 071
10:29
Oliver Laeyendecker, Ethan Wilson, Owen Baker, Estelle Piwowar-Manning, Barry Kosloff, Anneen van Deventer, Ayana Moore, Peter Bock, Helen Ayles, Sian Floyd, Sarah Fidler, Richard Hayes, Susan H. Eshleman, Deborah Donnell
Research Group: HPTN 071 (PopART study team)

155 INCIDENCE OF CANCER AMONG MEDICAID BENEFICIARIES WITH AND WITHOUT HIV: 2001-2015
11:00
Jacqueline E. Rudolph, Keri Calkins, Bryan Lau, Corinne Joshu
Research Group: HPTN 071 (PopART study team)

156 CAUSES OF DEATH AMONG ADULTS WITH HIV ON ART IN EUROPE AND NORTH AMERICA: 1996-2019
11:08
Adam Trickey, Kathleen McGinnis, M John Gill, Sophie Abgrall, Juan Berenguer, Christoph Wyen, Mojgan Hessamfar, Peter Reiss, Lei Zhang, Suzanne M Ingle, Jonathan AC Sterne
Research Group: Antiretroviral Therapy Cohort Collaboration (ART-CC)

157 MOLECULAR HIV CLUSTERING OF INDIVIDUALS WITH MPOX/HIV-CO-MORBIDITY
11:16
Randall Collura, Thomas O’Grady, Carol-Ann Swain, Wendy Patterson, Deepa Rajulu

158 ISOLATING THE EFFECT OF COVID-19 RELATED DISRUPTION ON HIV DIAGNOSES IN THE US, 2020
11:24
Alex Viguerie, Ruiguang Song, Anna Satcher Johnson, Cynthia Lyles, Angela Hernandez, Paul Farnham

CME Continuing Medical Education LB Late-Breaking NIS New Investigator Scholarship NP Next-Session Presenter
Oral Abstracts and Themed Discussions by Day

Oral Abstract Session-08 ALL MODES LEAD TO PrEP
Ballroom 3 (Level 5) 10:00 AM - 12:00 PM

Moderators
Jean-Michel Molina, University of Paris Cité, Hospital Saint Louis/Lariboisière, Paris, Ile-de-France, France
Valdilea Veloso, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil

159  CABOTEGRAVIR PHARMACOLOGY IN THE BACKGROUND OF DELAYED INJECTIONS IN HPTN 084
10:05
Mark A. Marzinke, Xu Guo, James Hughes, Brett Hanscom, Estelle Piwowar-Manning, Craig Hendrix, Scott Rose, Jim Rooney, Alex R. Rinehart, Susan Ford, Adeola Adeyeye, Myron S. Cohen, Mina Hosseinipour, Sinead Delany-Morettlwe
Research Group: HPTN 084 Study Team

160  THE LEVI SYNDROME: CHARACTERISTICS OF EARLY HIV INFECTION WITH CABOTEGRAVIR FOR PrEP
10:13
Research Group: for the HPTN 083 and 084 Study Teams

161  CABOTEGRAVIR FOR HIV PrEP IN US BLACK MEN AND TRANSGENDER WOMEN WHO HAVE SEX WITH MEN
10:21
Hyman Scott, Brett Hanscom, Craig Hutchinson, Jonathan Lucas, Aditya Gaur, Colleen Kelley, Debora Dubar, Paul Richardson, Jim Rooney, Alex R. Rinehart, Adeola Adeyeye, Beatriz Grinsztejn, Raphael J. Landovitz, Sheldon Fields
Research Group: HPTN 083 Study Team

162  CAB LA FOR HIV PREVENTION IN AFRICAN CISGENDER FEMALE ADOLESCENTS (HPTN 084-01)
10:29
Research Group: HPTN 08-01 Study Team

163  8+ YEARS POOLED ANALYSIS: ADHERENCE AND HIV INCIDENCE IN 6000 WOMEN ON F/TDF FOR PrEP
11:00
Jeanne Marrazzo, Marissa Becker, Linda-Gail Bekker, Connie Celum, Michael Kiragu, Ashley Leech, Allan Taylor, Faith Ussery, Juan Yang, Melanie de Boer, Christoph Carter, Moupali Das, Jared M. Baeten, Li Tao

164  SAFETY AND PK/PD OF A TENOFOVIR ALAFENAMIDE/ELVITEGRAVIR INSERT ADMINISTERED RECTALLY
11:08
Sharon A. Riddler, Clifton Kelly, Craig Hoesley, Ken Ho, Jeanna Piper, Stacey Edick, Faye Heard, Yuqing Jiao, Gustavo F. Doncel, Sherri Johnson, Ratiya Pamela Kunjara Na Ayudhya, José Bauermeister, Craig Hendrix
Research Group: MTN-039 Protocol Team

165  ULTRA-LONG-ACTING REFILLABLE ISLATRAVIR IMPLANT FULLY PROTECTS NHP AGAINST SHIV
11:16
Fernanda Pons-Faudoa, Nicola Di Trani, Corrine Ying Xuan Chua, Laneushman, Simone Capuani, Jocelyn Nikita Campa Carranza, Kathryn Shelton, Pramod Nehete, Joan Nichols, Jason Kimata, Peter L. Anderson, Roberto C. Arduino, Alessandro Grattoni

CROI 2023
Oral Abstract Session-09 LATE-BREAKING CLINICAL STUDIES ON COVID-19 AND MPOX

Moderators
Joseph J. Eron, Jr., University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Anne F. Luetkemeyer, University of California San Francisco, San Francisco, CA, USA

166 10:05 ENSITRELVIR FOR MILD-TO-MODERATE COVID-19: PHASE 3 PART OF PHASE 2/3 STUDY
Genki Ichihashi, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Masaya Yamato, Takumi Imamura, Takuhiro Sonoyama, Takao Sanaki, Yuko Tsuge, Takeki Uehara, Hiroshi Mukae

167 10:13 EFFECT OF EARLY TREATMENT WITH PEGYLATED INTERFERON LAMBDA FOR COVID-19
Gilmar Reis, Eduardo Augusto dos Santos Moreira Silva, Daniela Carla Medeiros Silva, Lehana Thabane, Vitoria Helena de Souza Campos, Thiago Santiago Ferreira, Castilho Vitor Quirino dos Santos, Ana Maria Ribeiro Nogueira, Ana Paula Figueiredo Guimaraes Almeida, Leonardo Cancado Monteiro Savassi, Adhemar Dias de Figueiredo Neto, Ana Carolina Filhão Dias Rocha, Carina Bitar, Lindsay Wilson, Edward Mills, Jeffrey S. Glenn
Research Group: The TOGETHER Investigators

168 10:21 CHARACTERIZATION OF SINGLE VERSUS DUAL ACTIVE MAB AGAINST SARS-CoV-2
Manish C. Choudhary, Rinki Deo, Teresa H. Evering, Kara W. Chew, Mark Giganti, Carlee Moser, Justin Ritz, David A. Wohl, Joseph J. Eron, David A. Margolis, Yun Ji, Michael D. Hughes, Davey M. Smith, Eric S. Daar, Jonathan Z. Li
Research Group: ACTIV-2/A5401 Study Team

169 10:29 SAFETY AND EFFICACY OF INHALED INTERFERON-B1A (SNG001) IN OUTPATIENTS WITH COVID-19
Research Group: ACTG A5401 Study Team

170 11:00 METFORMIN REDUCED SARS-CoV-2 VIRAL LOAD IN A PHASE 3 RANDOMIZED CLINICAL TRIAL
David R. Bouware, Carolyn Bramante, Matthew Pullen, John Buse, David Odde, Tanvi Mehta, Christopher Tignanelli, Kenneth Beckman, Amy Karger, David Liebovitz, Hirshikesh Belani, Jacinda Nicklas, Michael Puskarich, Spencer Erickson, Thomas A. Murray

171 11:08 SYMPTOM AND VIRAL REBOUND IN UNTREATED COVID-19 INFECTION
Rinki Deo, Manish C. Choudhary, Carlee Moser, Justin Ritz, Eric S. Daar, David A. Wohl, Alexander L. Greninger, Joseph J. Eron, Judith S. Currier, Michael D. Hughes, Davey M. Smith, Kara W. Chew, Jonathan Z. Li
Research Group: ACTIV-2/A5401 Study Team
172 COVID-19 HOSPITALIZATION RISK AFTER SARS-CoV-2 VACCINATION AND OUTPATIENT TREATMENT
Heather Henderson, David A. Wohl, William Fischer, Luther Bartelt, David van Duin, Joseph J. Eron, Sonia Napravnik

173 MPXV IN PEOPLE LIVING WITH HIV AND CD4 COUNTS <350 CELLS/MM³ - A GLOBAL CASE SERIES
Oriol Mitjà, Andrea Alemany, Jezer Ivan Lezama Mora, Juan Carlos Rodríguez-Aldama, Ever Arturo Corral Herrera, Beatriz Grinsztejn, Nicolo Girometti, Valentina Mazzotta, Aniruddha Hazra, Jade Goshin, María Fernanda Peña Vázquez, Juan J. Montenegro Idrogo, Cristina Galvan-Casas, Michael Marks, Chloe Orkin
Research Group: SHARE-net writing group

Themed Discussion-06 DYNAMICS OF PROVIRAL INTEGRATION
Flex A (Level 2) 1:30 PM - 2:30 PM

Moderator
Lillian Cohn, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

453 DISTINCT INTEGRATION SITES OF INTACT HIV-1 PROVIRUSES IN POST-TREATMENT CONTROLLERS
Isabelle C. Roseto, Xiaodong Lian, Kyra Seiger, Elizabeth Parsons, Gregory Gladkov, Ce Gao, Karam Mounzer, Emmanouil Papasavvas, Pablo Tebas, Tae-Woo Chun, Luis J. Montaner, Xu G. Yu, Mathias Lichterfeld

451 CTL SELECTION ENRICHES FOR HIV INTEGRATION SITE FEATURES AND EXPANDED CLONES IN VIVO

452 IMPACT OF HIV RESERVOIR IN THE LOSS OF NATURAL ELITE CONTROL OF HIV-1 INFECTION
Carmen Gasca-Capote, Xiaodong Lian, Ce Gao, Isabelle C. Roseto, María de los Reyes Jiménez-León, Gregory Gladkov, Alberto Pérez-Gómez, Nuria Espinosa, Francesc Vidal, Antonio Rivero, Luis Fernando López-Cortes, Xu G. Yu, Mathias Lichterfeld, Ezequiel Ruiz-Mateos

455 EFFECT OF HIV-1 INFECTION AND VIRUS PRODUCTION ON CD4+ T CELL PROLIFERATION

456 A NOT-SO-STABLE RESERVOIR: HIV DRIVES INFECTED CELLS TO DIE AND DIVIDE
Sam Weissman, Marilia Pinzone, Alfonso Oceguera, Ashley Ginda, Liam Swiggard, LaMont Cannon, Ryan Zurakowski, Una O’Doherty
Themed Discussion-07 A VIRUS ON MY MIND: UNRAVELING LINKS BETWEEN HIV AND MENTAL HEALTH SYMPTOMS
Ballroom 1 (Level 5) 1:30 PM - 2:30 PM

Moderator
Sean Rourke, University of Toronto, Toronto, ON, Canada

469 EFFECT OF COMMON ANTIRETROVIRAL COMBINATIONS ON DEPRESSIVE SYMPTOMS IN WOMEN WITH HIV
1:35

476 (NEURO)INFLAMMATORY BIOMARKERS MEDIATE THE ASSOCIATION BETWEEN HIV AND DEPRESSION
1:40
Arish Mudra Rakshasa-Loots, Nicholas Bakewell, David Sharp, Magnus Gißlén, Henrik Zetterberg, Jasmini Alagaratnam, Ferdinand Wit, Neeltje Kootstra, Alan Winston, Peter Reiss, Caroline Sabin, Jaime Vera
Research Group: COmorBidity in Relation to AIDS (COBRA) cohort

472 PSYCHIATRIC SYMPTOMS IN PLHIV: PREVALENCE, INTERACTIONS AND CONSEQUENCES
1:45
Research Group: 2000HIV

474 BIOSYPSYCHOSOCIAL PHENOTYPES IN PEOPLE WITH HIV IN THE CHARTER COHORT
1:50
Bin Tang, Ronald J. Ellis, Florin Vaida, Anya Umlauf, Donald Franklin, Raha M. Dastgheyb, Leah H. Rubin, Robert K. Heaton, Scott L. Letendre

473 SLEEP DISTURBANCES ARE ASSOCIATED WITH COGNITIVE FUNCTION IN WOMEN LIVING WITH HIV
1:55
Raha M. Dastgheyb, Kathleen Weber, Elizabeth Daubert, Anjali Sharma, Deborah Gustafson, Deborah Jones Weiss, Catalina Ramirez, Deborah Konkle-Parker, Sushma Cribs, Bradley Aouizerat, Christine Alden, Seble Kassaye, Audrey French, Leah H. Rubin
Oral Abstracts and Themed Discussions by Day

**Themed Discussion-08 LAI CAB/RPV: WHERE ARE WE NOW AND WHERE ARE WE GOING?**

*Flex C (Level 2)*

**1:30 PM - 2:30 PM**

**Moderator**

**Babafemi Taiwo, Northwestern University, Chicago, IL, USA**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Room</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>516</td>
<td>PREDICTORS OF POST SWITCH VIREMIA IN PATIENTS ON INJECTABLE CABOTEGRAVIR/RILPIVIRINE</td>
<td>Ballroom 2</td>
<td>1:35</td>
</tr>
<tr>
<td>518</td>
<td>HIGH VIROLOGIC SUPPRESSION RATES ON LONG-ACTING ART IN A SAFETY-NET CLINIC POPULATION</td>
<td>Flex C</td>
<td>1:40</td>
</tr>
<tr>
<td>517</td>
<td>PROJECTED BENEFITS OF LONG-ACTING ART IN PWH WITH VIREMIA DESPITE PRESCRIBED ORAL ART</td>
<td>Ballroom 2</td>
<td>1:45</td>
</tr>
</tbody>
</table>

**Themed Discussion-09 ADVANCES IN PrEP DELIVERY IN SUB-SAHARAN AFRICA**

*Ballroom 2 (Level 5)*

**1:30 PM - 2:30 PM**

**Moderator**

**Andrew Mujugira, Makerere University, Auburn, WA, USA**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Room</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>999</td>
<td>A PILOT RCT ASSESSING UPTAKE OF PrEP AND CONTRACEPTION IN HAIR SALONS IN SOUTH AFRICA</td>
<td>Ballroom 2</td>
<td>1:35</td>
</tr>
<tr>
<td>978</td>
<td>PHARMACY-BASED PrEP DELIVERY IN KENYA: FINDINGS FROM A PILOT STUDY EXTENSION</td>
<td>Flex C</td>
<td>1:40</td>
</tr>
<tr>
<td>977</td>
<td>EFFECTS OF 6-MONTH PrEP DISPENSING WITH HIV SELF-TESTING ON SEXUAL BEHAVIORS IN KENYA</td>
<td>Flex C</td>
<td>1:45</td>
</tr>
</tbody>
</table>
975  RANDOMIZED TRIAL OF DYNAMIC CHOICE PREVENTION AT OUTPATIENT DEPARTMENT IN EAST AFRICA
1:55
Catherine Koss, James Ayieko, Jane Kabami, Laura Balzer, Elijah Kakande, Helen Sunday, Marilyn Nyabuti, Erick Wafula Mugoma, Melanie Bacon, Elizabeth A. Bukusi, Gabriel Chamie, Maya Petersen, Moses Kamya, Diane V. Havlir
Research Group: SEARCH Study Team

976  INCREASED UPTAKE OF BIOMEDICAL HIV PREVENTION BY YOUTH THROUGH COMMUNITY-BASED SRH
1:50
Maryam Shahmanesh, Glory Chidumwa, Natsayi Chimbindi, Carina Herbst, Nonhlanhla Okesola, Jaco Dreyer, Thembelihle Zuma, Kobus Herbst, Jana Jarolimova, Thandeka Khoza, Deenan Pillay, Theresa Smit, Osee Behuhuma, Jean-Michel Molina

975  RANDOMIZED TRIAL OF DYNAMIC CHOICE PREVENTION AT OUTPATIENT DEPARTMENT IN EAST AFRICA
1:55
Catherine Koss, James Ayieko, Jane Kabami, Laura Balzer, Elijah Kakande, Helen Sunday, Marilyn Nyabuti, Erick Wafula Mugoma, Melanie Bacon, Elizabeth A. Bukusi, Gabriel Chamie, Maya Petersen, Moses Kamya, Diane V. Havlir
Research Group: SEARCH Study Team

976  INCREASED UPTAKE OF BIOMEDICAL HIV PREVENTION BY YOUTH THROUGH COMMUNITY-BASED SRH
1:50
Maryam Shahmanesh, Glory Chidumwa, Natsayi Chimbindi, Carina Herbst, Nonhlanhla Okesola, Jaco Dreyer, Thembelihle Zuma, Kobus Herbst, Jana Jarolimova, Thandeka Khoza, Deenan Pillay, Theresa Smit, Osee Behuhuma, Jean-Michel Molina
WEDNESDAY FEBRUARY 22, 2023

Oral Abstract Session-10 IMMUNOPATHOGENESIS AND VACCINES
Ballroom 3 (Level 5) 10:00 AM - 12:00 PM

Moderators
Richard A. Koup, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
Cynthia Derdeyn, University of Washington, Seattle, WA, USA

174  CD8+ T CELLS INDUCE HIV LATENCY IN CD4+ T CELLS THROUGH THE DOWNMODULATION OF NF-kB
Simona Mutascio, Hong Wang, Mirko Paiardini, Guido Silvestri, Deanna A. Kulpa
10:05

175  BLOCKING CD4+ T CELL MIGRATION DELAYS VIRAL SPREAD FOLLOWING VAGINAL SIV CHALLENGE
Christine M. Fennessey, David R. Morcock, Jorden L. Welker, James A. Thomas, Charles M. Trubey, Caroline Widmaier, Kristin Killoran, Jeffrey D. Lifson, Brandon F. Keele, Claire Deleage
10:13

176  DEPLETION OF SIV-SPECIFIC CD8+ T CELLS DOES NOT ALTER VIRAL LOAD DURING SIV INFECTION
Jennifer Simpson, Carly Starke, Alexandra Ortiz, Amy Ransier, Sam Darko, Daniel C. Douek, Sian Llewellyn-Lacy, David Price, Jason Brenchley
10:21

177  PROTECTION AGAINST HTLV-1 CHALLENGE BY VACCINATION INDUCING ANTIBODIES IN MACAQUES
Midori Nakamura-Hoshi, Hiroshi Ishii, Takushi Nomura, Midori Okazaki, Yuriko Suzaki, Kenzo Yonemitsu, Yasushi Ami, Tetsuro Matano
10:29

178  SHIFTS IN SYSTEMIC INFLAMMATION AFTER FECAL MICROBIOTA TRANSPLANT IN PEOPLE WITH HIV
Claudio Díaz-García, Elena Moreno, Alba Talavera, José A. Pérez-Molina, Fernando Dronda, María José Gosalbes, Jorge Díaz-Alvarez, Javier Martínez-Sanz, Raquel Ron, María Jesús Vivancos, Santiago Moreno, Sergio Serrano-Villar
11:00

179  AUTOLOGOUS NEUTRALIZING ANTIBODY RESPONSES IN bNAb-TREATED RHESUS MACAQUES
Elise Viox, Ryan Krause, Emily Lindemuth, Jin Wang, Sadia Samer, Kevin Nguyen, Steffen Docken, Suvadip Mallick, Brandon F. Keele, Michael R. Betts, Miles Davenport, Mirko Paiardini, Katharine Bar
11:08

180  ANALYSIS OF EPITOPE-SPECIFIC T CELLS IN SARS-CoV-2 INFECTION AND VACCINATION
Kristin L. Boswell, Lauren A. Bowman, Amy Ransier, Jasmine Roberts-Torres, Jakob T. Samsel, David R. Ambrozak, Phillip A. Swanson, Giune Padilla, Sam Darko, Ingelise Gordon, Irini Sereti, Adrian B. McDermott, Martin Gaudinski, Daniel C. Douek, Richard A. Koup
11:16

181  ANTI-PD-1 THERAPY INDUCED RAPID INNATE INTERFERON RESPONSES DRIVE HIV RESERVOIR DECAY
Ashish Arunkumar Sharma, Aarthi Tallia, Ana B. Enriquez, Gabriela Sanchez, Adam Pelletier, Leonard D’Amico, Nicolas Chomont, Sharon Lewin, Steven G. Deeks, Kathryn Lucraft, Elad Sharon, Steven Fling, Martin Cheever, Thomas Uldrick, Rafick P. Sekaly
11:24
182 SINGLE INFUSION OF STEM LIKE CCR5-MODIFIED CD4 T CELLS PROVIDE LONG-TERM HIV CONTROL
Ana B. Enriquez, Ashish Arunkumar Sharma, Jounmana Zeidan, Gary Lee, Slim Fourati, Khader Ghneim, Gabriela Sanchez, Francesco Procopio, Robert Balderas, Nicolas Chomont, Dale Ando, Steven G. Deeks, Rafick P. Sékaly, Rémi Fromentin

Oral Abstract Session-11 NEUROPATHOGENESIS AND NEUROLOGIC COMPLICATIONS OF HIV AND SARS-CoV-2

Ballroom 2 (Level 5) 10:00 AM - 12:00 PM

Moderators
Serena S. Spudich, Yale University, New Haven, CT, USA
Michael Corley, Weill Cornell Medicine, New York, NY, USA

183 SEX MODIFIES THE ASSOCIATION OF AGE AND VIREMIA WITH STROKE RISK IN HIV
Felicia C. Chow, Robin Nance, Emily Ho, Andrew Huffer, Rizwan Kalani, Christina Marra, Joseph Zunt, Laura Barnham, Greer Burgholder, Edward Cachay, Mari Kitahata, Sonia Napravnik, David Tirschwell, Joseph Delaney, Heidi Crane

184 INCREASED IMMUNE ACTIVATION IN HIV+ MSM ON ART, BUT NOT WHEN COMPARED TO MSM ON PrEP
Josefin Robertson, Arvid Eden, Aylin Yilmaz, Lars Hagberg, Lars-Magnus Andersson, Johanna Gostner, Dietmar Fuchs, Henrik Zetterberg, Magnus Gisslén

185 CEREBROSPINAL FLUID HIV RNA AND VIRAL NUCLEIC ACID DETECTION IN PERSONS WITH HIV
Merle Henderson, Nuala Pepper, Manraj Bawa, David Muir, Alex Everett, Nicola Mackie, Alan Winston

186 HIV CLINICAL, COMORBID, AND SOCIAL DETERMINANTS OF HEALTH ARE LINKED WITH BRAIN AGING
Kalen J. Petersen, Tina Lu, Julie Wisch, June Roman, Nicolas Metcalf, Hyejung Won, Schahram Akbarian

187 CHANGES TO MICROGIAL GENOME STRUCTURE AND FUNCTION IN THE HIV-INFECTED HUMAN BRAIN
Amara Plaza-Jennings, Aditi Valada, Benjamin K. Chen, Susan Morgello, Sandhya Vasan, Vitor Valcunc, Serena Spudich

188 BRAIN AND BEHAVIOR PREDICTORS OF SARS-CoV-2 INFECTION AMONG PEOPLE WITH HIV
Robert Paul, Jacob Bolzenius, Somchai Sripiplienchan, Carlo Saccodale, Napapon Sailasuta, Julie A. Ake, Donn Colby, Phillip Chan, Faron F. Ocampo, Denise Hsu, Lishomwa Ndhlovu, Adam W. Carrico, Sandhya Vasan, Vitor Valcunc, Serena Spudich

189 NO CSF BIOMARKER EVIDENCE OF PERSISTING CNS INFECTION AFTER SARS-CoV-2 INFECTION
Arvid Eden, Anna Grath, Nelly Kanberg, Erika Stentoft, Staffan Nilsson, Aylin Yilmaz, Daniel Bremler, Marie Studahl, Daniel Romero, Mingyue Wang, Martin Stengelin, George Sigal, Michael Schöll, Henrik Zetterberg, Magnus Gisslén
Research Group: SEARCH 010/RV254 Study Team

190 CSF & PLASMA SOLUBLE BIOMARKERS IN NEURO-PASC: PRELIMINARY RESULTS FROM COVID MIND
Shell Farhadian, Lindsay S. McAlpine, Hailey Reisert, Jennifer Yoon, Jennifer Chiarella, Priya Kosana, PeiXi Chen, Kaj Blennow, Debajana Chakravarty, Samuel Pleasure, Michael Wilson, Magnus Gisslén, Henrik Zetterberg, Serena Spudich

Oral Abstracts and Themed Discussions by Day
Oral Abstract Session - 12 ANTIVIRAL STRATEGIES FOR TREATMENT AND PREVENTIONS
Ballroom 1 (Level 5)   10:00 AM - 12:00 PM

Moderators
Angela Kashuba, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Anton L. Pozniak, Chelsea and Westminster Hospital, London, England, United Kingdom

191 SOLAR 12-MONTH RESULTS: RANDOMIZED SWITCH TRIAL OF CAB+RPV LA VS ORAL B/FTC/TAF

192 EFFECT OF ISLATRAVIR ON TOTAL LYMPHOCYTE AND LYMPHOCYTE SUBSET COUNT
10:13 Kathleen E. Squires, Todd A. Correll, Michael N. Robertson, Stephanie O. Klopfer, Peggy May Tan Hwang, Yun-Ping Zhou, Elizabeth Martin, Elizabeth G. Rhee

193 LENACAPAVIR WITH bNabs GS-5423 AND GS-2872 DOSED EVERY 6 MONTHS IN PEOPLE WITH HIV
10:21 Joseph J. Eron, Susan R. Little, Gordon Crofoot, Paul Cook, Peter Ruane, Dushyantha Jayaweera, Edwin DeJesus, Sarah E. Waldman, Megha L. Mehrrota, Laurie A. VanderVeen, Hallin Huang, Sean E. Collins, Jared M. Baeten, Marina Caskey

194 TARGET3D: GLECAPREVIR-PIBRENTASVIR FOR FOUR WEEKS IN PEOPLE WITH RECENT HCV INFECTION
10:29 Marianne Martinello, Sanjay Bhagani, David Shaw, Chloe Orkin, Graham Cooke, Edward Gane, Margaret Hellard, Andrew Ustianowski, Ranjaban Kulasegaram, Catherine Stedman, Elise Tu, Jason Grebely, Gregory Dore, Mark Nelson, Gail Matthews

195 LOW CONCENTRATIONS OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE IN PATIENTS WITH HIV
11:00 Emma Rubenstein, Myriam Diemer, Lauriane Goldwirt, Caroline Lacoux, Matthieu Lafaurie, Jeremy Zeggagh, Mariagrazia Tateau, Diane Ponscarme, Julien Gras, Blandine Denis, Agathe Rami, Pierre Sellier, Marie-Laure Chaix, Constance Delaugerre, Jean-Michel Molina

196 SWITCH TO DOR/ISL (100/0.75MG) QD: WEEK 48 RESULTS FROM AN OPEN-LABEL PHASE 3 TRIAL
11:08 Jean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, Alejandro Afani Saud, Alexandra Calmy, Shinichi Oka, Federico Hinestrosa, Princy Kumar, Pablo Tebas, Sharon Walmsley, Anjana Grandhi, Inas Noel Gendrano, Karen Eves, Jason Kim, Todd A. Correll

197 SWITCH TO DOR/ISL (100/0.75MG) QD FROM B/F/TAF: WEEK 48 RESULTS FROM A PHASE 3 TRIAL
11:16 Anthony M. Mills, Giuliano Rizzardini, Moti Ramgopal, Olayemi Osiyemi, Johannes R. Bogner, Debbie Hagens, Roger Paredes, Jacques Reyne, Jürgen Rockstroh, Andrew Carr, Feng-Hsiu Su, Stephanie O. Klopfer, Rebeca M. Plank, Michelle C. Fox, Todd A. Correll
Oral Abstracts and Themed Discussions by Day

198  11:24  D2EFT: DOLUTEGRAVIR AND DARUNAVIR EVALUATION IN ADULTS FAILING FIRST-LINE HIV THERAPY

Gail Matthews, Margaret Borok, Nnekelu Eriobou, Richard Kaplan, N Kumarasamy, Anchalee Avihingsanon, Marcelo H. Losso, Iskander Shah Azwa, Muhammad Karyana, Sounkalo Daoo, Mohamed Cisse, Emmanuelle Papot, Simone Jacoby, Jolie Hutchison, Matthew G. Law, 
Research Group: D2EFT Study Group

Oral Abstract Session-13 OPTIMIZING THE HIV TREATMENT CASCADE
Flex A (Level 2)  10:00 AM - 12:00 PM

Moderators
Landon Myer, University of Cape Town, Cape Town, Western Cape, South Africa
Euphemia Sibanda, Centre for Sexual Health & HIV/AIDS Research, Harare, Zimbabwe

199  10:05  HIV RECENCY TESTING WITH INDEX TESTING CAN IDENTIFY NEW INFECTIONS EARLIER IN RWANDA

Suzue Saito, Giles Reid, Eugenie Poirot, Jean-Claude Irabona, Collins Kamanzi, Veronica Ichugsha, Beata Sangwayire, Eric Remera, Tom Olouch, Richard Mwesigwa, Elysee Tuyishime, Kamba Lee, David A. Miller, Amitabh B. Suthar, Gallican N. Rwibasira, 
Research Group: Rwanda HIV Recency Evaluation Study Team

200  10:13  RANDOMIZED TRIAL OF DYNAMIC CHOICE HIV CARE FOR HIGHLY MOBILE PERSONS IN EAST AFRICA

James Ayieko, Colette Inviolata, Elijah Kakande, Fred Opel, Erick Wafula Mugoma, Laura Balzer, Jane Kabami, Elizabeth A. Bukusi, Carol Camlin, Edwin Charlebois, Melanie Bacon, Maya Petersen, Diane V. Havlir, Moses Kamya, Gabriel Charnie, 
Research Group: SEARCH Study Team

201  10:21  THE IMPACT OF PATIENT-CENTRED CARE ON HIV TREATMENT IN ZAMBIA: A STEPPED-WEDGE TRIAL

Kombatende Sikombe, Aaloke Mody, Charles Goss, Ingrid Eshun-Wilson, Sandra Simbeza, Anjali Sharma, Laura K Beres, Jake M. Pry, Njewka Mukamba, Brian Rice, Jacob Mutale, Carolyn Bolton Moore, Charles B Holmes, Izuankanji Sikhize, Elving Geng

202  10:29  A RANDOMIZED CONTROL TRIAL OF MHEALTH TOOL EFFECT ON VIRAL SUPPRESSION IN YOUTHS

Agnes Bwanika Naggirinya, Maria S. Nabaggala, David B. Meya, Joseph Rujumba, Peter Waiswa, Rosalind Parkes-Ratanshi

203  11:00  SUPPRESSING VIRAL LOAD IN PEOPLE WITH HIV WHO INJECT DRUGS IN RUSSIA: LINC-II RCT

Jeffrey H. Samet, Elena Blokhina, Debbie M Cheng, Sydney Rosen, Dmitry Lioznov, Karsten Lunze, Ve Truong, Natalia Gnatienko, Emily Quinn, Natalia Bushara, Anita Raj, Evgeny Krupitsky

204  11:08  URINE TENOFOVIR LEVELS PREDICT VIRAL SUPPRESSION IN PATIENTS ON TENOFOVIR ALAFENAMIDE

Kelly A. Johnson, Okochi Hideaki, Mireya Arrequin, Joseph Watabe, David V. Glidden, Anindita Chattopadhyay, Elizabeth Imbert, Matthew D. Hickey, Monica Gandhi, Matthew A. Spinnelli
Oral Abstracts and Themed Discussions by Day
CROI 2023

Oral Abstracts and Themed Discussions by Day
• Wednesday
Continuing Medical Education
• Late-Breaking
• New Investigator Scholarship
• Nonauthor Presenter

Oral Abstract Session-14 EPIDEMIOLOGY AND PREVENTION OF MPOX AND SARS-CoV-2
Flex C (Level 2) 10:00 AM - 12:00 PM

Moderators
Adaora Adimora, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
François Dabis, University of Bordeaux, Bordeaux, Aquitaine, France

205 11:16 TENOFOVIR DIPHOSPHATE IN DRIED BLOOD SPOTS AND HIV-1 RESISTANCE IN SOUTH AFRICA
Yashna Singh, Jose Castillo-Mancilla, Lauren Jennings, Richard Madimabe, Christopher Ferraris, Reuben N. Robbins, Peter L. Anderson, Robert H. Remien, Catherine Orrell

206 11:24 ART SHARING IS COMMON AND ASSOCIATED WITH VIREMIA: A POPULATION-BASED STUDY IN UGANDA
Caitlin E. Kennedy, Xinyi Feng, Joseph G. Rosen, Joseph Ssekasanvu, Robert Ssekubugu, Godfrey Kigozi, David M. Serwadda, Joseph Kabanda, Ping Teresa Yeh, Joseph Kagaayi, Steven J. Reynolds, Larry William W. Chang, Fred Nalugoda, Mary K. Grabowski
Research Group: The Rakai Health Sciences Program

207 10:05 EFFECTIVENESS OF SMALLPOX VACCINATION TO PREVENT MPOX IN MILITARY PERSONNEL

208 10:13 IMPACT OF VACCINATION ON MPOX INCIDENCE IN MSM ON PrEP IN THE ANRS 174 DOXYVAC TRIAL
Jade Ghosn, Lambert Assoumou, Moussa Ouattara, Michele Algarte-Genin, Emma Rubenstein, Gilles Pialoux, Christine Katlama, Laure Surgers, Claudine Duvivier, Juliette Pavie, Jean-Paul Viard, Severine Gribowski, Manon Ollivier, Dominique Costagliola, Jean-Michel Molina

209 10:21 HOUSEHOLD TRANSMISSION OF MONKEYPOX TO CHILDREN AND ADOLESCENTS
Darpun Sachdev, Rilene Ng, Cameron Stainken, Meredith Haddix, Erin Peterson, Kristen Wendorf

210 10:29 ASSOCIATION BETWEEN OBSERVED MASKING AND SARS-CoV-2 PRESENCE IN SCHOOL WASTEWATER
Rebecca Fielding-Miller, Tommi Gaines, Ashkan Hassani, Vinton Omaleki, Marlene Flores, Araz Majnoonian, Carrissa Wijaya, Richard Garfein

211 11:00 VARIABLE REDUCTIONS IN SARS-CoV-2 VARIANT IMPORTATIONS FOLLOWING TRAVEL RESTRICTIONS
Angela McLaughlin, Jeffrey B Joy

212 11:08 INTERVENTION EFFICACY ON COVID-19 TESTING AND VACCINATION IN PEOPLE WHO INJECT DRUGS
Angela R. Bazzi, Daniela Abramovitz, Alicia Harvey-Vera, Tara Stamos-Buesig, Carlos F. Vera, Irina Artamonova, Janna Logan, Thomas L. Patterson, Steffanie A. Strathdee
Oral Abstracts and Themed Discussions by Day

**CROI 2023**

---

### Themed Discussion-10 CELLULAR IMMUNE CONTROL OF HIV

**Ballroom 2 (Level 5)**

**Moderator**

Marcus Altfeld, *Leibniz Institute for Virology, Hamburg, Germany*

#### 1:30 PM - 2:30 PM

**313 CLUSTER-RANDOMIZED TRIAL COMPARING TWO SARS-CoV-2 TESTING MODELS IN AFRICA**

*Oral Abstracts and Themed Discussions by Day* 2023


**11:16**

---

**314 COVID-19 BIVALENT BOOSTER EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION**

*Oral Abstracts and Themed Discussions by Day* 2023


**Research Group**: National COVID Cohort Collaborative
The oral abstracts and themed discussions for CROI 2023 are structured as follows:

### Oral Abstracts and Themed Discussions by Day

**Wednesday, 1:30 PM - 2:30 PM**

**Themed Discussion-11 WEIGHT GAIN: DOES WHAT GOES UP ALWAYS COME DOWN?**

**Ballroom 1 (Level 5)**

**Moderator**

**Peter Hunt, University of California San Francisco, San Francisco, CA, USA**

**Oral Abstracts and Themed Discussions by Day**

**1077**  
**WEIGHT LOSS AND METABOLIC CHANGES AFTER SWITCHING FROM TAF/FTC/DTG TO TDF/3TC/DTG**  
**Bronwyn E. Bosch,** Godspower Akpomienie, Nomathemba Chandiwana, Simiso Sokhela, Andrew Hill, Kaitlyn McCann, Ambar Qavi, Manya Mirchandani, Francois Venter

**1078**  
**FAVORABLE METABOLIC OUTCOMES 48 WEEKS AFTER SWITCH TO DTG/3TC**  
**Sophie Degroote,** Sophie Vanherrewege, Els Tobbak, Els Caluwe, Lara Vincze, Wim Tryptsteen, Mareva Delporte, Evy Blomme, Linos Vandesekerckhove, Marie-Angélique De Scheerder

**1079**  
**REVERSIBILITY OF TAF- AND/OR INSTI-ASSOCIATED WEIGHT GAIN**  
**Myrthe L. Verburgh,** Ferdinand Wit, Anders Boyd, Peter Reiss, Marc van Der Valk  
**Research Group:** the ATHENA national observational cohort

**1080**  
**WEIGHT GAIN AMONG PARTICIPANTS SWITCHING TO A DOLUTEGRAVIR-BASED HIV REGIMEN IN KENYA**  
**Kassem Bourgi,** Susan Ofner, Beverly Musick, Kara Woolf-Kaloustian, Lameck Diero, Constantin Yannoutsos, Samir Gupta

**1:30 PM - 2:30 PM**

**Themed Discussion-12 HIV SERVICES IN TIMES OF CRISIS**

**Flex A (Level 2)**

**Moderator**

**Siobhan Crowley, The Global Fund, Geneva, Switzerland**

**1077**  
**A MODEL OF SUCCESSFUL ART INITIATION IN THE CONTEXT OF MASSIVE CIVIL UNREST IN HAITI**  
**Jean Bernard Marc,** Samuel Pierre, Vanessa Rivera, Zion Abigail, David Montreuil, Fabienne Homeus, David Andre, Carl Frederic Duchatellier, Elizabeth Fox, Vanessa Rouzier, Bernard Liautaud, Patrice Severe, Collette Güiteau, Jean William Pape, Serena Koenig

**1078**  
**CONDUCTING RESEARCH IN A SETTING OF SEVERE POLITICAL INSTABILITY: THE GHESKIO MODEL**  

**1079**  
**EMERGENCY RESPONSE TO RESTORE HIV TREATMENT SERVICES IN AMHARA REGION, ETHIOPIA, 2022**  

**Research Group:** National and Amhara Regional Emergency Response Team
Themed Discussion-13 PRECLINICAL STUDIES OF NEW PREVENTION INTERVENTIONS
Ballroom 3 (Level 5) 1:30 PM - 2:30 PM

Moderator
Ariane van der Straten, University of California San Francisco, Kensington, CA, USA

992 LENACAPVIR PROTECTS AGAINST RECTAL SHIV ACQUISITION IN MACAQUE MODEL
1:35
Elena Bekerman, Stephen Yant, Laurie A. VanderVeen, Derek Hansen, Bing Lu, William Rowe, Kelly Wang, Christian Callebaut

990 EXTENDED POST-EXPOSURE PROTECTION AGAINST SHIV VAGINAL INFECTION WITH TAF/EVG INSERTS
1:40
Natalia Makarova, Tyana Singletry, Missy Peet, James Mitchell, Angela Holder, Chuong Dinh, Yi Pan, María Corazon Bueno Mendoza, Meredith Clark, Wald Héneine, James Smith, Gerardo Garcia-Lerma, Gustavo F. Doncel

989 VAGINAL PrEP EFFICACY OF BIODEGRADABLE ISLATRAVIR IMPLANTS IN MACAQUES
1:45
Michele B. Daly, Daniel Kim, Linying Li, Archana Krovi, Chasity Norton, Catalina Forero, Marie Brake, Chuong Dinh, Tiancheng Edwards, Mackenzie Cottrell, Walid Héneine, Gerardo Garcia-Lerma, Charles Dobard, James Mitchell, Leah Johnson

991 PHARMACOKINETICS AND XRAY IMAGING OF LONG-ACTING CABOTECGRAVIR IN SITU FORMING IMPLANT
1:50
Isabella Young, Panita Maturavongsadit, Alka Prasher, Roopali Shrivastava, Craig Sykes, Mackenzie Cottrell, Angela DM. Kashuba, S. Rahima Benhabbour

Please Note: The bolding of presenting authors in the Poster Sessions By Day may be inconsistent and incorrect. Please refer to the Abstract eBook and CROI 2023 Conference Platform for the correct notation of presenting authors.
**POSTER SESSIONS BY DAY**

**MONDAY FEBRUARY 20, 2023**

**Poster Session-A1 EARLY EVENTS**

**2:30 PM - 4:00 PM**

215 LENACAPAVIR DISRUPTS HIV-1 CORE INTEGRITY WHILE STABILIZING THE CAPSID LATTICE
Chenglei Li, Ryan C. Burdick, Wei-Shau Hu, Vinay K. Pathak

216 SINGLE-VIRUS IMAGING OF HIV-1 NUCLEAR IMPORT
Anayat Bhat, Ivan Nombela, Barbara V. Remoortel, Frauke Christ, Zeger Debyser

 Research Group: Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven

217 RESTRICTION OF LENTIVIRAL CAPSIDS BY PRIMATE TRIM34
Joy Twentyman, Abby Felton, Michael Emerman, Molly Ohainle

**Poster Session-B1 GENETICS, EARLY HIV INFECTION, NATURAL CONTROL**

**2:30 PM - 4:00 PM**

240 EARLY EVOLUTION OF HIV-1 FROM TRANSMITTED FOUNDERS DURING ACUTE INFECTION
Valerie F. Boltz, Wei Shao, Clarissa Halpern, Adam A. Capoferri, Morgane Rolland, Nittaya Phanuphak, Denise Hsu, Carlo Sadaian, John W. Mellors, John M. Coffin, Mary F. Kearney

 Research Group: RV254/SEARCH 0101 Study Team

241 ASSOCIATION OF MBL2 GENE POLYMORPHISMS WITH HIV-1 INFECTION IN MOROCCO
Meryem Bouqdayr, Hanâ Baba, Asmae Saïh, Anass Abbad, Salsabil Hamdi, Anass Kettani, Lahcen Wakrim

242 DIFFERENTIAL INFECTION OF ECTO- AND ENDOCERVIX BY TRANSMITTED/FOUNDER HIV-1 EX VIVO
Teresia A. Muhomah, Robert Langat, Michael McRaven, Ramon Redondo, Ann Marie Carias, Marianne Mureithi, Omu Anzala, Thomas J. Hope

243 PD-1 IS AN INSENSITIVE MARKER FOR HIV/SIV RNA+ LYMPH NODE TFH IN UNTREATED INFECTION
Joy Folkvord, Matthew Ollerton, Andria Albert, Eva Rakasz, Pamela Skinner, Elizabeth Connick

244 IDENTIFICATION OF HIV-2 EXTREME ELITE CONTROLLERS OFFERS INSIGHT TO FUNCTIONAL CURE
Zsófia I. Szojka, Emil Johansson, Angelica Palm, Jacob Lindman, Sara Karlson, Lydia Scharf, Fredrik Månsson, Antonio Biague, Marcus Bugger, Annika C. Karlsson, Hans Norrgren, Joakim Espbjörnsson, Patrik Medstrand, Marianne Jansson

 Research Group: SWEGUB CORE group

245 T CELLS HOMEOSTASIS DISTURBANCES IN A COHORT OF LONG-TERM ELITE CONTROLLERS
Norma Rallón, Daniel Jiménez-Carretero, Maria A. Navarrete-Muñoz, José M. Ligos, Jaime Valentín-Quiroga, Clara Restrepo, Alfonso Cabello, Miguel Górgolas, Eduardo López-Collazo, Fátima Sánchez-Cabo, José M. Benito
246  LOW Tryptophan Catabolism Marks Immune Preservation in HIV+ Viremic Non-Progressors  
Angel Bayon-Gil, Aaron Goldman, Judith Dalmay, Kai Ying Hong, Jane Koshy, Leila Giron, Mohamed Abdel-Mohsen, Javier Martinez Picado, Maria C. Puertas  

247  Phenotype of SIV-Infected Cells in Blood and Tissues Using a New Single-Cell Approach  
César A. Trifone, Manon Nayrac, Michael Nekorchuk, Kathleen Busman-Sahay, Rémi Fromentin, Daniel Kaufmann, Jacob Estes, Nicolas Chomont

Poster Session-B6 SARS-CoV-2 Pathogenesis  
2:30 PM - 4:00 PM

271  Plasma Lipids and Amino Acids Linked to Low SARS-CoV-2 Susceptibility  
Elena Moreno, Oihane E Albóniga, Javier Martinez-Sanz, Pilar Vizcarra, Raquel Ron, Jorge Díaz-Álvarez, Matilde Sanchez-Conde, Claudio Díaz-Garcia, Juan Carlos Galán, Santiago Moreno, Coral Barbadas, Sergio Serrano-Villar

272  Early Inflammatory Profiles Predict Maximal Disease Severity in COVID-19  
Grace Kenny, Gurvin Saini, Colette Marie Gaillard, Riya Negi, Dana Alalwan, Alejandro Garcia Leon, Willard Tinago, Eoin R. Feeney, Aoihe Cotter, Eoghan Debarra, Mary Horgan, Obada Yousif, Cecilia O’Kane, Danny McAuley, Patrick Mallon

Research Group: All Ireland Infectious Diseases Study Group

273  Differential Association of Cytomegalovirus with Acute and Post-Acute COVID-19  
Michael J. Peluso, Harry Pickering, Fay Chan, Gabrielle C. Ambaye, Gabriele Beck-Engeser, Katherine Wick, Michael Matthay, Carolyn Calfee, Jeffrey Martin, Steven G. Deeks, Smita Iyer, Holden Maecker, Timothy Henrich, Elaine F. Reed, Peter W. Hunt

Research Group: IMPACC, COMET, and LIINC study teams

274  Baseline and Temporal Differences in Proteomics Following SARS-CoV-2 Infection in PWH  
Márton Kolossváry, Christopher Defilippi, Sara McCallum, Kathleen V. Fitch, Heather J. Ribaudo, Carl J. Fichtenbaum, Judith A. Aberg, Carlos Malvestutto, Judith S. Currier, Jose L. Casado, Félix Gutiérrez, Irini Sereti, Pam S. Douglas, Markella V. Zanni, Steven K. Grinspoon

Research Group: BQC -19 Biobank

275  SARS-CoV-2 BA.5 Causes Higher Replication and Lethal Infection in K18-hACE2 Mice  
Rahul K. Suryawanshi, Maria McCavitt-Malvido, Melanie Ott

276  Autophagy and Acyl-CoA-Binding Protein Influence COVID-19 Severity  
Stephane Isnard, Léna Royston, Tsoarello Mabanga, Simeng Bu, Carolina Berini, John Lin, Brandon Fombuena, Cecilia Costiniuk, Bertrand Lebouché, Nicole Bernard, Guido Kroemer, Madeleine Durand, Jean-Pierre Routy

Research Group: BQC-19 Biobank

277  Inflammatory Pathways Associated with COVID-19 Severity Differ Based on Obesity Status  
Stefano Savinelli, Grace Kenny, Colm O’Brien, Kathleen McCann, Alejandro García Leon, Gurvin Saini, Colette Marie Gaillard, Rya Negi, Dana Alalwan, Alan Landay, Cecilia O’Kane, Aoife Cotter, Patrick Mallon, Eoin R. Feeney, Eoghan de Barra, Obada Yousify

Research Group: All Ireland Infectious Diseases Cohort

CME Continuing Medical Education  LB Late-Breaking  NIS New Investigator Scholarship  NP Next Generation Presenter

CROI 2023
278 SARS-CoV-2 VARIANTS-DEPENDENT INFLAMMASOME ACTIVATION
Elisa Teyssou, Stephane Marot, Adelie Gothland, Isabelle Malet, Karen Zaflilaza, Valentin Leducq, Theophile Cocherie, Cathia Soulié, Anne-Geneviève Marcelin, Vincent Calvez

279 HIGH FAT AND SUGAR DIET INDUCES GUT LEUKOCYTE DISRUPTIONS EXACERBATED BY SARS-CoV-2
Kelsie Brooks, Quentin Le Hingrat, Anna Jasinska, Lilas Tarnus, Makheni Jean Pierre, Ankur Sharma, Christine Nelson, Mark Lewis, Daniel Barber, Cristian Apetrei, Jason Brenchley, Ivona Pandreia

280 ACE2 SUBSTRATE CLEAVAGE EFFECT ASSOCIATED WITH COVID-19 PATIENT PLASMA IMMUNOGLOBULIN
Yufeng Song, Regan Myers, Lila Murphy, Bailey Brooks, Alexandra Kadl, Judith Woodfolk, Steven Zeichner

281 SARS-CoV-2 VARIANTS’ TEMPORAL AND VL DISTRIBUTIONS IN IMMUNOCOMPROMISED PATIENTS
Research Group: ANRS MIE - EMERGEN Consortium

Poster Session-D1 ANTIBODY AND BROADLY NEUTRALIZING RESPONSES
2:30 PM - 4:00 PM

298 MYCOBACTERIUM TUBERCULOSIS ASSOCIATES WITH HIGHER HIV-1-SPECIFIC ANTIBODY RESPONSES
Bukola Adeoye, Lydia Nakijyingi, Yetane Moreau Moreau, Ethel Nankya, Alex Olson, Mo Zhang, Karen Jacobson, Amita Gupta, Yukari C. Manabe, Mina Hosseinipour, Johnstone Kumwenda, Manish Sagar, Joseph B. McWhirter
Research Group: AIDS Clinical Trials Group A5274 (REMEMBER) Study Team

299 IMPACT OF THE INTRAUTERINE HIV EXPOSURE ON THE INFANTS VIRUS ANTIBODY REPertoire
Rachael Gachogo, Anna-Ursula Happel, Berenice Alinde, Clive M Gray, Heather Jaspan, Sonwabile Dzanibe

300 VIRUS PANEL CLASSIFICATION: A STRATEGY TOWARD DELINEATION OF PLASMA bNAb ACTIVITY
Research Group: Swiss HIV Cohort Study

301 INFERRING IMMUNOGENIC PROPERTIES OF ENV TRIMERS BY REACTIVITY TO bNAb INDUCER PLASMA
Irene A. Abela, Chloe Pasin, Nicolas Friedrich, Peter Ruset, Merle Schanz, Rogier W. Sanders, Ralf Wagner, Marit J. van Gils, Winfried Weissenhorn, Peter D. Kwong, Huldrych F. G. Günthard, Roger D. Kouyos, Alexandra Trkola
Research Group: Swiss HIV Cohort Study

302 GLYCAN-DEFICIENT SHIVS TO ELICIT BROADLY NEUTRALIZING ANTIBODIES IN MACAQUES
Daniel Morris, Hui Li, Shuyi Wang, Jinyra Lora, Craig Lauer, Kirsten Sowers, Tongqing Zhou, Peter D. Kwong, George Shaw
303 IDENTIFICATION OF HIV BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES TARGETING MPER
Lauren N. Smith, Gina Donofrio, Rajeshwer Sankhala, Vincent Dussupt, Letzibeth Mendez-Rivera, Bonnie Sliker, Nicole Doria-Rose, Victoria Polonis, Sandhya Vasan, Julie A. Ake, Merlin L. Robb, Gordon Joyce, Shelly Krebs

304 NASCENT HIV-1 ENV-REACTIVE bNAb INDUCTION IN SHIV-INFECTED NEONATAL RHESUS MACAQUES
Bhavna Hora, Hui Li, Shauuna Shen, Mitchell Martin, Yue Chen, Madison Berry, Thomas Denny, M. Anthony Moody, Mark Lewis, Kevin Wiehe, Derek Cain, David Montefiori, George Shaw, Wilton B. Williams

305 AUTOLOGOUS NEUTRALIZING ANTIBODIES DEVELOP AFTER EARLY BUT NOT ACUTE ART INITIATION
Greg Whitehill, Ryan Krause, Francesco Marino, Jaimy Joy, Suvidap Mallick, Rebecca Hoh, Steven G. Deeks, Rebecca M. Lynch, Sulggi Lee, Katharine Bar

306 ART-DIX: A NOVEL STRATEGY TO MONITOR BROADLY NEUTRALIZING ANTIBODY ACTIVITY ON ART
Magdalena Schwarzmüller, Merle Schanz, Irene A. Abela, Selina Epp, Martina Curcio, Peter Ruset, Roger D. Koyous, Huldrych F. Günthard, Alexandra Trkola

307 EFFICACY AND COMPLEMENTARITY OF HIV-1 SUPPRESSION BY CD4-BINDING bNAbs
Sabrina Helmold Hait, Hannah Shrader, Sarah Lovelace, Emily Coates, Ro Shauna Rothwell, Eileen Donaghy, Carl J. Fichtenbaum, Jorge Santana, Rachel Presti, Jhoanna Roa, Anjali Bhatnagar, Rebecca M. Lynch, Pablo Tebas, John R. Mascola, Amarendra Pegu

308 ASSESSING IMMUNOGENICITY BARRIERS OF THE HIV-1 Envelope Trimer
Nikolas Friedrich, Liridona Maliqi, Matthias Glögl, Peter Ruset, Maryam Zaheri, Chloe Pasin, Stefan Schmutz, Irene A. Abela, Roger D. Koyous, Huldrych F. Günthard, Marit J. van Gils, Rogier W. Sanders, Ralf Wagner, Andreas Plückthun, Alexandra Trkola

309 ISOLATION OF PAN-SARBEVIRUS mAbs THAT NEUTRALIZE SARS-CoV-1 AND SARS-CoV-2 VARIANTS
Felicitas Ruiz, Jamie Guenthoer, Michelle Lilly, Vrasha Chohan, Will Foreman, Ashley Taylor, Jesse Bloom, Helen Chu, Tyler Starr, Julie M. Overbaugh

310 BROAD ANTIBODIES TO FUNCTIONALLY CONSTRAINED REGIONS OF SARS-CoV-2 SPIKE
Jamie Guenthoer, Michelle Lilly, Tyler Starr, Bernadeta Dadonaite, Klaus Lovendahl, Jacob Croft, Caitlin Stoddard, Vrasha Chohan, Shilei Ding, Felicitas Ruiz, André Finzi, Jesse Bloom, Helen Chu, Kelly Lee, Julie M. Overbaugh, Mackenzie Kopp

Poster Session-D2 ELITE CONTROLLERS
2:30 PM - 4:00 PM

311 IL-15 DEPENDENT NK CELLS AND DENDRITIC CELLS CROSS-TALK IN HIV-1 ELITE CONTROLLERS
Ciputra A. Hartana, Ce Gao, Yelizaveta Rassadkina, Mathias Lichterfeld, Xu G. Yuxi
312 DISTINCT NK CELL RESPONSES DEFINE DURABLE CONTROL IN ELITE CONTROLLERS
Nerea Sánchez Gaona, Ana Gallego Cortés, Antonio Astorga Gamaza, Norma Rallón, José Miguel Benito, Ezequiel Ruiz-Mateos, Vicenç Falcó, Meritxell Genescà, Maria J Buzon
Research Group: HIV Translational Research Group

313 MONOCYTES OF HIV-1 ELITE CONTROLLERS AND RELATIVES SHOW ENHANCED TRAINED IMMUNITY
Research Group: 2000HIV

314 TRAINED IMMUNITY FEATURES IN NK CELLS OF HIV-1 ELITE CONTROLLERS
Albert L. Groenendijk, Adriana Navas, Willem A. J. W. Vos, Marc J. T. Blaauw, Louise E. van Eekeren, Mike van Der Kolk, Casper Rokx, Annelies Verbon, Mihai G. Netea, Leo A. B. Joosten, Andre J.A.M. van Der Ven, Jéssica C. Dos Santos
Research Group: 2000HIV

315 ELITE CONTROLLERS WITH DISTINCT VIRAL RESERVOIR HAVE ROBUST CTL TO NETWORKED EPITOPES
David Collins, Clarety Kaseke, Umar Urshad, Xiaodong Lian, Bridget Coffey, Daniel Worrall, Alicja Piechocka-Trocha, Micyala George, Benjamin R. Bone, Mathias Lichterfeld, Xu G. Yu, Bruce D. Walker, Gaurav Gaia

Poster Session-D5 NK CELLS, NEUTROPHILS, AND B CELLS
2:30 PM - 4:00 PM

333 AGING IMPAIRS HIV RESPONSES IN NEUTROPHILS FROM BLOOD AND THE FEMALE GENITAL TRACT
Laura Moreno de Lara, Anna Borchers, Alexandra Werner, Francisco J. Carrillo-Salinas, Christina Ochsenbauer, Charles R. Wira, Marta Rodriguez Garcia

334 RAPID EXPANSION OF MEMORY NK CELLS IN ACUTE HIV INFECTION WHICH PERSIST DESPITE ART
Anna Hearps, Jingling Zhou, Phuongnhi Ha, Silvia Lee, Patricia Price, Eugene Kroon, Nittaya Panuphak, Denise Hsu, Paul Agius, Alexandra Schuetz, Sandhya Vasan, Jintanat Ananworanich, Anthony Jaworowski

335 HIERARCHICAL CLUSTERING SHOWS B-CELL PERTURBATIONS INDEPENDENT OF HIV-2 VIRAEMIA
Research Group: SWEGUB CORE Group

336 EARLY ART TREATMENT PREVENTS B CELL LOSS AND DYSFUNCTION IN PEOPLE LIVING WITH HIV
Samantha Townsley, Yuwadee Phuang–Ngem, Ningbo Jian, David Leggat, Vincent Dussupt, Suteeraporn Pinyakorn, Merlin L. Robb, Suchada Sukhumvitthaya, Julie A. Ake, Sandhya Vasan, Denise Hsu, Nittaya Panuphak, Shelly Krebs, Alexandra Schuetz
Research Group: RV217 and RV254/RV304 study groups
337  NK CELL BIOMARKERS THAT PREDICT TIME-TO-REBOUND IN HIV+ INDIVIDUALS UNDERGOING ATI
Ashley F. George, Tongcui Ma, Min-Gyoung Shin, Reuben Thomas, Mauricio Montano, Satish Pillai, Martin Tolstrup, Ole S. Søgaard, Jonathan Z. Li, Davey M. Smith, Steven G. Deeks, Katherine S. Pollard, Warner C. Greene, Nadia R. Roan

338  CHARACTERIZATION OF TISSUE-RESIDENT NK CELLS IN A TISSUE MODEL OF HIV INFECTION
David Perea-Pérez, Nerea Sánchez Gaona, Ana Gallego Cortés, Stefania Landolfi, Félix Pumarola, Núria Ortiz, Juan Lorente, Vicenç Falcó, Meritxell Genesca, María J Buzon
Research Group: HIV Translational Research

339  LOW-DENSITY GRANULOCYTES DISPLAY IMMATURE CELLS WITH PRIMED PHENOTYPE IN PLWH
Juwon Park, Logan Dean, Jack Heckl, Michelle Tallquist, Dominic Chow, Cecilia Shikuma
Research Group: Hawaii Center for AIDS

Poster Session-D6 SARS-CoV-2 IMMUNOPATHOGENESIS
2:30 PM - 4:00 PM

340  NK CELLS ARE CRITICAL FOR IN VIVO CONTROL OF SARS-CoV-2 REPLICATION AND DISEASE
Harikrishnan Balachandran, Rhianna Jones, Kyle Kroll, Cordelia Manickam, Brady Hueber, Matthew Mosher, Andrew Hudson, Karen Terry, Amanda Martinot, Griffin Woolley, R. Keith Reeves

341  SIGLEC-9 RESTRAINS ANTIBODY-DEPENDENT NK CELL CYTOTOXICITY AGAINST SARS-CoV-2

342  ICAM-1 MEDIATES PLASMACYTOID DENDRITIC CELL SENSING OF SARS-CoV-2-INFECTED CELLS
Chenrongrong Cai, Tram N. Q. Pham, Eric Cohen

343  POLYFUNCTIONAL SARS-CoV-2-SPECIFIC T CELLS PERSIST IN TISSUE OF COVID19 CONVALESCENTS
Kyrlia C. Young, Ashley F. George, Matthew McGregor, Xiaoyu Luo, Rebecca Marquez, Kailin Yin, Tongcui Ma, Trimble Spitzer, Nadia R. Roan

344  HIGH RNAemia ASSOCIATES WITH SKEWED T-CELL RESPONSE IN PLWH HOSPITALIZED FOR COVID-19
Matteo Augello, Valeria Bono, Roberta Rovito, Camilla Tincati, Silvia Bianchi, Lucia Taramasso, Antonio Di Biagio, Annapaola Callegaro, Franco Maggiolo, Elisa Borghi, Antonella D’Arminio Monforte, Giulia C. Marchetti

345  HIGH-RESOLUTION MAPPING OF T-CELL HYBRID IMMUNITY TO THE ENTIRE SARS-CoV-2 PROTEOME
Raúl Pérez-Caballero, Laia Bernad, Athina Kilpeläinen, Oscar Blanch-Lombarte, Luis Romero, Ruth Peña, Gabriel Felipe Rodríguez-Lozano, Josep Maria Manresa-Dominguez, Bonaventura Clotet, Alex Olvera, Christian Brander, Eva Maria Martinez Caceres, Concepción Violán, Pere Torán-Monserrat, Julia G. Prado
346 **UNIQUE DIFFERENTIATION AND HOMING FEATURES OF T CELLS IN INDIVIDUALS WITH LONG COVID**  
Kailin Yin, Michael J. Peluso, Reuben Thomas, Jason Neidleman, Xiaoyu Luo, Rebecca Hoh, Scott Lu, Sarah A. Goldberg, Sulggi Lee, Kara Lynch, John D. Kelly, Jeffrey Martin, Steven G. Deeks, Timothy Henrich, Nadia R. Roan

347 **LONGITUDINAL CORONAVIRUS ANTIBODY RESPONSES IN AFRICA BETWEEN 2013 AND 2021**  
Yifan Li, Mélanie Merbah, Suzanne Wollen-Roberts, Bradley Beckman, Thembi Mduli, Allahna L. Esber, Jonah Maswai, John Owuwoh, Hannah Kibuuka, Michael Iorezindu, Emmanuel Bahemana, Kayvon Modjarrad, Sandhya Vasan, Julie A. Ake, Morgane Rolland

348 **IMPACT OF COVID-19 AND HOST FACTORS ON THE HUMORAL IMMUNE REPERTOIRE IN TREATED HIV**  

349 **LYMPHOCYTE TRAJECTORIES AND OUTCOMES OF COVID-19 INFECTION IN PEOPLE WITH HIV**  
Jerry Liu, Richard Medford, Roger Bedimo, John Hanna

350 **CHRONIC HIV INFECTION IMPACTS THE IMMUNE RESPONSE DURING ACUTE SARS-CoV-2**  
Skye Opsteen, Tim Fram, Nathan Erdmann, Dustin M. Long

351 **PRIOR SARS-CoV-2 INFECTION PROTECTS AGAINST SYMPTOMATIC COMMON COLD CORONAVIRUSES**  
David Bean, Janet Monroe, Janice Weinberg, Manish Sagar

352 **RESPIRATORY DISEASE FACTORS LINK WITH REDUCED SARS-CoV-2 SUSCEPTIBILITY IN PWH**  
Irene A. Abela, Anthony Hauser, Chloe Pasin, Magdalena Schwarzmüller, Huldrych F. Günthard, Alexandra Trkola, Roger Koudys

353 **DELINEATING FACTORS ASSOCIATED WITH ASYMPTOMATIC PRIMARY SARS-CoV-2 INFECTION**  
Irene A. Abela, Chloe Pasin, Magdalena Schwarzmüller, Agne Ulyte, Radtke Thomas, Audigé Annette, Huber Michael, Berger Christoph, Barbara Hasse, Peter Ruset, Huldrych F. Günthard, Roger Koudys, Milo Puhun, Kriemler Susi, Alexandra Trkola

354 **HIGHER SPIKE GENETIC DIVERSITY OF DELTA/OMICRON VARIANTS IN IMMUNOCOMPROMISED HOSTS**  
Romain Coppée, Antoine Bridier-Nahmias, Valentín Leducq, Anna-Maria Franco Yusti, Karen Zafilaza, Eve Todesco, Cathia Soulé, Antoine Fauchois, Quentin Le Hingrat, Anne-Geneviève Marcellin, Vincent Calvez, Charlotte Charpentier, Diane Descamps, Stéphane Marot, Valentine M. Ferré

---

**Poster Session-E1 CONTROLLERS AND POSTTREATMENT CONTROLLERS**  
2:30 PM - 4:00 PM

380 **CD103 EXPRESSION ON CD8 T CELLS PREDICTS LONGER TIME REBOUND OF HIV AFTER ATI**  
Tongcui Ma, Ashley F. George, Min-Gyoung Shin, Mauricio Montano, Satish Pillai, Katherine S. Pollard, Jonathan Z. Li, Davey M. Smith, Steven G. Deeks, Reuben Thomas, Warner C. Greene, Nadia R. Roan

---

**Poster Sessions • Monday**
381 THE CIRCULATING CELL-FREE DNA METHYLOME PREDICTS HIV POST-TREATMENT CONTROL
Akshay Gala, Zain Dossani, Prema Dabral, Michael J. Peluso, Steven G. Deeks, Jonathan Z. Li, Satish K. Pillai

382 WHICH ENDPOINT TO CHOOSE DURING ANTIRETROVIRAL TREATMENT INTERRUPTION?
Rodolphe Thiebaut, Marie Alexandre, Mélanie Prague, Yves Levy
Research Group: ANRS 118 ILIADE, ANRS 149 VIRIO2 LIGHT, ANRS VRI DALIA trials

383 PREEXISTING HOST EPigenetic States Associated with HIV REBOUND KINetics
Michael Corley, Nathalia Mantovani, Leila Giron, Alina Pang, Juliana Galinskas, Danilo Dias, Paulo Ferreira, Gisele Gosuen, James Hunter, Andrea Savarino, Ricardo Diaz, Lishomwa Ndhlouvu

384 PARTICIPANT EXPERIENCES IN A CURE-DIRECTED LONG-TERM ANALYTIC TREATMENT INTERRUPTION
Eion Plenn, Frances K. Barg, Katharine Rendle, Andrea Bilger, William B. Carter, Andrea Lamour-Harrington, Christopher Roebuck, Beth Peterson, Pablo Tebas, Karam Mounzer, David Metzger, Luis J. Montaner, Karine Dube

385 PLASMA CD33 LEVEL IS A MARKER OF VIRUS CONTROL POST-KICK-AND-KILL CURE INTERVENTION
Clara Duran Castells, Anna Prats, Bruna Oriol Tordera, Anukas Llano, Cristina Galvez, Javier Martinez Picado, Ester Ballana, Edurne García-Vidal, Bonaventura Clotet, Jose A. Muñoz Moreno, Tomas Hanke, José Moltó, Beatriz Mothe Pujades, Christian Brandner, Marta Ruiz Riol

386 COMPREHENSIVE ANALYSIS OF VIRAL RESERVoirs IN HIV-INFECTED ELITE CONTROLLER

387 PREDICTORS OF HIV REBOUND AFTER INTERRUPTION OF ART STARTED DURING PRIMARY INFECTION
Antoine Chaillon, Caroline Ignacio, Merle Schanz, Tingting Yu, Rui Wang, Roger D. Kouyos, Gemma Caballero, Noah Gaitan, Stephen Rawlings, Celsa Spina, Herbert Kuster, Karin Metzner, Huldrych F. F. Günthard, Davey M. Smith, Sara Gianella Weibel

Poster Session-E2 DYNAMICS OF THE HIV RESERVOIR
2:30 PM - 4:00 PM

388 SHORT- AND LONG-TERM DYNAMICS OF SIV-INFECTED CELL POPULATIONS ON ART
Emily Fray, Fengting Wu, Francesco R. Simonetti, Carolin Zitzmann, Narmada Sambaturu, John Ventura, Thomas Leitner, Ruy Ribeiro, Alan S. Perelson, Dan Barouch, Janet M. Siliciano, Robert F. Siliciano

389 PRESENTATION OF COGNATE ANTIGENS BY DENDRITIC CELLS CAUSES STOCHASTIC HIV EXPRESSION

390 STABILITY AND INSTABILITY OF THE CELLULAR HIV RESERVOIR AFTER REBOUND DURING ATI
Vincent Wu, Jayme Nordin, Son Nguyen, Katharine Bar, Laura Vella, Michael R. Betts
LACK OF DETECTABLE ONGOING REPLICATION ON ART IN SIV-INFECTED RHESUS MACAQUES
Taina T. Immonen, Christine M. Fennessey, Brandon F. Keele

SLOWING OR REVERSAL OF DECAY OF INTACT PROVIRUSES OVER 2 DECADES OF SUPPRESSIVE ART
Research Group: AIDS Clinical Trials Group A5321 Team

DIFFERENTIAL TRANSCRIPTION LEVELS OF HIV-1 FULL-LENGTH AND HIGHLY DELETED PROVIRUSES
Thuy Thi Thu Nguyen, Lindsey Adams, Mary-Elizabeth Zipparo, Annie Glassy, Erin Madeen, Ulisses Santamaria, Catherine Rehm, Jessica Earhart, Wei Shao, Chuen-Yen Lau, Frank Maldarelli

HUMAN GALECTIN-9 PROMOTES THE EXPANSION OF HIV RESERVOIRS IN VIVO IN HUMANIZED MICE
Zhe Yuan, Leila Giron, Colin Hart, Kwasi Gyampoh, Jane Koshy, Kai Ying Hong, Toshiro Niki, Thomas Premeaux, Lishomwa Ndhlouvou, Luis J. Montaner, Mohamed Abdel-Mohsen

HIV-1 CLADE C RESERVOIR CHARACTERISTICS IN EARLY AND CHRONIC TREATED INFECTION

PERSISTANCE OF INDUCIBLE REPLICATION-COMPETENT HIV-1 AFTER LONG-TERM ART
Natalie F. McMyn, Joseph Varriale, Jun Lai, Anushka Singhal, Mauro A. Garcia, Vivek Hariharan, Brianna Lopez, Robert F. Siliciano, Janet M. Siliciano

IN-DEPTH TRANSCRIPTOMIC ANALYSIS OF THE TRANSLATION-COMPETENT HIV-1 RESERVOIR
Marion Pardons, Basiel Cole, Laurens Lambrechts, Willem van Snippenberg, Sofie Rutsaert, Ytse Noppe, Nele De Langhe, Annemieke Dhondt, Jerel Vega, Erik Nijs, Ellen Van Gulck, Daniel Boden, Linos Vandekerckhove

DIFFERENTIATION ENHANCES REACTIVATION OF HIV-1 IN CD4+ T CELLS AFTER LONG-TERM ART
Yury V. Kuzmichev, Krupa Subramanian, Sonia Bakkour, Carol Lackman-Smith, Mars Stone, Christina H. Mallarino-Haeger, Roger G. Ptak, Michael P. Busch, Elizabeth R. Wonderlich, Deanna A. Kulpa

A NUCLEOSOMAL MODIFICATION COMPLEX FOR SILENCING HIV
Zichong Li, Melanie Ott, Warner C. Green
Research Group: The HOPE Collaboratory

CCNT1 IS A NONESSENTIAL GENE IN JURKAT T CELLS REQUIRED FOR HIV RELEASE FROM LATENCY
Terry L. Hafer, Emily Hsieh, Carley Gray, Michael Emerman

DIFFERENTIATION ENHANCES REACTIVATION OF HIV-1 IN CD4+ T CELLS AFTER LONG-TERM ART
Yury V. Kuzmichev, Krupa Subramanian, Sonia Bakkour, Carol Lackman-Smith, Mars Stone, Christina H. Mallarino-Haeger, Roger G. Ptak, Michael P. Busch, Elizabeth R. Wonderlich, Deanna A. Kulpa

A NUCLEOSOMAL MODIFICATION COMPLEX FOR SILENCING HIV
Zichong Li, Melanie Ott, Warner C. Green
Research Group: The HOPE Collaboratory

CCNT1 IS A NONESSENTIAL GENE IN JURKAT T CELLS REQUIRED FOR HIV RELEASE FROM LATENCY
Terry L. Hafer, Emily Hsieh, Carley Gray, Michael Emerman

DIFFERENTIATION ENHANCES REACTIVATION OF HIV-1 IN CD4+ T CELLS AFTER LONG-TERM ART
Yury V. Kuzmichev, Krupa Subramanian, Sonia Bakkour, Carol Lackman-Smith, Mars Stone, Christina H. Mallarino-Haeger, Roger G. Ptak, Michael P. Busch, Elizabeth R. Wonderlich, Deanna A. Kulpa

A NUCLEOSOMAL MODIFICATION COMPLEX FOR SILENCING HIV
Zichong Li, Melanie Ott, Warner C. Green
Research Group: The HOPE Collaboratory

CCNT1 IS A NONESSENTIAL GENE IN JURKAT T CELLS REQUIRED FOR HIV RELEASE FROM LATENCY
Terry L. Hafer, Emily Hsieh, Carley Gray, Michael Emerman
441 ncRNA PROFILE IN EXTRACELLULAR VESICLES REVEALS A POTENTIAL MECHANISM OF HIV-CONTROL
Maria A. Navarrete-Muñoz, Ignacio Maillo, Héctor Peinado, Ricardo Ramos, María L. García-Gil, Alfonso Cabello, Miguel Górgolas, José M. Benito, Norma Rallón

442 c-Myc AND NR4A REGULATE STOCHASTIC REACTIVATION OF LATENT HIV-1
Rajiv Pathak, Annalena La Porte, Carolina Eliscovich, Estah L. Bock, Laura J. Martins, Adam Spivak, Masako Suzuki, Vicente Planelles, Robert H. Singer, Ganjam V. Kalpana

443 HIV TEM-SEQ: TARGETED ENZYMATIC METHYLATION SEQUENCING OF HIV-1 PROVIRUSES
Alina Pang, Lishomwa Ndhlovu, Michael Corley

444 EX-VIVO IMPACT OF LRA AND SPECIFIC LIGANDS ON ESTROGEN RECEPTOR IN CD4+ T CELLS
Cristina Ceriani, Anthony Abeyta-Lopez, Kena J. Lemu, Brigitte Allard, Katherine S. James, David Margolis, Nancie Archin

445 ENHANCED HIV-INDUCED LINEAGE TRACING REPORTER SYSTEM REVEALS EARLY LATENCY PHENOTYPE
Don Nguyen, Namita Satija, Tia Robinson, Gerrit Schmidt, Foramben Patel, Benjamin K. Chen

446 TARGETING 2 NEUTRAL SPHINGOMYLINASE 2 PROMOTES DEATH OF HIV-INFECTED CELLS
Seung-Wan Yoo, Abdul A. Waheed, Pragney Deme, Rana Rais, Ajit Thomas, Matthew D. Smith, Peter A. Calabresi, Eric O. Freed, Barbara S. Slusher, Norman J. Haughey

447 DPP9 INHIBITION ENHANCES NNRTI-MEDIATED CLEARANCE OF HIV-1 LATENT RESERVOIRS
Kolin Clark, Josh Kim, Qiankun Wang, Liang Shan

448 INTERLEUKIN-2-INDUCIBLE T-CELL KINASE (ITK) INHIBITION PREVENTS HIV LATENCY REVERSAL
Prerna Dabral, Li Du, Mohamed Bouzidi, Richard Miller, Steven G. Deeks, Satish K. Pillai

Poster Session-F1 CLINICAL AND BIOMARKER ASSOCIATIONS WITH COGNITION IN PEOPLE WITH HIV
2:30 PM - 4:00 PM

460 COGNITIVE TRAJECTORIES AMONG PEOPLE WITH HIV MODELED BEFORE AND AFTER SUSTAINED ART
Robert Paul, Jacob Bolzenius, Peter Brandes, Eduardo Ruiz, Cecilia Correa, Kevin Robertson, Ann Duerr

461 THE COURSE OF NEUROCOGNITIVE PERFORMANCE OVER FOUR YEARS IN WELL-TREATED PLWH
José Damas, Bruno Ledergerber, Mélanie Bieler-Aeschlimann, Philip Tarr, Marcel Stöckle, Hachfeld Anna, Alexandra Calmy, Frédéric Assal, Patrick Schmid, Thomas Hundsberger, Caroline Di Benedetto, Barbara Hasse, Renaud Du Pasquier, Katherine Darling, Matthias Cavassini
Research Group: Swiss HIV Cohort Study

462 NEUROCOGNITIVE IMPAIRMENT NEGATIVELY AFFECTS VIRAL CONTROL IN ART-TREATED PWH
Mattia Trunfio, Elisa Vuaran, Daniela Vai, Alessandro Di Stefano, Daniele Imperiale, Stefano Bonora, Giovanni Di Perri, Andrea Calcagno
ASSOCIATIONS BETWEEN PLASMA BIOMARKERS AND CHANGES IN COGNITIVE FUNCTION OVER 2 YEARS
Nicholas Bakewell, Caroline Sabin, Patrick Mallon, Memory Sachikonye, Nicki Doyle, Alan Winston, Ken M. Kunisaki

Poster Session-F2 INTERPLAY BETWEEN VASCULAR AND NERVOUS SYSTEM FUNCTION IN HIV
2:30 PM - 4:00 PM

ASSOCIATIONS BETWEEN PLASMA BIOMARKERS AND CHANGES IN COGNITIVE FUNCTION OVER 2 YEARS
Nicholas Bakewell, Caroline Sabin, Patrick Mallon, Memory Sachikonye, Nicki Doyle, Alan Winston, Ken M. Kunisaki

464 VASCULAR AGE AND COGNITIVE OUTCOMES IN AN ACUTE HIV COHORT AFTER 6 YEARS OF ART
Kathryn Holroyd, Carlo Sacdalan, Suteeraporn Pinyakorn, Varaporn Unsombut, Somchai Sriplietchan, Robert Paul, Nittaya Phanuphak, Denise Hsu, Sandhya Vasan, Serena Spudich, Phillip Chan
Research Group: RV254/SEARCH 010 Study Team

465 NON-CLASSICAL MONOCYTES CORRELATE NEGATIVELY WITH HIV-ASSOCIATED COGNITIVE IMPAIRMENT

466 COCAINE USE INDEPENDENTLY PREDICTS WHITE MATTER LESION BURDEN IN HIV DISEASE
Christina Meade, Ryan Bell, Sheri Towe, Christopher Lascola

467 EXTRACELLULAR VESICLES IN ALWH PROMOTE CEREBRAL ENDOTHELIAL PROFILES LINKED TO STROKE
Hannah Fandl, Vinicius Garcia, Kelly Stockelam, William Hollenbach, John Treuth, Aubern Berry, Hannah Cardenas, Noah Desouza, Cynthia Finnhaber, Jared Greiner, Brian Stauffer, Elizabeth Connick, Christopher Desouza

468 NEUROFILAMENT LIGHT IS ASSOCIATED WITH CARDIORESPIRATORY AND METABOLIC HEALTH IN HIV
Sarah Cooley, Beau Ances

Poster Session-F3 ANTIRETROVIRAL EFFECTS ON CENTRAL NERVOUS SYSTEM OUTCOMES
2:30 PM - 4:00 PM

469 EFFECT OF COMMON ANTIRETROVIRAL COMBINATIONS ON DEPRESSIVE SYMPTOMS IN WOMEN WITH HIV

470 DTG IMPACTS ZEBRAFISH BEHAVIOUR THROUGH DOPAMINERGIC PATHWAYS: RESCUE BY FOLATE
Daniela Zizioli, Sara Ferretti, Luca Mignani, Samuele Storti, Isabella Zanella, Francesco Castelli, Eugenia Quiros-Roldan

471 DOLUTEGRAVIR IS ASSOCIATED WITH MORE DEPRESSIVE SYMPTOMS IN OLDER PEOPLE WITH HIV
Poster Session-F8 POST-ACUTE NERVOUS SYSTEM SEQUELAE OF COVID-19 IN PEOPLE WITH AND WITHOUT HIV

2:30 PM - 4:00 PM

492 POST-COVID COGNITIVE IMPAIRMENT MRI BRAIN SCAN ABNORMALITIES: A POTENTIAL BIOMARKER
Joga Chaganti, Lucette Cysique, Xin Zhang, Benjamin Heng, David Darley, Anthony Byrne, Chansavath Phetsouphanh, Anthony D. Kelleher, Gregory Dore, Gail Matthews, Gilles Guillemin, Bruce Brew
Research Group: St Vincent’s Centre for Applied Medical Research

493 COGNITIVE, MOTOR, & NEGATIVE VALENCE SYSTEMS IN NEUROLOGIC PASC: A PRELIMINARY STUDY
Lindsay S. McAlpine, Raha M. Dashtgheyb, Jennifer Chiarella, Robert K. Fulbright, Todd Constable, Cheryl Lacadie, Jennifer Yoon, Hailey Reisert, Shelli Farhadian, Serena Spudich, Leah H. Rubin
Research Group: The COVID Mind Study

494 CHARACTERISTICS AND OUTCOMES OF COVID-19 IN AN EARLY-TREATED HIV COHORT IN THAILAND
Ferron F. Ocampo, Misti Paudel, Carlo Sacdalan, Suteeraporn Pinyakorn, Suwanna Puttasawin, Somchai Sriprielsen, Robert Paul, Nittaya Phanuphak, Phillip Chan, Denise Hsu, Serena Spudich
Research Group: RV254/SEARCH010 Study Team

495 TRAJECTORY OF POST-COVID NEUROCOGNITIVE RECOVERY IN PEOPLE LIVING WITH AND WITHOUT HIV
Alisha Dziarski, Nuria Gallego Marquez, Armaan Jamal, Samantha N. Walch, Arianna Romero, Mariana Araujo-Pereira, Artur T L Queiroz, Christina Bunch, Ashley Zelaya, Enam Akasreku, Bruno B. Andrade, Michael J. Peluso, Alan Landay, Tracy Vannorsdall, Annukka A R. Antar

496 INFLAMMATORY AND BLOOD-BRAIN BARRIER MARKERS AFTER COVID-19 AMONG PEOPLE WITH HIV
Daniel Adesse, Maria L. Alcaide, Deborah Jones Weiss, Michel Toborek

Poster Session-G1 IMPORTANT ISSUES IN CLINICAL PHARMACOLOGY

2:30 PM - 4:00 PM

497 MODELING TO OPTIMIZE ISLATRAVIR QW DOSE IN HIV VIROLOGICALLY SUPPRESSED PWH
Ryan Vargo, Seth Robey, Xiaowei Zang, Lihong Du, Bhargava Kandala, Jessica Roberts, Stephanie O. Klopfer, Kathleen E. Squires

498 ESTRADIOL CONCENTRATIONS IN TRANS WOMEN ON InSTIs COMPARED TO THOSE WITHOUT HIV
Mona Loutfy, Ashley Lacome–Duncan, Yasmeen Persad, Ian Armstrong, Raymond Fung, Kimberly K. Scarsi, Alice Tseg, Louie Chan, Quang Nguyen, Thea Weidorf, Sue Hranilovic, Roberta Halpenny, Nirubini Jeyarajah, George Kovchazov, Harshita Iyer

499 NgLS WITH rHuPH20 ENABLES SAFE HIGH-DOSE MONOCLONAL ANTIBODY SUBCUTAENOUS DELIVERY
Research Group: VRC 609 Study Team

500 TFV-DP & FTC-TP IN BLOOD CELL SUBSETS OF PERSONS WITH HIV
Vincent A. Mainella, Jose R. Castillo Mancilla, Brian Branchford, Travis Nemkov, Seth Hosford, Bethany Johnson, Ye Ji Choi, Pang Xiong, Martin Williams, Jia-Hua Zheng, Lucas Ellison, Lane Bushman, Jennifer Kiser, Peter L. Anderson, Kristina M. Brooks

CME Continuing Medical Education  LB Late-Breaking NIS New Investigator Scholarship NP Poster Session - Monday
Poster Sessions

501 IN SILICO PHARMACOKINETICS EVALUATION OF FORGIVENESS FOR DORAVIRINE & RILPIVIRINE
Yeleen Fromage, Najwa Jamal, Cyrielle Codde, Jean-François Faucher, Jean-Baptiste Woillard

502 SCREENING APPROACHES AND CLINICAL DESCRIPTION OF THE ANTICHOLINERGIC BURDEN IN PWH
Maria Mazzitelli, Mattia Trunfio, Alessandra Coin, Lolita Sasset, Jacopo Farina, Monica Brundu, Vincenzo Scaglione, Giuseppe Sergi, Anna Maria Cattelan

503 PHARMACOKINETICS & SAFETY OF SUSTAINED-RELEASE FLUCYTOSINE PELLET FORMULATION
Edrich Krantz, Francois Simon, Jean-Yves Gillon, Amaria Saayman, Anouk Neven, Stephen Robinson, Johanna Eriksson, Sarika Victor, Carol Ruffell, Aljosa Celebic, Henri Caplain, Mathieu Louis, Vishal Goyal, Isabela Ribeiro
Research Group: SFC-HIV-CRYPTO Consortium

504 POPULATION PK ANALYSIS TO GUIDE DOSING WINDOW FOLLOWING LENACAPAVIR SC ADMINISTRATION
Naveed A. Shaik, Francesco Bellanti, Craig Comisar, Martin S. Rhee, Sandhya Girish, Ramesh Palaparthi, Renu Singh

Poster Session-H3 ANTIRETROVIRAL THERAPY: OBSERVATIONS FROM COUNTRIES, CLINICS, AND PWH
2:30 PM - 4:00 PM

528 HIGH SUPPRESSION AMONG PLHIV ON DOLUTEGRAVIR WITH VIROLOGICAL FAILURE IN UGANDA
Grace Namayanja, Juliana de Fatuma Da Silva, Elur Bill, Pamela Nasiirumi Munina, Elliot Raizes, Julius Ssempira, Esther Nazziwa, Miriam Nabukunya, Jennifer Balaba, Ntale Jonathan, Jackie Calnan, Estella Birabwa, Juliet Akao, Christina Mwangi, Emilio Dilrikov

529 EARLY VIROLOGICAL OUTCOME OF DTG-BASED REGIMEN IN ADULT ARV-NAIVE PLHIV IN RWANDA
Simeon Tuyishime, Bienvenu Niyongabo, Michel Gasana, Madeleine M. Uwungutse, Damascene J. Nirene, Benjamin Bizimana, Gallican N. Rwibasira, Samuel Malamba

531 TRENDS IN TDR TO FIRST-LINE ANTIRETROVIRALS IN SPAIN: 2007-2021
Laura Viñuela, Adolfo de Salazar, Ana Fuentes, Adriana Pinto, José Antonio Iribarren, Mar Masía, Marta Montero, Iker Falces-Romero, Nuria Espinosa, Begoña Baza, Antonio Aguiler, Joaquim Peraire, Rebeca de Miguel, Federico García
Research Group: CoRIS group

532 WHAT INFLUENCES SWITCHING TO DTG/3TC VS B/F/TAF IN CLINICAL PRACTICE?
Paul Sax, Joseph J. Eron, Janna Radtchenko, Megan Dunbar, Joshua Gruber, Moshe Fridman, Moti Ramgopal, Karam Mounzer, Gregory Huhn, Steven Santiago, Richard A. Elion

533 ASSOCIATION OF WEIGHT GAIN ON DOLUTEGRAVIR WITH CHANGES IN ADHERENCE AND VIRAL LOAD
Matthew L. Romo, Ajay Parikh, Allahna L. Esber, Joseph S. Cavanaugh, Susannah Colt, Emma Duff, Trevor A. Crowell, Valentine Sing’o’ei, John Owuoth, Josaphat Maswai, Michael Iroejindu, Emmanuel Bahemana, Hannah Kibuuka, Neha Shah, Julie A. Ake

534 PREDICTIVE VALIDITY OF A MEASURE OF BARRIERS TO ART ADHERENCE FOR HIV CARE (I-SCORE)
Kim Engler, Serge Vicente, David Lessard, Karine Lacombe, Dominic Chu, Hayette Rougier, Lucas Delvallez, Jean-Pierre Routy, Alexandra De Pokomandy, Marina Klein, Bertrand Lebouché
535  US PATIENT PREFERENCES FOR LONG-ACTING HIV TREATMENT: A DISCRETE CHOICE EXPERIMENT
Susan M. Graham, Douglas Barthold, Brett Hauber, Aaron Brah, Enrique Saldarriaga, Ann C. Collier, Rodney Ho, Vincent C. Marconi, Jane Simoni
Research Group: Emory PREFER Team

536  ANTIRETROVIRAL THERAPY CONCEALMENT, ADHERENCE, AND PREFERENCES IN PEOPLE WITH HIV
Christina E. Parisi, Rebecca Fisk-Hoffman, Nanyangwe Siuluta, Delaney D. Ding, Maya Widmeyer, Charurut Somboonwit, Robert L. Cook
Research Group: Southern HIV and Alcohol Research Consortium

530  VIROLOGIC FAILURE AFTER ROUTINE SWITCHING TO DTG-BASED FIRST-LINE ART

---

Poster Session-H5 NEW AGENTS FOR TREATMENT OF SARS-CoV-2 AND RELATED VIRUSES 2:30 PM - 4:00 PM

542  ZINC ADJUVANT TREATMENT IN SARS-CoV-2: A RANDOMIZED CLINICAL TRIAL
Silvia Gómez-Zorrilla, Juan Du, Elena Sendra, Merce Espona, Ana Siverio, Alicia Rodríguez-Alarcon, Claudia Navarro-Valls, Oriol Rins-Lozano, Esperanza Cañas-Ruano, Itziar Arrieta-Aldea, Alejandro Fierro-Villegas, Cristina Plata, Natalia Garcia-Giral, Ruben Vicente, Robert Guerri-Fernandez

543  RETHINKING REMDESIVIR: ENHANCING ANTI-SARS-CoV-2 ACTIVITY OF ORAL LIPID RVn PRODRUGS
Aaron Carlin, James Beadle, Alex Clark, Kendra Gully, Fernando Moreira, Ralph Baric, Rachel Graham, Nadejda Valiaeva, Sandra Leibel, William Bray, Rachel McMillan, Xing-Quan Zhang, Joyce Murphy, Robert Schooley, Karl Hostetler

544  SARS-CoV-2 ANTIVIRAL ACTIVITY OF ZOTATIFIN, A HOST-TARGETING EIF4A INHIBITOR
Sam Sperry, Peggy Thompson, Craig Stumpf, Gary Chiang, Stephen Worland, Amy Patick

545  A PHASE 1B STUDY OF ZOTATIFIN FOR THE TREATMENT OF MILD TO MODERATE COVID (PROpel)
Harry Malech, Almena Free, Enola Okonkwo, Patricia Littel, Nicole Rooths, Priscilla Quackenbush, Martha Marquesen, Michael Hodges, Amy Patick, Sam Sperry, Bin Yao, Nawaid Rana, Doug Warner

546  WITHDRAWN

547  SMALL MOLECULE INHIBITOR FOR BLOCKING SARS-CoV-2 ENTRY
Enming Xing, Yuexiu Zhang, Rajni Kant Shukla, Jianrong Li, Valarmathy Murugaih, Xiaolin Cheng, Pui Kai Li, Amit Shama
Research Group: The Ohio State University

548  PLITIDEPSIN IS A BROAD-SPECTRUM ANTIVIRAL SHAPING THE CELL PROTEOSTATIC BALANCE
Daniel Perez-Zsolt, Elisa Molina Molina, Joan Josep Bech-Serra, Roger Badia, Eva Riveira-Munoz, Sachse Martin, Sandra Franco, Pablo Avilés, Miguel A. Martínez, Roger Paredes, Bonaventura Clotet, Cristina Risco, Ester Ballana, Carolina De la Torre, Nuria Izquierdo-Us eros
Research Group: Broad-Spectrum Antivirals Study Group
549  TARGETING THE HOST-VIRUS INTERFACE TO BLOCK SARS-CoV-2 ASSEMBLY IN AIRWAY CELLS
Li Du, Fred Deiter, Mohamed Bouzidi, Jean-Noël Billaud, Graham Simmons, Prerna Dabral, Suganya Selvarajah, Anuradha Lingappa, Maya Michon, Shaofeng Yu, Kumar Paulvannan, Vishwanath Lingappa, Homer Boushey, John Greenland, Satish K. Pillai

550  SAFETY AND PHARMACOKINETICS OF A NOVEL DOUBLE PRODRUG ASC10 IN HEALTHY SUBJECTS
Yunqing Qiu, Jian Liu, You Zhai, Qingwei Zhao, Yuemei Yan, Handan He, Jinzi J. Wu

551  MECHANISM AND RESISTANCE STUDIES OF SARS-CoV-2 MPRO INHIBITOR POMOTRELVIR (PBI-0451)
Xiao Tong, Laura Stevens, Walter Keung, Lee Arnold, Uri Lopatin, Mark Denison, Ann Kwong

552  SARS-CoV-2 E-PROTEIN VIROPORIN INHIBITOR BIT225 ACTIVE IN hACE2 TRANSGENIC MICE
Michelle Miller, Gary Ewart, Michael Bobardt, Bo Bentzen, Audrey Thomson, Klaus Klumpp, Stephen Becker, Mette Rosenkilde, Gallay Philippe

Poster Session-H6 CAN ANTIVIRAL AGENTS PREVENT SARS-CoV-2 TRANSMISSION?
2:30 PM - 4:00 PM

553  NAFAMOSTAT AS NASAL CHEMOPROPHYLAXIS FOR SARS-CoV-2 IN HAMSTERS
Megan Neary, Joanne Sharp, Eduardo Gallardo-Toledo, Joanne Herriott, Edyta Kijak, Chloe Bramwell, Helen Cox, Lee Tatham, Paul Curley, James Hobson, Steve Rannard, Anja Kipar, James Stewart, Andrew Owen
Research Group: CELT Pharmacology

554  PHASE 1 CLINICAL TRIALS OF A Q-GRIFFITHSIN NASAL SPRAY FOR SARS-CoV-2 PROPHYLAXIS

555  NIRMATRELVIR AND MOLNUPIRAVIR COADMINISTRATION MODIFIES PRECLINICAL VIRAL EXPOSURE
Lee Tatham, Henry Pertinez, Megan Neary, Joanne Sharp, Edyta Kijak, Joanne Herriott, Anthony Valentijn, Chloe Bramwell, Helen Cox, Paul Curley, Usman Arshad, Rajith Rajoli, Richard Pleass, James Stewart, Andrew Owen
Research Group: Drugs for Neglected Diseases initiative (DNDi) Study Group

Poster Session-I2 HIV RESISTANCE TO NEUTRALIZING ANTIBODIES
2:30 PM - 4:00 PM

580  SUSCEPTIBILITY SCREENING TO bNAbs GS-5423 AND GS-2872 IN ART-SUPPRESSED PARTICIPANTS
Lisa Selzer, Laurie A. Vanderveen, Aiyappa Parvangada, Ross Martin, Sean E. Collins, Megha L. Mehrotra, Christian Callebaut
**Poster Sessions CROI 2023**

**Poster Session-J5 STEATOSIS AND STEATOHEPATITIS**

**2:30 PM - 4:00 PM**

**581** **PHENOTYPIC SUSCEPTIBILITY TO VRC07-523LS AND ITS CORRELATES IN THE ACTG A5357 STUDY**


Research Group: AIDS Clinical Trials Group

**582** **HIGH PREDICTED bNAb RESISTANCE AMONG ADULTS WITH HIV-1 SEROCONVERSION IN BOTSWANA**


---

**Poster Session-J5 STEATOSIS AND STEATOHEPATITIS**

**609** **PREVALENCE AND FACTORS ASSOCIATED WITH NAFLD IN PEOPLE WITH HIV**

Louise E. van Eekeren, Marc J. T. Blaauw, Nadira Vadaq, Vasiliki Matzaraki, Wilhelm A. J. W. Vos, Albert L. Groenenfeld, Adriana Navas, Gert Weijers, Mike van Der Kolk, Andre J.A.M. van Der Ven, Quirijn De Mast, Leo Joosten, Eric Tjwa

Research Group: 2000HIV

**610** **LIVER STEATOSIS AND FIBROSIS IN WOMEN WITH HIV BY INTEGRASE INHIBITOR USE**


**611** **SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC-FATTY LIVER DISEASE**

Dana Kablawi, Thierry Fotsing Tadjo, Jovana Milic, Wesal Elgretli, Claudia Gioe, Bertrand Lebouché, Antonio Cacso, Giovanni Guaraldi, Giovanni Mazzola, Giada Sebastiani

**612** **NAFLD AND ITS COMBINATION WITH NASH PREDICT DM DEVELOPMENT IN PEOPLE WITH HIV**

Win Min Han, Tanakorn Apornpong, Jedsadakorn Bonrungsirisap, Thanathip Wichiangsan, Hay Mar Su Lwin, Sivapon Gatechompol, Sasiwimol Ubolyam, Stephen J. Kerr, Anchalee Avhingsan

**613** **AUTOMATED LIVER ATTENUATION ASSESSMENT FOR STEATOSIS IN CLINICAL IMAGES BY HIV STATUS**


Research Group: Veterans Aging Cohort Study

**614** **CONTROLLED ATTENUATION PARAMETER IS A VISCERAL ADIPOSITY MARKER IN HIV-RELATED NAFLD**

Wesal Elgretli, Nathalie Pârisable, Cecilia Costiniuk, Joseph Cox, Dana Kablawi, Marina Klein, Nadine Kronfli, Jean-Pierre Routy, Julian Falutz, Giovanni Guaraldi, Bertrand Lebouché, Giada Sebastiani
**Poster Session-K3 KAPOSISARCOMA AND KHSV-RELATED DISEASES: PATHOPHYSIOLOGY AND TREATMENT**

2:30 PM - 4:00 PM

630  **RATIONALE FOR THE USE OF PACRITINIB IN KSHV-MULTICENTRIC CASTLEMAN DISEASE**
Yiquan Wu, Victoria Wang, Robert Yarchoan

631  **IFN-IL18 AXIS CYTOKINES DISCERN MYCOBACTERIAL AND KHSV INFLAMMATORY SYNDROMES IN PWH**
Joseph Rocco, Ramya Ramaswami, Kathryn Lurain, Elizabeth Laidlaw, Andrea Lisco, Frances Galindo, Adam Rupert, Denise Whitby, Maura Manion, Robert Yarchoan, Irini Sereti

632  **STUDY OF CHARACTERISTICS AND OUTCOMES OF KSVH INFLAMMATORY CYTOKINE SYNDROME (KICS)**
Ramya Ramaswami, Kathryn Lurain, Mark Polizzotto, Anaïda Widell, Ralph Mangusan, Irene Ekwedro, Tishya Carey, Crystal Lu, Jomy George, Denise Whitby, Thomas Uldrick, Robert Yarchoan

633  **KAPOSISARCOMA IN ART-TREATED PWH: DISTINCT VIRAL AND IMMUNE CHARACTERISTICS**
Léna Royston, Stephane Isnard, Aude Jarry, Carolina Berini, Tsoarello Mabanga, John Lin, Valentín Leducq, Vincent Calvez, Anne-Geneviève Marcelin, Jean-Pierre Routy

**Poster Session-K4 CERVICAL CANCER: SCREENING AND TREATMENT**

2:30 PM - 4:00 PM

634  **IMPLICATIONS OF CERVICAL CANCER SCREENING AND TREATMENT PROGRAM ROLL OUT IN UGANDA**
Josephine C. Ninsiima, Julius Namonyo Kalama, Ibrahim Lutalo, Joseph Kabanda, Evelyn Akello, Alice Namale, Mina Ssali, Simon Muhumuza, Rhoda Wanyenze, Emilio Dirlikov, Sarah Alger

635  **INTEGRATING POINT-OF-CARE HPV TESTING INTO HIV CARE FOR KENYAN WOMEN LIVING WITH HIV**
James Kangethe, John Kinuthia, Kenneth Mutai, Jillian Pintye

636  **PROGRESS TOWARDS THE ELIMINATION OF CERVICAL CANCER AMONG WOMEN LIVING WITH HIV**
Laura J. McCormick Viens, Catherine Godfrey, Oluwatosin Adeoye, Ismail Ahmed, Fana Tefera, Michele Montandon, Elizabeth Carter, Michelle Chevalier, Daniel Magesa, Timothy A. Efuntayo, Emily Coard, Catherine Motswere Chiwa, Julius Namonyo Kalama, Jessica Setswalo Maf, Brigitte Zemburuka
HUMAN PAPILLOMA VIRUS INFECTION PREVALENCE AMONG WOMEN LIVING WITH HIV IN ETHIOPIA
Fana Tefera, Ismael Ahmed, Yared Tedla, Hiwot Berhanu, Daniel Atnafu, Agraw Abdulkadir, Addis Zewdie, Dessie Adugna, Takelech Moges, Daniel M. Desalegn, Hezkiel Petros

CORONARY ARTERY PLAQUE COMPOSITION AND SEVERITY RELATE TO THE INFLAMMASOME IN HIV

BURDEN OF CORONARY DISEASE IN TRANSGENDER WOMEN WITH AND WITHOUT HIV

MUSCLE QUALITY IS ASSOCIATED WITH CORONARY ARTERY PLAQUE & PHYSICAL FUNCTION IN PWH
Research Group: REPRIEVE Study Team

PERICORONARY ADIPOSE TISSUE DENSITY AND SUBCLINICAL CORONARY ARTERY DISEASE IN HIV
Borek Foldyna, Thomas Mayrhofer, Markella V. Zanni, Asya Lyass, Tricia H. Burdo, Kathleen V. Fitch, Carl J. Fichtenbaum, Judith A. Aberg, Udo Hoffmann, Heather J. Ribaudo, Joseph Massaro, Michael T. Lu, Pam S. Douglas, Steven K. Grinspoon
Research Group: REPRIEVE Study Team

SPATIAL PROFILING OF CORONARY PLAQUE SUGGESTS UNIQUE IMMUNE PATHWAYS IN HIV

HIGH PLASMA APOE IN PEOPLE WITH HIV COMPARED WITH UNINFECTED CONTROLS
Anne Marie Reimer Jensen, Ruth Frikke-Schmidt, Marco Gelpi, Thomas Lars Benfield, Børge G. Nordestgaard, Tor Biering-Sørensen, Susanne Dam Poulsen

PERFORMANCE OF LDL CHOLESTEROL POLYGENIC RISK SCORE IN INDIVIDUALS WITH HIV INFECTION
Roger S. Zou, Yunfeng Ruan, Bui Truong, Romit Bhattacharya, Michael T. Lu, Heather J. Ribaudo, Hilary C. Martin, David A. van Heel, Kathleen V. Fitch, Markella V. Zanni, Pam S. Douglas, Steven K. Grinspoon, Aniruddh P. Patel, Pradeep Natarajan
653  **CHOLESTEROL EFFLUX IS REDUCED IN ART TREATED PWH BUT ASSOCIATED WITH SUBCLINICAL CAD**  

**Poster Session-M4 BIOMARKERS OF MORBIDITY AND MORTALITY**  
**2:30 PM - 4:00 PM**

689  **ANY LEVEL OF DETECTABLE VIREMIA IS ASSOCIATED WITH SERIOUS NON-AIDS EVENTS**  
Anuradha Ganesan, Hsing-Chuan Hsieh, Xiuping Chu, Rhonda Colombo, Catherine Berjohn, Tahaniyat Lalani, Jason Blaylock, Karl Kronmann, Jason Okulicz, Brian Agan  
**Research Group:** Infectious Disease Clinical Research Program

690  **CD4/CD8 AT 2 YEARS OF ANTIRETROVIRAL THERAPY AND INCIDENCE OF SERIOUS NON-AIDS EVENTS**  
Javier Martínez-Sanz, Jorge Díaz-Álvarez, Marta Rosas, Raquel Ron, Cristina Roca-Oporto, Carmen Busca, Maria José Galindo, Miguel Cervero, Roberto Muga, Santiago Moreno, Sergio Serrano-Villar  
**Research Group:** CoRIS

691  **SOLUBLE IMMUNOREGULATORY PROTEINS PREDICTIVE FOR COMORBID EVENTS IN PEOPLE WITH HIV**  
Thomas Premeaux, Scott Bowler, Courtney Friday, Carlee Moser, Alan Landay, Sara Gianella, Lishomwa Ndhlovu  
**Research Group:** AIDS Clinical Trials Group NWCS 411 study team

692  **TELOMERE LENGTH IN AVIREMIC PWH: HOW DIFFERENT IS IT FROM PERSONS WITHOUT HIV?**  
Julen Cadiñanos, Javier Rodríguez-Centeno, Rocio Montejano, Andrés Esteban-Cantos, Beatriz Mena-Garay, María Jiménez-González, Gabriel Saiz-Medrano, Rosa de Miguel, Fernando Rodriguez-Artejufe, José Ignacio Bernardino, Cristina Marcelo-Calvo, Lucia Gutiérrez-García, Patricia Martínez-Martín, Berta Rodes, José R. Arribas, Mario Mayoral-Muñoz

693  **BLOOD TELOMERE LENGTH GAIN IN PLWH SWITCHING TO DTG+3TC VS CONTINUING TRIPLE REGIMEN**  
Francesca Lombardi, Alessia Sanfilippo, Massimiliano Fabbiani, Alberto Borghetti, Arturo Ciccullo, Iolanda Mozzetta, Enrica Tamburrini, Simona Di Giambenedetto

694  **COMPARISON OF TELOMERE LENGTH CHANGES OVER 48 WEEKS IN SALSA STUDY: DTG/3TC VS CAR**  
Mark Underwood, James Qyee, Joseph Horton, Tatini Chakraborty, Chris Parry, Ruolan Wang, Jue Lin, Myooran Sithamparanathan, Bryn Jones, Brian Wynne, Choy Man, Andrew Zolopa

695  **SEVERAL INSTI AFFECT IMMUNE CELL MITOCHONDRIA, PROLIFERATION, AND APOPTOSIS EX VIVO**  
Renyung Cai, Anthony Hsieh, Aya Zakaria, Helene C. F. Côté

**Poster Session-N1 PASC (LONG COVID)**  
**2:30 PM - 4:00 PM**

710  **INFLAMMATORY PROFILES ARE ASSOCIATED WITH LONG COVID 6 MONTHS AFTER ILLNESS ONSET**  
Elke Wynberg, Alvin X. Han, Lisa van Pul, Irma Maurer, Ester van Leeuwen, Anouk Verveen, Hugo van Willigen, Menno D. de Jong, Maria Prins, Neeltje Kootstra, Godelieve de Bree  
**Research Group:** The RECoVERED Study Group
711 CYTOKINE PROFILE IN DIFFERENT POST-COVID-19 CONDITION PHENOTYPES
Maria Nevot, Francisco Muñoz-López, Marina Martínez-Velasco, Macedonia Trigueros, Sergio España-Cueto, Gemma Ladós, Cora Loste, Cristina Lopez, Jose Ramon Santos, Ruth Toledo, Bonaventura Clotet, Roger Paredes, Lourdes Mateu, Marta Massanella

712 NEW ONSET AUTOIMMUNE DISEASE MORE COMMON AFTER COVID-19
Corrilynn O. Hileman, Nirav T. Patil, Grace A. McComsey

713 INCIDENT NEW ONSET DIABETES AFTER COVID-19 INFECTION: A NATIONAL MULTICENTER COHORT
Sokratis N. Zisis, Jared C. Durieux, Jamie A. Perez, Christian Mouchati, Mary Chong, Betul Hatipoglu, Grace A. McComsey

714 WORSE ARTERIAL STIFFNESS, AND NOT ENDOTHELIAL DYSFUNCTION, IS ASSOCIATED WITH PASC
Sokratis N. Zisis, Jared C. Durieux, Christian Mouchati, Mary Chong, Danielle Labbato, Grace A. McComsey

715 OLFACTORY PERFORMANCE IN POST MILD-TO-MODERATE ACUTE COVID-19 ACROSS 2 YEARS
Lucette Cysique, Faye Yang, Amy Regan, Valerie Bramah, Benjamin Heng, Sharron Chow, David Darley, Anthony Byrne, Anthony D. Kelleher, Gregory Dore, Gail Matthews, Gilles Guillemin, Bruce Brew

716 OLFACTORY FUNCTION AND BRAIN STRUCTURAL EFFECTS FOLLOWING SARS-CoV-2 INFECTION
Erin E. O’Connor, Nikita Rednam, Andrea Levine, Thomas Zeffiro, James Becker

717 SEX MODIFIES THE EFFECT OF COVID-19 AND PASC STATUS ON ARTERIAL STIFFNESS
Jared C. Durieux, Sokratis N. Zisis, Christian Mouchati, Mary Chong, Jamie C. Perez, Grace A. McComsey

718 INCIDENCE OF LONG COVID SYMPTOMS IN PATIENTS PREVIOUSLY HOSPITALIZED FOR COVID-19
Mark Berry, Amanda Kong, Julie Paone, Rohan Shah, Rebecca Taylor, Essy Mozaffari, Rikisha Gupta, Jason Goldman, Anand Chokkalingam

719 FACTORS ASSOCIATED WITH LONG COVID-19 IN ZAMBIA, 2020 TO 2022
Warren Malambo, Lily Besa, Duncan Chanda, Daniella Engamba, Linos Mwiinga, Mundia Mwitumwa, Jonas Hines, Sombo Fwoloshi

720 15-MONTH ATTRIBUTES OF POST-COVID SYNDROME IN THERAPEUTICALLY VACCINATED OUTPATIENTS
Max Augustin, Melanie Stecher, Hauke Wuestenberg, Veronica Di Cristanziano, Elisabeth Pracht, Dominic Rauschning, Henning Gruell, Florian Klein, Michael Hallek, Philipp Schommers, Clara Lehmann

721 POST-ACUTE COVID OUTCOMES: AMUBARVIMAB/ROMLUSEVIMAB VS PLACEBO IN THE ACTIV-2 TRIAL
722 SYMPTOMS AND BIOMARKERS OF LONG COVID IN PEOPLE LIVING WITH AND WITHOUT HIV
Annukka A R. Antar, Nuria Gallego Marquez, Armaan Jamal, Alisha Dziarski, Jia Fu, Samantha N. Walch, Arianna Romero, Artur T L Queiroz, Mariana Araújo-Pereira, Ashley Zelaya, Enam Akasreku, Bruno B. Andrade, Michael J. Peluso, Alan Landay

723 SEVERITY CLUSTERS AND LIKELIHOOD OF RECOVERY FROM POST-COVID-19 CONDITION
Lourdes Mateu, Christian Tebe, Cora Loste, Cristina López, Sergio España, José Ramón Santos, Gemma Lladós, María Nevot, Francisco Muñoz-López, Bonaventura Clotet, Roger Paredes, Marta Massanella

741 ADVERSE DRUG REACTIONS ON TB TREATMENT: A PREDICTION MODEL INCLUDING HIV AND HBA1C
Felipe Ridolfi, Lauren Peetluk, Gustavo Amorim, Mariana Araújo-Pereira, Marcelo Cordeiro-Santos, Afriano Kritski, Marina Figueiredo, Bruno B. Andrade, Valeria Rolla, Timothy R. Sterling
Research Group: Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil consortium

743 ISONIAZID TOXICITY AMONG PWH WITH LATENT TB WHO CONSUME ALCOHOL: A SINGLE ARM TRIAL
Judith A. Hahn, Christine Ngabirano, Robin Fatch, Nneka Emenyonu, Debbie M. Cheng, Julian Adong, Adah Tumwegamire, Karen Jacobson, Benjamin Linas, Kendall Bryant, Winnie Muyindiike

744 RISK FACTORS FOR ADRS RELATED TO IPT AMONG PLHIV ON DOLUTEGRAVIR-BASED ART IN UGANDA

742 PREDICTORS OF POOR OUTCOMES IN PATIENTS WITH TUBERCULOSIS SYMPTOMS AT HIV DIAGNOSIS

745 TREATMENT OUTCOMES OF PERSONS WITH DSTB ON A MEDICATION MONITOR AND ADHERENCE SUPPORT
Salome Charalambous, Noriah Maraba, Lauren Jennings, Kavindran Velen, Piotr Hippner, Israel Rabothata, Rachel Mukora, Stembridge Mpemba, Lihle McHunu, Dophina Cogill, Pren Naidoo, Catherine Orrell, Catherine Orrell, Katherine Fielding

746 HIGH MORTALITY IN HOSPITALISED VIRALLY SUPPRESSED ADULTS WITH HIV IN SOUTH AFRICA
Firdaus Nabeemeeah, Kennedy Otwombe, Khuthadzo Hlongwane, Nadia Sabet, Pattamukkil Abraham, Alex Van Blydenstein, Phetho Mangena, Ebrahim Variava, Neil Martinson
747  LONG-TERM OUTCOMES OF PNEUMOCYSTIS JIROVECCI PNEUMONIA IN THE ANTIRETROVIRAL ERA
Brian Epling, Maura Manion, Arlene Sirajuddin, Elizabeth Laidlaw, Frances Galindo, Megan Anderson, Anela Kellogg, Irini Sereti

748  RISK FACTORS ASSOCIATED WITH NEURO-COGNITIVE IMPAIRMENT IN CRYPTOCOCCAL MENINGITIS
Laura J. Nsangi, Mahsa Abassi, David B. Meya, David R. Boulware, Biyue Dai, Darlisha A. Williams, Kenneth Ssebambulidde, Lillian Tugume, Edwin Nuwagira, Abdu Musubire

749  CEREBROSPINAL FLUID PROTEIN CLINICAL IMPACT IN HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS

Research Group: ASTRO-cm group

Poster Session-P5 NOVEL UNDERSTANDINGS OF BIRTH OUTCOMES WITH ART
2:30 PM - 4:00 PM

787  ANGIogenic BIOMARKERS OF POOR OUTCOMES IN PREGNANT WOMEN WITH HIV IN BOTSWANA
Caroline E. Dunk, Kathleen M. Powis, Justine Legbedze, Shan Sun, Keoleboqile Mmasa, Samuel W. Kgole, Gosego Masasa, Sikhulile Moyo, Terence Mohammed, Lynn Yee, Mompati O. Mmalane, Joseph Makhema, Jennifer Jao, Lena Serghides

788  Dolutegravir Exposure and Congenital anomalies in Sub-Saharan Africa

Research Group: IeDEA Multiregional MANGO Collaboration

789  ALLOSTATIC LOAD AND SPONTANEOUS PRETERM BIRTH AMONG WOMEN WITH HIV IN LUSAKA, ZAMBIA
Joan T. Price, Yuri Sebastiao, Katelyn Rittenhouse, Humphrey Mwape, Bellington Vwalika, Mwansa Ketty Lubebya, Margaret Kasaro, Kristina De Paris, Jeffrey Stringer

790  NEUROtUBE AND OTHER BIRTH DEFECTS BY HIV STATUS AND ART REGIMEN IN ESWATINI
Michelle M. Gill, Philiwise Khumalo, Caspian Chouraya, Mthokozisi Kunene, Futhi Dlamini, Heather J. Hoffman, Angela E. Scheuerle, Bonisile Nhlabatsi, Wiseman Mngometulu, Lynne Mofenson

791  VAGINAL InFLAMMATORY MARKERS ASSOCIATED WITH PRETERM BIRTH IN ZAMBian WOMEN WITH HIV
Dominique Davis, Hazel Milla, Humphrey Mwabe, Yuri Sebastiao, Margaret Kasara, Bellington Vwalika, Joan T. Price, Kristina De Paris, Jeffrey Stringer

792  MATERNAL ART USE AND PRETERM DELIVERY: THE IMPACT OF DATA SOURCES AND DATA QUALITY
793  PREGNANCY HORMONAL DYSREGULATION CORRELATES WITH HIV-EXPOSED INFANT GROWTH OUTCOMES
Kathleen M. Powis, Caroline E. Dunk, Keolebogile Mmasa, Gosego Masasa, Samuel W. Kgole, Justine Legbedze, Shan Sun, Sihkullie Moyo, Nyaladze C. Maphorisa, Terence Mohammed, Mompati O. Mmalane, Joseph Makhema, Jennifer Jao, Lena Serghides

Poster Session-Q1 OUTCOMES OF HIV-EXPOSED UNINFECTED CHILDREN
2:30 PM - 4:00 PM

797  HIV-EXPOSED UNINFECTED (HEU) INFANTS DISPLAY UNIQUE PRO-INFLAMMATORY BIOPROFILES
Li Yin, Bernard Fischer, Guglielmo Venturi, Upasana Nepal, Shivangi Choudhary, Jerry Shen, Kai-Feng Chang, Isaac Raplee, Samiksha Borkar, Julie Kim-Chang, Kristina De Paris, Maureen Goodenow, John Sleasman

798  NO EVIDENCE OF PERTURBATIONS OF THE BREAST MILK MICROBIOME BY ANTIRETROVIRAL THERAPY
Nicolette H. Tobin, Fan Li, Sean Brummel, Patricia Flynn, Sufia Dadabhai, Dhayendre Moodley, Lameck Chinula, Mandisa Nyati, Mary Glenn Fowler, Grace Aldrovandi

Research Group: 1077BF/1077FF PROMISE (Promoting Maternal and Infant Survival Everywhere) Team

799  NO EVIDENCE OF PERTURBATIONS OF THE BREAST MILK MICROBIOME BY ANTIRETROVIRAL THERAPY

Research Group: 1077BF/1077FF PROMISE (Promoting Maternal and Infant Survival Everywhere) Team

800  RBC FOLATE CONCENTRATIONS IN MOTHERS/INFANTS RANDOMIZED IN PREGNANCY: DTG VS EFV
Denise L. Jacobson, Krista Crider, Patricia Demarrais, Sean Brummel, Mindy Zhang, Christine Pfeiffer, Cynthia Moore, Katie McCarthy, Sihkullie Moyo, Tichaona Vhembo, Enid Kabugho, Gerald Muzorah Agaba, Nahida Chakhtoura, Lameck Chinula, Shashiin Lockman

801  EFFECT OF IN-UTERO HIV AND ANTIRETROVIRAL THERAPY EXPOSURE ON GROWTH DURING INFANCY
Ashenafi S. Cherko, Sylvia M. Lacourse, John Kinuthia, Jerphason Mecha, Daniel A. Enquobahrie, Jaclyn Escudero, Grace John-Stewart

802  IPT DURING INFANCY HAS NO ADVERSE EFFECT ON GROWTH AMONG HEU CHILDREN
Ashenafi S. Cherko, Sylvia M. Lacourse, Daniel A. Enquobahrie, Jaclyn Escudero, Jerphason Mecha, Daniel Matemo, John Kinuthia, Grace John-Stewart

803  IMPACT OF IN-UTERO EXPOSURE TO HIV AND LATENT TB ON INFANT HUMORAL RESPONSES
Kimberly Shankwitz, Lesley de Armas, Grace Montepiedra, Suresh Pallikkuth, Lynda Stranix-Chibanda, Gaerolwe Masheto, Philippa Musoke, Enid Kabugho, Jyoti Mathad, Renee Browning, Rajendra Pahwa, Galit Alter, Adriana Weinberg, Amita Gupta, Savita Pahwa

Research Group: for the IMPAACT P1078/TB APPRISE Study Team

804  LOWER ACADEMIC PERFORMANCE AMONG CHILDREN WITH PERINATAL HIV EXPOSURE IN BOTSWANA
Kathleen M. Powis, Lesedi Lebanna, Sara Schenkel, Gosego Masasa, Samuel W. Kgole, Martha Ngwaca, Paige L. Williams, Amy L. Slogrove, Roger L. Shapiro, Shahin Lockman, Mompati O. Mmalane, Joseph Makhema, Jennifer Jao, Adam R. Cassidy

805  PSYCHIATRIC DISORDERS IN HIV-EXPOSED UNINFECTED VS NON-HIV-EXPOSED CHILDREN
Ellen Moseholm, Sammy Ameri, Merete Storgaard, Gitte Pedersen, Isik S. Johansen, Terese L. Katzenstein, Nina Weis
805 EVALUATING ASSOCIATIONS BETWEEN IN UTERO HIV/ART EXPOSURE AND PUBERTAL STATUS
Lena Serghides, Denise L. Jacobson, Jessica Lee, Mitchell E. Geffner, Elizabeth J. McFarland, Linda Dimeglio, Kathleen M. Powis, Paige L. Williams, Jennifer Jao
Research Group: Pediatric HIV/AIDS Cohort Study

Poster Session-Q5 ARVs AND bNAbS FOR CHILDREN AND ADOLESCENTS
2:30 PM - 4:00 PM

826 PK & SAFETY OF ABC/3TC DISPERSIBLE TABLETS & LPV/r GRANULES IN NEONATES: PETITE STUDY
Adrie Bekker, Helena Rabie, Nicolas Salvadori, Samantha Du Toit, Kanchana Than-In-At, Maria Groenewald, Edmund Capparelli, Ratchada Cressey, Marc Lallemant, Mark Cotton, Tim R. Cressey
Research Group: PETITE Study Team

827 TWICE DAILY 50 MG DOLUTEGRAVIR IN TUBERCULOSIS–HIV COINFECTED CHILDREN 20–35 KG
Anushka Naïdoo, Kogieulem Naïdoo, Gabriella Crohmout, Marothi Letsoalo, Mounier Almett, Roeland E. Wasmann, Paolo Denti, Lubbe Wiesner, Kelly E. Dooley, Moherdran Archary

828 CAREGIVERS OF CHILDREN WITH HIV IN BOTSWANA PREFER MONTHLY IV bNABs TO DAILY ORAL ART
Maureen Mosethi, Gbolahan Ajibola, Roxanna Haghighat, Oganne Batlang, Kenneth Maswabi, Molly Pretorius Rolme, Kathleen M. Powis, Shahin Lockman, Joseph Makhema, Mathias Lichterfeld, Daniel Kuritzkes, Roger L. Shapiro

829 SIX-MONTH OUTCOME OF F/TAF COBICISTAT-BOOSTED DARUNAVIR IN CHILDREN 14 TO < 25 KG
Hilda A. Mujuru, Renate Strehlau, Natella Rakhmanina, Kulkanya Chokephaibulkit, Pope Kosalaraaka, Vinicius Vieira, Kathryn Kersey, Rory Leisengang, Shaolan Xiang

830 BIC/FTC/TAF IN FRENCH CHILDREN: FREQUENT VIRAL FAILURE BUT RARE ACQUIRED RESISTANCE
Pierre Frange, Florence Veber, Stephane Blanche, Veronique Avettand-Fenoel

831 ADEQUATE DTG EXPOSURE IN INFANTS ON RIFAMPICIN TREATMENT RECEIVING TWICE-DAILY DTG
Tom G. Jacobs, Vivian Mumbiro, Uneisse Cassia, Damalie Nalwanga, Kevin Zimba, Sara Dominguez, Constantine Mutata, W. Chris Buck, Chishala Chabala, Victor Musiime, Mutsa Bwakura-Dangarembizi, Cinta Moraleda, David Burger, Pablo Rojo, Angela Colbers, Hilda A. Mujuru
Research Group: EMPIRICAL clinical trial group

832 MODEL-INFORMED DOLUTEGRAVIR DOSE SELECTION IN PEDS WITH 1ST GENERATION INSTI-R
Hardik Chandasana, Ann Buchanan, Michael McKenna, Cindy Vavro, Linda Lewis, Mary Paul, Ana Puga, Lionel Tan, Cindy Brothers, Theodore Ruel

833 IMPACT OF MALNUTRITION ON DOLUTEGRAVIR EXPOSURE AND ALTERNATIVE DOSING
Alexander J. Floren, Belen Perez Solans, Kendra K. Radtke, Rada Savic
843 STUDY ON THE FREQUENCY OF DUAL INFECTIONS IN NEW HIV-1 DIAGNOSES IN SPAIN
Ana Donoso, Javier Enrique Cañada-García, Elena Delgado, Sara Monzón, Horacio Gil, Maria Moreno-Lorenzo, Mónica Sánchez, Isabel Cuesta, Ángel Zaballos, Pilar Jiménez, Michael M. Thomson
Research Group: the Spanish Group for the Study of New HIV Diagnoses

844 EPIDEMIOLOGICAL AND MOLECULAR EVOLUTION OF THE HIV-1 CRF94: BIRTH OF CRF132
Marc Wirden, Fabienne De Oliveira, Marie-Laure Chaix, Stephanie Marque Juillet, Sidonie Lambert-Niclot, Basma Abdi, Benedicte Roquebert, Charlotte Charpentier, Jean-Christophe Plantier, Diane Descamps, Vincent Calvez, Anne-Geneviève Marcelin, Benoit Visseaux
Research Group: ANRS-MIE AC43 Medical Virology Network

845 ACCURACY OF MOLECULAR EPIDEMIOLOGICAL INFERENCES IN A SIMULATED EPIDEMIC
Fabricia Naciemento, Sanjay Mehta, Susan R. Little, Erik Volz

846 PRESENCE OF CXCR4-USING HIV-1 VIRUS IN NEWLY DIAGNOSED INDIVIDUALS IN NORTH CAROLINA
Shuntai Zhou, Nathan Long, Matt Moeser, Erika Samoff, Scott Shone, Collin Hill, Michael Clark, Ronald Swanstrom, Ann Dennis
Poster Session-R2 RECENT HIV INFECTIONS

2:30 PM - 4:00 PM

847 HOTSPOTS OF RECENT HIV INFECTIONS AMONG ADULT PEOPLE LIVING WITH HIV IN NIGERIA
Amobi A. Onovo, Pamela Gado, Angela Agweye, Abiyel Kalaiwo, Ughweroghone Omo-Emmanuel, Konrad Bradley, Kristina Bishop, Helina Meri, Rachel Goldstein

848 PROGRAMMATIC IMPLICATIONS OF NATIONAL RECENT HIV INFECTION SURVEILLANCE IN CAMBODIA
Vichea Ouk, Sovannarith Samreth, Bora Ngauw, Bunthoeun Eng, Rommel Bain, Chhaily Hy, Alexandra Ernst, George W. Rutherford, Chunfu Yang, Vanthy Ly, Amitabh B. Suthar, Rachel Albalak

849 AN ANALYSIS OF HIV RECENT INFECTION SURVEILLANCE DATA AMONG YOUNG PEOPLE IN MALAWI

850 HIV RECENT INFECTION IN SEXUAL AND GENDER MINORITIES IN BRAZIL AND PERU: ImPrEP STUDY
Thiago S. Torres, Sylvia L. M. Teixeira, Brenda Hoagland, Kelika A. Konda, Monica Derrico, Juan V. Guanira, Marcos Benedetti, Sandro Nazer, Silver K. Vargas, Cristina Pimenta, Beatriz Grinsztejn, Celia Landmann Szwarcwald, Carlos Caceres, Valdilea Veloso

Research Group: ImPrEP Seroincidence Study Group

851 HIV TIME-SPACE ALERTS AMONG PWID AND MSM IN THE UNITED STATES, 2018-2021
Camden J. Hallmark, Laurie Linley, Agha Ajmal, Olivia O. Russell, Mary Plaster, Sheryl B. Lyss, Nivedha Fanneer, Rashida Hassan, Anne Marie France, Alexandra M. Oster

Poster Session-R3 HIV INFECTION CLUSTERS

2:30 PM - 4:00 PM

852 EVOLUTION OF CLUSTERS TRANSMISSION PATTERNS IN FRANCE DURING THE LAST DECADE
Benoit Visseaux, Mathilde Roussel, Stéphanie Teixeira, Eric Hedbaut, Laura Verdurme, Sabine Trombert, Stéphanie Haim-Boukobza, Benedicte Roquebert

853 BEYOND FAST-TRACK CITIES: DYNAMIC OF HIV CLUSTERS IN A FRENCH REGION NEAR PARIS
Nived Collercandy, Antoine Chaillon, Marc-Florent Tassi, Leslie Grammatico-Guillon, Emeline Laurent, Laurent Hocqueloux, Jerome Guinard, Clémence Guillaumé, Adrien Lemaignen, Guillaume Gras, Karl Stefic

854 NOT ALL CLUSTERS ARE EQUAL: STATEWIDE MOLECULAR HIV CLUSTER DYNAMICS IN RHODE ISLAND
Vlad Novitsky, Jon A. Steingrimsson, Mark Howison, Casey Dunn, Fizza Gillani, John Fulton, Thomas Bertrand, Katharine Howe, Lila Bhattrai, Guillermo Ronquillo, Meghan MacAskill, Utpala Bandy, Joseph W. Hogan, Rami Kantor

855 HIV SEQUENCING AT DIAGNOSIS ENHANCES DETECTION OF CLUSTERS AND POTENTIAL CARE GAPS
Poster Session-R6 HIV MORTALITY
2:30 PM - 4:00 PM

870  TRENDS IN MORTALITY IN PEOPLE LIVING WITH HIV IN AN INTERNATIONAL COHORT (RESPOND)
Erich Tusch
Research Group: The RESPOND Study Group

871  NON-AIDS DEFINING MALIGNANCY MORTALITY IN PEOPLE LIVING WITH HIV
Marta Rava, Félix Gutierrez, José A. Pérez-Molina, Inés Suarez-García, Francisco J. Vera Méndez, Fernando Baigorria Feltrin, Mar Masiá, Juan Macias, Gemma Navarro, Santiago Moreno, Immaculada Jarrín
Research Group: Cohorte de la Red de Investigación en Sida (CoRIS)

872  PROPORTION OF DEATHS OCCURRING OUTSIDE OF HEALTH FACILITIES ATTRIBUTABLE TO HIV/AIDS
Newton L. Kalata, Alinune N. Kabaghe, George Mtonga, Emmanuel Mkambankhani, Masauso Musa, Amos Nyaka, Kondwani Nikanaunena, Verita Buie, Ramesh Sethi, Rodrick Langwe, Kelsey Mirkovic, Nellie Wandonda-Kabondo

873  MEASURING EXCESS MORTALITY ASSOCIATED WITH HIV: ESTIMATES FROM THE PHIA PROJECT
Shannon M. Farley, Giles Reid, Katharine Yuengling, Connor Wright, George Bello, James M. Juma, Stephane Helleringer, Jessica Justman

874  ONE-YEAR MORTALITY OF PEOPLE WITH HIV AFTER INTENSIVE CARE UNIT ADMISSION
Nicholas Bakewell, Caroline Sabin, Tanmay Kanitkar, Maggie Symonds, Oshani Dissanayake, Stephanie Rimmer, Amit Adlakha, Marc Lipman, Sanjay Bhagani, Banware Agarwal, Robert Miller

875  REGISTRY LINKAGE IMPROVES SURVIVAL ESTIMATION AMONG PEOPLE WITH HIV IN LATIN AMERICA
Research Group: Caribbean, Central and South America network for HIV epidemiology (CCASAnet)

Poster Session-S1 COVID-19 CHARACTERISTICS AND OUTCOMES
2:30 PM - 4:00 PM

884  12-MONTH CONSEQUENCES IN PEOPLE WITH HIV/SARS-CoV-2 COINFECTION: NATIONAL EHR COHORT
Yuanzhen Yue, Chen Liang, Sharon Weissman, Tianchu Lyu, Bankole Olatosi, Xiaoming Li
Research Group: National COVID Cohort Collaborative Consortium
885  TRENDS IN COVID-19 ADMISSIONS AND DEATHS AMONG PEOPLE WITH HIV IN SOUTH AFRICA
Waasila Jassat, Lovelyn Ozougwu, Caroline Mudara, Richard Welch, Tracy Arendse, Maureen Masha, Lucille Blumberg, Tendesayi Kufa, Adrian Puren, Michelle Groome, Pedro Pisa, Ian Sanne, Heena Brahmbhatt, Lauren Parmley, Cheryl Cohen, Sharlene Govender, Pappie Majuba, Petro Rousseau, Milani Wolmarans
Research Group: DATCOV author group

886  A MULTICENTER STUDY OF COVID-19 INFECTION IN PEDIATRIC INTENSIVE CARE UNITS IN THE US
German A. Contreras, Gabriela Delbianco, Michael Chang, Gilhen Rodriguez, Elizabeth Aguiller, James Murphy, Gloria Heresi

887  IDENTIFICATION OF CLINICAL FEATURES ASSOCIATED WITH SARS-CoV-2 REINFECTIONS
Francisco Muñoz-López, Antoni E. Bordoy, Ignacio Blanco, Elisa Matró, Pere-Joan Cardona, Roger Paredes, Bonaventura Cotet, Marc Noguera Julian, José Ramón Santos, Marta Massanella, Lourdes Mateu, Cristina Casañ, Ana Blanco-Suárez
Research Group: Translational Research in Immunology and Ageing (TRIA)

888  ANEMIA AS A PREDICTOR OF POOR CLINICAL OUTCOME IN PATIENTS ADMITTED FOR COVID-19
Francesco Di Gennaro, Francesco Vladimiro Segala, Luca Carruba, Anna La Carrubba, Diletta Agnello, Davide Fiore Bavaro, Mario Barbagallo, Nicola Veronese, Annalisa Saracino

889  CLINICAL OUTCOMES BY SARS-CoV-2 VARIANT AT A SINGLE ACADEMIC MEDICAL CENTER
Pankaja Desai, Juan Rojas, Yi-Shuan Chen, Susan Gawel, Hannah Barbarian, Anthony Orzechowski, Gavin Cloyd, Alan Landay

890  EXCESS OF MORTALITY IN OLDER PEOPLE DURING THE COVID-19 PANDEMIC IN MOZAMBIQUE
Inacio Mandomando, Richard Sheppard, Arsenia Massinga, Rita Ernesto, Auria de Jesus, Augusto Messa Jr, Ariel Nhacolo, Arsenio Nhacolo, Charfudin Sacoor, Patrick Walker, Alfredo Mayor

Poster Session-S2 IMPACT OF COVID-19 ON HIV AND MALARIA SERVICES AND OUTCOMES
2:30 PM - 4:00 PM

891  HIV VIRAL LOAD SUPPRESSION AND RACIAL DISPARITIES DURING THE COVID-19 PANDEMIC IN NYC
Emma Tucker, Harry Reyes Nieva, Kayla Schiffer, Lindsay Grant, Michael T. Yin, Delivette Castor, Peter Gordon, Noémie Elhadad, Jason Zucker

892  HIV AND CHRONIC COMORBIDITIES: MEDICATION ADHERENCE AND CLINICAL ENDPOINT COVARIATION
Michael J. Miller, Celeena R. Jefferson, Lindsay G. Eberhart, Michael A. Horberg

893  HIGH PANDEMIC-RELATED MORTALITY AMONGST PEOPLE WITH HIV IN SASKATCHEWAN, CANADA
Kirsten Hall, Molly Trecker, Sarah Craddock, Raynell Lang, Danielle Myrah, Kumudhini Karunakaran, Lanre Medu, Alexander Wong

894  IMPACT OF THE COVID-19 PANDEMIC ON MALARIA SERVICES IN UGANDA: A TIME SERIES ANALYSIS
Francesco Di Gennaro, Francesco Vladimiro Segala, Jerry Ictho, Mariangela L'Episcopia, Emmanuel Onapa, Davide Fiore Bavaro, Samuel Okori, Giovanni Dall'Oglio, Giovanni Putoto, Carlo Severini, Peter Lochoro, Annalisa Saracino
928 WITHDRAWN

929 HIGH PERFORMANCE OF BLOOD-BASED HIV SELF-TESTS AT PRIVATE PHARMACIES IN KENYA
Katrina F. Ortblad, Benn Kwach, Shengruo Zhang, Magdaline Asewe, Kendall Harkey, Rachel Malen, Josephine Odoyo, Daniel Were, Kenneth Ngure, Victor Omollo, Elizabeth A. Bukusi

930 REMOVAL OF A SUBSIDY FOR HIV SELF-TESTING KITS REDUCES ONLINE KIT SALES IN KENYA
Obinna I. Ekwunife, Carlos Culquichicon, Maeve Rafferty, Paulami Naik, Nicky Nyamasyo, Tony Wood, Daniel Were, Kenneth Ngure, Melissa Mugambi, Annie Haakenstand, Katrina F. Ortblad

931 VIRTUAL SUPPORT IMPROVES CLIENT EXPERIENCES WITH AN ONLINE HIV SELF-TESTING SERVICE

932 PEOPLE WHO INJECT DRUGS’ WILLINGNESS TO USE AND DELIVER HIV SELF-TEST KITS TO PEERS
Heather A. Pines, William H. Eger, Britt Skaathun, Claire C. Bristow, Carlos F. Vera, Alicia Harvey-Vera, Steffanie A. Strathdee, Irina Artamonova, Angela R. Bazzi

933 OVERCOMING ACCESS BARRIERS TO VIRAL SUPPRESSION TESTING BY SELF-MICROCOLLECTED BLOOD
Poster Session-U1 MPOX TESTING

2:30 PM - 4:00 PM

948 CLINICAL DIAGNOSIS IS HIGHLY PREDICTIVE OF LAB-CONFIRMED MPOX IN A SEXUAL HEALTH CLINIC
Chase Cannon, Ellora Karmarkar, Meena Ramchandani, Julia C. Dombrowski, Matthew Golden

949 WITHDRAWN

950 MPOX TESTING AMONG MEN WHO HAVE SEX WITH MEN WHO REPORTED RECENT HIV OR STI TESTING
Yasmin Ogale, Alison Ridpath, Travis H. Sanchez, Marissa Hannah, Kevin Delaney, Stefan Baral, Patrick S. Sullivan, Thomas Carpino, Kaitlyn Atkins, Eboni Galloway, Bruce Furness, Laura H. Bachmann, Winston Abara

951 FACTORS ASSOCIATED WITH MPOX SYMPTOMS AND TESTING AMONG MSM IN THE US, AUGUST 2022

952 UTILITY OF A VIRAL VESICULAR PANEL MULTIPLEX PCR ASSAY FOR THE DIAGNOSIS OF MPOX
Eli Wilber, Paulina A. Rebolloedo, Vyjayanti Kasinathan, Stephanie Merritt, Boghuma K. Titanji, Bruce Aldred, Sheetal Kandiah, Susan Ray, Anandi N. Sheth, Jonathan Colasanti, Yun Wang

953 MPOX VIRAL LOAD BY SPECIMEN TYPE AND DIAGNOSTIC TESTING IN A CLINICAL LABORATORY
Nancy Matic, Matthew Young, Gordon Ritchie, Christopher F. Lowe, Marc G. Romney

954 MPOX VIRUS (MPXV) OUTBREAK IN BERLIN: IMPLEMENTATION OF MOLECULAR DIAGNOSTICS
Martin J. Obermeier, Ivanka Krznaric, Stefan Breuer, Kudor Harb, Robert Ehret

955 PERFORMANCE OF A DUAL TARGET MPOX VIRUS REAL-TIME PCR ASSAY
Ron M. Kagan, Susan E. Realegeno, Gwynngelle A. Borillo, Amy A. Rogers, Taekkyun Kim, Lamela Umaru, Clemente I. Montero, Hollis J. Batterman, Elizabeth M. Marlowe

Poster Session-V1 COST EFFECTIVENESS OF PEP AND PrEP

2:30 PM - 4:00 PM

967 COST-EFFECTIVENESS OF THE DUAL PREVENTION PILL FOR CONTRACEPTION AND HIV PROPHYLAXIS
Masabho Milali, David Kafant, Ingrida Platais, Hae-Young Kim, Danielle Resar, Danny Edwards, Jenny Campbell, Sarah Jenkins, Anna Bershteyn

968 POTENTIAL IMPACT & COST-EFFECTIVENESS OF WIDELY ACCESSIBLE TLD IN SUB-SAHARAN AFRICA
Andrew Phillips, Loveleen Bans-Matharu, Maryam Shahmanesh, James Hargreaves, Paul Revill, Euphemia Sibanda, Jens Lundgren, Catherine Godfrey, Frances M. Cowan, Valentina Cambiano
Research Group: The HIV Modelling Consortium
**Poster Sessions - Monday**

**Poster Session-V2 PrEP and PEP: Adherence Measures and STIs**

**970** RANDOMIZED EVALUATION OF THE IMPACT OF STI POINT-OF-CARE TESTING ON PrEP INITIATION

Alex de Voux, Miriam Silliman, Rufaro Mvududu, Nyiko Mashele, Landon Myer, Dvora Joseph Davey

**971** SEXUAL BEHAVIOR AND STI INCIDENCE DURING THE FIRST 4 YEARS OF PrEP USE AMONG MSM

Mark van den Elshout, Eline Wijstma, Vita Jongen, Liza Coyer, Anders Boyd, Udi Davidovich, Henry de Vries, Maria Prins, Maarten Schim Van Der Loeff, Elske Hoornenborg

Research Group: Amsterdam PrEP Project team in the HIV Transmission Elimination Amsterdam (H-TEAM) Initiative

**972** PEP-IN-POCKET (PIP): LONG-TERM FOLLOW-UP OF ON DEMAND HIV POST-EXPOSURE PROPHYLAXIS

Maxime J. Billick, Karla N. Fisher, Samantha Myers, Darrell H. S. Tan, Isaac I. Bogoch

**973** ACCEPTABILITY AND FEASIBILITY OF A NEW URINE-BASED TENOFOVIR ADHERENCE TEST IN KENYA

Kenneth Ngure, Phelix Okello, Vallery Ogello, Peter Mogere, Stephen Gakuo, Deepalika Chakravarty, Charlene Biwott, Purba Chatterjee, Jennifer Velloza, Nelly Mugo, Monica Gandhi

**974** WITHDRAWN

**Poster Session-W1 MPOX Prevention**

**1000** DISPARITIES IN MPOX VACCINATION UPTAKE IN SAN FRANCISCO AMONG PLWH AND PEOPLE ON PrEP

Elise S. Mara, Ling Hsu, Julia Janssen, Melissa Ongpin, Michelle Kirian, Melissa A. Sanchez, Stephanie Cohen

**1001** ESTABLISHING AN OBSERVATIONAL MPOX VACCINATION STUDY WHILE THE OUTBREAK EVOLVES

Angelica C. Kottkamp, Marie Samanovic, Ellie Carmody, Lalitha Parameswaran, Heekoung Allison Youn, Olivia Frank, Stephanie Retting, Lisa Zhao, Julia Wagner, Celia Engelson, Miguel Rodriguez, Trishala Karmacharya, Jane R. Zucker, Jennifer B. Rosen, Mark J. Mulligan, Aaron Oom

Research Group: NYC OSMI Study Group
1002 EVALUATING THE USE OF DOSE-SPARING VACCINATION STRATEGIES FOR MPXV
Dobromir Dimitrov, Blythe Adamson, Laura Matrajt

1003 IDENTIFYING DISPARITIES IN MPXV VACCINATION IN A SOUTHEASTERN ACADEMIC HIV CLINIC
Edwin Wilbur, Woodhouse, Ahmad Mourad, Emily Niehaus, Hayley Cunningham, Naseem Alavian, Sofia Zavala, Patricia Kohler, Steven Pappas, Michael Yarrington, Nwora Lance Okeke, Cameron R. Wolfe, Gary Cox, Kristen V. Dicks, Jason E. Stout

1004 MPXV AWARENESS, RISK REDUCTION, AND VACCINE ACCEPTANCE AMONG PWH IN WASHINGTON, DC
Amanda D. Castel, Elisabeth Andersen, Anne Monroe, Jose Lucar, Rachel Lee, Debra Benator, Alan Greenberg
Research Group: The DC Cohort Executive Committee

Poster Session-X1 SPECIAL TOPICS IN SRH AND HIV
2:30 PM - 4:00 PM

1021 COMPARISON BETWEEN HIV+ WOMEN TRANSITIONING THROUGH MENOPAUSE AND MEN OF SIMILAR AG
Hachfeld Anna, Andrew Atkinson, Catrina Mugglin, Petra Stute, Alexandra Calmy, Philip Tarr, Katherine Darling, Baharak Babouee-Flury, Christian Polli, Leila Sultan-Beyer, Irene Abela, Chloé Pasin, Andri Rauch, Karoline Aebi-Popp
Research Group: Swiss HIV Cohort Study (SHCS)

1022 DISTINCT EFFECT OF SEX HORMONE INTAKE ON IMMUNITY IN CIS AND TRANS WOMEN WITH HIV
Chloé Pasin, David García Nuñez, Katharina Kusejko, Hachfeld Anna, Karoline Aebi-Popp, Hélène Buvélot, Matthias Cavassini, Lauro Damonti, Christoph Fux, Begoña Martinez de Tejada, Julia Notter, Alexandra Trkola, Huldrych F. F. Günthard, Roger D. Kouyos, Irene A. Abela
Research Group: Swiss HIV Cohort Study

1023 ACCEPTABILITY OF EMERGENCY CONTRACEPTION IN ACTG A5375
Elizabeth Barr, Laura Smeaton, Maxine Olesky, Susan E. Cohn, Rosie Mngqibisa, Kimberly K. Scarsi, Catherine Godfrey
Research Group: A5375 Protocol Team

1024 THE EFFECT OF FP EDUCATION ON KNOWLEDGE AND USE OF FP IN UGANDAN FISHING COMMUNITIES

Poster Session-Y01 ACCESS TO ART
2:30 PM - 4:00 PM

1036 WITHDRAWN

1037 INEQUITIES IN TRAVEL-TIME TO HIV TREATMENT IN AFRICA: A 3-COUNTRY COMPARISON
Justin T. Okano, Andrea Low, Luckson Dullie, Wongani Mzumara, Sally Blower
1038 EVALUATION OF MEDICAL DRONES FOR ANTIRETROVIRAL DELIVERY IN AN ISLAND POPULATION
Rosalind Parkes-Ratanshi, Patrick Mr. Ssesaazi, Agnes Bwanika Naggirinya, Jackie Lydia N. Ssemata, Johan Akullo, Dickson Masoni, Agnes Kiragga, Therese Pattery, Robert Kimbui, Andrew Kambugu, Tom Kakaire

Poster Session-YO2 MODELS TO ACHIEVE VIRAL LOAD SUPPRESSION
2:30 PM - 4:00 PM

1038.5 A LOW-COST, RAPID URINE TEST FOR TFV INCREASES ART ADHERENCE AND VIRAL SUPPRESSION
Leonard Bikinesi, Matthew A. Spinelli, Ntombizodwa Nyoni, Jesaya Hifindwako, Assegid Mengistu, Jacques Kamangu, Gram Mutandi, Daniella Mouton, Fekir Negussie, Guohong Wang, Rachel Suzanne Beard, Monica Gandhi, Steven Y. Hong

1039 DOES TYPE OF PICK-UP POINT INFLUENCE 12-MONTH VIROLOGIC SUPPRESSION IN SOUTH AFRICA?
Ingrid Bassett, Joyce Yan, Sabina Govere, Anele Khumalo, Zinhle Shazi, Milpionhle Nzuza, Taing N. Aung, Danielle Zions, Nduduzo Dube, Laura Bogart, Robert Parker

1040 AN ADAPTIVE INTERVENTION TRIAL TO SUPPORT VIRAL SUPPRESSION AMONG FEMALE SEX WORKERS
Sheree Schwartz, Carly Comins, Mfezi McNgana, Syianda Makama, Lillian Shipp, Ntambule Mulumba, Rene Phetlhu, Vijay Guddera, Katherine Young, Pravi Moodley, Kerusha Govender, Harry P. Hauser, Stefan Baral
Research Group: Siyaphambili study team

1041 TRENDS IN PERSISTENT HIV VIREMIA DURING UNIVERSAL TEST-AND-TREAT SCALE-UP IN UGANDA

Poster Session-Y03 ACHIEVING TARGETS
2:30 PM - 4:00 PM

1042 USAGE PATTERNS AND OUTCOMES IN A LARGE COMMUNITY ART PROGRAMME IN SOUTH AFRICA
Lara Lewis, Yukteshwar Sookrajh, Johan van Der Molen, Muntha Devi Maraj, Thokozani Khubone, Rosemary Van Heerden, Francesca Little, Reshma Kassanjee, Nigel Garrett, Jienchi Dorward

1043 HIGH COVERAGE OF HIV TREATMENT, LOW COVERAGE OF PREVENTION SERVICES AMONG KP IN INDIA
Allison M. McFall, Viswanathan Arumugam, Jade Bell, Saya Okram, Aditya Singh, Rose Pollard, Ajay Enugu, Shruti H. Mehta, Sunil S. Solomon

1044 ACHIEVING THE EHE INCIDENCE REDUCTION GOALS AMONG AT-RISK POPULATIONS IN THE SOUTH
Deven T. Hamilton, Karen Hoover, Dawn Smith, Kevin Delaney, Li Yan Wang, Jingjing Li, Tamika Hoyte, Samuel Jenness, Steven M. Goodreau

1045 PROGRESS ON UNAIDS 95-95-95 TARGETS AMONG KEY POPULATIONS IN 3 TANZANIA REGIONS
Tara Pinto, Werner Maokola, Gulam Abdulkarim, George Mgomella, Mucho Mzinduko, Joyce Neal, Prince Mutalemw, Samwel Sumba, Mark Breda, Ananthy Thambinayagam, Nyambura Moremi, Jessica Greene, Mahesh Swaminathan, Shannon M. Farley, Elias Bukundi
1046  INCREASING IN LIFE EXPECTANCY OF THAI LIVING WITH HIV IN THE ERA OF TREAT ALL
Sirinya Teeraananchai, Stephen J. Kerr, Cheewanan Lertpitiyasuwat, Rattaphon Triamwichan, Patchara Benjarattanaporn, Win Min Han, Matthew G. Law, Ancharlee Avihingsan, Kiat Ruxrungtham

1047  REACHING THE THIRD 95 IN UGANDA AFTER LOWERING HIV VIRAL LOAD SUPPRESSION CUTPOINTS

1048  GETTING TO ZERO: ACHIEVEMENT OF 95-95-95 AND DECLINING HIV INCIDENCE IN ESWATINI
Harriet Nuwagaba-Biribonwoha, Sindiswie Dlamini, Neena Philip, Choice Ginindza, Michelle Li, Kristin Brown, Nokuthula Mahlalela, Yvonne Mavengere, Daniel Catano, Kelsie Decker-Pulice, Jessica Justman, Ruben Sahabo, Rejoice Nkambule, David Hoos, Wafaa El-Sadr

Research Group: SHIMS3 Team

**Poster Session-Y04 HIV TESTING**

2:30 PM - 4:00 PM

**1049**  EARLY CASE-FINDING IS STILL NEEDED IN THE HIV TEST-AND-TREAT ERA TO PREVENT MORTALITY
Sasi Jonnalagadda, Jacques Muthusi, Anthony Waruru, Wanjiru Waruiru, Kevin Kintungu, Margaret Ndisha, Mary Mwangome, Kenneth Masamaro, Abraham Katana, Appolonia Aoko, Lucy Nganga, Rachael Joseph

**1050**  RE-NORMING OF HIV TESTING IN TB CONTACT INVESTIGATION: A RANDOMIZED CONTROLLED TRIAL
Mari Armstrong-Hough, Joseph Ggita, Amanda Gupta, Joanita Nangendo, Achilles Katamba, J. Lucian Davis

Research Group: Uganda TB Implementation Research Consortium (U-TIRC)

**1051**  MODELED IMPACT OF HIV SELF-TESTING FOR PrEP SCALE-UP ON DRUG RESISTANCE IN KENYA
TUESDAY FEBRUARY 21, 2023

Poster Session-A2 IFN AND ANTIViral FACTORS
2:30 PM - 4:00 PM

218 HIV INFECTION OF TFH: INTERROGATING THE SAMHD1 CONTRIBUTION THROUGH HIV-2
André Pires, Rita Moura, Guilherme B. Farias, Carolina M. Conceição, Ana V. Antão, Tiago Ferreira, Bárbara Tavares, Amelia C. Trombeta, Ana Godinho-Santos, Ana E. Sousa, Robert Badura

219 NEF FROM PRIMARY HIV INFECTION COUNTERACTS IFITM3 AND RESTORES VIRION INFECTIVITY
Mahesh Agarwal, Saliaha Majdoul, Abigail A. Jolley, Alex A. Compton

220 Vpu OF AN SIV ISOLATE CAN TARGET HUMAN BST-2
Weitong Yao, Akhil Chennuru, Preston Moore, Klaus Strebel, Tetsuro Matano, Taisuke Izumi, Takeshi Yoshida

221 STinging CD4+ T CELLS TO RENDER THEM REFRACTORY TO HIV INFECTION
Naseem Sadek, Sarah Welbourn, David Gordon, Rafick P. Sékaly, Jeffrey A. Tomalka

222 PAN-CASPASE INHIBITION PREVENTS HIV REPLICATION BY THE INDUCTION OF THE IFN I PATHWAY
Jordi Senserrich, Sònia Pedreño, Elisabet García, Elisabet Gómez, Bonaventura Clotet, Cecilia Cabrera

223 THE SPIKE OF SARS-CoV-2 VARIANTS ALLOWS FOR MORE EFFICIENT COUNTERACTION OF BST2
Yuhang Shi, Yuexuan Chen, Ruth Serra-Moreno

224 cGAS-STING PATHWAY LIMITS SARS-CoV-2 REPLICATION IN ACE2+ AIRWAY CELL LINES
Maritza N. Puray-Chavez, Kyle M. Lapak, Ria Jasuja, Shawn Mohammed, Dana Q. Lawson, M. Ben Major, Dennis Goldfarb, Sebla B. Kutluay

225 LONG NON-CODING RNA REGulates IFN-I RESPONSE AND SARS-CoV-2 REPLICATION
Smita Kulkarni

Poster Session-B3 HIV NON IMMUNO PATHOGENESIS, COINFECTION
2:30 PM - 4:00 PM

253 BODY MASS INDEX AND INFLAMMATION IN PEOPLE LIVING WITH HIV AND UNINFECTED CONTROLS
Marco Gelpi, Rebekka Faber Thudium, Malene Hove-Skovsgaard, Thomas Lars Benfield, Sisse Rye Ostrowski, Susanne Dam Poulsen

254 IRON METABOLISM IN CHRONIC HIV: IMPAIRED HEPcidIN-SOLUBLE TRANSFERRIN RECEPTOR AXIS
Vanessa Garrido-Rodriguez, Ana Isabel Alvarez-Rios, Israel Olivas-Martínez, María Del Mar Pozo-Balado, Ángel Bulnes-Ramos, Manuel Leal, Yolanda Pacheco

255 ENDOthelial GM-CSF IN PLWH CONTRIBUTES TO PROINFLAMMATORY VASCULAR MICROENVIRONMENT
Soumya Panigrahi, Elizabeth Mayne, Nicholas Funderburg, Archeesha Chakraborty, Michael M. Lederman, Michael L. Freeman, Scott F. Sieg
256  **EFFECT OF *P. FRAGILE* COINFECTION ON ART AND IMMUNITY IN SIV-INFECTED RHESUS MACAQUES**
Sydney Nemphos, Hannah Green, Kelly Goff, Matilda Moström, Coty Tatum, Chad Massey, Robert Blair, Carolina Allers, Monica Embers, Nicholas Maness, Preston Marx, Brooke Gasperske, Amitinder Kaur, Jennifer Manuzak

257  **INNATE IMPAIRMENT DURING SIV INFECTION ALTERS ZIKV VIRAL PATHOGENESIS**
Jennifer Tisonck-Go, Thomas B. Lewis, Skyler Niemeyer, Andrew Gustin, Rene A. Ruiz, Paul Kim, Kai Hubbell, Naoto Iwayama, Solomon Wangari, Chul Ahrens, Robert Murnane, Kathryn A. Guerriero, Michael Gale, Deborah H. Fuller, Megan A. O’Connor

258  **LYMPHOID TISSUE VOLUMES AND GLUCOSE METABOLISM IN EARLY SIV INFECTION OF AGM AND RM**
Hyukjin Jang, Dongzhu Ma, Sharat Srinivasula, Brad Long, Heather Brown, Cui Ling Xu, Cristian Apetrei, Ivona Pandrea, Michele Di Mascio

259  **THE BREADTH AND POLYFUNCTIONALITY OF T CELL RESPONSES TO CMV DIFFER BY HIV STATUS**
Weiyi Zhang, Tricia L. Nilles, Jay H. Bream, Huifen Li, Sean X. Leng, Joseph B. Margolick

**Poster Session-B5 HIV IMMUNOPATHOGENESIS**
2:30 PM - 4:00 PM

265  **GERMINAL CENTER B CELLS INDUCE TFH ACTIVATION AND HIV REPLICATION**
Matthew Ollerton, Joy Folkvord, David Parry, Elizabeth Connick

266  **SIALIDASE INHIBITION PREVENTS HIV-MEDIATED INFLAMMATION AND IMMUNE ACTIVATION IN VIVO**
Leila Giron, Shalini Singh, Kai Ying Hong, Joshua Glover, Eric Balboa, Derrick Dogpin, Michelle Burrows, Anthony Secreto, Nicolas Skuli, Todd T. Brown, Alan Landay, Ali Keshavarzian, Ivona Pandrea, Paul Denton, Mohamed Abdel-Mohsen

267  **EXPRESSION OF UNSPLICED HIV-1 RNA INDUCES INFLAMMASOME ACTIVATION IN MYELOID CELLS**
Sallieu Jalloh, Ivy Hughes, Chelsey Skeete, Hisashi Akiyama, Aldana Gojanovich, Gustavo Mostoslavsky, Rahm Gummuluru

268  **IMPACT OF EARLY ART ON TISSUE RESIDENT MEMORY T CELLS IN THE GASTROINTESTINAL TRACT**
Aloysious Ssemaganda, Yuwadee Phuang-Ngern, Chayada Sajjaweerawan, Phil Ehrenberg, Henok Gebrebrhan, Sandra Choi, Michael Corley, Giulia Severini, Nittaya Phanuphak, Carlo Sacdalan, Denise Hsu, Rasmi Thomas, Lyle McKinnon, Alexandra Schuetz
Research Group: RV254/SEARCH010 and SEARCH013/RV304 study groups

269  **MULTOMIC BIOMARKERS ACROSS ART INITIATION TIMEPOINTS REVEAL INTERFEROME ENRICHMENT**
Harrison B. Lindley, Cheryl Cameron, Brian Richardson, Jillian Petroski, Wendy Lin, Jared M. Baeten, Connie Celum, Florian Hladik, Jairam Lingappa, Romel Mackelprang, Mark Cameron

270  **HIV SUPPRESSION IS LINKED TO SHIFTING EPIGENETIC/TRANSCRIPTOME FEATURES IN MONOCYTES**
Guido Massaccesi, Brittany White, Eric S. Rosenberg, Todd Allen, Eileen P. Scully
282 **PLASMA-BASED ANTIGEN PERSISTENCE IN THE POST-ACUTE PHASE OF SARS-CoV-2 INFECTION**  
Michael J. Peluso, Zoe Swank, Sarah A. Goldberg, Yasmine Senussi, Scott Lu, Rebecca Hoh, Khamal Anglin, Beatrice Huang, Matthew S. Durstenfeld, John D. Kelly, Timothy Henrich, Steven G. Deeks, David V. Glidden, David Walt, Jeffrey Martin  
Research Group: LIINc study team

283 **PLASMA ANTIBODY AND N ANTIGEN STATUS PREDICT OUTCOMES IN OUTPATIENTS WITH COVID-19**  
Nikolaus Jilg, Mark Giganti, Kara W. Chew, Katy Shaw-Saliba, Justin Ritz, Carlee Moser, Teresa H. Evering, Eric S. Daar, Joseph J. Eron, Judith S. Currier, Michael D. Hughes, Henry C. Lane, Robin Dewar, Davey M. Smith, Jonathan Z. Li

284 **VIRAL DYNAMICS AND FACTORS FAVOURING THE DURATION OF COVID-19-POSITIVE IN CAMEROON**  
Research Group: Chantal Biya International Reference Center COVID-19 team

285 **MITOCHONDRIAL DYSFUNCTION IS ASSOCIATED WITH POST-ACUTE SEQUELAE OF COVID-19**  
Saheera Dirajlal-Fargo, Jared C. Durieux, Anastasia Andrukhiv, David Maison, Mariana Gerschenson, Grace A. McComsey

286 **SINGLE-CELL ANALYSIS REVEALS CHARACTERISTICS OF MYELOID CELLS IN PULMONARY PASC**  
Hyundong Yoon, Boonyanudh Jiyarom, Logan Dean, Dominic Chow, Cecilia Shikuma, Gehan Devendra, Youngil Koh, Juwon Park

287 **ADAPTIVE IMMUNITY DYSREGULATION IS ASSOCIATED TO THE DEVELOPMENT OF LONG COVID**  
Roberta Rovito, Valeria Bono, Matteo Augello, Francesca Bai, Camilla Tincati, Guillaume Beaudoin-Bussières, Alexandra Tauszin, Silvia Bianchi, Joanna Mikulak, Elisa Borghi, Antonella D’Arminio Monforte, Silvia Della Bella, André Finzi, Domenico MAVilio, Giulia C. Marchetti

288 **INCREASED GUT PERMEABILITY AND OXIDIZED LIPIDS IN PASC**  
Christian Mouchati, Jared C. Durieux, Sokratis N. Zisis, Mary Chong, Danielle Labbato, Grace A. McComsey

289 **NONHUMAN PRIMATE MODEL OF LONG COVID: IMMUNE INSIGHTS OF GLYCOMETABOLIC DYSFUNCTIONS**  
Clovis C. Palmer, Chrysostomos Perdios, Mohamed Abdel-Mohsen, Nicholas Maness, Gabrielle Lehrnicke, Joseph mudd, Kasi Russell-Lordique, Angela Binbaum, Rudolf Bohm, Jason Dufour, Robert Blair, Ahmed Saied, Jay Rapaport, Cecily Midkiff, Carol Coyne, Nadia Golden

290 **PROLONGED SARS-CoV-2 VIRAL BURDEN IN SIV/SARS-CoV-2 COINFECTED MACAQUES**  
Megan N. Fredericks, Hillary C. Tunggal, Cecily C. Midkiff, Jeana E. Barrow, Anthony L. Cook, Robert Blair, Ankur Sharma, Deborah H. Fuller, Megan A. O’Connor
Poster Session-C1 BASIC SCIENCE OF TUMOR VIRUSES: HTLV, HBV, EBV, AND ENDOGENOUS RETROVIRUSES

2:30 PM - 4:00 PM

294 INNATE IMMUNITY IN HTLV-1 INFECTION: IFN-GAMMA LEVELS ARE UP-REGULATED IN EARLY HAM
Marta S. Porto, Sandy V. Teixeira, Gabriela S. Prates, George Gonçalves, Jorge Casseb

295 HIV COINFECTION INCREASES HBV-INDUCED HEPATIC FIBROGENESIS THROUGH HIF-1α
Min Xu, Charlotte Warner, Xiaogiong Duan, Andre Jeyarajan, Zhimeng Cheng, Zachary Manickas-Hill, Tuo Shao, Shadi Salloum, Xu G. Yu, Raymond Chung, Wenyu Lin

296 WITHDRAWN

297 ENDOGENOUS RETROVIRAL DYSREGULATED EXPRESSION IN PEDIATRIC CROHN’S DISEASE
Konstantina Kitsou, Vana Spoulou, Pagona Lagiou, Gkikas Magiorkinis

Poster Session-D3 IMMUNE MODULATION AND VACCINES

2:30 PM - 4:00 PM

316 DNA LAUNCHED BROADLY NEUTRALIZING KILLERS: A DOUBLE-EDGED THERAPEUTIC AGAINST HIV-1
Sukanya Ghosh, Mansi Purwar, Samson Adeniji, Abhijeet Kulkarni, Zhe Yuan, Pratik Bhojnagarwala, Giselle Lopez Fernandez, Luis J. Montaner, Mohamed Abdel-Mohsen, David B. Weiner

317 LAIR-1: NEGATIVE REGULATOR OF SIV- SPECIFIC CD8 T CELLS DURING CHRONIC SIV INFECTION
Sakthivel Govindaraj, Ashish Arunkumar Sharma, Syed Ali, Hemalatha Babu, Kathleen Busman-Sahay, Deepa Machiah, Steven Bosinger, Jacob Estes, Rafick P. Sékaly, Francois Villinger, Rama R. Amara, Vijayakumar Velu

318 TIGIT/CD155 BLOCKADE BOOSTS T-CELL IMMUNITY AND HIV- SPECIFIC DEGRANULATION IN PLWH
Miguel Marin, Julieta Carabelli, Eudald Vehi, Ruth Peña, Gabriel Felipe Rodríguez-Lozano, Natalia Isabel Rodrigo, Carlo Carolis, Luis Álvarez-Vallina, Jorge Carrillo, Bonaventura Clotet, Julia G. Prado
Research Group: VIRAL IMMUNE EVASION AND VACCINES (VIRIEVAC)

319 EVALUATION OF HIV-SPECIFIC T CELL RESPONSE IN BEAT2 CLINICAL TRIAL
M.Betina Pampena, Pablo Tebas, Livio Azzoni, Emmanouil Papasavvas, Matthew Fair, Karam Mounzer, Luis J. Montaner, Michael R. Betts

320 ONE-YEAR TREATMENT WITH PONATINIB INDUCES SUSTAINED CYTOTOXIC ACTIVITY AGAINST HIV
Fernando Ramos-Martín, Mario Manzanares, Montserrat Torres, Elena Mateos, Lorena Vigón, Guiomar Casado Fernández, Sara Rodríguez Mora, Vicente Planelles, Valentín García-Gutiérrez, Mayte Coiras

321 DECREASED HIV-SPECIFIC POLYFUNCTIONAL RESPONSES FOLLOWING DIPYRIDAMOLE TREATMENT
Benjamin C. Morris, Emily Hixson, Cynthia Klamar-Blain, Edwin Jackson, Kaleab Abebe, Lori Caruso, John W. Mellors, Charles Rinaldo, Sharon A. Riddler, Bernard Macatangay
322 **URACIL TREATMENT DOES NOT INCREASE SUSCEPTIBILITY TO RECTAL SIV INFECTION**  
Alexandra Ortiz, Charlotte Langner, Jason Brenchley

323 **HETEROLOGOUS ChAd/samRNA SIV VACCINE INDUCES ROBUST T CELL RESPONSES IN MACAQUES**  
Amy Rappaport, Elena Bekerman, Greg Boucher, Janette Sung, Brian Carr, Cesar Corzo, Sue-Jean Hong, Heather Larson, Ciaran Scallan, Bill Wang, Romas Gelezianus, Devi Sengupta, Karin Jooss

324 **CD40.HIVRI.Env VACCINE INDUCES STRONG AND DURABLE IMMUNE RESPONSES: ANRS VRI06 TRIAL**  
Jean-Daniel Leelievre, Christiane Moog, Aurélie Wiedemann, Christine Lacabarat, Fabio Candotti, Melany Durand, Véronique Rieux, Lucile Hardel, Alpha OB, Diallo, Song Ding, Mireille Centlivre, Rodolphe Thiembaut, Giuseppe Pantaleo, Laura Richert, **Yves Levy**

325 **THE ROLE OF MYELOID-DERIVED SUPRESSOR CELLS IN STI-MEDIATED ENHANCED HIV INFECTION**  
Daan K.J. Pieren, Núria Massanasa, Vicente Descalzo, Maider Arando, Jorge García-Pérez, Patricia Alvarez, Laura Mañalich-Barrachina, Cristina Centeno-Mediavilla, Desideria Martinez, Josep Castellvi, Clara Ramírez Serra, Daniel Alvarez-de la Sierra, Vicenç Falcó, María J Buzon, Merixell Genescà

326 **BEAT2: PEG-IFN-ALPHA + 3BNC117 & 10-1074 REBOUND VIRUS PHENOTYPE AND EVOLUTION**  

327 **TIGIT BLOCKADE RESTORES FUNCTIONAL NKG2C+ NK CELLS AND LIMITS SPREAD OF HIV-1 IN Vivo**  
Ildefonso Sánchez-Cerrillo, Marta Calvét-Mirabent, Olga Popova, Ignacio De Los Santos, Jesús Sanz, Patricia Fuentes, Juan Alcaín, Ilya Tsukalov, Arantxazu Alfranca, Maria J Buzon, María Luisa Toribio, Ángeles Muñoz-Fernández, Francisco Sánchez-Madrid, **Enrique Martin-Gayo Research Group: CIBERINFECC**

328 **GERMLINE-TARGETING ENV TRIMER ELICITS bNAb PRECURSORS IN INFANT, NOT JUVENILE MONKEYS**  
Yasmine Iassah, John Isaac, Xintao Hu, Shaunna Shen, Gabe Orozowski, Shiyu Zhang, Andrew Ward, David Montefiori, Rogier Sanders, Koen Van Rompay, Kristina De Paris, **Sallie R. Permar**

**Poster Session-D7 SARS-CoV-2 VACCINES AND PREVENTION**  
2:30 PM - 4:00 PM

355 **REAL-WORLD EFFECTIVENESS OF mRNA, SUBUNIT, AND VECTOR-BASED VACCINES AGAINST COVID-19**  
Cheng-Yi Lee, Hung-Wei Kuo, Yu-Lun Liu, Jen-Hsiang Huang, Jih-Haw Chou

356 **IMMUNOGENICITY OF SARS-CoV-2 VACCINES BY VACCINE TYPE IN RANDOMISED CLINICAL TRIALS**  
Sreenidhi Venkatesh, Andrea Navarro Perez, Andrew Hill

357 **IVSV-BASED COVID VACCINE FOR THE PREVENTION OF BREAKTHROUGH SARS-CoV-2 INFECTIONS**  
Ryan Troyer, Mansour Haeryfar, Stephen Barr, **C. Yong Kang**
358  HOSPITAL PROTECTION CORRELATES IN OUTPATIENT COVID-19 CONVALESCENT PLASMA RECIPIENTS
Anna Yin, Caelan Barranta, Han-Sol Park, John Lee, Christopher Caputo, Judith S. Currier, Sonya L. Heath, Moises A. Huaman, Oliver Laeyendecker, Aaron Tobian, Andrew Pekosz, Kelly Gebo, David J. Sullivan, Sabra L. Klein, Daniel F. Hanley, Arturo Casadevall, Evan M. Bloch, Shmuel Shoham
Research Group: CSSC Group

359  SARS-CoV-2 INFECTIONS AMONG 275 PATIENTS WITH TIXAGEVIMAB/CILGAVIMAB PROPHYLAXIS
Valentine M. Ferré, Laura Kramer, Christophe Rioux, Tiphaine Goulenok, Nathan Peiffer-Smadja, Mathilde Salpin, Quentin Le Hirngart, Eric Daugas, Michael Thy, Richard Dorent, Sébastien Ottaviani, Yazdan Yazdanpanah, Diane Descamps, Jade Ghosn, Veronique A. Joly

360  CD8+ T CELL CLONES FROM PRIOR SARS-CoV-2 INFECTION PREDOMINATE AFTER mRNA VACCINATION

361  LIMITED INDUCTION OF LUNG-RESIDENT MEMORY T CELLS BY SARS-CoV-2 mRNA VACCINATION
Daan K.J. Pieren, Sebastián Kuguel, Joel Rosado, Alba González Robles, Joan Rey-Canó, Cristina Mancebo Pérez, Juliana Esperalba, Vicenç Falcó, Maria J Buzon, Meritxell Genescà

362  CD40.SARS.Cov2 VACCINE, BUT NOT mRNA, INDUCES SPECIFIC CD8+ T MEMORY STEM CELLS
Laury Nguema, Manwa El Hajj, Florence Picard, Craig Fenwick, Sylvain Cardinaud, Aurélie Wiedemann, Giuseppe Panteleo, Sandy Zurawski, Mireille Centlivre, Gerard Zurawski, Yves Lévy, Veronique Godot

363  SARS-CoV-2 VACCINE-INDUCED T CELL RESPONSES IN CANCER PATIENTS UNDERGOING TREATMENT
Chad Poloni, Xiaojiao Wang, Andrew Sze, Stephen Chia, Laura Cook, Ted Stein

364  NEUTRALIZING ACTIVITY AND T CELL RESPONSE AFTER BIVALENT THIRD BOOSTER DOSE IN PLWH
Alessandra Vergori, Giulia Matusali, Alessandro Cozzi Lepri, Eleonora Cimini, Marisa Fusto, Francesca Colavita, Stefania Cicalini, Stefania Notari, Valentina Mazzotta, Davide Mariotti, Roberta Gagliardini, Enrico Girardi, Francesco Vaia, Fabrizio Maggi, Andrea Antinori, Silvia Meschi, Gianluca Prota, Massimo Francalancia, Marika Rubino, Giuseppe Giannico
Research Group: HIV-VAC Study Group

365  12-MONTH HUMORAL RESPONSE AFTER mRNA COVID-19 VACCINATION IN PEOPLE LIVING WITH HIV
Paul Loubet, Linda Wittkop, Alexis Francois, Karine Lacombe, Valérie Pourcher, Alain Makinson, Pierre-Olivier Girodet, David Chirio, Philippe Vanhems, Maeva Lefebvre, Catherine Schmidt-Mutter, Xavier de Lamballerie, Julie Longobardi, Jean-Daniel Lelievre, Odile Launay
Research Group: ANRS0001S COV-POPART cohort study group

366  SARS-CoV-2 LIVE VIRUS NEUTRALIZATION AFTER FOUR COVID-19 VACCINE DOSES IN PWH ON ART
Research Group: COVID-19 vaccine immunity study team

CME  Continuing Medical Education  LB  Late-Breaking  NIS  New Investigator Scholarship  NP  Nonspeaker Presenter
367  IMMUNOCITY OF SARS-CoV-2 mRNA VACCINATION IN IDIOPATHIC CD4 LYMPHOPENIA

368  RESTORATION OF HUMORAL RESPONSE TO COVID-19 VACCINATION IN RITUXIMAB-TREATED PATIENTS
Wang-Da Liu, Tai-Chung Huang, Jann-Tay Wang, Hsin-Yun Sun, Shang-Ju Wu, Huai-Hsuan Huang, Chia-Yi Lin, Guei-Chi Li, Sui-Yuan Chang, Chien-Ching Hung

369  THREE DOES OF COVID-19 VACCINES IN PWH: IMMUNOCITY AND EFFECTS ON HIV RESERVOIR
Vitaliy Matveev, Erika Benko, Erik Mihelic, Terry Lee, Karen Colwill, Robert Reinhard, Sebastian Grocott, Patrick Budylowski, Lela Kardava, Susan Moir, Jennifer Gommperman, Anne-Claude Gingrich, Colin Kovacs, Mario Ostrowski

370  EFFECTS OF COVID-19 mRNA VACCINATION ON HIV VIREMIA AND RESERVOIR SIZE IN PWH ON ART
Maggie Duncan, F Harrison Omondi, Natalie Kinloch, Hope Laponthe, Sarah Speckmaier, Nadia Moran-Garcia, Tanya Lawson, Mari Demarco, Janet Simons, Daniel Holmes, Christopher F. Lowe, Marc G. Romney, Marianne Harris, Mark Brockman, Zabrina Brumme

371  COVID-19 VACCINATION IMPACTS FUNCTIONAL IMMUNE RESPONSES AND PLASMA PROTEOME IN PLWH
Research Group: 2000 HIV Functional Genomics Partnership Program

372  IMPACT OF GUT MICROBIOTA ON IMMUNOCITY TO COVID-19 VACCINES IN PLWH
Shilpa Ray, Aswathy Narayanan, Jan Vesterbacka, Giorgio Gabarrini, Yu Gao, Hans-Gustaf Ljunggren, Marcus Buggert, Soo Aleman, Anders Sönnerborg, Margaret Sällberg Chen, Piotr Nowak

373  SEQUENTIAL IMMUNIZATION OF UPDATED COVID-19 DNA AND RNA VACCINES IN NONHUMAN PRIMATES
Sandra Dross, Megan N. Fredericks, Mathias D. Maughan, Justin T. Ulrich-Lewis, Thomas B. Lewis, Yuqi Dong, James T. Fuller, Solomon Wangari, Alexander Cohen, Pamela B. Bjorkman, Arlene I. Ramsingh, Janice Pata, Jesse Erasmus, Kenneth C. Bagley, Deborah H. Fuller

415  UNRAVELING ONGOING INFLAMMATION AFTER EARLY ART BY IN-DEPTH ANALYSIS OF LYMPH NODES
Jozefien De Clercq, Kathleen Busman-Sahay, Laurens Lambrechts, Sofie Rutsaert, Sol Taylor-Brill, Stephen Boodoos, Marie-Angélique De Scheerder, Jacob Estes, Sarah Gerlo, Lino Vandenkerckvove
Research Group: HIV Cure Research Center

416  UNEQUAL DISTRIBUTION OF INTACT HIV PROVIRUSES IN CELLS
Katie Fisher, Timothy Schlub, Zoe Boyer, Thomas Rasmussen, Ajantha Rhodes, Rebecca Hoh, Frederick Hecht, Steven G. Deeks, Sharon Lewin, Sarah Palmer

Poster Session-E4 HIV RESERVOIRS IN CELLS AND TISSUES
2:30 PM - 4:00 PM

CME Continuing Medical Education | LB Late-Breaking | NIS New Investigator Scholarship | NP Investigator Presenter

98 CROI 2023
417 DECIPHERING THE SOURCE OF VIRAL REBOUND IN SIV-INFECTED RHESUS MACAQUES
Antonio Solís-Leal, Nongthombam Boby, Suvadip Mallick, Yilun Cheng, Fei Wu, Grey De La Torre, Jason Dufour, Xabier Álvarez, Vinay Shivanna, Jeffrey D. Lifson, Qingsheng Li, Brandon F. Keele, Binhua Ling

418 AN INTESTINAL TISSUE MODEL FOR TARGETED STRATEGIES DIRECTED TO TISSUE RESERVOIRS
Ana Gallego Cortés, Nerea Sánchez Gaona, Cristina Mancebo Pérez, Stefania Landolfi, Vicenç Falcó,Meritxell Genescà, Maria J Buzon

419 MONOCYTE-DERIVED MACROPHAGES CONTAIN LONG-LIVED LATENT HIV RESERVOIRS
Rebecca Veenhuis, Celina Abreu, Pedro Costa, Edna Ferreira, Janaysha Ratliff, Lily Pohnlenz, Erin Shirk, Joel N. Blankson, Lucio Gama, Janice Clements

420 SYSTEMIC INFLAMMATION, GUT DYSBIOSIS AND GUT MICROBIOME IMPACT HIV MIGRATION DYNAMICS
Ravi Goyal, Sara Gianella, Christophe Vanpouille, Wendy Fitzgerald, Gemma Caballero, Caroline Ignacio, Magali Porrachia, Victor De Gruttola, Davey M. Smith, Antoine Chaillou

421 T-TRACE ENABLES SINGLE-CELL MULTI-OMICS ANALYSIS OF HIV RESERVOIR CELLS FROM TISSUES
Julie Frouard, Xiaoyu Luo, Jason Neidleman, Kailin Yin, Sushama Telwatte, Steven Yuki, Jennifer Cohen, Anastasia Polos, Carol Thuman, Rebecca Hoh, Steven G. Deeks, Pavitra Roychoudhur, Sulggi Lee, Phyllis C. Tien, Nadia R. Roan

422 HIV VIRION PROFILING SUGGEST THAT CXCR3+CD4 T CELLS ARE THE MAIN HIV-PRODUCING CELLS
Olivia Muñoz, Riddhima Banga, Alessandra Noto, David Vinals, Francesco Procopio, Andrea Mastrangelo, Rachel Schelling, Craig Fenwick, Christine Lacabartaz, Yves Levy, Laurent Perez, Matthias Cavassini, Giuseppe Pantaleo, Matthieu Perreau

Poster Session-E6 INTERVENTIONS TO TARGET THE VIRAL RESERVOIR AND DELAY VIRAL REBOUND
2:30 PM - 4:00 PM

428 REDUCTION IN HIV RESERVOIR MARKERS WITH GAG/POL/IL-12 DNA THERAPEUTIC VACCINATION
Kara W. Chew, David V. Glidden, Rémi Fromentin, Jana Jacobs, Amélie Pagliuzza, Gregory M. Laird, Nicolas Chomont, Mansi Purwar, Laurent Humeau, John W. Mellors, David B. Weiner, Rafick P. Sékaly, Steven G. Deeks, Rachel L. Rutishauser

429 DOUBLING DOLUTEGRAVIR DOSAGE REDUCES HIV PERSISTENCE MARKERS IN ART-TREATED ADULTS
Céline Fombellida-Lopez, Alexander Pasternak, Aurelija Cicilionytė, Nathalie Maes, Céline Vanwinge, Aurélie Laclang, Etienne Cavalier, Lee Winchester, Courtney V. Fletcher, Fabrice Susin, Dolores Vaira, Marie-Pierre Hayette, Catherine Reenaers, Michel Moutschen, Gilles Darcis

430 RANDOMIZED CONTROLLED TRIAL OF VRC01 MONOCLONAL ANTIBODY DURING ACUTE HIV INFECTION
Julie A. Ake, Somchai Sripiyechan, Josphat Kosgei, Hannah Kibukua, Joel Mwakisisile, Caroline Subra, Christine Orndahl, Leigh Anne Eller, Nelson L. Michael, Sheila A. Peel, Randall Tressler, Richard A. Koup, Morgane Rolland, Merlin L. Robb
Research Group: RV398 Study Team
BEAT2 PRIMARY TRIAL OUTCOMES: PEG-IFN-α2B +3BNC117 & 10-1074 IN CHRONIC HIV INFECTION

LONG-TERM PROTECTION OF CD4+ T CELLS AGAINST HIV BY ONE-YEAR TREATMENT WITH PONATINIB
Mario Manzanares, Fernando Ramos-Martín, Guiomar Casado-Fernández, Montserrat Torres, Elena Mateos, Lorena Vigón, Vicente Planelles, Sara Rodríguez Mora, Valentín García-Gutierrez, Mayte Coiras

A PLACEBO-CONTROLLED RANDOMIZED TRIAL OF THE HTI IMMUNOGEN VACCINE AND VESATOLIMOD
Beatriz Mothe Pujades, Adrià Curran, Juan Carlos López, Julen Cadiñas, Ignacio De Los Santos, Juan Ambrosioni, Arkaiz Imaiz, Santiago Moreno, Pere Domingo, Yanhui Cai, Romas Geleziunas, Devi Sengupta, Ian McGowan, Christian Brander, Jose R. Arribas, Álvaro Arribas, Margarida Garcia-Garcia, Isabel Leal, Heinz Lubenaub
Research Group: The AELIX-003 Study Team

HIV-1 VIRAL RESERVOIR REACTIVATION AFTER CCR5 DELTA 32/32 STEM CELL TRANSPLANTATION

REBOUND DYNAMICS FOLLOWING IMMUNOTHERAPY WITH AN HIV VACCINE, TLR9 AGONIST, AND bNAb
Michael J. Peluso, Amelia Deitchman, Gesham Magombedze, Meghan Williams, Nitasha Kumar, James Mullins, Barbara K. Felber, George Pavlakis, Rowena Johnston, Jackie Reeves, Lucio Gama, Michel C. Nussenzweig, Timothy Henrich, Rachel L. Rutishauser, Steven G. Deeks
Research Group: UCSF-amfAR Clinical Trial Team

HIV GAG X CD3 SOLUBLE TCR BSPECIFIC: SAFETY AND ACTIVITY IN A FIRST IN HUMAN TRIAL
Linos Vandekerckhove, Julie Fox, Borja Mora-Peris, Jordi Navarro, Sabine D. Allard, Alison Uriel, Santiago Moreno, Marta Boffito, Frank Post, Vicente Estrada, Beatriz Mothe Pujades, Yuan Yuan, Adel Benlahrech, Lucy Dorrell, Sarah Fidler

VESATOLIMOD PHARMACODYNAMIC RESPONSE IS ASSOCIATED WITH TIME TO HIV REBOUND
Liao Zhang, Mary Wire, Yanan Zheng, Susie SY. Huang, Lisa Selzer, Donovan Verrill, Christiaan R. de Vries, Devi Sengupta, Jeffrey J. Wallin, Yanhui Cai

IN-DEPTH ASSESSMENT OF THE HIV-1 VIRAL RESERVOIR IN EARLY TREATED INDIVIDUALS
Tine Struyve, Marion Pardons, Liesbet Termote, Jozefien De Clercq, Laurens Lambrecht, Jerel Vega, Daniel Boden, Mathias Lichterfeld, Sofie Rutsaert, Linos Vandekerckhove

HIV-1 RESERVOIRS IN YOUNG ADULTS AFTER LONG-TERM ART FOR CONGENITAL INFECTION
Benjamin R. Bone, Nicola Cotugno, Ce Gao, Catherine Koofhethile, Xiaodong Lian, Isabelle C. Roseto, Libera Sessa, Seoyhun Hong, Xu G. Yu, Paolo Palma, Mathias Lichterfeld
451 CTL SELECTION ENRICHES FOR HIV INTEGRATION SITE FEATURES AND EXPANDED CLONES IN VIVO

452 IMPACT OF HIV RESERVOIR IN THE LOSS OF NATURAL ELITE CONTROL OF HIV-1 INFECTION
Carmen Gasca-Capote, Xiaodong Lian, Ce Gao, Isabelle C. Roseto, María de los Reyes Jiménez-León, Gregory Gladkov, Alberto Pérez-Gómez, Nuria Espinosa, Francesc Vidal, Antonio Rivero, Luis Fernando López-Cortes, Xu G. Yu, Mathias Lichterfeld, Ezequiel Ruiz-Mateos

453 DISTINCT INTEGRATION sITES OF INTACT HIV-1 PROVIRUSES IN POST-TREATMENT CONTROLlERS
Isabelle C. Roseto, Xiaodong Lian, Kyra Seiger, Elizabeth Parsons, Gregory Gladkov, Ce Gao, Karam Mouzner, Emmanouil Papasavvas, Pablo Tebas, Tae-Wook Chun, Luis J. Montaner, Xu G. Yu, Mathias Lichterfeld

454 EFFECTS OF CHEMORADIATION ON EXPANDED PROVIRAL CLONES IN AN ELITE CONTROLLER
Filippo Dragoni, Abena K. Kwaa, Caroline G. Carliss, Bezawit A. Woldemeskel, Angelica Camilo-Contreras, Rebecca Veenhuis, Haley Raymond, Eileen P. Scully, Amanda M. Rosecrans, Frederic D. Bushman, Francesco R. Simonetti, Joel N. Blankson

455 EFFECT OF HIV-1 INFECTION AND VIRUS PRODUCTION ON CD4+ T CELL PROLIFERATION

456 A NOT-SO-STABLE RESERVOIR: HIV DRIVES INFECTED CELLS TO DIE AND DIVIDE
Sam Weissman, Marilia Pinzone, Alfonso Oceguera, Ashley Ginda, Liam Swigard, Lamont Cannon, Ryan Zurakowski, Uma O’Doherty

Poster Session-E9 HIV RESERVOIRS IN CHILDREN AND YOUTH
2:30 PM - 4:00 PM

457 ACUTE/RECENT HIV INFECTION IN YOUTH: HIV RESERVOIRS AND ANTIBODY FOLLOWING EARLY ART
Karin Nielsen-Saines, Ruth Cortado, Myung Shin-Sim, Tara Kerin, Manuel Ocasio, Sue Ellen Abdalian, Risa Flynn, Robert Bolan, Dallas Swendeman, Sophia Paiola, Yetunde Adebambo, Bonnie Ank, Yvonne Bryson, Maria Isabel Fernandez
Research Group: CARES ATN Team

458 LEUKAPHERESIS: A FEASIBLE TOOL TO INFORM ATI THROUGH HIV RESERVOIR STUDY IN CHILDREN
Nicola Cotugno, Giuseppe Rubens Pascucci, Elena Morrocchi, Benjamin R. Bone, Chiara Pighi, Chiara Medri, Marco Sanna, Nicole Colantonio, Simona Tedde, Giovanna Leone, Giovanna Del Principe, Stefania Bernardi, Paolo Rossi, Mathias Lichterfeld, Paola Palma

459 SIV CLEARANCE FROM NEONATAL MACAQUES FOLLOWING TRANSIENT CCR5 DEPLETION
Jesse Deere, David Merriam, Kathar Leggat, Wen-Lan William Chang, Gema Méndez-Lagares, Joseph Dutra, Ning Chin, Corey Miller, Steven G. Deeks, Kathleen Engelmann, Diogo Magnani, Keith Reimann, Jeffrey D. Lifson, Mario Stevenson, Dennis Hartigan-O’Connor, Connie Chen, Justin Fontaine, Hung Kieu, Wenze Lu, Jessica Salinas
<table>
<thead>
<tr>
<th>Session F4</th>
<th>PSYCHIATRIC SYMPTOMS, SLEEP DISTURBANCE, AND ASSOCIATED BIOMARKERS IN PEOPLE WITH HIV</th>
</tr>
</thead>
<tbody>
<tr>
<td>472</td>
<td>PSYCHIATRIC SYMPTOMS IN PLHIV: PREVALENCE, INTERACTIONS, AND CONSEQUENCES</td>
</tr>
<tr>
<td>Research Group: 2000HIV</td>
<td></td>
</tr>
<tr>
<td>473</td>
<td>SLEEP DISTURBANCES ARE ASSOCIATED WITH COGNITIVE FUNCTION IN WOMEN LIVING WITH HIV</td>
</tr>
<tr>
<td>Raha M. Dastgheyb, Kathleen Weber, Elizabeth Daubert, Anjali Sharma, Deborah Gustafson, Deborah Jones Weiss, Catalina Ramirez, Deborah Konkle-Parker, Sushma Cribbs, Bradley Aouizerat, Christine Alden, Seble Kassaye, Audrey French, Leah H. Rubin</td>
<td></td>
</tr>
<tr>
<td>474</td>
<td>BIOPSYCHOSOCIAL PHENOTYPES IN PEOPLE WITH HIV IN THE CHARTER COHORT</td>
</tr>
<tr>
<td>Bin Tang, Ronald J. Ellis, Florin Vaida, Anya Umlauf, Donald Franklin, Raha M. Dastgheyb, Leah H. Rubin, Robert K. Heaton, Scott L. Letendre</td>
<td></td>
</tr>
<tr>
<td>475</td>
<td>SEX-SPECIFIC ASSOCIATION BETWEEN IL-6 AND DEPRESSION IN PERSONS WITH AND WITHOUT HIV</td>
</tr>
<tr>
<td>Kalen J. Petersen, Xiaoying Yu, Judith Lobo, Mary Clare Masters, Tina Lu, Scott L. Letendre, Ronald J. Ellis, Erin Sundermann</td>
<td></td>
</tr>
<tr>
<td>476</td>
<td>(NEURO)INFLAMMATORY BIOMARKERS MEDIATE THE ASSOCIATION BETWEEN HIV AND DEPRESSION</td>
</tr>
<tr>
<td>Arish Mudra Rakshasa-Loots, Nicholas Baskwell, David Sharp, Magnus Gisslen, Henrik Zetterberg, Jasmin Alagaratnam, Ferdinand Wit, Neeltje Kootstra, Alan Winston, Peter Reiss, Caroline Sabin, Jaime Vera</td>
<td></td>
</tr>
<tr>
<td>Research Group: COmorBidity in Relation to AIDS (COBRA) cohort</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Session F5</th>
<th>CNS HIV INFECTION, PERSISTENCE, AND CURE STUDIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>477</td>
<td>ESTABLISHMENT OF HIV LATENCY AND MICROGLOSIS IN PRIMARY HUMAN MICROGLIA CELLS</td>
</tr>
<tr>
<td>Eun Hye Grace, Kim, Roy Missall, Lubbertus C. Mulder, Lotje De Witte, Viviana Simon</td>
<td></td>
</tr>
<tr>
<td>478</td>
<td>REBOUND HIV-1 IN CSF AFTER TI IS DOMINATED BY CLONALLY AMPLIFIED T CELL-TROPIC VIRUS</td>
</tr>
<tr>
<td>479</td>
<td>IMPACT OF IL-15 NEUTRALIZATION ON CNS PATHOGENESIS IN ACUTE HIV/SIV INFECTION</td>
</tr>
<tr>
<td>Raja Gopalakrishnan, Daniel Ram, Malika Boudries, Caitlin Davis, Gikundo Eunico, Rhianna Jones, Valerie Varner, Elizabhere McAuley, Lifton Michelle, Steven Bosingher, Dan Barouch, Brandon F. Reeve, L. Keith Reeves, C. Sabrina Tan</td>
<td></td>
</tr>
<tr>
<td>480</td>
<td>A FRESH SINGLE-CELL STUDY DETECTS MULTI-COMPARTMENT PERSISTENT HIV RNA DESPITE ART</td>
</tr>
<tr>
<td>Michael Corley, Suparnee Buranapraditkun, Alina Pang, Alexandra Schuetz, Sodsai Tovanebutra, Shelli Farhadian, Morgane Rolland, Nittaya Phanuphak, Jennifer Chiarell, Carlo Sacdalan, Denise Hsu, Sandhya Vasan, Serena Spudich, Lishomwa Ndhlovu</td>
<td></td>
</tr>
<tr>
<td>Research Group: SEARCH013/RV304 study group</td>
<td></td>
</tr>
<tr>
<td>481</td>
<td>INTERACTIONS BETWEEN GUT MICROBIOTA SIGNATURES AND CNS STATUS IN A HIV CURE STRATEGY</td>
</tr>
<tr>
<td>Alessandra Borgognone, Anna Prats, Bonaventura Clotet, José Molto, Beatriz Motte Puejadas, Roger Paredes, Jose A. Muñoz- Moreno</td>
<td></td>
</tr>
</tbody>
</table>
Poster Session-G2 DRUG-DRUG INTERACTIONS: A FOCUS ON TB, EFAVIRENZ SWITCHING

2:30 PM - 4:00 PM

505 GENETICS OF HIV AND TB DRUG INTERACTIONS WITH LEVONORGESTREL EMERGENCY CONTRACEPTION

Nana Agyemang, Kimberly K. Scarsi, Paxton Baker, Laura Smeaton, Anthony T. Podany, Maxine Olefsky, Sajeeed Mawlan, Khuanchai Supparatpinyo, Sivaporn Gatechompol, Emilia M. Jalil, Pablo F. Belaunzaran-Zamudio, Catherine Godfrey, Susan E. Cohn, Rosie Mngqibisa, David W. Haas

Research Group: AIDS Clinical Trials Group A5375 Study Team

506 IMPACT OF OBESITY ON THE DRUG-DRUG INTERACTION BETWEEN DOLUTEGRAVIR AND RIFAMPICIN

Mattia Berton, Sara Bettonte, Felix Stader, Manuel Battegay, Catia Marzolini

507 PHARMACOKINETICS OF STANDARD VS DOUBLE-DOSE DOLUTEGRAVIR AFTER SWITCH FROM EFAVIRENZ

Rulan Griesel, Clifford Banda, Ying Zhao, Phumla Sinxadi, Zaayid Omar, Graeme Meintjes, Gary Maartens

508 INTRAMUSCULAR CABOTEGRAVIR/RILPIVIRINE CONCENTRATIONS AFTER SWITCHING FROM EFAVIRENZ

Sara Bettonte, Mattia Berton, Felix Stader, Manuel Battegay, Catia Marzolini

509 SWITCHING OFF EFAVIRENZ TO NON-EFAVIRENZ ART LOWERS NICOTINE METABOLITE RATIO IN PWH

Robert Gross, Warren Bilker, Xiaoyan Han, Jessica Merlin, Michael Plankey, Jeffrey Martin, Heidi Crane, Leila Hojat, Laura Bamford, Robert Schnoll, Rachel Tyndale, Rebecca Ashare

Research Group: CNICS

Poster Session-H1 LAI CAB/RPV: WHERE ARE WE NOW AND WHERE ARE WE GOING?

2:30 PM - 4:00 PM

516 PREDICTORS OF POST SWITCH VIREMIA IN PATIENTS ON INJECTABLE CABOTEGRAVIR/RILPIVIRINE

Stephanie Kenney, Nimish Patel, Lucas Hill

517 PROJECTED BENEFITS OF LONG-ACTING ART IN PWH WITH VIREMIA DESPITE PRESCRIBED ORAL ART

Wanyi Chen, Monica Gandhi, Paul Sax, Anne Neilan, Justine Scott, Timothy Wilkin, Andrea L. Ciaramello, Joseph J. Eron, Kenneth A. Freedberg, Emily P. Hyle

518 HIGH VIROLOGIC SUPPRESSION RATES ON LONG-ACTING ART IN A SAFETY-NET CLINIC POPULATION

Monica Gandhi, Jorge Salazar, Matthew D. Hickey, Katerina Christopoulos, Jon Oskarsson, Mary Shiels, John Szumowski, Janet Grochowski, Francis Munoz-Mayorga, John Sauceda, Elizabeth Imbert, Janet Nguyen, David V. Glidden, Diane V. Havlir

519 THIGH INJECTIONS OF CABOTEGRAVIR+RILPIVIRINE IN VIRALLY SUPPRESSED ADULTS WITH HIV-1

Franco Felizarta, Ronald D’Amico, Kehui Wang, Herta Cruewels, Mar Masià, Miguel Garcia Deltoro, Olaf Deben, Jonathan Angel, Chiu-Bin Hsiao, Vasiliki Chounta, Kelong Han, Conn Harrington, Kelly Rimler, William R. Spreen, Susan Ford
Poster Sessions

Poster Session-H7 SARS-CoV-2 TREATMENT: THE IMPACT OF REMDESIVIR
2:30 PM - 4:00 PM

556 REMDESIVIR REDUCES MORTALITY IN HOSPITALIZED COVID-19 PATIENTS ACROSS VARIANT ERAS
Essy Mozaffari, Aastha Chandak, Robert L. Gottlieb, Chidinma Chima-Melton, Stephanie H. Read, Heng Jiang, Celine Der-Torossian, Eunyoung Lee, Lauren Dau, Mark Thrun, Mark Berry, Richard Haubrich, Andre C. Kalil

557 REMDESIVIR REDUCES MORTALITY IN IMMUNOCOMPROMISED PATIENTS HOSPITALIZED FOR COVID-19
Essy Mozaffari, Aastha Chandak, Robert L. Gottlieb, Andre C. Kalil, Stephanie H. Read, Heng Jiang, Mel Chiang, Eunyoung Lee, Rikisha Gupta, Mark Thrun, Chidinma Chima-Melton

558 REMDESIVIR IS ASSOCIATED WITH REDUCED READMISSION AFTER COVID-19 HOSPITALIZATION
Essy Mozaffari, Aastha Chandak, Robert L. Gottlieb, Andre C. Kalil, Vishnudas Sarda, Celine Der-Torossian, Thomas Oppelt, Lauren Dau, Mark Berry, Chidinma Chima-Melton

559 RISK OF DEATH IN REMDESIVIR TREATED ANDUNTREATED PATIENTS WITH COVID-19 INFECTION
Adeel Butt, Victor Talisa, Peng Yan, Obaid Shaikh, Florian G. Mayr

560 REMDESIVIR IN HOSPITALIZED COVID-19 PATIENTS: INDIVIDUAL PATIENT DATA META-ANALYSIS
Alain Amstutz, Benjamin Speich, France Mentré, Corina Silvia Rueegg, Drifa Belhadi, Lambert Assoumou, Dominique Costagliola, Inge Christoffer Olsen, Matthias Briel

561 REMDESIVIR RESISTANCE ANALYSES FROM THE PINETREE STUDY IN OUTPATIENTS WITH COVID-19
Lauren Rodriguez, Hery W. Lee, Jian Li, Ross Martin, Dong Han, Simin Xu, Gregory Camus, Jason K. Perry, Robert Hyland, Danielle P. Porter, Mazin Abdelghany, Matthias Gütte, Charlotte Hedskog

562 REMDESIVIR RETAINS POTENT ACTIVITY AGAINST SARS-CoV-2 VARIANTS OF CONCERN
Lauren Rodriguez, Tien-Ying Hsiang, Jian Li, Dong Han, Xianghan Lu, Ross Martin, Nicholas C. Riola, Jared Pitts, Jason K. Perry, John P. Bilello, Michael Gale, Danielle P. Porter, Charlotte Hedskog

Poster Session-I1 HIV RESISTANCE EMERGENCE AND OUTCOMES
2:30 PM - 4:00 PM

573 FACTORS ASSOCIATED WITH HIV-1 RESISTANCE TO INTEGRASE STRAND TRANSFER INHIBITORS
Horacio Gil, Elena Delgado, Sonia Benito, María Moreno-Lorenzo, Michael M. Thomson
Research Group: Spanish Group for the Study of Antiretroviral Drug Resistance

574 Efficacy of 3TC-DTG VS 3-DRUG REGIMENS IN VIROLOGICALLY-SUPPRESSED PLWH
Alberto Borghetti, Arturo Ciccillo, Francesca Lombardi, Rosanna Passerotto, Francesco Lamanna, Damiano Farinacci, Alex Dusina, Gianmaria Baldin, Maurizio Zazzi, Simona Di Giambenedetto

575 INFREQUENT DETECTION OF EMERGENT HIV DRUG RESISTANCE IN LOW VIRAL LOAD SPECIMENS
Hanwei Sudderuddin, Walter Scott, Charlotte Beelen, Anh Le, Tetyana Kalnyak, Rob Hollebakken, Amanda Granados, Sakshi Khanna, Weiyan Dong, Viviane D. Lima, Julio Montaner, Chanson J. Brumme
576  **DRUG RESISTANCE IN PEOPLE FAILING DOLUTEGRAVIR-BASED ART: HIV COHORT COLLABORATION**


577  **LOW-FREQUENCY NNRTI MUTATIONS CORRELATE WITH HIV ART FAILURE IN PREGNANT WOMEN**


578  **EMERGING INTEGRASE INHIBITOR HIV DRUG RESISTANCE MUTATIONS: TANZANIAN NATIONAL SURVEY**


579  **INCIDENCE OF ACQUIRED INTEGRASE RESISTANCE AFTER TRANSITION TO DOLUTEGRAVIR IN UGANDA**


Poster Session-J1 HBV PREVENTION AND TREATMENT

2:30 PM - 4:00 PM

586  **KINETICS OF HBV RNA AND CORE-RELATED ANTIGEN LEVELS IN PLWH WITH FUNCTIONAL HBV CURE**


Research Group: Swiss HIV Cohort Study

587  **LONG-TERM HEPATITIS B OUTCOMES IN ZAMBIA WITH TENOFOVIR-TREATED HBV/HIV COINFECTION**

Michael Vinikoor, Kalongo Hamusonde, Guy Muula, Mah Asombang, Debika Bhattacharya, Edford Sinkala, Georg Lauer, Raymond Chung, Wilson Mbewe, Matthias Egger, Samuel Bosomprah, Gilles Wandelers

Research Group: IeDEA Southern Africa

588  "MICRO-INFECTION" OF HBV CAN OCCUR IN MSM WITH VACCINATION OR TENOFOVIR-BASED PrEP

Daisuke Mizushima, Misao Takano, Takahiro Aoki, Koji Watanabe, Haruka Uemura, Hiroyuki Gatanaga, Shinichi Oka

589  **BULEVIRIDE +/- PEG-IFN IN HIV/HBV/HDV COINFECTED PATIENTS IN REAL-LIFE SETTINGS**

Victor de Ledinghen, Anne Gervais, Marie-Noelle Hilleret, Karine Lacombe, Patrick Mailhes, Bruno Roche, Louis D’Alteroche, Jean-Pierre Arpurt, Isabelle Rosa, Antonia Le Gruyer, Marc-Antoine Valantin, Helene Regnault, Christiane Stern, Tarik Asselah, Stanislas Pol

Research Group: cATU

Poster Session-J2 NEW DEVELOPMENTS IN HCV EPIDEMIOLOGY AND TREATMENT

2:30 PM - 4:00 PM

590  **HCV INCIDENCE AMONG MSM ON PrEP AND MSM WITH HIV IN NEW YORK CITY OVER 2 DECADES**

Richard J. Silvera, Antonio Urbina, Keith Sigel, Daniel Fierer
591  HEPATITIS C BURDEN IN GREECE, ITALY, PORTUGAL, AND SPAIN: 2000-2019
Claudia Palladino, Ifeanyi Jude Ezeonwumelu, Nuno Taveira, Verónica Briz

592  USABILITY AND ACCEPTABILITY OF HCV SELF-TESTING IN THE GENERAL POPULATION FROM BRAZIL
Hugo Perazzo, Cristiane Villela-Nogueira, Maria Kátia Gomes, Andre Daher, Cristiane Valle, Ana Cristina G. Ferreira, Elton C. Almeida, Sandra Cardoso, Beatriz Grinsztejn, Valdirea Veloso
Research Group: Grupo de Pesquisa Clínica em Hepatologia (GPC-HEPATOL)

593  UPTAKE AND LINKAGE TO CARE FOR HCV SELF-TESTING: RESULTS FROM A MULTI-COUNTRY RCT
Sonjelle Shilton, Saeed Hamid, Muhammad Radzi Abu Hassan, Ketevan Stvilia, Aliya Hasnain, Xiaohai Sem, Maia Japaridze, Nino Tsereteli, Dali Usharidze, Anushya Karunanithy, Niklas Luhmann, Brooke Nichols, Jessica Markby, Elena Reploid

594  MOBILIZING PRIMARY CARE PROVIDERS TO TREAT HEPATITIS C IN RURAL WEST VIRGINIA
Judith Feinberg, Adam Baus, Garret Cooper, Joy Juskowich, Andrea Calkins, John Guilfoose

595  OPTIMAL FREQUENCY OF HCV RNA TESTING FOR PLWH AT RISK FOR ACUTE HCV INFECTION

596  SVR12 OUTCOMES FOR NOVEL HCV GENOTYPE/SUBTYPES WITH SOF/VEL IN MINMON STUDY
Win Min Han, Sunil S. Solomon, Sandra Wagner-Cardoso, Jiani Li, Aiyappa Parvanga, Mark S. Sulkowski, Susanna Naggie, Ross Martin, Hongmei Mo, Evgenia Maierova, David Wyles

597  SOFOSBUVIR/VELPATASVIR PHARMACOKINETICS IN PREGNANT WOMEN WITH HEPATITIS C VIRUS
Catherine Chappell, Jennifer Kiser, Riley Randolph, Ingrid Macio, Leslie Meyn, Sam Mawhinney, Anne-Marie Rick, Gyssella Muniz, Kyung-Min Kwon, Cathleen Letterio, Sarjita Naik, Bruce Kreter, Sharon L. Hillier

654  SMOKING CESSATION AND SHORT-TERM VASCULAR IMPROVEMENT IN A COHORT OF PEOPLE WITH HIV
Rodrigo Moreira, Angela Rodrigues, Carla Renata, Beatriz Leonardo, Daniel Arabe, Sandra Wagner Cardoso, Beatriz Grinsztejn, Valdirea Veloso, Antonio G. Pacheco

655  AORTIC ANEURYSMS AND MARKERS OF ENDOTHELIAL AND PLATELET ACTIVATION IN PLWH
Sylvester Gronbaek, Julie Hogh, Michael Pham, Andreas D. Knudsen, Andreas Fuchs, Sisse Ostrowski, Thomas Lars Benfield, Klaus Kofoed, Susanne Dam Poulsen
Research Group: COCOMO study

656  BMI MEDIATES THE LINK BETWEEN HIV-RELATED FACTORS AND HYPERTENSION BUT NOT DIABETES
Peter-Vanes Ebasone, Anastase Dzudie, Nasheeta Peer, Andre Pascal Kengne
657 RACIAL AND HIV DISPARITIES IN HYPERTENSION TREATMENT CASCADE AMONG WOMEN
Jessica Blair, Mirjam Colette-Kempf, Jodie Dionne-Odom, Zeroria Causey-Pruitt, Jenni Wise, Elizabeth Jackson, Paul Muntt, David B. Hanna, Jorge R. Kizer, Margaret Fischl, Igbo Ofotokun, Adaora Adimora, Stephen Gange, Emily B. Levitan

658 DOLUTEGRAVIR EXPOSURE, BUT NOT BICTEGRAVIR, INCREASES IN VITRO PLATELET AGGREGATION
Renos Kenyipoulos, Akif A. Khawaja, Mike Emerson

659 MARIJUANA USE AND THE RISK OF INCIDENT VENOUS THROMBOEMBOLISM IN PEOPLE WITH HIV
Lara Haidar, Robin Nance, Stephanie Ruderman, Alekhyra Lavu, Laila Aboulatta, Payam Peymani, Andrew Hahn, Amanda Willig, Katerina Christopoulous, Jeannie Keruly, Kristina Crothers, Joseph Delaney, Heidi Crane, Sherif Eltonsy

Poster Session-M2 METABOLIC COMPLICATIONS

2:30 PM - 4:00 PM

675 RANDOMIZED CLINICAL TRIAL OF TRANSGENDER WOMEN SWITCHING TO BIC/F/TAF (MOBETTA TRIAL)
Ana Hyatt, Han Feng, Paula Debroy, Aaren Kettelhut, Hongyu Miao, Liming Peng, Shalender Bhasin, Todd T. Brown, Nicholas Funderburg, Jordan E. Lake

676 METABOLOMIC PROFILING SHOWS MORE LIPID ABNORMALITIES IN NNRTI COMPARED TO InStI USERS
Wilhelm A. J. W. Vos, Nadira Vadaq, Albert L. Groenendijk, Marc J. T. Blauuw, Louise E. van Eekeren, Vasiliki Matzaraki, Kees Brinkman, Quirijn De Mast, Mike van Der Kolk, Jan van Lunzen, Janneke E. Stalenhoef, Willem L. Blok, Andre J.A.M. van Der Ven
Research Group: 2000HIV

677 INSULIN RESISTANCE, DM 2, AND POTENTIAL IMPACT OF FIRST ART IN NAIVE HIV-SUBJECTS
Maria Luisa Montes, Carmen Busca, Maria Lagarde, Inés Suárez-Garcia, Maria Rivero, Arkaitz Imaiz, Julián Olalla, Cristina Hernández-Gutiérrez, Félix Gutierrez, José Antonio Iribarren, Miguel Górgolas, Miguel de Zarraga, José Ignacio Bernardino, Luz Martín-Carbonero, Juan González-Garcia
Research Group: RIS, Red Investigación en SIDA

678 MITOCHONDRIAL HAPLOGROUPS, ANTIRETROVIRAL DRUGS, AND DIABETES RISK AMONG MEN WITH HIV
Jing Sun, Todd T. Brown, David Samuel, WeiQin Tong, Sudipa Sarker, Alison Abraham, Jeremy Martinson, Shehnaz Hussain, Steven Wolinsky, Todd Hulgan
Research Group: MWCCS

679 ASSOCIATION OF SEX HORMONES WITH INCIDENT DIABETES IN WOMEN WITH AND WITHOUT HIV
Rebecca A. Abelman, Michael Schneider, Christopher Cox, Jennifer C. Price, Margide Cohen, Deborah Gustafson, Michael Plankey, Anjali Sharma, Phyllis C. Tien

680 IMMUNE CHECKPOINTS AND PANCREATIC BETA CELL DYSFUNCTION IN HIV
Luke Pryke, Ziyue Liu, Alka Khaitan, Emily Sims, Samir Gupta

681 AGREEMENT BETWEEN HBA1C AND INTERSTITIAL GLUCOSE IN PEOPLE LIVING WITH HIV
Harriet Daultrey, Belinda Chihota, Nick Oliver, Matthias Egger, Gilles Wandelier, Carolyn Bolton Moore, Guy Muula, Juliet Wright, Tom Levett, Jaime Vera, Ali Chakera
682  A RANDOMIZED CONTROLLED TRIAL OF BERBERINE EFFICACY ON METABOLIC SYNDROME PLUS HIV

Poster Session-M3 BONE, RENAL, PULMONARY, AND HEMATOLOGIC DISEASE 2:30 PM - 4:00 PM

683  HIV, GENOTYPE, AND CKD: DOES TENOFOVIR EXPOSURE MATTER IN AFRICAN AMERICAN PWH?
Skye Opsteen, Ashutosh Tamhane, Chris Mathews, Cheryl Winkler, Christina Wyatt, Mari Kitahata, Heidi Crane, Richard Moore, Jeffrey Jacobson, Katerina Christopoulos, Kenneth Mayer, Michael S. Saag, Michael J. M. Mugavero, Thibaut Davy Mendez, Ellen Eaton
Research Group: Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS)

684  VITAMIN C DYSREGULATION IN HIV: CROSS-SECTIONAL STUDY OF RENAL LEAK IN HIV+ WOMEN
Ifechukwu E C Ebenuwa, Pierre-Christian Violet, Kate Michel, Hongbin Tu, Kenneth Wilkins, Seble Kassaye, Daniel Merenstein, Mark Levine

685  RECOVERY OF BONE MASS IN WOMEN ON DEPO-PROVERA AND TDF-BASED ART SWITCHED TO B/F/TAF
Flavia Matovu Kiweewa, Magi E. Beksinska, Martin Nabwana, Juliet Allen Babiry, Esther Isingel, Noah Kiwanula, John Pettifor, Todd T. Brown
Research Group: BONE:STAR STUDY TEAM

686  QUARTERLY VITAMIN D3 SUPPLEMENTATION TO MITIGATE TENOFOVIR-ASSOCIATED BONE LOSS
Evelyn Hsieh, Wei Cao, Hongxin Zhao, Wen Wang, Wei Pan, Xiaojing Song, Yang Han, Wenmin Guan, Yunshan Xu, Michael T. Yin, Karl Insogna, Liana Fraenkel, Wei Yu, Weibo Xia, Taisheng Li, Fuping Guo, Ting Zhu

687  IL-1B AND IL-10 ARE ASSOCIATED WITH FASTER LUNG FUNCTION DECLINE IN PEOPLE WITH HIV
Rebekka Faber Thudium, Nicoline Stender Arentoft, Hedda Hoel, Jakob Hjorth Von Stemmann, Julie Lyng Forman, Jon Torgny Wilcke, Thomas Lars Benfield, Marius Trøseid, Álvaro Humberto Borges, Sisse Rye Ostrowski, Jørgen Vestbo, Ken M. Kunisaki, Jens-Ulrik Staehr Jensen, Susanne Dam Poulsen

688  ASSOCIATION OF ANEMIA ON SURVIVAL AMONG PEOPLE WITH HIV AFTER ART INITIATION
Raynell Lang, Sally B. Coburn, M. John Gill, Ronald J. Bosch, Michael A. Horberg, Amy C. Justice, Mona Loufty, Angel Mayor, Richard Moore, Charles Rabkin, Michael J. Silverberg, Kelly Gebo, Keri Althoff
Research Group: North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA

Poster Session-M5 FRAILTY, FUNCTIONAL STATUS, AND HEALTH 2:30 PM - 4:00 PM

696  SARCOPENIA, FRAILTY, NUTRITION, AND HCV INFECTION AMONG OLDER PEOPLE WITH HIV
Hay Mar Su Lwin, Win Min Han, Tanakorn Apornpong, Thanathip Wichiansan, Jedasakorn Bonrungsirisap, Chanya Chatjikaronkul, Matthew Sirisukaskulchai, Papitchaya Sukruen, Sivaponate Gatechompol, Stephen J. Kerr, Anchalee Avihingsanon
Research Group: HIV-NAT
CMV IgG IS ASSOCIATED WITH MUSCLE FUNCTION BUT NOT QUALITY OR MASS IN PEOPLE WITH HIV
Research Group: REPRIEVE Study Team

VALIDITY OF A SELF-REPORTED MODIFIED FRAILTY PHENOTYPE AMONG PEOPLE WITH HIV
Stephanie Ruderman, Allison Weibel, Amanda Willig, Lydia Drumright, Annette Fitzpatrick, Michelle Odden, John Cleveland, Christine Davey, Julia Fleming, Thomas Buford, Raymond Jones, Meredith Greene, Charles Kamen, Chintan Pandya, Heidi Crane

COMORBIDITIES AND SYMPTOMS ASSOCIATED WITH FALLS: 2020-2021
Lydia Drumright, Stephanie Ruderman, Amanda Willig, Bridget Whitney, Robin Nance, Andrew Hahn, Sarah Mixson, Jimmy Ma, Rob Fredericksen, Jeff Jacobson, Katerina Christopoulos, Sonia Napravnik, Edward Cachay, Allison Weibel, Heidi Crane

PREVALENCE, INCIDENCE, AND RISK FACTORS FOR FALLS IN OLDER PEOPLE WITH AND WITHOUT HIV
Emanuele Focà, Stefania Arsuffi, Jovana Milic, Chiara Mussi, Alessandra Marengoni, Micol Ferrara, Benedetto Maurizio Celesia, Giordano Maddeddu, Anna Maria Cattelan, Stefano Calza, Andrea Calcagno, Giovanni Guaraldi

A 12-WEEK MULTICOMPONENT EXERCISE PROGRAM REVERSES FRAILTY IN OLDER ADULTS WITH HIV
Fátima Brañas, Jorge Díaz-Álvarez, Jesús Fernández-Luna, Brian Vásquez, Rafael García-Molina, Elena Moreno, Pablo Ryan, Javier Martinez-Sanz, Laura Luna, Marta Martinez, Fernando Dronda, Matilde Sánchez-Conde

SMOKING CESSATION AND ASSOCIATED FACTORS IN THE HIV OUTPATIENT STUDY: 2007-2021
Jun Li, Carl Armon, Alexander Ewing, Jonathan Mahnken, Ellen Tedaldi, Frank Palella, Richard Novak, Cynthia Firnhaber, Stockton Mayer, Andrea Wendrow, Gina Simoncini, Linda Battalora, Kimberly Carlson, Marcus Durham, Kate Buchacz
Research Group: HIV Outpatient Study (HOPS) Investigators

HIV INFECTION INCREASES RISK OF PASC WHILE COVID-19 VACCINATION IS PROTECTIVE
George A. Yendewa, Jamie A. Perez, Nirav T. Patil, Grace A. McComsey

IMMUNE STATUS AND SARS-CoV-2 VIRAL DYNAMICS
Yijia Li, Carlee Moser, Evgenia Aga, Judith S. Currier, David A. Wohl, Eric S. Daar, Justin Ritz, Robert Coombs, Michael D. Hughes, Joseph J. Eron, Davey M. Smith, Kara W. Chew, Jonathan Z. Li
Research Group: ACTIV-2/A5401

PROLONGED VIABLE VIRAL SHEDDING IN IMMUNOCOMPROMISED PATIENTS WITH COVID-19
Sung-Woon Kang, Jun-Won Kim, Ji Yeun Kim, So Yun Lim, Choi-Young Jang, Euijin Chang, Jeong-Sun Yang, Kyung-Chang Kim, Hee-Chang Jang, Dasol Kim, Younmin Shin, Joo-Yeon Lee, Sung-Han Kim

SUICIDAL RISK AMONG PEOPLE WITH HIV AFTER LOCKDOWN DUE TO COVID-19 PANDEMIC
Yanink Caro-Vega, Jessica Mejía-Castrejón, Atena Alvarez, Alvaro López Iñiguez, Juan Sierra-Madero, Brenda E. Crabtree-Ramirez

Poster Session-N2 COVID-19 IN THOSE WITH HIV AND IMMUNOCOMPROMISING CONDITIONS
2:30 PM - 4:00 PM

HIV INFECTION INCREASES RISK OF PASC WHILE COVID-19 VACCINATION IS PROTECTIVE
George A. Yendewa, Jamie A. Perez, Nirav T. Patil, Grace A. McComsey

IMMUNE STATUS AND SARS-CoV-2 VIRAL DYNAMICS
Yijia Li, Carlee Moser, Evgenia Aga, Judith S. Currier, David A. Wohl, Eric S. Daar, Justin Ritz, Robert Coombs, Michael D. Hughes, Joseph J. Eron, Davey M. Smith, Kara W. Chew, Jonathan Z. Li
Research Group: ACTIV-2/A5401

PROLONGED VIABLE VIRAL SHEDDING IN IMMUNOCOMPROMISED PATIENTS WITH COVID-19
Sung-Woon Kang, Jun-Won Kim, Ji Yeun Kim, So Yun Lim, Choi-Young Jang, Euijin Chang, Jeong-Sun Yang, Kyung-Chang Kim, Hee-Chang Jang, Dasol Kim, Younmin Shin, Joo-Yeon Lee, Sung-Han Kim

SUICIDAL RISK AMONG PEOPLE WITH HIV AFTER LOCKDOWN DUE TO COVID-19 PANDEMIC
Yanink Caro-Vega, Jessica Mejía-Castrejón, Atena Alvarez, Alvaro López Iñiguez, Juan Sierra-Madero, Brenda E. Crabtree-Ramirez
Poster Session-N3 COVID-19: CLINICAL AND PROGNOSTIC FEATURES AND EFFECTS OF THERAPEUTIC INTERVENTIONS
2:30 PM - 4:00 PM

728 SIGNIFICANCE OF ELEVATED SARS-CoV-2 ANTIGEN LEVELS DURING EARLY HOSPITALIZATION
Mamta K. Jain
Research Group: ACTIV-3/TICO Study Group

729 IMMEDIATE AND CONTRIBUTORY CAUSES OF DEATH IN PATIENTS HOSPITALIZED WITH COVID-19

730 ANTI-S-RBD TITER AND RISK OF CLINICAL PROGRESSION IN PATIENTS WITH COVID-19 PNEUMONIA
Giuseppe Lapadula, Luca Mezzadri, Giustina Lo Cascio, Sergio Malandrin, Alice Ranzani, Silvia Limonta, Annalisa Cavallero, Paolo Bonfanti

731 AI-BASED PREDICTION OF LUNG TISSUE INVOLVEMENT IS PREDICTIVE OF COVID-19 SEVERITY
Miłosz Parczewski, Bogusz Aksak-Wąs, Daniel Chober, Laura Lesiewska, Malwina Karasińska-Cieśiak, Krystian Awgul, Adam Majchrzak, Karol Serwin

732 A JOINT ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS ON ENOXAPARIN FOR COVID-19
Giovanni Dolci, Cinzia Del Giovane, Massimo Arquati, Valeria Coluccio, Erica Franceschini, Roberto D’Amico, Roberto Vicini, Pasquale Miglioli, Riccardo Colombo, Alba Taino, Pietro Facchinetti, Lucia Trombetta, Francesca Tonelli, Marco Marietta, Maddalena Alessandra Wu

733 THE IMPACT OF EARLY OUTPATIENT TREATMENTS FOR COVID-19: A RETROSPECTIVE STUDY
Silvia Amadasi, Paola Bertuccio, Melania Degli Antoni, Francesca Viola, Davide Minisci, Francesco Rossini, Alex Francesco Bolandrini, Francesco Castelli, Anna Odone, Eugenia Quiros-Roldan

Poster Session-O3 STRATEGIES FOR OPTIMIZING TB TREATMENT AND PREVENTIVE THERAPY
2:30 PM - 4:00 PM

750 HIGH-DOSE ISONIAZID EARLY BACTERICIDAL ACTIVITY AGAINST DRUG-RESISTANT TUBERCULOSIS
Research Group: ACTG A5312 study team

751 TWICE-DAILY DOsing OF ATAZANAVIR SAFELY OVERCOMES THE INTERACTION WITH RIFAMPICIN
Kamunkhwala Gausi, Henry Mugerwa, Marco Siccardi, Maiara Montanha, Antonio D’Avolio, Lubbe Wiesner, Letisha Najjamba, Gary Maartens, Shamim Nakubaye, Cissy Kityo, Helen Mcclerlon, Saye Khoo, Mohammed Lamoerde, Paolo Denti, Catrina Waitt

752 LINEZOLID REACHES TARGET SITE IN PATIENTS WITH TB MENINGITIS AND HIV COINFECTION
Rob van Wijk, Freddie Kibeng, Paddy Kafeero, Anita Kabarambi, Patrick Muhumuza, Maria Nakimbuge, Anthony Ssemaganda, Colman Tayebwa, Matthew Zimmerman, Fiona Cresswell, Veronique Dartois, Payam Nahid, Rada Savic, Felicia C. Chow
753 PREDICTIVE VALIDITY OF POPULATION MODELS FOR LINEZOLID EXPOSURE AND TOXICITY IN ZeNIX
Marjorie Imperial, Belen Perez Solans, Jerry Nedelman, Rada Savic

754 HARD-TO-TREAT PHENOTYPES INCREASE TIME TO CULTURE CONVERSION IN DRUG-RESISTANT TB
Belen Perez Solans, Marjorie Imperial, Morounfolu Olugbosi, Rada Savic

755 EFFECTIVENESS OF DOLUTEGRAVIR IN PEOPLE ON RIFAMPIN-BASED TUBERCULOSIS TREATMENT
N. Sarita Shah, Cissy Kityo, Michael D. Hughes, Caitlyn McCarthy, Carole Wallis, Mina Hosseinipour, Deborah Langat, Mulinda Nyirenda, Mohammed Rassool, Rodney Dawson, Elizabeth Woolley, Catherine Godfrey, John W. Mellors, Charles Flexner, Gary Maartens
Research Group: AIDS Clinical Trials Group A5381/Hakim Study Team

756 DIFFERENTIATED SERVICE DELIVERY FOR PEOPLE COINFECTED WITH DRUG RESISTANT TB AND HIV
Karl Reis, Jennifer Zelnick, Allison Wolf, Rubeshan Perumal, Kogieuleum Naidoo, Boitumelo Seepamore, Kevin Guzman, Jesse Ross, Ken Cheung, K. Rivet Amico, Gerald Friedland, Amrita Daftary, Max O’Donnell
Research Group: PRospective study of Adherence in M/XDR-TB Implementation Science (PRAXiS) Research Group

757 ACCELERATING TUBERCULOSIS PREVENTIVE TREATMENT AMONG TANZANIANS LIVING WITH HIV
Alexander Kailembo, Jaiving Kazitanga, Daniel Magesa, Peter Neema, Diana Forno Rodriguez, Anand Date, Eva Matiko, Nicolas Schaad, Jonathan Grund, Brian Baker, Mahesh Swaminathan, Mohamed Jalilho

758 LOWER TB INCIDENCE AMONG PWH AFTER PREVENTIVE TREATMENT IN HIGH-BURDEN MDR TB SETTING
Olutomi Sodeke, Juliana de Fatuma Da Silva, Snigdha Vallabhaneni, Sherri L. Pals, N. Sarita Shah

774 ANTEPARTUM WEIGHT GAIN AND ADVERSE PREGNANCY OUTCOMES: A MEDIATION ANALYSIS
Research Group: IMPAACT 2010

775 UNIQUE EICOSANOID/LIPID PROFILES IN PREGNANT WOMEN LIVING WITH HIV IN BOTSWANA
Jennifer Jao, Lauren Bonner, Shan Sun, Justine Legbedeke, Keolebogile Mmasa, Gosego Masasa, Samuel W. Kgole, Sikhulile Moyo, Joseph Makhma, Mitchell E. Geffner, Elaine J. Abrams, Mariana Gerschenson, Yunping Qiu, Kathleen M. Powis, Irwin Kurland

776 CARDIOMETABOLIC RISK IN SOUTH AFRICAN POSTPARTUM WOMEN LIVING WITH HIV
Hlengiwe P. Madlala, Landon Myer, Azetta Fisher, Mushי Matjila, Gregory Petro, Zandile Maqwatini, Angela Bengtson

777 IMMUNE MARKERS IN PREGNANT WOMEN LIVING WITH HIV ON ART THERAPY BY MATERNAL BMI
Jessica Moore, Thokozile R. Malaba, Elton Mukonda, Shameem Jaumdally, Hlengiwe P. Madlala, Landon Myer, Marie-Louise Newell

782 PBPK MODEL PREDICTION OF LONG-ACTING CAB AND RPV CONCENTRATIONS IN PREGNANCY
Yifan Yu, Adrie Bekker, Xinnong Li, Robert Bies, Rachel Scott
783  PHARMACOKINETICS AND VIROLOGIC OUTCOMES OF BICETEGRAVIR IN PREGNANCY AND POSTPARTUM
Kathleen M. Powis, Mauricio Pinilla, Lauren Bergam, Alice Stek, Kristina M. Brooks, David Shapiro, Kevin Knowles, Kathleen George, Renee Browning, Nahida Chakhtoura, Priyanka Arora, Brooke M. Best, Mark Mirochnick, Jeremiah D. Momper
Research Group: IMPAACT 2026 Protocol Team

784  LONG-ACTING NANOFORMULATIONS REDUCE DOLUGETRAVIR EXPOSURE TO EMBRYO BRAIN
Emma G. Foster, Benson Edagwa, Howard E. Gendelman, Aditya Bade

785  DAPIVIRINE RING SAFETY AND DRUG DETECTION IN BREASTFEEDING MOTHER-INFANT PAIRS
Research Group: MTN-043/B-PROTECTED Study Team

786  PREGNANCY AND BIRTH OUTCOMES FOLLOWING ORAL PrEP USE BY OBJECTIVE LEVELS OF TDF/FTC
Dvora Joseph Davey, Dorothy C. Nyemba, Rufaro Mvududu, Nyiko Mashele, Linda-Gail Bekker, Pamina M. Gorbach, Thomas J. Coates, Landon Myer
Research Group: PrEP-PP Study Group

Poster Session-P6 COVID-19 IN PREGNANCY: EVOLVING INSIGHTS
2:30 PM - 4:00 PM

794  SARS-CoV-2 ANTIBODY RESPONSES POST-INFECTION IN PREGNANCY BY VACCINATION STATUS
Sylvia M. Lacourse, Erica Wetzler, Morgan C. Aurelio, Jaclyn Escudero, Stacy Selke, Alexander L. Greninger, Alisa B. Kachikis, Janet A. Englund, Alison L. Drake

795  SARS-CoV-2 SEROPREVALENCE TREND AMONG PREGNANT WOMEN IN ZAMBIA, 2021-2022
Elizabeth Heilmann, Taniya Tembo, Felix Chilambe, Sombo Fwoloshi, Kalubi Kalenga, Mpanji Siwingwa, Samuel Yingst, Warren Malambo, Victoria Seffren, Ruchi Yadav, Theodora Savory, Andrew Auld, Jonas Hines, Lloyd B. Mulenga, Izuanki Sikazwe

795.5  SARS-CoV-2 SEROPREVALENCE BY HIV STATUS AMONG PREGNANT WOMEN IN ZAMBIA, 2021-2022
Elizabeth Heilmann, Taniya Tembo, Sombo Fwoloshi, Kalubi Kalenga, Mpanji Siwingwa, Samuel Yingst, Julie Gutman, Victoria Seffren, Ruchi Yadav, Theodora Savory, Izuanki Sikazwe, Jonas Hines

796  COVID-19 VACCINATED MATERNAL/CORD BLOOD DON’T HAVE NEUTRALIZATION FOR OMICRON VARIANTS
Sakthivel Govindaraj, Narayanaiah Cheedarla, Suneetha Cheedarla, Les’Shon S Irby, Andrew Neish, John Roback, Alicia K. Smith, Vijayakumar Velu

Poster Session-Q2 INFLAMMATION AND IMMUNITY IN CHILDREN
2:30 PM - 4:00 PM

806  MORTALITY LINKED TO HIGHER INFLAMMATION IN PERINATALLY-INFECTED HIV+ KIDS
Elena Morrocchi, Giuseppe Rubens Pascucci, Nicola Cotugno, Chiara Medri, Chiara Pighi, Sara Dominguez, Alfredo Tagarro, Lesley de Armas, Savita Pahwa, Maria Raffaella Pettrara, Anita De Rossi, Ofer Levy, Paolo Rossi, Carlo Giaquinto, Paolo Palma
Research Group: EPIICAL Consortium
INFECTED NAIVE CD4+ T CELLS IN CHILDREN WITH HIV CAN PROLIFERATE AND PERSIST ON ART
Mary Grace Katusiime, Shuang Guo, Victoria Neer, Sean C. Patro, Xiaolin Wu, Anna Horner, Ann Chahoudi, Maud Mavigner, Mary F. Kearney

LONGITUDINAL T CELL IMMUNE PROFILING IN HIV-EXPOSED INFECTED AND UNINFECTED INFANTS
Lesley de Armas, Suresh Pallikkuth, Stefano Rinaldi, Vinh Dinh, Paula Vaz, Nadia Sito, Nicola Cotugno, Rajendra Pahwa, Paolo Palma, Maria Grazia Lain, Savita Pahwa

TORQUETENOVIRUS: MARKER OF IMMUNE RECONSTITUTION IN PERINATALLY HIV-INFECTED PATIENTS
Laura Tarancon-Diez, Itziar Carrasco, Laura Montes, Iker Falces, Santiago Jimenez de Ory, Marta Dapena, Luis López-Cortés, Elena Colino, Ana Isabel Menasalvas, Jose Antonio Iribarren, Cristina Diez, José Ignacio Bernardino, M+ Angeles Muñoz-Fernández, Marisa Navarro, Talia Sainz

Poster Session-Q3 REAL-WORLD OUTCOMES IN CHILDREN AND YOUTH WITH HIV
2:30 PM - 4:00 PM

HIGH MORTALITY IN AFRICAN INFANTS HOSPITALIZED WITH SEVERE PNEUMONIA AND ADVANCED HIV
Alfeu Passanduca, W. Chris Buck, Alfredo Tagarro, Victor Musiime, Hilda A. Mujuru, Chishala ChaBala, Lola Madrid, Sara Domínguez, Pui-Ying Iroh Tam, Tisungane Mvalo, Justina Magalhaes-Bramugy, Raoul Moh, Álvaro Ballesteros, Cinta Moraleda, Pablo Rojo
Research Group: EMPIRICAL Clinical Trial Group

MORTALITY RISK AMONG CHILDREN < 5 YEARS OLD LIVING WITH HIV ON ART
Nickolas T. Agathis, Iyiola Faturiyele, Kiva Fisher, Stephanie Hackett, Elfriede Agyemang, Susan Hrapcak, George Siberry, Catherine Godfrey

RELATIVE GAP IN HIV VIRAL LOAD SUPPRESSION IN YOUNGER CHILDREN IN ETHIOPIA
Dereje Habte, Alemayehu Mekonnen, Tekeste Kebede, Wondimu Teferi, Daniel M. Desalegn, Caroline A Ryan

FANMI: A RANDOMIZED TRIAL OF COMMUNITY COHORT HIV CARE FOR ADOLESCENT GIRLS, HAITI
Vanessa Rouzier, Lindsey Reif, Joseph Marie Bajo Joseph, Rose Riche, Heejung Bang, Elaine J. Abrams, Jean William Pape, Daniel W. Fitzgerald, Margaret McNairy
Research Group: The FANMI Clinical Trial Team

ECONOMIC STRENGTHENING INTERVENTION TO IMPROVE ART ADHERENCE IN HIV-INFECTED YOUTH
Samuel Kizito, Flavia Namuwoonge, Proscovia Nabunya, Josephine Nabayinda, Fred Ssewamala

Poster Session-R4 SEX, GENDER, AND VIOLENCE AND ASSOCIATION WITH OUTCOMES
2:30 PM - 4:00 PM

SEX DIFFERENCES IN NON-FATAL OVERDOSES: A POPULATION-BASED COHORT STUDY
Megan E. Marziali, Katherine W. Kooij, Jason Trigg, Michael O. Budu, Monica Ye, Viviane D. Lima, Julio Montaner, Robert S. Hogg

TRANSGENDER WOMEN BASELINE PROFILE IN transCITAR: TRANS-SPECIFIC COHORT IN ARGENTINA
Claudia E. Froia, Romina Caballero, Carina César, Emilia Frontini, María I. Figueroa, Carolina F. Pérez, Nicolás Doudchtzky, Nadir Cardozo, Virginia Zalazar, Ana Gun, Pedro E. Cahn, Valeria Fink, Inés Aristegui
Research Group: transCITAR Study Group
**Poster Sessions**

**CROI 2023**

### Poster Sessions

**114**

**Poster Sessions** • Tuesday

<table>
<thead>
<tr>
<th>860</th>
<th>INTIMATE PARTNER VIOLENCE IN A COHORT OF PERSONS WITH HIV IN CARE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rob Fredericksen, Lydia Drumright, Sarah Mixson, Robin Nance, Bridget Whitney, Stephanie Ruderman, Jimmy Ma, Andrew Hahn, Sonia Napravnik, Amanda Willig, Jeff Jacobson, Katerina Christopoulos, Edward Cachay, Mari Kitahata, Heidi Crane</td>
</tr>
</tbody>
</table>

**861** SYNERGISM BETWEEN VIOLENCE & HIV STATUS ON SUICIDAL IDEATION AMONG TRANSGENDER WOMEN

Evelyn Olansky, Kathryn Lee, Ruthanne Marcus, Susan Cha, Patrick C. Eustaquio

Research Group: NHBS-Trans Study Group

**862** PREVALENCE AND CORRELATES OF VIOLENCE AMONG PARTNERS OF PWID LIVING WITH HIV IN KENYA


**Poster Session-R5 RISK FACTORS FOR HIV ACQUISITION AND TRANSMISSION**

2:30 PM - 4:00 PM

<table>
<thead>
<tr>
<th>863</th>
<th>PERSISTENTLY HIGH HIV INCIDENCE AMONG MSM AND PWID ATTENDING CARE CENTRES IN INDIA</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>864</th>
<th>NOT GETTING TO ZERO HIV FOR PEOPLE WHO INJECT DRUGS, SAN FRANCISCO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Moranda Tate, Bow Suprasert, Danyion Reagan, Katherine Gao, Katherine McNaughton, Raul Ruiz, Kassandra Miller, Alexander Marr, Kelly D. Taylor, Willi McFarland, Erin C. Wilson</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>865</th>
<th>RACIAL DISPARITIES IN HIV PRE-EXPOSURE PROPHYLAXIS-RELATED OUTCOMES IN MALE VETERANS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dagan Coppock, Benjamin Viernes, Michael Kauth, Robert Gross, Kristine Lynch</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>866</th>
<th>BEHAVIOR CHANGE AMONG HIV-NEGATIVE MEN WHO HAVE SEX WITH MEN NOT USING PrEP IN THE US</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Steven M. Goodreau, Michael P. Barry, Deven T. Hamilton, Travis H. Sanchez, Kevin Delaney</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>867</th>
<th>REASONS FOR MIGRATION AND ASSOCIATIONS WITH HIV RISK AMONG SEXUAL MINORITY MEN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Jane J. Lee, Roxanne P. Kerani, Gabriel Robles, Travis H. Sanchez, David A. Katz</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>868</th>
<th>SEXUAL RISK AND ROLE OF LOW-LEVEL VIREMIA TO HIV TRANSMISSION IN SUB-SAHARAN AFRICA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>olanrewaju Edun, Lucy Okell, Helen M. Chun, Kyle Milligan, Emilio Dirlkiv, Ray W. Shiraishi, Jeffrey W. Eaton</td>
</tr>
</tbody>
</table>

Research Group: Viremia HIV Transmission Investigation Group

<table>
<thead>
<tr>
<th>869</th>
<th>REDUCTION OF HIV INCIDENCE AFTER ELIMINATION OF LYMPHATIC FILARIASIS</th>
</tr>
</thead>
</table>

---

**Poster Sessions - Tuesday**

**CME**

**Continuing Medical Education**

**LB** Late-Breaking

**NIS** New Investigator Scholarship

**NP** Nonauthor Presenter

**114** CROI 2023
Poster Session-S3 MPOX EPIDEMIOLOGY, IMPACT ON SEXUAL BEHAVIORS, AND STIGMA
2:30 PM - 4:00 PM

895 NEW HIV DIAGNOSES IDENTIFIED FROM LINKAGE TO CARE AFTER MPOX INFECTION, TEXAS 2022
Analise Monterosso, Kristyn Krolikowski, Kenneth Davis, Rania Milleron, Stephen White

896 MPOX VIRUS IN THE PHARYNX OF MEN HAVING SEX WITH MEN: A CASE SERIES
Silvia Limonta, Laura Corsico, Giuseppe Lapadula, Francesca Rovida, Alice Ranzani, Fausto Baldanti, Paolo Bonfanti

897 MPOX AMONG MSM IN THE NETHERLANDS PRIOR TO MAY 2022, A RETROSPECTIVE STUDY
Elske Hoornenborg, Henry de Vries, Hannelore Götz, Sylvia Bruisten, Annemie van Der Eijk, Maria Prins, Bas Oude Munnik, Matthijs Welkers, Marcel Jonas, Richard Molenkamp, Benda Westerhuis, Daphne Mulders, Leonard Schule, Mariken van Der Liubben, Marion Koopmans, Arjen Stam

898 CHANGES IN SEXUAL BEHAVIORS DUE TO MPOX: A CROSS-SECTIONAL STUDY OF SGM IN ILLINOIS
Gregory Phillips, Michael Curtis, Dylan Felt, Shahin Davoudpour, Anthony Rodriguez-Ortiz, Alfred Cortez, Audrey French, Sybil Hosek, Pedro Serrano

899 SEXUAL BEHAVIOR REDUCTION DO NOT EXPLAIN DECREASED MPOX INCIDENCE AMONG PrEP USERS.
Roberto Rossotti, Daniele Calzavara, Massimo Cernuschi, Anna De Bona, Alessandro Tavelli, Simona Bossolasco, Camilla Muccini, Daniele Tesoro, Davide Moschese, Giovanni Mulé, Antonella D’Arminio Monforte

900 STIGMA RELATED TO HUMAN MPOX VIRUS AMONG MSM IN THE US, AUGUST 2022
Thomas Cargino, Kaitlyn Atkins, Kevin Delaney, O. Winslow Edwards, Evan Eschliman, Amrita Rao, Saskia Vos, Sarah Murray, John Mark Wriginton, Travis H. Sanchez, Stefan Baral

901 HIGH LEVEL OF MPOX KNOWLEDGE AND STIGMA AMONG LGBTQIA+ COMMUNITIES IN BRAZIL
Thiago S. Torres, Mayara S. T. Silva, Carolina Coutinho, Brenda Hoagland, Sandra Wagner-Cardoso, Julio Moreira, Paula M. Luz, Valdilea G. Veloso, Beatrix Grinsztejn
Research Group: The INI-Fiocruz Mpx Study Group

Poster Session-S4 MPOX CHARACTERISTICS AND OUTCOMES
2:30 PM - 4:00 PM

902 CHARACTERISTICS AND DISPARITIES AMONG HOSPITALIZED PERSONS WITH MPOX IN CALIFORNIA

903 CD4 COUNT < 350 CELLS/MM³ INCREASES RISK OF HOSPITALIZATION WITH MPOX IN PWH
David CE. Philpott, Robert Bonacci, Paul J. Weidle, Kathryn G. Curran, John Brooks, George Khalil, Lauren Barrineau-Veijajiva, Amanda Feldpausch, Jessica Pavlick, Pascale Wortley, Jesse O’Shea
Research Group: CDC Mpx Special Studies Team

904 MPOX VIRUS INFECTION IS MORE SEVERE IN PATIENTS WITH UNCONTROLLED HIV INFECTION
Anais Corma-Gómez, Marta Santos, Alfonso Cabello, Miguel Morante-Ruiz, Aws Waleed Al-Hayani, Irene Carrillo Acosta, Lucio García-Fraile, Cristina Gómez-Ayerbe, David Rodrigo-Dominguez, Sergio Reus, Ana C. Silva Klug, Sandra De la Rosa-Riestra, Ana Ferrer-Ribera, Juan A. Pineda, Juan Macías
905 IMPACT OF HIV INFECTION ON MPOX-RELATED HOSPITALIZATIONS IN BRAZIL
Research Group: INI-Fiocruz Mpxox Study Group

906 CHARACTERISTICS OF THE 2022 MPOX OUTBREAK IN A SOUTHEASTERN US CITY
Bruce Aldred, Colleen Kelley, Jonathan Colasanti, Vincent C. Marconi, Anandi N. Sheth, Minh Nguyen, Jane Yoon Scott, Sheetal Kandiah, Aley G. Kalapila, Daniel Gromer, Amalia Aldredge, Brittany Szabo, Betsy Hall, Valeria D. Cantos
Research Group: Emory MAPS Study Group

907 CLINICAL OUTCOMES AMONG IN- AND OUTPATIENTS WITH MPOX IN AN URBAN HEALTH SYSTEM
William M. Garneau, Joyce L. Jones, Gabriella Dashler, Nathan Kwon, Matthew Hamill, Elizabeth Gilliams, David Rudolph, Jeannie Keruly, Eili Klein, Bhakti Hansoti, Kelly Gebo

908 HIV CARE AND PREVENTION CHARACTERISTICS AMONG PERSONS WITH MPOX AND HIV, TEXAS 2022
Kristyn Krolkowsk, Kenneth Davis, Rania Milleron, Stephen White

909 MPOX OUTBREAK IN PLWHA AND PrEP USERS IN A BRAZILIAN STI CENTER: DIFFERENT CHALLENGES
Alvaro Costa, Simone Queiroz Rocha, MyIva Fonsi, Roberta Schiavon Nogueira, Arthur Olhovetchi Kalichman, Jose V. Madruga, Maria Clara Gianna, Rosa Alencar, Rosangela Rodrigues, Angela Tayra, Lucas Ramos, Marisa Vono Tancredi
Research Group: MONKEYPOX GROUP - CRT CASA DA PESQUISA

910 MPOX IN THE CONTEXT OF POPULATION-LEVEL HIV TREATMENT AND HIV PrEP PROGRAMS IN BC
K. Junine Toy, Raquel M. Espinoza, Paul Sereda, Erin Ready, Wendy W. Zhang, Viviane D. Lima, Kate Salters, Rolando Barrios, Julio Montaner

911 MPOX IN AMSTERDAM: CROSS-SECTIONAL STUDY AMONG MSM AT THE CENTRE FOR SEXUAL HEALTH
Elkke Hoornenborg, Matthias Siegenbeek Van Heukelom, Vita Jongen, Jason Schouten, Sylvia Bruisten, Benda Westerhuis, Mathijs Welkers, Maria Prins, Maarten Schim Van Der Loeff, Henry de Vries

912 CHARACTERISTICS OF PATIENTS HOSPITALIZED WITH MPOX DURING THE 2022 US OUTBREAK
Research Group: Centers for Disease Control Severe Mpox Investigations Team

913 EQUITY FOCUSED EVALUATION OF MPOX CARE METRICS IN KING COUNTY, WA
Ellora Karmarkar, Chase Cannon, Matthew Golden, Sargis Pogosjans, Eric Chow, Meena Ramchandani, Kaitlin Zinsli, Julia C. Dombrowski

914 DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF MPOX WITHIN A NEW YORK CITY HEALTH SYSTEM
Christopher A. Vo, Rustin Zomorodi, Richard J. Silvera, Logan Bartram, Amarilis Lugo, Erna Kojic, Antonio Urbina, Judith A. Aberg, Keith Sigel, Rachel Chasan, Gopi Patel

915 MPOX INFECTION IN WOMEN: A CASE SERIES FROM BRAZIL
Carolina Coutinho, Luciane Velasque, Mayara Silva, Thiago S. Torres, Eduardo Peixoto, Sandra Wagner Cardoso, Gabriella Nazário, Maira Mendonça, Marianna Menezes, Paula Maria Almeida, Shonon Bia Bedin, Aline Maria Almeida, Silvia Carvalho, Valdilea Veloso, Beatriz Grinsztejn
Research Group: The INI-Fiocruz Mpxox Study Group
Poster Session-T2 DISPARITIES AND SOCIAL CONTEXT FOR HIV TESTING
2:30 PM - 4:00 PM

934 RACIAL/ETHNIC DISPARITIES IN HIV TESTING EXPERIENCE BEFORE HIV DIAGNOSIS: 2014-2019
Sonia Singh, Xueyuan Dong, Laurie Linley

935 CDC-FUNDED HIV TESTING AND UNDIAGNOSED HIV INFECTION IN ENDING THE HIV EPIDEMIC AREAS
Deesha Patel, Weston O. Williams, Carolyn Wright, Aba Essuon, Guoshen Wang, Mesfin Mulatu

936 FACTORS ASSOCIATED WITH HIV POSITIVITY UNAWARENESS AMONG TANZANIANS LIVING WITH HIV
Alexander Kailumbo, Oscar Rwabiyaayo, George Mogomella, Kokuhumbya Kazaure, Eva Matiko, Prosper Njau, Brian Baker, Mahesh Swaminathan, Mohamed Jalloh

937 OVER- AND UNDER-REPORTING IN HIV TESTING, STATUS, AND TREATMENT IN RURAL SOUTH AFRICA
Hannah H. Leslie, Chodziwadziwa Kabudula, Rebecca West, Mi-Suk Kang Dufour, Aimée Julien, Nkosinathi Masilela, Stephen Tollman, Audrey Pettifor, Kathleen Kahn, Sheri Lippman

938 SIGNS OF LATE HIV DIAGNOSIS AND OUTBREAKS IN TRANSMISSION NETWORKS IN JAPAN
Teichiro Shiino, Machiko Otani, Tadashi Kikuchi, Kazuhiisa Yoshimura, Wataru Sugiuira
Research Group: Japanese Drug Resistance HIV-1 Surveillance Network

939 PATTERNS OF HIV-1 RECENT INFECTIONS AMONG GENERAL AND KEY POPULATIONS IN NIGERIA
Adebola Sunday Adekogbe, Blessing Salako, Ray-Desmond Umechinedu, David Barnabas, Fadke Abuwonronye, Abimbola Phillips, Livinus Ibiang, Oluseyi Adegbulugbe, Collins Imarihiagbe, Bolanle Oyeledun

940 NO INCREASED VIOLENCE VICTIMIZATION AFTER RETURN OF RECENCY TEST RESULTS IN RWANDA
Eugenie Poirot, Giles Reid, Suzue Saito, Jean-Claude Irabona, Collins Kamanzi, Vusumuzi Mwalia, Veronica Mugisha, Beata Sangwayire, Eric Remera, Eugenie Kayirangwa, Samuel Malamba, Meagan Cain, Jennifer Hegle, Stephanie Behel, Gallican N. Rwibasira
Research Group: Rwanda HIV Recency Evaluation Study Team

Poster Session-U2 SARS-CoV-2 SELF-TESTING
2:30 PM - 4:00 PM

956 COVID-19 SELF-TESTING AMONG HEALTHCARE WORKERS AND GENERAL POPULATION IN MALAWI
Madalo Mukoka, Euphemia Sibanda, Constancia Wadzauzhe, Moses Kumwenda, Florence Abok, Elizabeth Corbett, Elena Reploid, Augustine Choko, Marriott Nliwasa

957 INTEGRATION OF SARS-CoV-2 RAPID ANTIGEN TEST IN HEALTH SERVICES IN KENYA AND CAMEROON

958 IMPACT AND COST-EFFECTIVENESS OF COVID-19 RAPID SELF-TESTING STRATEGIES IN SCHOOLS
Joshua M. Chevalier, Alvin X. Han, Megan A. Hansen, Ethan Klock, Hiromi Pandithakoralage, Tom Ockhuisen, Sarah Girdwood, Nkgomeleng Lekodeba, Alexandra de Nooy, Helen E. Jenkins, Colin A. Russell, Brooke Nichols
959  COST-EFFECTIVENESS OF WORKPLACE COVID-19 SELF-TESTING: A MATHEMATICAL MODELING STUDY
Ethan Klock, Alvin X. Han, Joshua M. Chevalier, Megan A. Hansen, Hiromi Pandithakoralage, Tom Ockhuisen, Sarah Girdwood, Nkgomeleng Lekodeba, Alexandra de Nooy, Helen E. Jenkins, Colin A. Russell, Brooke Nichols

960  HOME VERSUS FACILITY SARS-CoV-2 TESTING AMONG OLDER ADULTS IN NEW YORK CITY
Abigail R. Greenleaf, Shannon M. Farley, David Hoos, Melissa Reyes, Takura Kupamupindzi, Kimberly Geoffrey, Wafaa El-Sadr
Poster Sessions

994 PRE-EXPOSURE PROPHYLAXIS PRODUCT CHOICE IN US PARTICIPANTS IN HPTN 083
Meredith E. Clement, Zhe Wang, Carl J. Fichtenbaum, Schuyler Thomas, Jose A. Bazan, Paul Richardson, Matthew A. Spinelli, Brett Hanscom, Alex R. Rinehart, Jim Rooney, Adeola Adeyeye, Marybeth McAuley, Myron S. Cohen, Beatriz Grinsztejn, Raphael J. Landovitz
Research Group: HPTN 083 Study Team

995 OPTIMIZING PRE-EXPOSURE PROPHYLAXIS WITH TDF-FTC AND TAF-FTC FOR INSERTIVE SEX
Carolina Herrera, Laura J. Else, Emily Webb, Azure-Dee Pillay, Thabiso B. Seipheto, Limakatso Lebina, Jennifer Serwanga, Andrew Sentongo Ssemata, Patricia Namiburui, Geoffrey Odoch, Clive M Gray, Francesca Chioldi, Saye Khoo, Neil Martinson, Julie Fox
Research Group: CHAPS study team

996 INTERACTION BETWEEN TAF-BASED PREP AND HORMONE THERAPY IN TRANSGENDER WOMEN: iFACT 3
Akarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen J. Kerr, Rena Janamnuaysok, Siriporn Nonenoy, Piranun Hongchookiat, Rapee Trichavaroj, Yardpironoon Tawon, Jakrapaphara Boonruang, Nipat Teeratakulpisarn, Tim R. Cressy, Nittaya Phanuphak
Research Group: the iFACT3 study team

997 PREP USE AMONG US VETERANS USING VETERAN HEALTH ADMINISTRATION SERVICES: 2017-2021
Ya-Lin A. Huang, Elliot Lowy, Lei Yu, Weiming Zhu, Wei Wei, Karen Hoover, Lauren A. Beste

998 ALIGNMENT OF PrEP USE WITH HIV RISK IN YOUNG WOMEN AND MEN IN UGANDA
Linxuan Wu, Andrew Mujugira, Timothy Muwonge, Timothy Ssebuliba, Felix Bambia, Olivia Nampewo, Renee Heffron

999 A PILOT RCT ASSESSING UPTAKE OF PrEP AND CONTRACEPTION IN HAIR SALONS IN SOUTH AFRICA
Ingrid Bassett, Joyce Yan, Sabina Govere, Sthabile Shezi, Lungile Ngcobo, Taing N. Aung, Jana Jarolimova, Danielle Zions, Christina Psaros, Nduduzo Dube, Robert Parker

Poster Session-W2 SARS-CoV-2 VACCINE STRATEGIES
2:30 PM - 4:00 PM

1005 LONG-TERM COVID-19 BOOSTER EFFECTIVENESS AND IMMUNE IMPRINTING
Hiam Chemaitelly, Houssein H. Ayoub, Jeremy Samuel Faust, Laith J. Abu-Raddad

1006 RESIDENTIAL SEGREGATION AS A BARRIER TO COVID-19 BOOSTER COVERAGE IN DEEP SOUTH
Chengbo Zeng, Jiajia Zhang, Zhenlong Li, Xiaowen Sun, Huan Ning, Xueying Yang, Sharon Weissman, Bankole Olatosi, Xiaoming Li, Chen Liang

1007 SARS-CoV-2 VACCINE EFFECTIVENESS IN A COHORT OF ACTIVE-DUTY US MILITARY PERSONNEL
Jessica J. Cowden, Vanessa Cox, Diane Epperson, Elissa Thomas, Genice Jacques, Sonya Arzola, Kelly McKee, Jason Okulicz
Research Group: VIRAMP Study Group

1008 EFFECTS OF PUBLIC HEALTH INTERVENTIONS AGAINST COVID-19 IN FRANCE
Iris Ganser, David L. Buckeridge, Mélanie Prague, Rodolphe Thiebaut

1009 EQUITY-BASED OPTIMIZATION FOR COVID-19 VACCINE ALLOCATION
Erin Stafford, Dobromir Dimitrov, Rachel Ceballos, Laura Matrajt
1010  VACCINE UPTAKE IN A PREDOMINANTLY BLACK AND LATINX
COHORT HOSPITALIZED FOR COVID-19
Michelle Chang, Jennifer Chang, Simian Huang, Joan Bosco, Meredith McNair, Sade Tukuru, Yi Hao Wu, Jonathan Kunkel-Jure, Jessica Weidler, Carlie Dorr, Renee Roberts, Brett Gray, Jason Zucker, Delivette Castor, Magdalena E. Sobieszczyn

1011  PREVALENCE AND CORRELATES OF SARS-CoV-2 VACCINE
HESITANCY AMONG US PEOPLE WITH HIV
Matthew A. Spinelli, Mallory O. Johnson, Nadra E. Lisha, Jennifer P. Jain, Carlos Moreira, David V. Glidden, Greer Burkholler, Heidi Crane, Jeffrey Jacobson, Edward Cachay, Kenneth H. Mayer, Sonia Napravnik, Richard Moore, Monica Gandhi, Katerina Christopoulous

1012  SAFETY OF HETEROLOGOUS MRNA-1273 BOOST AFTER AD26.
CoV2.S PRIME IN SOUTH AFRICA
Research Group: SHERPA Study Team

1013  REACTOGENICITY AMONG PEOPLE LIVING WITH HIV AFTER
MRNA-1273 VACCINE IN UBUNTU STUDY
Asa Tapley, Jessica Andriesen, Yunda Huang, Azzidihwai Talakani, Bongile Mabilane, Manuel V. Villaran, Taraz Samandari, Sufia Dadabhai, Linda-Gail Bekker, Margaret Yacovone, Aaron Hudson, Lawrence Corey, Glenda E. Gray, Philip Kotze, Nigel Garrett
Research Group: CoVPN 3008 Ubuntu Study Team

1014  COVID-19 VACCINATION IN PERSONS WITH AND WITHOUT HIV:
VETERANS AGING COHORT STUDY
Emily J. Cartwright, Kathleen McGinnis, Janet P. Tate, Christopher T. Rentsch, Kendall Bryant, Emily C. Williams, Sheldon T. Brown, Evelyn Hsieh, Amy C. Justice, Lesley S. Park

1015  THE CHANGING IMPACT OF VACCINES IN THE COVID-19
PANDEMIC: A MODELING STUDY
Robyn Stuart, Jamie Cohen, Jasmina Panovska-Griffiths, Edinah Mudimu, Romesh Abeyesuriya, Cliff Kerr, Michael Famulare, Daniel Klein

1016  HIV VIRAL LOAD AND TIME-TO-COVID-19 VACCINATION AMONG
PEOPLE WHO INJECT DRUGS
Pieter Baker, Javier Cepeda, Becky Genberg, Greg Kirk, Shruti H. Mehta, Kenneth Feder, Jacqueline E. Rudolph, Jing Sun

1017  COVID-19 VACCINE COVERAGE AMONG PEOPLE WITH HIV IN THE
VACCINE SAFETY DATALINK
Rulin Hechter, Lei Qian, In-Lu Amy Li, Lina Sy, Denison Ryan, Joshua Williams, Laura Hurley, Nicola Klein, Robyn Kaiser, Elizabeth Liles, Hung Fu Tseng

1018  CORRELATES OF COVID-19 VACCINE UPTAKE IN MALAWIAN
ADULTS
Hannah Whitehead, John Songo, Pericles Kalande, Khumbo Phiri, Eric Lungu, Sam Phiri, Joep J Van Oosterhout, Agnes Moses, Risa Hoffman, Corrina Moucheraud

AMONG ADULTS IN MALAWI
NP
Lucky D. Makonokaya, Lester Kapanda, Thulani Maphosa, Louiser Kalitera, Harrid Nkhoma, Rachel Chamanga, Cathy Golowa, Suzgo Zimba, Godfrey Woelt, Malocho Phoso, Nilesh Bhatt

1020  COMPARISON OF THE EFFECTIVENESS OF DIFFERENT COVID-19
VACCINES AMONG PLWH
1025 INCREASED HIV, HCV & STIs AMONG ADULTS REPORTING SEX WORK IN ALABAMA: 2008-2022
Kaitlyn Atkins, Josh Bruce, Emma Kay, Karen Musgrove, Polly Kellar, Sarah MacCarthy

1026 PREVALENCE OF CHLAMYDIA AND GONORRHEA AMONG ADOLESCENTS IN KISUMU, KENYA
Hong-Ha M. Truong, Elsa Heylen, Kevin Kadede, Sayo Amboka, Damaris Odeny, Maurice Opiyo, Marion Hewa, Fidel Opondo, Beatrice Otieno, Hanningtone Odhiamb, David Ogolla, Mary Guzé, Lara E. Miller, Craig R. Cohen, Elizabeth A. Bukusi
Research Group: Maneno Yetu Study Team

1027 PATTERNS OF STI AMONG TRANSGENDER WOMEN LIVING WITH AND WITHOUT HIV IN THE US
Research Group: American Cohort To Study HIV Acquisition Among Transgender Women (LITE) Study Group

1028 SEXUALLY TRANSMITTED INFECTIONS AMONG YOUNG ADULTS AFFECTED BY PREINATAL HIV
Anna-Barbara Moscicki, Yanling Hoo, Lisa B. Haddad, Deborah Kacanek, Claude A. Mellins, Sharon Nichols, Kunjal Patel, Katherine K. Tassiopoulos, Tzy-Jyun Yao
Research Group: Pediatric HIV AIDS Cohort Study Network

1033 MPOX AND SEXUALLY TRANSMITTED INFECTION AMONG MEN WHO HAVE SEX WITH MEN
Jesse J. Carlson, Karen Wendel, Kellie Hawkins, Oluyomi Obafemi, Edward M. Gardner, Michael Breyer, Laura Podewils

1034 HIV AND SEXUALLY TRANSMITTED INFECTIONS AMONG MPOX CASES, TEXAS 2022
Analise Monterosso, Kacey Russell, Enyinnaya Merengwa, Kristyn Krolakowski, Abigail Jordan, Kenneth Davis, Rania Milleron, Stephen White

1035 CONCURRENT STI TESTING AMONG PATIENTS TESTED FOR MPOX AT DUKE UNIVERSITY HEALTH
Emily Niehaus, Ahmad Mourad, Edwin Wilbur, Woodhouse, Hayley Cunningham, Naseem Alavian, Sofia Zavala, Patricia Kohler, Steven Pappas, Michael Yarrington, Nwora Lance Okeke, Cameron R. Wolfe, Gary Cox, Kristen V. Dicks, Jason E. Stout

1052 PREDICTORS OF PLWH NEWLY PRESENTING TO CARE WITH VIRAL SUPPRESSION IN LUSAKA, ZAMBIA
Jake M. Pry, Chilambwe Mwila, Herbert Kapesa, Musunge Mulabe, Christiana Frimpong, Theodora Savory, Carolyn Bolton Moore, Michael E. Herce, Shilpa S. Iyer

1053 LATE PRESENTATION IN OLDER PWH IS ASSOCIATED WITH MORTALITY AND POOR IMMUNE RESPONSE
Win Min Han, Sirinya Teeraananchai, Cheewanan Lertpiriyasuwat, Rattaphon Triamwichanon, Anchalee Avihingsanon, Stephen J. Kerr, Kiat Ruxrungtham
Poster Session - Y06 LONG-ACTING ART

1054 POTENTIAL IMPACT OF LONG-ACTING ANTIRETROVIRAL THERAPY ON LOCAL HIV INCIDENCE
Preetham Bachina, Parastu Kasaie, Melissa Schnure, David Dowdy, Maunank Shah, Anthony Fojo

1055 IDENTIFYING PREFERRED PROGRAM DELIVERY ATTRIBUTES FOR LONG-ACTING INJECTABLE ART
Jose Gutierrez, Elizabeth Montgomery, Moira McNulty, Jonathan Colasanti, Mallory O. Johnson, Torsten Neilands, Kimberly Koester, John Saucedo, Samantha E. Dilworth, Xavier Erguera, Kaylin Dance, Manami Diaz Tsuchi, John Schneider, Elvin Geng, Katerina Christopoulos

Poster Session - Y07 ART REGIMENS

1056 UPTAKE AND OUTCOMES OF FIRST-LINE DOLUTEGRAVIR IN A LARGE SOUTH AFRICAN COHORT
Jienchi Dorward, Yukteshwar Sookrajh, Thokozani Khubone, Johan van Der Molen, Riona Govender, Sifiso Phakathi, Lara Lewis, Christian Bottomly, Munthra Maraj, Richard Lessells, Kogieulem Naidoo, Christopher Butler, Rosemary Van Heerden, Nigel Garrett

1057 SEX DISPARITIES IN THE ROLLOUT OF DOLUTEGRAVIR IN LATIN AMERICA AND THE CARIBBEAN
Fernanda F. Fonseca, Paridhi Ranadive, Bryan E. Shepherd, Beatriz Grinsztejn, Sandra Wagner Cardoso, Valdilea Veloso, Flávia Ferreira, Maria Fernanda Rodriguez, Daisy Maria Machado, Vanessa Rouzier, Diana Varela, Emilia M. Jalil, Jessica L. Castillo
Research Group: CCASAnet

1058 MONITORING HIV DUAL-THERAPY IMPLEMENTATION AS REGIMEN SIMPLIFICATION POLICY IN BRAZIL
Nazle Veras, Rosana Pinho, Alexandre Ferreira, Ana Cristina G. Ferreira, Beatriz Kamiensky, Ana Francisca Kolling, Gerson Fernando M. Pereira, Ana Roberta Pascom

1059 A NATIONWIDE OPTIMIZATION STRATEGY USING SECOND-GENERATION InSTIs IN MEXICO
Alicia Piñeirúa-Menéndez, Yanink Caro-Vega, Juan Luis Mosqueda-Gómez, Santiago Ávila-Ríos, Florentino Badial-Hernández, Andrea González-Rodríguez, Gustavo Reyes-Terán, Juan Sierra-Madero, Alethea De La Torre-Rosas

1060 PEOPLE FAILING FIRST-LINE REGIMENS REMAIN AT RISK FOR ADVERSE SECOND-LINE OUTCOMES
Pupe Sudsila, Sirinya Teeraananchai, Sasisopin Kiertiburanakul, Cheewanan Lertpiriyasuwat, Rattaphon Triamwichanon, Sivaporn Gateompol, Opas Putcharoen, Ploenchon Chetchotisakd, Anchalee Avihingsanon, Stephen J. Kerr, Kiat Ruxrungtham

1061 PREDICTORS OF TRANSITIONING TO A FIRST-LINE DOLUTEGRAVIR REGIMEN IN WEST AFRICA
Research Group: LeDEA West Africa Collaboration

1062 TRANSITION TO DOLUTEGRAVIR-BASED ART IN LOW-AND MIDDLE-INCOME COUNTRIES IN LeDEA
Research Group: the International epidemiology Databases to Evaluate AIDS (LeDEA) consortium
1063 NATIONAL TRENDS IN ART REGIMENS FILLED FOR PEOPLE WITH HIV ON MEDICARE: 2013-2019
Jose Figueroa, Jessica Phelan, Luke Ang, Emily P. Hyle

Poster Session-Y12 ADVANCED HIV DISEASE
2:30 PM - 4:00 PM

1085 COST DRIVERS OF PROVIDING ADVANCED HIV DISEASE CARE THROUGH HUB/SPOKE MODEL IN MALAWI
Mario Songane, Sushant Mukherjee, Rachel Chamanga, Barry Longwe, Joseph Namathanga, Thulani Maphosa, Allan Ahimbisibwe, Rebecca Bailey, Apollinaire Tiam

1086 ADVANCED HIV DISEASE CARE PACKAGE IMPLEMENTATION IN LESOTHO AND SOUTH AFRICA
Tinne Gils, Lutgarde Lynen, Kamele Mashaete, Josephine Muhairwe, Thulani Ngubane, Philip Joseph, Klaus Reither, Moniek Bresser, Alastair van Heerden

Poster Session-Y13 PREVENTION AND PrEP MODELS
2:30 PM - 4:00 PM

1087 ARE VENUE-BASED STRATEGIES THE TICKET TO THE LAST MILE IN HIV PREVENTION IN MALAWI?
Emmanuel Singogo, Sharon Weir, Evaristar Kudowa, Maganizo Chagomerana, Jessie Edwards, John Chapola, Confidence Banda, Gift Kwalizira, Andreas Jahn, Yohane Kamgwira, Lucy Platt, Brian Rice, James Hargreaves, Mina Hosseinipour, Thomas Hartney
Research Group: CLOVE Study

1088 COMMUNITY-ENGAGED PrEP DEMONSTRATION PROJECT FOR MSM IN CHINA
Bin Yu, Cao Fang, Zhuoheng Yin, Chunyan Li, Haojie Huang, Kun Wang, Quanmin Li, Linghua Li, Ke Liang, Ivy Jiang, Joseph Tucker, Renslow Sherer, Jonathan Lio, Aniruddha Hazra, Weiming Tang

1089 RANDOMIZED TRIAL LEVERAGING ELECTRONIC HEALTH RECORD DATA TO INCREASE HIV PrEP UPTAKE

1090 COSTS OF PROVIDING PHARMACY-INITIATED PrEP IN KENYA: FINDINGS FROM A PILOT STUDY
Alexandra Kuo, Obinna I. Ekwunife, Peter Mogere, Victor Omollo, Josephine Odoyo, Yilin Chen, Jared M. Baeten, Elizabeth A. Bukusi, Kenneth Ngure, Katrina F. Ortblad, Monisha Sharma

1091 CLIENT PREFERENCES FOR PrEP REFILLS AT FACILITIES VS PHARMACIES: A PILOT IN KENYA
Peter Mogere, Alexandra Kuo, Stephen Gakuo, Njeri Wairimu, Stephanie Roche, Mary Mugambi, Jared M. Baeten, Kenneth Ngure, Katrina F. Ortblad

1092 MALE CIRCUMCISION IN BOTSWANA: EFFECT OF QUALITY IMPROVEMENT ON ADVERSE EVENT RATES
Ludo S. Monene, Mooketsi Molefi, Keikantse Matlaghela, Billy M. Tsimba

Poster Session-Y14 COVID-19 EFFECT ON HIV SERVICES AND OUTCOMES
2:30 PM - 4:00 PM

1093 HIV OUTCOMES AFTER EXTENDED 12-MONTH SCRIPTS FOR ART DURING COVID-19 IN SOUTH AFRICA
Lara Lewis, Yukteshwar Sookrajh, Johan van Der Molen, Thokozani Khubone, Phelelani Sosibo, Riona Govender, Sifiso Phakathi, Munthra Maraj, Rosemary Van Heerden, Francesca Little, Reshma Kassanjee, Nigel Garrett, Jienci Dorward
1094** VIRAL SUPPRESSION TRAJECTORIES DESTABILIZED AFTER COVID-19 AMONG US PEOPLE WITH HIV**
Matthew A. Spinelli, Katerina Christopoulou, Nadra E. Lisha, Jennifer P. Jain, Carlos Moreira, David V. Glidden, Greer Burgholder, Heidi Crane, Jeffrey Jacobson, Edward Cachay, Kenneth H. Mayer, Sonia Napravnik, Richard Moore, Monica Gandhi, Mallory O. Johnson

1095** HIV CARE DURING THE SARS-CoV-2 PANDEMIC IN BLACK PEOPLE WITH HIV IN THE UK**
Zoe Ottaway, Lucy Campbell, Laura Cechin, Julie Fox, Fiona Burns, Lisa Hamzah, Stephen Kegg, Rose Rosenvinge, Sarah Schoeman, David Price, Rachael Jones, Denis Onyango, Robert Miller, Shema Tariq, Frank Post

Research Group: CoV-AFRICA study group

1096** DISRUPTIONS IN HEALTH CARE AMONG MWCCS PARTICIPANTS DURING THE COVID-19 PANDEMIC**
Jenni Wise, Lorie Benning, Mackey Friedman, Tracey Wilson, Catalina Ramirez, Adaora Adimora, Bradley Aouizerat, Anjali Sharma, Matthew Mimiaga, Anandi N. Sheth, Michael Plankey, Markde Cohen, Deborah Jones Weiss, Gypsyamber D'Souza, Mirjam Colette-Kempf

Research Group: Multicenter AIDS Cohort Study and the Women’s Interagency HIV Study Combined Cohort Study (MWCCS) Research Group

1097** UTILITY OF DIGITAL SOLUTIONS IN SUSTAINING ACCESS AND IMPROVING EFFICIENCY OF HIV VL**
Ughweroghene Omo-Emmanuel, Victor Obiaineri, Omosalewa Oyelaran, Helina Meri, Abiye Kalaiwo, Dolapo Ogundehin, Rachel Goldstein, Jason Williams, Timothy Yakubu

1098** MITIGATING THE IMPACT OF COVID-19 ON HIV VIRAL LOAD ACCESS AMONG KEY POPULATIONS**
Ughweroghene Omo-Emmanuel, Victor Obiaineri, Abiye Kalaiwo, Omosalewa Oyelaran, Jason Williams, Timothy Yakubu, Mark Akhigbe, Usman Haliru

1099** IMPACT OF COVID-19-INDUCED PROGRAM ADAPTATIONS ON HIV SUPPRESSION IN THREE COUNTRIES**
Vamsi Vasireddy, Neha Shah, Allahna L. Esber, Trevor A. Crowell, Joseph S. Cavanaugh, Hannah Kibuuka, Ajay Parikh, Jonah Maswai, Valentine Sing Oei, Emmanuel Bahemana, Michael Iroezindu, Julie A. Ake

Research Group: African Cohort Study (AFRICOS) group

1100** CHANGES IN SERVICE ACCESS AMONG PEOPLE WHO INJECT DRUGS IN PHILADELPHIA, 2018-2022**
Tanner B. Nassau, Kathleen A. Brady
WEDNESDAY FEBRUARY 22, 2023

Poster Session-A3 VIRUS REPRODUCTION
2:30 PM - 4:00 PM

226  ELEVATED HIV VIRAL LOAD IS ASSOCIATED WITH HIGHER VIRAL RECOMBINATION RATE IN VIVO
Elena V. Romero, Alison F. Feder

227  Vpr ENHANCES HIV REPLICATION BY INHIBITING T CELL PROLIFERATION
Rodrigo A. Matus Nicodemos, David R. Ambrozak, Daniel C. Douek, Richard A. Koup

228  A HUMAN-SPECIFIC CARD8 MUTATION AFFECTS INFLAMMASOME ACTIVATION AFTER HIV-1 INFECTION
Jessie Kulsuptrakul, Elizabeth Turcotte, Michael Emerman, Patrick Mitchell

229  CARD8 INFLAMMASOME MODULATES HIV-1 INFECTION IN CD4+ T CELLS
Qiankun Wang, Liang Shan

230  VHH DIMER P559-R45L NEUTRALIZES SARS-CoV-2 BY STABILIZING SPIKE IN UP CONFORMATION
Kayoko Nagata, Junso Fujita, Ryota Maeda, Kotaro Shirakawa, Tsuyoshi Inoue, Keiichi Namba, Akihiro Imura, Akifumi Takaori-Kondo, Akhide Ryo, Kei Sato

231  FC RECEPTOR-MEDIATED INFECTION OF MYELOID CELLS BY SARS-CoV-2
Suzanne Pickering, Harry D. Wilson, Enrico Bravo, Marianne R. Perera, Nathalia Almeida Dos Santos, Katie J. Doores, Michael H. Malim, Stuart Neil

232  OMICRON SPIKE ENDOWS SARS-CoV-2 WITH ENHANCED INFECTIVITY IN NASAL EPITHELIA
Guoli Shi, Tiansheng Li, Kinkui Lai, Jonathan Yewdell, Alex A. Compton

233  SARS-CoV-2 REPLICONS REVEAL SPIKE-INDEPENDENT ATTENUATION OF THE OMICRON VARIANT
Taha Y. Taha, Irene Chen, Melanie Ott

234  SARS-CoV-2 USES ENDOSONAL MEMBRANES TO BUILD REPLICATION ORGANELLES
Yuexuan Chen, Ruth Serra-Moreno

235  WITHDRAWN

Poster Session-A4 VIRUS DIVERSITY IN POPULATIONS
2:30 PM - 4:00 PM

236  MPOX VIRUS SEQUENCES DIVERSITY IN PARIS AREA DURING THE 2022 OUTBREAK
Géraldine Piorkowski, Jade Ghosn, Valentine M. Ferré, Morgane Mailhe, Romain Coppée, Nadhira Houhou-Fidouh, Yazdan Yazdanpanah, Quentin Le Hingrat, Hervé Raoul, Charlotte Charpentier, Diane Descamps, Xavier de Lamballerie
Poster Sessions

237

WITHDRAWN

238

WITHDRAWN

239

GENOMIC SURVEILLANCE OF SARS-CoV-2 REVEALS SEVERITY OF DELTA VARIANT IN CAMEROON


Poster Session-B2 HIV AND THE MICROBIOME

2:30 PM - 4:00 PM

248

CHANGES IN GUT MICROBIOTA PROFILE IN PWHIV WHO SWITCH FROM EFV/FTC/TDF TO BIC/FTC/TAF

Sandra Pinto-Cardoso, Monserrat Chávez-Torres, Adriana Aguilar, Santiago Ávila-Ríos

249

PROTEOMIC ANALYSIS OF TRANSLOCATING BACTERIAL TAXA REVEALS NOVEL THERAPEUTIC TARGET

Jacob K. Flynn, Alexandra Ortiz, Marlon Deleon, Samantha Knodel, Kenzie Birse, Laura Noel-Romas, Adam Burgener, Jason Brenchley

250

THE EFFECTS OF CD4+ LYMPHOPENIA ON THE HUMAN SKIN MICROBIOME

Irini Sereti, Jungmin Han, Andrea Lisco, Julia A. Segre, Heidi H. Kong

251

COMMENSAL BACTERIA WITHIN THE FAMILY LACHNOSPIRACEAE ROBUSTLY INHIBIT HIV INFECTION


252

BACTERIAL DYSBIOSIS PERSISTS IN WOMEN LIVING WITH HIV-1 AFTER ART

Katherine M. Bricker, Andrea Lisco, Alessandra Borgegogne, Maura Manion, Andrew Redd, Frances Galindo, Sarah Kalibbala, Aggrey Anok, Stephen Tomusange, Steven J. Reynolds, Marc Nogueria Julian, Irini Sereti

Poster Session-B4 HIV AND AGING

2:30 PM - 4:00 PM

260

GLYCOMIC BIOMARKERS OF BIOLOGICAL AGING ARE ALTERED DURING SUPPRESSED HIV INFECTION

Leila Giron, Xiangfan Yin, Susan Langan, Jinbing Zhang, Jane Koshy, Igho Ofotokun, Jason M. Lazar, Margaret Fischl, Sabina Haberlen, Lawrence Kingsley, Alan Landay, Wendy Post, Qin Liu, Todd T. Brown, Mohamed Abdel-Mohsen

Research Group: MACS/WIHS Combined Cohort Study

261

SEX DIFFERENCES IN CYTOKINE DYNAMICS IN PEOPLE WITH HIV ON ART DURING AGING

Alan B. Wells, Christophe Vanpouille, Victor De Gruttola, Miranda Lynch, Xinyi Huang, Jinyuan Liu, Wendy Fitzgerald, Xin Tu, Antoine Chailllon, Alan Landay, Eileen P. Scully, Leonid Margolis, Jonathan Karn, Sara Gianella

Research: Late-Breaking

Research: New Investigator Scholarship

Research: Nonauthor Presenter

Research: NIS

CME

Continuing Medical Education

Poster Sessions • Wednesday

126

CROI 2023
262  AGING IN WOMEN WITH HIV: SINGLE-CELL TRANSCRIPTOME ANALYSIS OF THE IMMUNE SYSTEM
Konstantin Leskov, Sara Gianella, Eileen P. Scully, Alan Landay, Antoine Chaillou, Jennifer Kinslow, Kathleen Weber, Saba Valadkhan, Victor De Gruttola, Alan B. Wells, Mary Ann Checkley, Benjamin Luttge, Jonathan Karn

263  MULTIPARAMETRIC CHARACTERIZATION OF TELOMERE LENGTH IN T CELLS FROM PLWH BY Flow-FISH
Macedonia Trigueros, Cora Loste, Maria Nevot, Francisco Muñoz-López, Diana Hernández, Ana Martínez, Marco A. Fernández, Yacine Kharraz, Julià Blanco, Eugenia Negredo, Marta Massanella
Research Group: TRANSLATIONAL RESEARCH IN IMMUNOLOGY AND AGEING (TRIA)

264  DURABLE ART SUPPRESSION IN AGED RHESUS MACAQUES IS ASSOCIATED WITH MHC-I ALLELES
Alejandra Marenco, Candice Nkoy, Benjamin Varco-Merth, Aparna N. Govindan, He Li, Devin N. Fachko, Anne Lewis, Brandy Dozier, Caralyn Labriola, Michael Axthelm, Scott W. Wong, Afam A. Okoye

Poster Session-B8 MPOX PATHOGENESIS
2:30 PM - 4:00 PM

291  DELAYED POSITIVIZATION OF NON-LESION SPECIMENS AMONG INDIVIDUALS WITH MPOX
Angelo Roberto Raccagni, Davide Mileto, Alberto Rizzo, Nicola Gianotti, Vincenzo Spagnuolo, Caterina Candela, Elena Bruzzesi, Riccardo Lolatto, Benedetta Trentacapilli, Emanuela Messina, Maria Rita Gismondo, Antonella Castagna, Silvia Nozza

292  LONGITUDINAL ASSESSMENT OF VIRAL SHEDDING AMONG PATIENTS WITH MPOX IN TORONTO, CANADA
Darrell H. S. Tan, Robert Kozak, Jacklyn Hurst, Maedeh Naghibosadat, Hui Ting Ma, Oscar Pico Espinosa, Shreya Shah, Natasha Christie-Holmes, Jessica Lam, Angel Ly, Reva Persaud, Charlie Tan, Matthew Muller, Sharmistha Mishra

293  MPOX DNA CLEARANCE IN SEMEN OVER SIX MONTHS FOLLOW-UP
Caterina Candela, Alberto Rizzo, Laura Galli, Davide Mileto, Diana Canetti, Nicola Gianotti, Maria Francesca Lucente, Costanza Bertoni, Angelo Roberto Raccagni, Maria Rita Gismondo, Antonella Castagna, Silvia Nozza

Poster Session-D4 LYMPH NODES
2:30 PM - 4:00 PM

329  DYNAMICS AND ROLE OF TOX+ TCF1+ CD39+ CD8 T CELLS IN LYMPHOID TISSUE IN SIV INFECTION
Zachary Strongin, Claire Deleage, Gregory Tharp, Kevin Nguyen, Andrew Rahmberg, Jason Brenchley, Steven Bosingher, Haydn Kissick, Mirko Paiardini

330  SPATIAL MAPPING OF SIV-INFECTED RHESUS MACAQUE LYMPH NODE ENVIRONMENT DURING REBOUND
Kristen Olivera, Muhammad Shoaih Arif, Yanique Thomas, Christopher Thuruthiyil, Michael McRaven, Yanxiang Deng, Yang Liu, Graham Su, Archibald Enninful, Jack Collora, Rong Fan, Thomas J. Hope, Ya-Chi Ho

331  LYMPH NODE IMMUNE MICROENVIRONMENT FOLLOWING ART INITIATED DURING ACUTE HIV INFECTION
Andrea Papadopoulos, Trevor Nkaba, Thandeka Nkosi, Krista Dong, Thumbi Ndung’U, Zaza Ndlovu
332 DEVELOPMENT OF A LYMPHOID ORGAN-CHIP TO EVALUATE COVID VACCINE BOOSTING STRATEGIES
Raphaël Jeger-Madiot, Jérôme Kerveyan, Isabelle Staropoli, Delphine Planas, Héloise Mary, Cassandre Garnier, Rémy Robinot, Stacy Gellenoncourt, Olivier Schwartz, Michael Bscheider, Céline Marban-Doran, Lorna Ewart, Samy Gobaa, Lisa A. Chakrabarti

374 NEUTRALIZING AND T-CELL RESPONSE AGAINST MPOX VIRUS AFTER MVA-BN VACCINE
Valentina Mazzotta, Giulia Matusali, Alessandro Cozzi Lepri, Eleonora Cimini, Simone Lanini, Francesca Colavita, Stefania Notari, Roberta Gagliardini, Silvia Meschi, Serena Vita, Emanuele Nicastrì, Enrico Girardi, Francesco Vaia, Fabrizio Maggi, Andrea Antinori, Priscilla Caputti, Flavia Cristofanelli, Francesca Faraglia, Daniele Lapa, Giorgia Natalini
Research Group: MPOX Vaccine Lazio Study Group

375 COMPARISON OF SUBCUTANEOUS VERSUS INTRADERMAL ROUTE OF ADMINISTRATION OF MVA VACCINE
Research Group: MPOX Vaccine Lazio Study Group

376 HUMORAL AND CELLULAR IMMUNE RESPONSE AFTER 3 MONTHS FROM MPOX VIRUS INFECTION
Valentina Mazzotta, Giulia Matusali, Eleonora Cimini, Francesca Colavita, Rita Casetti, Carmela Pinnetti, Annalisa Mondi, Aurora Bettini, Germana Grassi, Serena Vita, Emanuele Nicastrì, Enrico Girardi, Francesco Vaia, Fabrizio Maggi, Andrea Antinori, Marta Camici, Silvia Di Bari, Silvia Meschi, Gianluca Prota, Elena Tartaglia
Research Group: MPOX Vaccine Lazio Study Group

377 IMMUNOGENICITY OF MVA-BN VACCINATION WITH HYBRID ADMINISTRATION ROUTE
Davide Moschese, Micol Bianchi, Maria Vittoria Cossu, Federica Salari, Andrea Giacomelli, Alberto Rizzo, Samuel Lazzarin, Federico Sabaini, Silvia Nozza, Davide Mileto, Andrea Gori, Spinello Antinori, Maria Rita Gismondo, Giuliano Rizzardini

378 IMMUNE RESPONSES AND VIRAL DYNAMICS AFTER MPOX INFECTION IN THE 2022 OUTBREAK
Susana Benet, Julieta Carabelli, Clara Suñer, Adrià Mendoza, Angel Rivero, Vicente Descalzo, Aurélien Marc, Michael Marks, Christian Brander, Alex Olivera, Nuria Izquierdo-Useros, José Moltó, Jorge Carrillo, Oriol Mitjà, Beatriz Mothe Pujades
Research Group: MoViE-Immune Study Group

379 NOVEL SEROASSAYS DETECT MPOX-SPECIFIC AND VACCINE-INDUCED ORTHOPOXVIRUS IMMUNITY
Jonah Kupritz, Savita Pahwa, Suresh Pallikkuth

398 CTL RESPONSES ARE NOT ASSOCIATED WITH DECAY OF INTACT PROVIRUSES OR HIV RNA ON ART
Research Group: ACTG A5321 Team
Poster Sessions

CROI 2023

Poster Sessions • Wednesday

Continuing Medical Education
Late-Breaking
New Investigator Scholarship
Nonauthor Presenter

Poster Sessions • Wednesday
Continuing Medical Education
Late-Breaking
New Investigator Scholarship
Nonauthor Presenter

129

TSCM/TCM-ENRICHED ANTI-HIV duoCAR-T CELLS EXERT POTENT HIV CONTROL
Kim Anthony-Gonda, Alex Ray, Hang Su, Vanessa Chilunda, Danica Lee, Jessica Weiselberg, Lily Zemelko, Yen Wang, Jane Reese, Rimas Orentas, Steven G. Deeks, Rachel L. Rutishauser, Joan W. Berman, Harris Goldstein, Boro Dropulic

bNAb ESCAPE HIV-ENV VARIANTS IN ORALLY SHIV-INFECTED, ART-TREATED INFANT MACAQUES
Ria Goswami, Stella J. Berendam, Sedem Dankwa, Elena E. Giorgi, Joshua Eudailey, Caroline Phan, Diane G. Carnathan, Bhrugu Yagnik, Chiamaka A. Enemuo, Veronica Obregon-Perko, Rama R. Ámara, Ann Chahroudii, Sallie R. Perm, Genevieve G. Fouda

BISPECIFIC ANTIBODIES PROMOTE NK CELL-MEDIATED ELIMINATION OF THE HIV-1 RESERVOIR
Nathan L. Board, Meghana Ravi, Fengting Wu, Milica Moskovljevic, Srona Sengupta, Francesco R. Simonetti, Kenneth Lynn, Luis J. Montaner, Rebecca Hoh, Steven G. Deeks, Janet M. Siliciano, Robert F. Siliciano

DONOR-DERIVED ENV MUTATION SCANNING REVEALS anAb AND bNAb VULNERABILITIES
Joseph Varriale, Brianna Lopez, Kshitij Wagh, Elena E. Giorgi, Robert F. Siliciano, Janet M. Siliciano

HIV-RESISTANT CAR T CELLS BY CRISPR/Cas-MEDIATED CAR INTEGRATION INTO THE CCR5 LOCUS
Frederik H. Rothemejer, Nanna Pi Lauritsen, Anna Karina Juhl, Mariane Høgsbjerg Schleimann, Saskia König, Ole Schmeltz Søgaard, Rasmus O. Bak, Martin Tostrup

GENERATING BROADLY NEUTRALIZING ANTIBODY-SECRETING CAR-T-CELLS AGAINST HIV INFECTION
Hang Su, Jianhua Zheng, Scott Garforth, Kim Anthony-Gonda, Boro Dropulic, Steven Almo, Harris Goldstein

CIRCULATING IMMUNE PREDICTORS OF INTACT HIV RESERVOIR DECAY DURING LONG-TERM ART
Sergio Serrano-Villar, Akshay Gala, Peter Bacchetti, Clara Di Germanio, Lilian Cohn, Peter W. W. Hunt, Gregory M. Laird, Satish K. Pillai, Steven G. Deeks, Michael J. Peluso

THE LEAKY RESERVOIRS ARE ASSOCIATED WITH HIV-SPECIFIC CD4 AND CD8 T CELL RESPONSES
Mathieu Dubé, Olivier Tastet, Gérémie Sannier, Nathalie Brassard, Gloria Gabrielle Ortega-Delgado, Amélie Pagliuzza, Alexandre Prat, Jean-Pierre Routy, Rémi Fromentin, Nicolas Chomont, Daniel Kaufmann

CTL EPITOPES FROM STRUCTURALLY IMPORTANT HIV PROTEINS ARE IDENTIFIED IN REBOUND HIV
Eunok Lee, Gabriel Duette, Katie Fisher, Anthony D. Kelleher, Steven G. Deeks, Sarah Palmer

 IMMUNE FEATURES ASSOCIATED WITH HIGHER T-CELL RESPONSES TO AN HIV THERAPEUTIC VACCINE
Lily Zemelko, Naseem Sadek, Kara W. Chew, Mansi Purwar, Laurent Humeau, David V. Glidden, Matthew H. Spitzer, David B. Weiner, Steven G. Deeks, Rafick P. Sékaly, Jeffrey A. Tomalka, Rachel L. Rutishauser

ANTIRETROVIRAL THERAPY REPAIRS CD4 T-CELL DYSREGULATION IN PEOPLE LIVING WITH HIV
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>410</td>
<td>REPROGRAMMING CMV-SPECIFIC CD8+ T CELLS TO TARGET HIV USING TCR GENE TRANSFER</td>
<td>April Mueller, Scott Garforth, Steven Almo, Harris Goldstein</td>
</tr>
<tr>
<td>411</td>
<td>NOVEL BISPECIFIC ENGAGER REDIRECTS CMV-SPECIFIC CTL TO ELIMINATE HIV-INFECTED CELLS</td>
<td>Christopher R. Hiner, Scott Garforth, Darien Woodley, Steven Almo, Harris Goldstein</td>
</tr>
<tr>
<td>412</td>
<td>HIV-1 RESISTANCE PROFILES AGAINST bNAb IN INTACT VS DEFECTIVE GENOMES ARE DISTINCT</td>
<td>Elena E. Giorgi, Pragya Khadka, Erika Benko, Colin Kovacs, Ria Goswami, Genevieve G. Fouda, Sallie R. Permar, Marina Caskey, R. Brad Jones, Guinevere Q. Lee</td>
</tr>
<tr>
<td>413</td>
<td>KIR+RA+ CD8 T-CELLS EXHIBIT ANTIGEN INDEPENDENCE AND CORRELATE WITH HIV RESERVOIR SIZE</td>
<td>Talia Mota, Jared Weiler, Paul Zumbo, Dennis C. Copertino, Noemi L. Linden, Andrea Gramatica, Adam R. Ward, Sandra Terry, Erika Benko, Colin Kovacs, Jeffrey Safrin, Mirko Paiardini, Deanna A. Kulpa, Guido Silvestri, R. Brad Jones</td>
</tr>
<tr>
<td>414</td>
<td>IMPACT OF SARS-CoV-2-MEDIATED CD4 T-CELL ACTIVATION AND HIV DNA PERSISTANCE IN VIVO</td>
<td>Tyler-Marie Deveau, Michael J. Peluso, Amanda M. Buck, Sadie Munter, Jane Srivastava, Rebecca Hohl, Nitasha Kumar, Rachel L. Rutishauser, Steven G. Deeks, Timothy Henrich</td>
</tr>
<tr>
<td>423</td>
<td>GLYCOENGINEERING ENHANCES HIV 10-1074 bNAb-DEPENDENT NATURAL KILLER CELL CYTOTOXICITY</td>
<td>Angela Corrigan, Samson Adeniji, Leila Giron, Shalini Singh, Costin Tomescu, Luis J. Montaner, Mohamed Abdel-Mohsen</td>
</tr>
<tr>
<td>424</td>
<td>SINGLE-CELL QUANTIFICATION OF HIV-1 AND LENTIVIRAL VECTOR IN GENE THERAPY STUDIES</td>
<td>Amanda M. Buck, Joanna Donnatelli, Corinna Gartner, Tyler-Marie Deveau, Isaac Thomas, Julie Beegle, Kim Anthony-Gonda, Mehrdad Abedi, Joseph Anderson, Timothy Henrich</td>
</tr>
<tr>
<td>425</td>
<td>MULTI-SEROTYPE NANOBODY-ENGINEERED AAV VECTORS FOR CD4-TARGETED GENE THERAPY</td>
<td>Martin Hamann, Daniel Foth, Priti Kumar, Ulrike Lange</td>
</tr>
<tr>
<td>426</td>
<td>AN IMMUNOCYTOCHEMISTRY METHOD TO INVESTIGATE THE TRANSLATIONALLY ACTIVE HIV RESERVOIR</td>
<td>Guoxin Wu, Yuan Li, Jan Kristoff, Carol Cheney, Jill Wiler Maxwell, Tracy Lauren Diamond, Paul Zuck, Carl Balbar, Jay Grobler, Bonnie Howell, Luca Sardo</td>
</tr>
<tr>
<td>427</td>
<td>DUAL ANTIRETROVIRAL-LOADED NANOPARTICLES FOR LONG-ACTING SUPPRESSIVE HIV THERAPY</td>
<td>Josiane Fofana, Behnaz Eshagh, Erik Schiferle, Chandra Roy, Zandrea Ambrose, Bjoern Reinhard, Rahm Gummuluru</td>
</tr>
</tbody>
</table>

Poster Session-E5 INNOVATIVE APPROACHES TO TARGET THE RESERVOIR

2:30 PM - 4:00 PM

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>483</td>
<td>CSF COMPLEMENT IS CORRELATED TO IMMUNE ACTIVATION IN UNTREATED BUT NOT TREATED HIV</td>
<td>Arvid Eden, Lars-Magnus Andersson, Aylin Yilmaz, Dietmar Fuchs, Lars Hagberg, Magnus Gisslen</td>
</tr>
</tbody>
</table>

Poster Session-F6 MECHANISMS OF HIV NEUROPATHOGENESIS

2:30 PM - 4:00 PM
484  **LONGITUDINAL ASSESSMENT OF GRAPH THEORY MEASURES IN EARLY HIV INFECTION**
Yufen Chen, Guixiang Ma, James Higgins, Ann Ragin

485  **SINGLE-COPY HIV AND NEURODEGENERATION, OXIDATIVE STRESS, AND NEUROINFLAMMATION**
Albert Anderson, Patricia K. Riggs, Anita McClernon, Daniel McClernon, Ronald J. Ellis, David B. Clifford, Benjamin Gelman, Susan Morgello, Payal Patel, Leah H. Rubin, Bin Tang, Donald Franklin, Robert K. Heaton, Scott L. Letendre
Research Group: The CHARTER group

486  **CHARACTERIZING THE ROLE OF MONOCYTES IN HIV NEUROPATHOGENESIS**
Veronica Veksler, Rosiris Leon-Rivera, Susan Morgello, Joan W. Berman

487  **PLASMA Aβ42:Aβ40 RATIOS ARE NOT REDUCED IN OLDER PERSONS WITH HIV**
Sarah Cooley, Beau Ances, Jane O’Halloran

---

**Poster Session-F7 COINFECTIONS AND THE NERVOUS SYSTEM IN PEOPLE WITH HIV**
2:30 PM - 4:00 PM

488  **THE CEREBROSPINAL FLUID VIROME IN VIRALLY SUPPRESSED PEOPLE LIVING WITH HIV**
Mattia Trunfio, Valeria Fox, Rossana Scutari, Vanessa Fini, Annarita Granaglia, Cristina Russo, Elisa Vuaran, Daniele Imperiale, Carlo Federico Perno, Stefano Bonora, Giovanni Di Perri, Claudia Alteri, Andrea Calcagno

489  **DIVERGENT NEUROIMMUNE SIGNATURES AND HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS SURVIVAL**
Samuel Okurut, Elizabeth Okafor, David R. Boulware, David B. Meyia, Edward N. Janoff, Yukari C. Manabe, Joseph O. Olobo, Joshua Rhein
Research Group: ASTRO Study Team and TIME Study Team

490  **CLINICAL AND LABORATORY OUTCOMES OF HEPATITIS C TREATMENT IN AN ACUTE HIV COHORT**
Ferron F. Ocampo, Carlo Sacdalan, Suteeraporn Pinyakorn, Misti Paudel, Donn Colby, Nathornson Poltubtim, Somchai Sriprienchon, Robert Paul, Nittaya Phanuphak, Denise Hsu, Serena Spudich, Phillip Chan
Research Group: RV254/SEARCH 010 Study Team

491  **CMV, SEX, AND COGNITION IN PEOPLE WITH HIV (PWH)**
Patricia K. Riggs, Gordon Honerkamp-Smith, Milenka Vargas, Gemma Caballero, Donald Franklin, Jennifer Iudicello, Leah H. Rubin, Robert K. Heaton, Ronald J. Ellis, Scott L. Letendre, Sara Gianella

---

**Poster Session-G3 PHARACOKINETICS/PHARMACODYNAMICS OF SARS-CoV-2 THERAPEUTICS**
2:30 PM - 4:00 PM

510  ** IMMUNE-VIRAL DYNAMICS MODELING OF THE BASIS FOR INDIVIDUAL VARIATION IN COVID-19**
Youfang Cao, Akshita Chawla, Brian Maas, Ruthie Birger, Laura Liao, Matthew Rizk, Julie Stone

511  **FACTORS INFLUENCING COVID-19 RISK: INSIGHTS FROM MOLNUPIRAVIR EXPOSURE-RESPONSE**
Akshita Chawla, Brian Maas, Ruthie Birger, Hong Wan, Youfang Cao, Matthew Johnson, Carisa De Anda, Matthew Rizk, Julie Stone

512  **NO DOSE ADJUSTMENTS FOR CYP3A4 SUBSTRATES WHEN COADMINISTERED WITH BEMNIFOSBUVIR**
Xiao-Jian Zhou, Gaetano Morelli, Maureen Montrond, Keith Pietropaolo, Bruce Belanger, Arantxa Horga, Janet Hammond
**513** BEMNIFOSBUVIR HAS LOW POTENTIAL TO INHIBIT P-gp, BCRP, AND OATP1B1 MEDIATED TRANSPORT  
Xiao-Jian Zhou, Gaetano Morelli, Maureen Montrond, Keith Pietropaolo, Bruce Belanger, Arantxa Horga, Janet Hammond

**514** PHARMACOKINETICS INFORMS REMDIESIVIR DOSING FOR PATIENTS WITH SEVERE RENAL IMPAIRMENT  
Rita Humeniuk, Rong Deng, Immaculada C. Sorribes, Sean Regan, Haeyoung Zhang, Richard Robson, Meghan Sise, Yanniou Kouliaj, Joe Llewellyn, Robert Hyland, Anu Osinus, Sandhya Sirish, Ana Ruiz-Garcia, Helen Winter

**515** GLOBAL COLLABORATION TO PROVIDE DRUG INTERACTION GUIDANCE FOR NIRMATRELVIR/RITONAVIR  
Safia Kurjakose, Alice Tseng, Sara Gibbons, Fiona Marra, Alison Boyle, Tessa Senneker, Gregory Eschenauer, Sarita Boyd, Jomy George, Kimberly K. Scarsi, Saye Khoo, Alice K. Pau, Catia Marzolini, Page Crew, Justin Chiong, Pamela S. Belperio, Claire Lund

**Poster Session-H2 ANTIRETROVIRAL THERAPY: PROSPECTIVE CLINICAL TRIALS**

**520** IMPACT OF BASELINE FACTORS ON VIROLOGIC RESPONSE TO bNab VH3810109 (N6LS) IN BANNER  
Peter Leone, Margaret Garlind, Judah Abberbock, Paul Wannamaker, Beta Win, Mark Baker, Viviana Wilches, Darren Bentley, Max Lataillade, Jan Losos

**521** RAPID ART INITIATION USING BIC/FTC/TAF AND TDF+3TC+EFV IN PEOPLE WITH HIV IN CHINA  
Shiyun Lv, Lijun Sun, Ping Ma, Lijing Wang, Yingquan Zhou, Cuisong Wu, Renfang Chen, Rugang Wang, Fengchi Zhang, Wei Hua, Lili Dai

**522** LONG-ACTING LENACAPAVIR IN A COMBINATION REGIMEN FOR TREATMENT-NAIVE PWH: WEEK 80  
Debbie Hagins, Ellen Koenig, Rachel Safran, Lizette Santiago, Michael Wohlfelder, Chi-Biu Hsiao, Shan-Yu Liu, Laurie A. Vanderveen, Hadas Dvory-Sobol, Martin S. Rhee, Jared M. Baeten, Samir Gupta

**523** WEEK 52 SUBGROUP EFFICACY OF LENACAPAVIR IN HEAVILY TREATMENT-EXPERIENCED PWH  
Onyema Ogbugu, Sorana Segal-Maurer, Antonella Castagna, Edwin Dejesus, Anchalee Avihingsanott, Christine Zurawski, Olayemi Osiyemi, Theo Hodge, Gordon Crofoot, Hui Wang, Hadas Dvory-Sobol, Martin S. Rhee, Jared M. Baeten, Jean-Michel Molina

**524** BASELINE nRTI HIV DRUG RESISTANCE AND EFFECT ON RECYCLED nRTI’s: THE VISEND TRIAL  
Suilnajj Sivile, Lloyd B. Mulenga, Nyuma Mbewe, Danielle Engamba, Sombo Fwoloshi, Mundia Mwitumwa, Mpanji Siwingwa, Lameck Chirwa, Kennedy Banda, Tiza Mpata, Davison Ngandu, Kai M. Nachilima, William C. Wester, Andrew Hill, Bryony Simmons  
Research Group: VISEND TRIAL GROUP

**525** INITIAL SUPPLEMENTAL DOLUTEGRAVIR DOSE IN SECOND-LINE ART: A PHASE 2 RANDOMISED TRIAL  
Ying Zhao, Rulan Griesel, Zaayid Omar, Bryony Simmons, Andrew Hill, Gert van Zyl, Claire Keene, Gary Maartens, Graeme Meinjies

**526** DORAVIRINE: SAFETY, TOLERABILITY & EFFICACY IN SOUTH AFRICAN WOMEN ON CONTRACEPTION  

**527** PLASMA AND URINE PK OF DOLUTEGRAVIR AND TENOFOVIR TO AID POINT-OF-CARE TESTING  
Laura J. Else, Laura Dickinson, Stacey Edick, Ashley Zhowski, Ken Ho, Sujan Dilly-Penchala, Beth Thompson, Saye Khoo, Rhonda Brand
**Poster Session-H4 ANTIRETROVIRAL THERAPY: COMPARTMENTS, HIV-2, AND NANOFORMULATIONS**

**2:30 PM - 4:00 PM**

537 **HIV-1 RNA DECAY IN SEMEN AND RECTUM AFTER INITIATING THERAPY WITH DTG PLUS 3TC**
Sofia C. Scevol, Jordi Niubo, Pere Domingo, Guillermo Verdejo, Adrià Curran, Vicens Díaz de Brito, Juan M. Tiraboschi, Sandra Morenilla, Benito Garcia, Irene Soriano, Daniel Podzamczer, Arkaitz Imaz

538 **ANTIVIRAL ACTIVITY OF LENACAPAVIR AGAINST HIV-2 ISOLATES**
Robert A. Smith, Dana Raugi, Robbie Nixon, Moussa Seydi, Nicolas Margot, Christian Callebaut, Geoffrey Gottlieb

539 **IMMUNO-VIROLOGICAL AND CLINICAL FOLLOW-UP OF HIV-2 PATIENTS RECEIVING BIC/FTC/TAF**
Véronique A. Joly, Valentine M. Ferré, Mélanie Cresta, Charlotte Charpentier, Marc Digumber, Florence Damond, Gilles Peytavin, Yazdan Yazdanpanah, Diane Descamps, Jade Ghosn

540 **ULTRA-LONG-ACTING BICTEGRAVIR NANOFORMULATIONS**
Mohammad Ullah Nayan, Srijanee Das, Brady Sillman, Brandon Hanson, Siddappa Byrareddy, Howard E. Gendelman, Benson Edagwa

**Poster Session-H8 SARS-CoV-2 TREATMENT: CLINICAL AND ANTIVIRAL ACTIVITY (OR NOT)**

**2:30 PM - 4:00 PM**

563 **SARS-CoV-2 VIRAL LOAD CHANGE IN A RANDOMIZED TRIAL ON THREE DIFFERENT EARLY THERAPIES**
Valentina Mazzotta, Simone Lanini, Giulia Matusali, Francesca Colavita, Alessandra Vergori, Emanuela Giombini, Silvia Rosati, Sabrina Minicucci, Martina Reuca, Francesca Gavaruzzi, Enrico Girardi, Emanuele Nicastri, Francesco Vaia, Fabrizio Maggi, Andrea Antinori, Priscilla Caputi, Fabrizio Carletti, Federico De Zottis, Gruber Ernesto Cesare Maria, Maria Maddalena Plazzi

Research Group: MONET Clinical Trial Group

564 **A RANDOMIZED TRIAL ON EARLY THERAPY IN COVID-19 HIGH-RISK OUTPATIENTS IN OMICRON ERA**
Valentina Mazzotta, Simone Lanini, Lavinia Fabeni, Alessandra Vergori, Alessandra D’Abramo, Maria Maddalena Plazzi, Licia Bordi, Samir Al Moghazhi, Enrico Girardi, Antonella D’Arminio Monforte, Loredana Sarmati, Emanuele Nicastri, Francesco Vaia, Fabrizio Maggi, Andrea Antinori, Federico De Zottis, Marisa Fusto, Alessandra Oliva, Silvia Rosati, Martina Rueca

Research Group: MONET Clinical Trial Group

565 **SARS-CoV-2 OMICRON VIRAL LOAD DECREASE AFTER MONOCLONAL ANTIBODIES OR ANTIVIRALS**

Research Group: INMI COVID-19 Outpatients Treatment Study Group

566 **INCIDENCE AND PREDICTORS OF CLINICAL PROGRESSION IN AN EARLY TREATED COVID-19 COHORT**
Valentina Mazzotta, Alessandro Cozzi Legri, Simone Lanini, Silvia Meschi, Alessandra Vergori, Tommaso Ascoli Bartoli, Giulia Gramigna, Giuseppina Giannico, Alessandra D’Abramo, Claudia Cimaglia, Enrico Girardi, Francesco Vaia, Fabrizio Maggi, Emanuele Nicastri, Andrea Antinori, Carlotta Cerva, Angelo Corpolonghi, Massimo Fracalancia, Francesca Gavaruzzi, Fabio Tucci

Research Group: INMI COVID-19 Outpatients Treatment Study Group
567 NIRMATRELVIR/RITONAVIR UPTAKE AMONG ADULTS WITH COVID-19, DECEMBER 2021-OCTOBER 2022
Yanhan Shen, McKaylee M. Robertson, Sarah G. Kulkarni, Laura Puzniak, Joann Zamparo, Kristen E. Allen, Saba A. Qasmieh, Christian Grov, Avantika Srivastava, Rebecca Zimba, John M. McLaughlin, Denis Nash
Research Group: CHASING COVID Cohort Study Team

568 VIRAL DYNAMIC MODELS PROVIDE AN EXPLANATION FOR SARS-CoV-2 REBOUND AFTER NIRMATRELVIR
Alan S. Perelson, Ruy Ribeiro, Tin Phan

569 NIRMATRELVIR USE AND HOSPITALIZATIONS OR DEATH IN INDIVIDUALS WITH COVID-19
Adeel Butt, Peng Yan, Obaid Shaikh, Victor Talisa, Saad Omer, Florian G. Mayr

570 MOLNUPAVIR IN PREVIOUSLY UNINFECTED NONHOSPITALIZED PERSONS WITH COVID-19
Adeel Butt, Peng Yan, Obaid Shaikh, Saad Omer, Florian G. Mayr, Victor Talisa

571 TIXAGEVIMAB/CILGAVIMAB IM AND IV FOR COVID-19: A RANDOMIZED CONTROLLED ACTIV-2 TRIAL
Rachel A. Bender Ignacio, Kara W. Chew, Carlee Moser, Judith S. Currier, Joseph J. Eron, Arzhang C. Javan, Evgenia Aga, Michael Gibbs, Herve Tchouakam, Matthew Newell, Eric S. Daar, Jonathan Z. Li, Michael D. Hughes, Davey M. Smith, David A. Wohl, Robert Coombs, Courtney V. Fletcher, Mark Giganti, Alexander L. Greninger, Justin Ritz
Research Group: ACTIV-2/A5401 Study Team

572 A RANDOMIZED TRIAL OF IVERMECTIN 600 MCG/KG VS PLACEBO IN MILD/MODERATE COVID-19
Research Group: for the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators

583 STATEWIDE TRENDS OF ACQUIRED HIV-1 DRUG RESISTANCE IN RHODE ISLAND: 2004-2021
Su Aung, Vlad Novitsky, Jon A. Steingrimsson, Fizza Gillani, Mark Howison, Katherine Nagel, Matthew Solomon, Thomas Bertrand, Katharine Howe, Lila Bhattachari, John Fulton, Utpala Bandy, Joseph W. Rami, Rami Kantor

584 FOSTEMSARIV RESISTANCE-ASSOCIATED MUTATIONS IN HIV-1C STRAINS FROM BOTSWANA

585 NO ANTAGONISM OR CROSS-RESISTANCE OBSERVED BETWEEN ISLATRAVIR AND LENACAPAVIR
Tracy Lauren Diamond, Winnie Ngo, Shih Lin Goh, Silveria Rodriguez, Min Xu, Jay Grobler, Ernest Asante-Apiah

598 HBV TRANSMISSION IN HOUSEHOLDS OF WOMEN ENGAGED IN DR CONGO'S HIV PMTCT PROGRAM
Camille Morgan, Patrick Ngimbi, Melchior Kashamuka Mwandagaliwa, Sarah Ntambua, Jolie Matondo, Martine Tabala, Nana Mbonze, Linda James, Marcel Yotebieng, Samuel Mampunza, Peyton Thompson, Jonathan Parr

Poster Session-I3 PRETREATMENT HIV DRUG RESISTANCE
2:30 PM - 4:00 PM

Poster Session-J3 VIRAL HEPATITIS IN SUB-SAHARAN AFRICA
2:30 PM - 4:00 PM
599 PREVALENCE AND EVALUATION OF HEPATITIS B VIRAL REPLICATION IN PREGNANT WOMEN IN MALI
Djeneba B. Fofana, Hamadi Sissoko, Sally McFall, Aminatou Coulibały, Adama Goita, Laurence Morand-Joubert, Joel Gozlan, Mamadou Diakité

600 EVOLUTIONARY HISTORY OF HEPATITIS B VIRUS SUB-GENOTYPE D3 IN BOTSWANA

601 HEPATITIS C TREATMENT OUTCOMES AMONG PEOPLE WHO INJECT DRUGS IN KENYA
Grace Umutesi, Joyce Boke, Aliza Monroe-Wise, Sarah Masyuko, Helgar Masyuki, David Bukusi, William Sinkele, John Scott, Carey Farquhar, Brandon L. Guthrie

602 HEPATOCELLULAR CARCINOMA SCREENING AMONG HIV/HBV-COINFECTED INDIVIDUALS IN ZAMBIA
Carlotta Riebensamh, Guy Muula, Helen Chitundu, Kalonga Hamusonde, Belinda Chihota, Edford Sinkala, Veronica Sunkutu, Martin Maurer, Annalisa Berzigotti, Matthias Egger, Carolyn Bolton Moore, Michael Vinikoor, Gilles Wandeler

Poster Session-J4 LIFE AFTER SVR
2:30 PM - 4:00 PM

603 RISK BEHAVIOUR TRAJECTORIES AMONG PEOPLE TREATED FOR RECENT HCV INFECTION
Joanne M. Carson, Evan Cunningham, Sebastiano Barbieri, Marc van Der Valk, Jürgen K. Rockstroh, Margaret Hellard, Arthur Kim, Sanjay Bhagani, Jordan Feld, Edward Gane, Andrei Rauch, Julie Bruneau, Gail Matthews, Marianne Martinello

604 BEHAVIORAL RISK FOLLOWING HCV TREATMENT AMONG MEN WHO HAVE SEX WITH MEN WITH HIV
Kris Hage, Anders Boyd, Daniëla van Santen, Kees Brinkman, Joop Arends, Fanny Lauw, Bart Rijnders, Arne van Eeden, Marc van Der Valk, Astrid Newsum, Amy Matser, Janke Schinkel, Maria Prins

605 LONG-TERM LIVER EVENTS IN PATIENTS WITH HCV CHRONIC INFECTION AFTER SVR
Jessica Martin Carmona, Anaïs Corma-Gómez, Francisco Tellez, Miriam Serrano-Fuentes, Luis Morano, Diana Corona Mata, María José Ríos, Francisco J. Vera Méndez, Isabel Barroso, Rosario Palacios, Ignacio De Los Santos, Paloma Geijo, Arkaitz Imaz, Juan A. Pineda, Juan Macías

606 PREDICTION OF HEPATIC DECOMPENSATION AFTER SVR IN PATIENTS WITH HCV CHRONIC INFECTION
Anaïs Corma-Gómez, Francisco Tellez, Luis Morano, Mario Friás, Miriam Serrano-Fuentes, María José Ríos, Isabel Barroso, Francisco J. Vera Méndez, Rosario Palacios, Paloma Geijo, Dolores Merino, Ignacio De Los Santos, Arkaitz Imaz, Juan A. Pineda, Juan Macías, Carlos Galera

607 LONG-TERM CHANGES IN LIVER STIFFNESS POST-SVR IN PATIENTS WITH HCV CHRONIC INFECTION
Anaïs Corma-Gómez, Francisco Tellez, Diana Corona Mata, Luis Morano, Miriam Serrano-Fuentes, Maria José Ríos, Francisco J. Vera Méndez, Isabel Barroso, Rosario Palacios, Ignacio De Los Santos, Paloma Geijo, Arkaitz Imaz, Dolores Merino, Juan A. Pineda, Juan Macías, Carlos Galera

Research Group: GEHEP-011
608 **METABOLOMİC PROFILE ASSOCIATED WITH HVPG CHANGE AFTER DAA IN HCV PTs WITH CIRRHOSS**
Ana Virseda Berdices, **Juan Berenguer**, David Rojo, Juan González-García, Oscar Brochado Kith, Amanda Fernández-Rodríguez, Daniel Sepulveda Crespo, Cristina Diez, Victor Hontaño, Leire Pérez-Latorre, Rafael Micán, Teresa Aldámiz Echevarría, Coral Barbas, Salvador Resino, María A. Jiménez-Sousa

**Poster Session-J6 PATHOGENESIS AND NATURAL HISTORY**
2:30 PM - 4:00 PM

617 **RİSK FACTORS FOR LİVER FİBROSIÇ PROGRÉSSİON IN HİV: A MULTI-CENTER LONGİTUDİNAL STUDY**
Giovanni Guaraldi, Jovana Milic, Stefano Renzetti, Federico Motta, Jenny Bischoff, Giulia Besutti, Giuseppe Mancini, Sara Esperti, Marianna Menozzi, Wesal Elgretli, Dana Kablawi, Stefano Calza, Cristina Mussini, Jürgen K. Rockstroh, Giada Sebastiani

618 **İNCİDENCE OF NON-HEPİCATİC CANCERS İN HİV, HCV, AND HBV/HCV CONİNECTED PERSONS**
Adeel Butt, Peng Yan, Obaid Shaikh
Research Group: ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans)

619 **CONTRİBUTİON OF ALCOHOL USE İN HİV/HCV CONİNECTİON TO ALL-CAUSE MORTALİTY**
Research Group: Antiretroviral Therapy Cohort Collaboration (ART-CC)

620 **SYNDÉMIC OF CHRONİC VIRAL İNFECTIONS ON THE RİSK OF END-STAGE RENAL DİSEASE**
Dahn Jeong, Stanley Wong, Jason Wong, Jean Damascene Makouza, Geoffrey McKee, Héctor A. Velásquez García, Zahid A. Butt, Prince A. Adu, Mawuena Binka, Sofia Bartlett, Amanda Yu, Maria Alvarez, Mel Kraided, Naveed Z. Januja

621 **LİVER NEUTROPHİLS EXPRESS STRONGER PD-L1 SIGNALİNG İN HİV/HBV THAN İN HBV ALONE**
Michael S. Wallace, Taonga Musonda, Christopher Oetheimer, Edford Sinkala, Paul Kelly, Mah Asombang, Hailey Patel, Simutanyi Mwakamui, Debika Bhattacharya, Georg Lauer, Raymond Chung, Michael Vinikoor, Nadia Alatrakchi

622 **YAP-MEDIATED HEPATOCYTE DAMAGE CONTRİBUTİONS TO LİVER FİBROSIÇ WITH HİV-RELATİED İNJURY**
Brian A. Fellenstein, Volney A. Spalding, Wenyu Lin, Raymond Chung, Shadi Salloum

623 **CHRONİC LİVER İMFLAMMATİON AND USE OF CONTEMPORARY ART AMONG PERSONS LİVİNG WITH HİV**
Ashley Roen
Research Group: RESPOND

624 **COVID-19 OUTCOME İN PATİENTS WITH AND WITHOUT CİRROHİSS**
Obaid Shaikh, Peng Yan, Adeel Butt

**Poster Session-K1 NON-AIDS DEFINİNG CANCERS: PATHOGENESIS**
2:30 PM - 4:00 PM

625 **ASSOCIATİON OF HİV CONTROL AND İMМUNOSUPPRESSİON WITH NADC RİSK AMONG PATİENTS ON ART**
Brittney Dickey, Elizabeth Yanik, Zachary Thompson, Greer Burkholder, Mari Kitahata, Richard Moore, Jeffrey Jacobson, W. Christopher Mathews, Katerina Christopoulos, Julia Fleming, Chad Achenbach, Anna E. Coghill
626  HIV-ASSOCIATED DIFFERENCES IN THE TUMOR IMMUNE MICROENVIRONMENT OF NADCs
Anna E. Coghill, Nathan Van Bibber, Brooke Fridley, Jordan Fenlon, Yoko Derose, Jon Mahlow, Gita Suneja

627  SPECIFIC EXOSOMAL PROTEOMIC PROFILE ASSOCIATED TO PLHIV PRESENTING NADCs
José M. Benito, Maria A. Navarrete-Muñoz, Manuel Pedregal, Héctor Callata, Héctor Peinado, Sara Nistal, Alejandro Velastegui, Edinson Caviedes, María L. Hernáez, María L. García-Gil, Jesús García-Foncillas, Norma Rallón

Poster Session-K2 CANCER (GENERAL): RISK AND MORTALITY
2:30 PM - 4:00 PM

628  RISK FACTORS FOR 5-YEAR MORTALITY IN PEOPLE WITH HIV AFTER CANCER DIAGNOSIS
Sally B. Coburn, Elizabeth Humes, Raynell Lang, Michael A. Horberg, Richard Moore, Michael J. Silverberg, Gypsyamber D’Souza, Lesley S. Park, M. John Gill, Amy C. Justice, Maile Karris, Charles Rabkin, Sonia Napravnik, Keri Althoff
Research Group: North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA

629  MARKERS OF IMMUNOSUPPRESSION AND MORTALITY AMONG CANCER PATIENTS WITH HIV
Emilia Ascanio Carerra, Qianlai Luo, Cameron Haas, Meredith Shiel, Eric Engels

Poster Session-K5 ANAL CANCER: PATHOGENESIS, PREVENTION, AND SCREENING
2:30 PM - 4:00 PM

638  WITHDRAWN

641  ASSESSING PERSPECTIVES AMONG PEOPLE WITH HIV WHO HAVE HAD HIGH RESOLUTION ANOSCOPY
Maria C. Geba, Divya Kalluri, Benjamin Cardenas, Emma Mitchell, Tabor Flickinger, Rebecca Dillingham, Tania Thomas

642  RISK FACTORS FOR ANAL DYSPLASIA AND LINKAGE TO HRA IN TRANSGENDER WOMEN
Omar Harfouch, Andrea Lisco, Rahwa Eysu, Amelia Cover, Ashley Davis, Emade Ebah, Phyllis Bijole, Grace Garrett, Tina Liu, Michelle Spikes, Imani Fnu, Henry Masur, Shyamasundaran Kottilil, Sarah Kattakuzhy, Elana Rosenthal

643  IMMUNOLOGICAL BIOMARKERS ASSOCIATED WITH ANAL DYSPLASIA IN PEOPLE LIVING WITH HIV
Cristina Mancebo Pérez, Joaquin Burgos, Núria Massanassa, Antonio Astorga Gamaza, Josep Castellví, Stefania Landolfi, Adrià Curran, Jorge N. García, Vicenç Falció, María J Buzon, Meritxell Genescà
Research Group: HIV Translational Research Group

644  NADIR CD4 AND ANAL CYTOLOGY PREDICT DEVELOPMENT OF INVASIVE ANAL CANCER
Edward Cachay, Tari Gilbert, Huifang Qin, Laura Bamford, William Mathews
645  TISSUE-RESIDENT T-CELL RESPONSES IN HIV+ PATIENTS WITH HPV-DRIVEN ANAL DYSPLASIA
Rehana V. Hewavisenti, Zhong-Hong Zhang, Cecilia Chang, Tony Wang, Priyanka S. Hastak, Fengyi Jin, Mary Poynten, Fabio Luciani, Alexander Swarbrick, Andrew Grulich, Anthony D. Kelleher, Sarah C. Sasson

Poster Session-L4 INFLAMMATION AND CARDIOVASCULAR DISEASE
2:30 PM - 4:00 PM

660  LOW CD4 NADIR AT HIV DIAGNOSIS ASSOCIATES WITH INCREASED RISK OF CLONAL HEMATOPOIESIS
Romit Bhattacharya, Aniruddh P. Patel, Md Mesbah Uddin, Abhishek Niroula, Kathleen V. Fitch, Michael T. Lu, Gerald Bloomfield, Judith A. Aberg, Carl J. Fichtenbaum, Heather J. Ribaudo, Markella V. Zanni, Benjamin Ebert, Pam S. Douglas, Steven K. Grinspoon, Pradeep Natarajan

661  CIRCULATING BIOMARKERS AND CARDIAC DYSFUNCTION IN WOMEN WITH OR AT RISK FOR HIV
David B. Hanna, Adam M. Whalen, Sanyog G. Shitole, Mahim Naveed, Jason M. Lazar, Karyn Anastos, Mario J. Garcia, Ryung S. Kim, Phyllis C. Tien, Robert C. Kaplan, Jorge R. Kizer

662  CD2/LFA-3 AXIS COSTIMULATION OF CD57+CD28- CD8 T CELLS IN HIV AND ATHEROSCLEROSIS
Nicole Winchester, Soumya Panigrahi, Anokhi Haria, Michael M. Lederman, Michael L. Freeman

663  ANTITRETROVIRAL THERAPY AMELIORATES SIV-ASSOCIATED MYOCARDITIS IN THE HEART
Jake A. Robinson, Meng Niu, Howard Fox, Tricia H. Burdo

664  EFFECT OF NICOTINE RECEPTOR AGONISTS ON INFLAMMATION AND RISK OF CHD AND DEATH IN HIV
Hilary A. Tindle, Debbie M. Cheng, Natalia Gnatienko, Elena Blokhina, Tatiana Yaroslavtseva, Sally Bendiks, Leah Forman, Judith A. Hahn, Kaku So-Armah, Michael D. Stein, Kendall Bryant, Dmitry Liozovn, Evgeny Krupitsky, Jeffrey H. Samet, Matthew Freiberg

665  CARDIOVASCULAR RISK AMONG PEOPLE ACCESSING DIFFERENTIATED HIV CARE IN SOUTH AFRICA
Maitreyi Sahu, Adam Szpiro, Heidi van Rooyen, Stephen Asisimwe, Maryam Shahanemesh, D. Allen Roberts, Meighan Krows, Kombi Sausi, Nsika Sithole, Torin Schaeffsma, Jared M. Baeten, Connie Celum, Adrienne E. Shapiro, Alastair von Heerden, Ruanne Barnabas
Research Group: Delivery Optimization of Antiretroviral Therapy (DO ART) Study Team

666  EXERCISE CAPACITY IS REDUCED IN HIV INDEPENDENT OF SARS-CoV-2 INFECTION
Matthew S. Durstenfeld, Michael J. Peluso, Matthew A. Spinelli, Danny Li, Eric Sander, Shreyo Swaminathan, Victor Arechiga, Rebecca Hoh, Mandal A. Aras, Carlin S. Long, Steven G. Deeks, Priscilla Hsue

Poster Session-L5 THE GUT MICROBIOME AND COMORBIDITIES
2:30 PM - 4:00 PM

667  GUT MICROBIOTA ASSOCIATED WITH OBSTRUCTIVE CORONARY ARTERY DISEASE IN HIV INFECTION
Marius Traseid, Marco Gelpi, Beate Vestad, Klaus Kofroed, Andreas Fuchs, Lars Kober, Hedda Hoel, Kristian Holm, Thomas Lars Benfield, Johanne Roksund, Susanne Dam Poulsen, Andreas D. Knudsen
Research Group: COCOMO study

668  TRYPTOPHAN METABOLISM, THE GUT MICROBIOME, AND CAROTID ARTERY PLAQUE IN WIHS WOMEN

Poster Sessions
**Poster Session-M1 DOES WHAT GOES UP ALWAYS COME DOWN?**

**2:30 PM - 4:00 PM**

**Poster Session-M6 WEIGHT GAIN AND ADIPOSE TISSUE**

**2:30 PM - 4:00 PM**

---

### Poster Session-M1

**WEIGHT LOSS AND METABOLIC CHANGES AFTER SWITCHING FROM TAF/FTC/DTG TO TDF/3TC/DTG**

Bronwyn E. Bosch, Godspower Akpomiemie, Nomathembra Chandiwana, Simiso Sokheka, Andrew Hill, Kaitlyn McCann, Ambar Qavi, Manya Mirchandani, Francois Venter

**FAVORABLE METABOLIC OUTCOMES 48 WEEKS AFTER SWITCH TO DTG/3TC**

Sophie Degroote, Sophie Vanherrewege, Els Tobbak, Els Caluwe, Lara Vincke, Wim Trypsteen, Mareva Delporte, Evy Blomme, Linos Vandekerckhove, Marie-Angélique De Scheerder

**REVERSIBILITY OF TAF- AND/OR InSTI-ASSOCIATED WEIGHT GAIN**

Myrthe L. Verburgh, Ferdinand Wit, Anders Boyd, Peter Reiss, Marc van Der Valk

**WEIGHT GAIN AMONG PARTICIPANTS SWITCHING TO A Dolutegravir-Based HIV Regimen in Kenya**

Kassem Bourgi, Susan Ofner, Beverly Musik, Kara Wools-Kaloustian, Lameck Diero, Constantin Yiamoutsos, Samir Gupta

---

### Poster Session-M6

**MITOCHONDRIAL HAPLOGROUPS AND WEIGHT GAIN AFTER INITIATING ART IN PATIENTS WITH HIV**

Juan Berenguer, Inmaculada Jarrin, José M. Bellón, Cristina Díez, María A. Jiménez-Sousa, Juan Carlos López, José R. Blanco, Joaquín Portilla, Alvaro Mena, María Novella, David Dalmau, Francesc Villarroya, Pere Domingo, Salvador Resino

**WEIGHT CHANGE AFTER 48 WEEKS ON Dolutegravir: A Prospective Study of PWH in Uganda**


**WEIGHT GAIN FOLLOWING SWITCH TO Dolutegravir Among Adult HIV Cohorts in West Africa**

Thierry Tiendrebeogo, Karen Malatest, Armel Poda, Albert K. Manga, Cecile D. Lahiri, Oliver Ezechi, Didier K. Ekouevi, Igbo Ofotokun, Antoine Jaquet

**Research Group:** CoRIS Collaboration
706 CHANGES IN BODY MASS INDEX WITH INTEGRASE INHIBITOR USE IN REPRIEVE
Emma Kileel, Carlos Malvestutto, Janet Lo, Kathleen V. Fitch, Carl J. Fichtenbaum, Judith A. Aberg, Markella V. Zanni, Esteban Martinez, Nwora Lance Okeke, Princy Kumar, Esau Joao, Sara McCallum, Pam S. Douglas, Heather J. Ribaudo, Steven K. Grinspoon

707 DISCOVERING SUBGROUPS WITH LARGER WEIGHT GAIN WHEN TAKING DOLUTEGRAVIR
Jiabei Yang, Ann W. Mwangi, Rami Kantor, Issa J. Dahabreh, Monicah Nyamburg, Allison Delong, Joseph W. Hogan, Jon A. Steingrimsson

708 SUBCUTANEOUS ADIPOSE TISSUE CELL COMPOSITION IS ASSOCIATED WITH VISCERAL FAT VOLUME

709 VISCERAL FAT REDUCTION WITH TESAMORELIN ASSOCIATED WITH METABOLIC SYNDROME REVERSAL
Roger Bedimo, Teresa Gonzalez, Colleen S. McGary, Taryn A. McLaughlin

Poster Session-N4 MPOX: CLINICAL FEATURES AND SEVERITY SCALES
2:30 PM - 4:00 PM

734 CLINICAL PREDICTORS OF MPOX SEVERITY IN AN ITALIAN MULTICENTER COHORT (MPOX-ICONA)
Valentina Mazzotta, Alessandro Tavelli, Francesca Colavita, Lorenzo Biasioli, Antonella Castagna, Annalisa Mondi, Fabrizio Carletti, Davide Moschese, Luca Pipito, Daniele Tesoro, Roberta Gagliardini, Fabrizio Maggi, Andrea Antinori, Antonella D’Arminio Monforte, Simone Lanini, Massimiliano Fabbiani, Francesco M. Fusco, Miriam Lightner, Claudio M. Mastroianni, Eliana Specchiarello
Research Group: MPOX-ICONA Study Group

735 SEVERE MPOX AMONG PEOPLE LIVING WITH HIV RECEIVING TECOVIRIMAT IN NEW YORK CITY
Elizabeth A. Garcia, Maura K. Lash, Tristan D. McPherson, Mary Foote, Karen A. Alroy, Ellen H. Lee, Wendy Wen, Jeannine Sullivan Meissner, Amma Bosompem, Alyssa Boussacaren, Marcia Wong

736 MANAGEMENT OF MPOX IN PWH ATTENDING A SEXUAL HEALTH DEPARTMENT IN LONDON, UK
Nicolo Girometti, Felicity Burton, Matthew Spencer, Simisola Agunbiade, Ruth Byrne, Margherita Bracci, Rachael Jones, Ellen Dwyer, Gary G. Whitlock, Victoria Tittle, Anton L. Pozniak, Marta Boffito

737 MOSAIC CLADE 2B MPOX COHORT STUDY: CLINICAL CHARACTERISATION AND OUTCOMES
Xavier Lescreur, Laura Merson, Cédric Lauquené, Elise Pesonel, Romain Palich, Jake Dunning, Minerva Cervantes Gonzalez, Christophe Batejat, Coralie Tardivon, Josephine Bourner, France Mentré, Yazdan Yazdanpanah, Diane Descamps, Alexandra Calmy, Piero Olliaro
Research Group: MOSAIC study group

738 DEVELOPMENT AND PILOT OF AN MPOX SEVERITY SCORING SYSTEM (MPOX-SSS)
Jason Zucker, Jacob McLean, Simian Huang, Clare Deaurentis, Shauna Gunaratne, Kate Stoeckle, Marshall J. Glesby, Timothy Wilkin, William Fischer, Inger Damon, John Brooks

739 CLINICAL PRESENTATION OF MPOX IN PEOPLE WITH AND WITHOUT HIV
Victoria Pilkington, Killian Quinn, Lucy Campbell, Michael Brady, Frank Post
Research Group: King’s College HIV and Sexual Health Research Group
**CROI 2023**

**Poster Sessions**

**Poster Session-O4 NOVEL TB AND OI DIAGNOSTICS AND THEIR PREDICTIVE VALUE**

2:30 PM - 4:00 PM

759  **MONOCYTE-TO-LYMPHOCYTE RATIO AND HEMOGLOBIN LEVEL TO PREDICT TB AFTER ART INITIATION**  
Sivaporn Gatechompol, Stephen J. Kerr, Sandra Wagner Cardoso, Wadzanai Samaneka, Srikant Tripathy, Cecilia Kanyama, Mulinda Nyirenda, Patcharapan Sugandhavesa, Andre Machado, Frank Van Leth, Thomas Campbell, Susan Swindells, Ananchalee Avihingsanon, Frank Cobelens  
*Research Group:* AIDS Clinical Trials Group DR067 team

760  **IMMUNE OMIC PROFILES TO DISTINGUISH TUBERCULOSIS AMONG ADVANCED HIV ADULTS IN INDIA**  
Vandana P. Kulkarni, Artur T. Queiroz, Rohidas Borse, Anita Gupta, Bruno B. Andrade, Neelou Nawani, Padmini Salgame, Vidya Mave

761  **PERFORMANCE OF URINE XPERT ULTRA VS ALERE LAM FOR DIAGNOSING TB IN HIV- PATIENTS**  
David F. Stead, Sean Wasserman, Ebrahim Steenkamp, Andrew G. Parrish, Graeme Meintjes

762  **CSF IMMUNE RESPONSE ASSOCIATED WITH FUNGAL BURDEN IN CRYPTOCOCCAL MENINGITIS**  
Julia Stumpf, Elizabeth Okafor, Samuel Okurut, John Kasibante, Kenneth Ssebambulidde, Caleb Skipper, David B. Meya, Tyler Bold, David R. Boulware

763  **COST-EFFECTIVENESS OF CCR5 SCREENING FOR PLHIV WITH ADVANCED HIV DISEASE IN MALAWI**  
Mary Feser, Amir Shroufi, Thulani Maphosa, Ajay Rangaraj, Eddie Matiya, Prakriti Shrestha, Nathan P. Ford, Justine Scott, Virginia Talbot, Appolinaire Tiam, Andrew Phillips, Kenneth A. Freedberg, Emily P. Hyle

764  **MYCO/F LYTIC VS STANDARD BLOOD CULTURES IN FUNGAL DETECTION IN AIDS PATIENTS**  

765  **MULTI-CENTER PROSPECTIVE VALIDATION STUDY OF A NOVEL ANTIGEN ASSAY FOR TALAROMYCOSIS**  
Thu Nguyen, Hao T. Nguyen, Dieu Ng, Phuong Th, Khanh D., Men Tt, Dao Pth, Thom Vt, Chau Tth, Ly VT, Jasper Fuk-Woo Chan, Yuen Ky, Dat Vq, Rogier Doorn, Thuy Le

**Poster Session-P1 HIV INCIDENCE AND PrEP IN PREGNANCY**

2:30 PM - 4:00 PM

766  **QUANTIFIED PRENATAL PrEP EXPOSURE AND PERINATAL OUTCOMES AMONG KENyan WOMEN**  
Lauren A. Gomez, John Kinuthia, Anna Larsen, Joshua Stern, Julia C. Dettinger, Mary M. Marwa, Felix Abuna, Ben Odhiambo, Nancy M. Ngumbau, Barbara Richardson, Pascal Omondi, Jared M. Baeten, Grace John-Stewart, Jillian Pintye

767  **HIGH ACCEPTABILITY OF STI TESTING AND EPT AMONG PREGNANT KENyan WOMEN INITIATING PrEP**  
Jerusha N. Mogaka, Felix Abuna, Julia C. Dettinger, Mary M. Marwa, Ben Ochieng, Salphine Watoyi, Eunina Akini, Nancy M. Ngumbau, Celestine Adogo, Peter Owiti, Lauren A. Gomez, Grace John-Stewart, Jillian Pintye, John Kinuthia  
*Research Group:* mWACH-PrEP Study team

768  **INTEGRATING PrEP INTO ANTEPARTUM CARE FOR HIV-NEGATIVE PREGNANT WOMEN IN SOUTH AFRICA**  
Dorothy C. Nyemba, Rufaro Mvududu, Nyiko Mashele, Linda-Gail Bekker, Pamina M. Gorbach, Thomas J. Coates, Landon Myer, Dvora Joseph Davey
**Poster Sessions**

**CROI 2023**

**Poster Sessions**

- **Wednesday**
  - **Continuing Medical Education**
  - **Late-Breaking**
  - **New Investigator Scholarship**
  - **Nonauthor Presenter**

---

**769** **PrEP CONTINUATION AMONG PERI-CONCEPTION, PREGNANT, AND LACTATING WOMEN IN KENYA**

*Priyanka Anand, Jared M. Baeten, Kenneth Ngure, Nelly Mugo, Elizabeth A. Bukusi, Elizabeth Irungu, Josephine Odoyo, Jennifer Morton, Kenneth Mugwanya*

**770** **PrEP LEVELS STRONGLY CORRELATED IN HAIR AND DBS DURING PREGNANCY AND POSTPARTUM**

*Linxuan Wu, Felix Abuna, Peter L. Anderson, Jared M. Baeten, Julia C. Dettinger, Laurén A. Gómez, Monica Gandhi, Grace John-Stewart, John Kinuthia, Marwa Motongori, Ben Ochieng, Pascal Omondi, Jillian Pintye*

**771** **LONGITUDINAL PrEP ADHERENCE AMONG KENYAN WOMEN WHO INITIATED PrEP DURING PREGNANCY**

*Jillian Pintye, John Kinuthia, Felix Abuna, Peter L. Anderson, Julia C. Dettinger, Laurén A. Gómez, Jessica E. Haberer, Marwa Motongori, Nancy M. Ngumbau, Ben Ochieng, Joshua Stern, Salphine Watoyi, Jared M. Baeten, Grace John-Stewart, Pascal Omondi*

**Research Group:** PrEP Implementation for Mothers in Antenatal Care (PrIMA) Study Team

---

**772** **INCIDENT HIV INFECTIONS IN PREGNANT/BREASTFEEDING WOMEN AND INFANTS IN MOZAMBIQUE**

*Marilena Urso, William P. Killam, Judite R. Langa, Elizabeth Carter, Laura J. McCormick Viens*

---

**773** **HIV RISK PERCEPTION AND PrEP USE AMONG KENYAN WOMEN DURING AND AFTER PREGNANCY**

*Mary M. Marwa, Anna Larsen, Felix Abuna, Julia C. Dettinger, Ben Odhiambo, Salphine Watoyi, Pascal Omondi, Nancy M. Ngumbau, Laurén A. Gómez, Grace John-Stewart, John Kinuthia, Jillian Pintye*

**Research Group:** PrIMA Study

---

**Poster Session-P3 UNDERSTANDING MOTHER-TO-CHILD TRANSMISSION: FROM MOLECULES TO POPULATIONS**

2:30 PM - 4:00 PM

---

**777.5** **MATERNAL HIV Viral Load Threshold for Guiding Extended Infant Prophylaxis Initiation**

*Dramane Kania, Jean-Pierre Moles, David Rutagwera, Franck Edgar Kadeba, Morgana D'Ottavi, Melany Tonga, Souleymane Tassembedo, Anaïs Mennecier, Beauty Matoka, Ajaní Óusmane Taoïfi, Paulin Fao, Thorkild Tylleskår, Chihepo Kankasa, Philippe Van De Perre, Nicolas Nagot, Léticia Sakana*

**Research Group:** ANRS 12397 PROMISE-EPI Study group

---

**778** **VERTICAL TRANSMISSION IN INFANTS BORN TO WOMEN WITH HIV ON ANTIRETROVIRAL TREATMENT**

*Kim Anderson, Emma Kalk, Alexa Heekes, Florence Phelanyane, Nisha Jacob, Andrew Boulle, Ushma Mehta, Gayathri Sridhar, Leigh Ragone, Vani Vannappagari, Mary-Ann Davies*

---

**779** **HIV Drug Resistance in Cases of Perinatal Transmission in IMPAACT 2010 (VESTED)**

*Marley D. Bishop, Violet Korutaro, Ceejay Boyce, Ingrid A. Beck, Lauren Ziemba, Anne Coletti, Patrick Jean Philippe, Nahida Chakhtoura, Tichaona Vhembo, Haseena Cassim, Maxensia Owor, Lameck Chinula, Shahin Lockman, Lisa M. Frenkel*

**Research Group:** IMPAACT 2010 Team

---

**780** **MATERNAL BROADLY NEUTRALIZING ANTIBODY ACTIVITY AND PERINATAL TRANSMISSION OF HIV-1**

*Krithika P. Karthigeyan, Ria Goswami, John Isaac, Elena E. Giorgi, Justin Pollara, Joshua Eudailey, Jackie Li, Megan Connors, Carolyn Weinbaum, Joshua Tu, Feng Gao, Manish Saggar, Sallie R. Permar*

---

**CME**

**Late-Breaking**

**NIS**

**Nonauthor Presenter**
Poster Sessions

781 RECONSTRUCTION OF THE ADCC ANTIBODY REPERTOIRE OF AN HIV-1 NON-TRANSMITTING MOTHER
Zak A. Yaffe, Kevin Sung, Vrasha Chohan, Laura E. Doepker, Duncan K. Ralph, Ruth Nduati, Frederick A. Matsen, Julie M. Overbaugh

Poster Session-Q4 COMORBIDITIES AND COMPLICATIONS AND IN CHILDREN AND YOUTH WITH HIV

2:30 PM - 4:00 PM

815 ORAL MICROBIOTA IN CHILDREN WHO STARTED ANTIRETROVIRAL THERAPY AT YOUNG AGES
Louise Kuhn, Tian Wang, Fan Li, Renate Strehlau, Nicole H. Tobin, Mandisa Nyati, Faeezah Patel, Aafaaq Liberty, Stephen Arpadi, Sunil Wadwa, Shuang Wang, Caroline Tiemessen, Grace Aldrovandi
Research Group: CHANGES Study Team

816 IMMUNE ACTIVATION AND NEUROCOGNITION IN UGANDAN ADOLESCENTS LIVING WITH HIV
Saheera Dirajlal-Fargo, Abdus Sattar, Monika Strah, Christine Karungi, Joy Gumikiriza-Onoria, Nana Asiedu, Angel Nanteza, Anthony F. Santoro, Christopher Ferraris, Daphne Tsapalas, Corey Morrison, Victor Musiime, Grace A. McComsey, Reuben N. Robbins

817 NEUROCOGNITIVE FUNCTION AMONG SCHOOL-AGED CHILDREN AFFECTED BY HIV IN BOTSWANA
Elizabeth D. Lowenthal, Tyler Moore, Ruben Gur, Ontibile Tshume, Jennifer Chapman, Boitumelo Thuto, Mogomotsi S. Matshaba, J. Cobb Scott
Research Group: Ntemoga Study

818 TRAUMATIC EVENT EXPOSURE AND MENTAL DISORDERS IN YOUTH PERINATALLY AFFECTED BY HIV
Corey Morrison, Thomas Corbeil, Luke Kluiszsa, Ohemaa Poku, Lucy Liotta, Naa-Djama Attioh-Okeine, Curtis Dolezal, Andrew Wiznia,
Elaine J. Abrams, Reuben N. Robbins, Claude A. Mellins

819 MULTIFACETED PREMATURE AGING IN ADOLESCENT/YOUNG ADULT WITH PERINATAL-ACQUIRED HIV
Maria Raffaella Petrara, Elena Ruffoni, Francesco Carmona, Ilaria Cavallari, Sandra Zampieri, Silvia Giunco, Paola Del Bianco, Osvalda Rampon, Paolo Palma, Paolo Rossi, Carlo Giaquinto, Anita De Rossi
Research Group: EPIICAL Consortium

820 CHILDREN WITH PERINATAL HIV EXHIBIT HIGH GDF15 LEVELS DESPITE ANTIRETROVIRAL THERAPY
Wei Li, Mussa Mwamzuka, Fatma Marshed, Aabid Ahmed, Alka Khaitan

821 48 MONTHS ANTHROPOMETRIC EVOLUTION OF ADOLESCENTS SWITCHING TO DOLUTEGRAVIR IN SPAIN
Talia Sainz, Santiago Jimenez de Ory, Luis Prieto, Luis Escosa, Claudia Fortuny, Antoni Noquera, Marie Antoinette Frick, Manuel Oltra, Lola Falcon, Matilde Bustillo, Jose Tomas Ramos, Pilar Collado, Jose Couceiro, Cesar Gavilan, Marisa Navarro
Research Group: CoRISpe (Spanish Network of pediatric HIV)

822 METABOLIC HEALTH AND BONE DENSITY IN YOUTH LIVING WITH PERINATAL HIV
Caroline Foster, Colette Smith, Merle Henderson, Moira Cheung, Sarah Fidler
Research Group: BONDY Study Research Group

823 THE BONDY STUDY: BONE DENSITY IN YOUTH LIVING WITH PERINATALLY ACQUIRED HIV
Merle Henderson, Colette Smith, Sarah Fidler, Moira Cheung, Caroline Foster
824  OUTCOMES IN CHILDREN LIVING WITH HIV WITH NON-SEVERE TUBERCULOSIS IN THE SHINE TRIAL
Chishala Chabala, Eric Wobudeya, Marieke van De Zalm, Monica Kapasa, Robert Mboizi, Megan Palmer, Aarti Kinikar, Syed Hissar, Veronica Mulenga, Philippa Musoke, Helen Mcllleron, Anneke Hesseling, Anna Turkova, Diana Gibb, Angela Crook
Research Group: SHINE Trial Team

825  TUBERCULOSIS INCIDENCE AMONG ADOLESCENTS AND YOUNG ADULTS WITH HIV IN KENYA
Danae Black, Sylvia M. Lacourse, Irene Njuguna, Kristin Beima-Sofie, Caren Mburu, Cyrus Mugo, Janet Itindi, Alvin Onyango, Dalton Wamalwa, Grace John-Stewart

834  NILMATREVIR-RITONAVIR TREATMENT IN CHILDREN WITH SARS-CoV-2 INFECTION
Stefania Bernardi, Costanza Triptician, Stefania Mercadante, Anna Markowich, Giulia Lorenzetti, Francesca Calo Carducci, Lorenza Romani, Laura Cursi, Emma Concetta Manno, Federica Galaverna, Leonardo Vallesi, Massimiliano Raponi, Emanuele Nicastr, Carlo Federico Perno, Paolo Rossi

835  COMORBIDITIES THAT INCREASE RISK FOR SEVERE ACUTE COVID-19 IN PEDIATRIC POPULATION
Alfredo Tagarro, Irati Gastesi, Andrea Ramirez Valera, Maria Lucia Mesa Rubio, Pablo Vásquez Hoyos, Gabriela Friedrich, Melissa Naranjo Vanegas, Sonia Restrepo-Gualteros, Olga Lucia Baquero, Inés Leoz Gordillo, Cristina Calvo Rey, Siobhan Crichton, Marthe Le Prevost, Carlo Giaguinto, Cinta Moraleda
Research Group: EPICO, EPICO Colombia and ORCHESTRA

836  PERSISTENT SYMPTOMS IN CHILDREN ADMITTRED WITH COVID SIMILAR TO CONTROLS 1 YEAR LATER
Alfredo Tagarro, Sara Villanueva, Ana Esteban Romero, María López Luengo, Marta Conde, Lucía de Pablo, David Aguiler-ALonso, Irati Gastesi, Sara Domínguez, Cristina Epalza, Álvaro Ballesteros, Carlota Pinto, Carlo Giaguinto, Cinta Moraleda
Research Group: EPICO, EPICO Colombia and ORCHESTRA

837  PERSISTENCE OF SYMPTOMS ONE YEAR AFTER MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN
Cinta Moraleda, Sara Villanueva, Olga Aldecoa Jiménez, Blanca Díaz Fuentes, Luis Prieto, Daniel Blázquez, Cristina Epalza, Elisa Fernández Cooke, Ángela Manzanares, Pablo Rojo, Serena Villaverde, Álvaro Ballesteros, Sara Domínguez, Alfredo Tagarro

838  PBMC IMMUNOPHENOTYPING AND PLASMA INFLAMMATORY PROFILE OF CHILDREN WITH LONG COVID
Jon Izquierdo-Pujol, Sara Moron-lopez, Judith Dalmau, Maria C. Puertas, Clara Carreras-Abad, Alba Gonzalez-Aumatell, Maria Mendez, Carlos Rodrigo, Javier Martinez Picado

839  INFLAMMASOME BUT NOT IFN-I/III RESPONSE IS ALTERED IN CHILDREN WITH LONG COVID
Matteo Fracella, Leonardo Sorrentino, Federica Frasca, Mirko Scordio, Alessandra D'Auria, Giuseppe Olivetti, Carla Selvaggi, Greta Di Mattia, Maria Giulia Conti, Luigi Matera, Domenico La Regina, Gabriella D'Ettorre, Guido Antonelli, Alessandra Pierangeli, Carolina Scagnolari, Luca Maddaloni

Poster Session-Q6 SARS-CoV-2 INFECTION AND PREVENTION IN INFANTS, CHILDREN AND ADOLESCENTS
2:30 PM - 4:00 PM
840 PROTECTION AGAINST HETEROLOGOUS CHALLENGE 1 YEAR AFTER INFANT SARS-CoV-2 IMMUNIZATION
Emma C. Milligan, Katherine Olstad, Caitlin Williams, David Montefiori, Michael Hudgens, Darin Edwards, Andrea Carfi, Kizzmekia Corbett, Christopher Fox, Mark Tomai, Rachel Reader, Dirk Dittmer, Koen Van Rompay, Sallie R. Permar, Kristina De Paris

841 mRNA VACCINES INDUCE A HIGHER ANTIBODIES RESPONSE IN CHILDREN WITH PREVIOUS COVID-19
Costanza Di Chiara, Anna Cantarutti, Francesco Bonfante, Maria Raffaella Petrara, Chiara Cosma, Matteo Pagliari, Nicola Cotugno, Alessandra Meneghel, Elisa Benetti, Luca Bosa, Paolo Palma, Anita De Rossi, Carlo Giaquinto, Daniele Dona', Andrea Padoan
Research Group: VERDI/ORCHESTRA study teams

842 EFFECT OF BNT162B2 ANTIGEN DOSAGE ON PROTECTION AGAINST SARS-CoV-2 OMICRON INFECTION
Hiam Chemaitelly, Houssein H. Ayoub, Laith J. Abu-Raddad

Poster Session-R7 FACTORS AFFECTING OUTCOMES FOR PEOPLE LIVING WITH HIV
2:30 PM - 4:00 PM

876 RACIAL/ETHNIC DISPARITIES IN TIMELY ANTIRETROVIRAL THERAPY INITIATION: 2007-2019
Research Group: North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA

877 IMPACT OF REDLINING ON TIME TO VIRAL SUPPRESSION AMONG PERSONS DIAGNOSED WITH HIV
Lauren J. Ostrenga, John R. Bassler, Dustin M. Long, Mariel Parman, Michael J. Mugavero, Ariann F. Nassel, Emily B. Levitan, Aadia Rana, D. Scott Batey

878 MONITORING CARE AND VIRAL SUPPRESSION AFTER HIV DIAGNOSIS IN UNITED STATES: 2017-2020
Shacara Johnson Lyons, Xiaohong Hu, Anna Satcher Johnson

879 VIRAL SUPPRESSION AND COMMUNITY VIRAL LOAD AMONG MSM WITH HIV IN 23 US CITIES: 2017
Savannah Harris, Shamaya Whitby, Silvina Masciota, Amanda J. Smith, Jeffrey A. Johnson, Lyssa Faucher, Cyprian Wejnert, Johanna Chapin-Bardales
Research Group: NHBS-MSM5 Study Group

880 HOSPITAL READMISSIONS AMONG ADULTS LIVING WITH HIV IN THE US
Xiaming Zhu, Eshan U. Patel, Mary K. Grabowski, Thomas C. Quinn, Kelly Gebo, Aaron Tobian

881 HIV AND THE VETERANS CHOICE ACT: A GEOSPATIAL ANALYSIS IN GEORGIA, 2020-2022
Kartavya Vyas, Vincent C. Marconi, Jodie Guest

882 INTERNALIZED HIV STIGMA AND MENTAL HEALTH/SUBSTANCE USE OVER TIME
Lydia Drumright, Duncan Short, Sonia Napravnik, Edward Cachay, Ellie Moffatt, Katerina Christopoulos, Torsten Neilands, Kenneth Mayer, Mallory O. Johnson, Jimmy Ma, Andrew Hahn, Robin Nance, Timothy Crawford, Geetanjali Chander, Rob Fredericksen, Bridget Whitney
RANDOMIZED TRIAL OF BRIEF ALCOHOL INTERVENTION FOR VIRAL SUPPRESSION AND ALCOHOL USE
Sarah Puryear, Florence Mwangwa, Fred Opel, Gabriel Chamie, Laura Balzer, Jane Kabami, James Ayieko, Elijah Kakande, John Schrom, Melanie Bacon, Sarah Woolf-King, Maya Petersen, Diane V. Havlir, Moses Kamya, Judith A. Hahn
Research Group: SEARCH Study Team

Poster Session-S5 SARS-CoV-2 SEROPREVALENCE AND SURVEILLANCE
2:30 PM - 4:00 PM

SARS-CoV-2 SEROPREVALENCE AMONG UGANDAN BLOOD DONORS: 2019-2022
Swetha Ashokkumar, Jodie L. White, Dorothy Kyeyune, Henry Ddungu, Ronnie Kasirye, Feben Habtehyimer, Owen Baker, Heather Hume, Andrew Redd, Steven J. Reynolds, Thomas C. Quinn, Paul Ness, Evan M. Bloch, Oliver Laeyendecker, Aaron Tobian

COVID-19 SEROPREVALENCE IN VACCINE-NAIVE POPULATIONS: DRC, GUINEA, LIBERIA, AND MALI
Sylvian Laverdure, Donatien Kazadi, Kadidia Kone, Renee Ridzon
Research Group: InVITE Study Team

SARS-CoV-2 SEROPREVALENCE AND RISKS FACTORS IN AFRICAN WLHIV ON ART AND THEIR INFANTS

SARS-CoV-2 INFECTION AMONG PERSONS WHO INJECT DRUGS AND THEIR PARTNERS IN KENYA

SARS-CoV-2 SEROPREVALENCE AMONG PEOPLE WHO INJECT DRUGS IN BALTIMORE
Eshan U. Patel, Shruti H. Mehta, Owen Baker, Becky Genberg, Catherine Schluth, Jacquie Astemborski, Reinaldo Fernandez, Thomas C. Quinn, Greg Kirk, Oliver Laeyendecker

QUANTIFYING POPULATION IMMUNITY TO COVID-19 IN WASHINGTON STATE AND OREGON
Mia Moore, Larissa Anderson, Jaiming Lin, Chloe Bracis, Eileen Burns, Dave Swan, Joshua Schiffer, Dobromir Dimitrov

WITHDRAWN

WITHDRAWN
Poster Session-S6 MODELLING MPOX AND COVID-19
2:30 PM - 4:00 PM

924 RETROSPECTIVE ASSESSMENT OF THE ACCURACY OF MPOX CASE PROJECTIONS IN NEW YORK CITY
David Kaftan, Hae-Young Kim, Charles Ko, James Howard, Anna Bershteyn

925 MODELLING THE MPOX EPIDEMIC IN THE UK OVER MAY-AUGUST 2022
Jasmina Panovska-Griffiths, Robert Hinch, Josie Park, Thomas Ward, Andre Charlett, Fergus Cumming, Nick Watkins, Christophe Fraser, Robyn Stuart

926 MODELLING THE RISK OF FUTURE MPOX OUTBREAKS IN THE NETHERLANDS
Marc C. Shamier, Luca Zaeck, Kai Jonas, Babs Verstrepens, Corine H. Geurtsvankessel, Rory D. de Vries, Jeroen van Kampen, Marion PG. Koopmans, David van de Vijver

927 WHAT IMPACT WILL WORSENING AIR POLLUTION HAVE ON THE BURDEN OF COVID-19?
Sherrie L. Kelly, Andrew J. Shattock, Martina S. Ragettli, Danielle Vienneau, Ana M. Vicedo-Cabrera, Nicole Probst-Hensch, Kees De Hoogh

Poster Session-T3 HIV TESTING IN CLINICAL SETTINGS
2:30 PM - 4:00 PM

941 NON-HIV ENTRY POINTS TO DELIVER HIV SERVICES TO TRANSGENDER WOMEN IN INDIA
Simran Shaikh, Parthasarathy Mugundu Ramien, Allison M. McFall, Jade Bell, Saya Okram, Ajay Enugu, Shrut1 H. Mehta, Maria Salvat Ballester, Viswanathan Arumugam, Rose Pollard, Aditya Singh, Alex Koueghlian, Kevin Ar, Kenneth Mayer, Sunil S. Solomon

942 DIRECTED SCREENING FOR HIV INFECTION IN EMERGENCY SERVICES: VIHGILA STUDY
Josep Guardiola, Emilia Miro, Daniel Iturriza, Rocio De Paz, Mireia Saura, Alexis Rebollo, Cristina Ramio, Miriam Carbo, Connie Leery, Alex Smithson, Emili Ge, Oscar Miro
Research Group: VIHGILA SOCMUE Study Group

943 HIV TEAMS AS A TOOL TO IMPROVE HIV INDICATOR CONDITION-GUIDED TESTING
Carlijn Jordans, Jaap Hanssen, Anna Roukens, Jeroen van Kampen, Femke Moliema, Jet Gisolf, Rachida El Moussaoui, Gonneke Hermanides, Bart Rijnders, Annelies Verbon, Casper Rokx

944 IMPACT OF MPOX OUTBREAK ON HIV TESTING IN A LARGE INTEGRATED HEALTHCARE SYSTEM
Christopher Polk, Mindy Sampson, Jeremy Thomas, Robert Fairman, Tom Ludden, Hazel Tapp, Catherine Passaretti, Michael Leonard

Poster Session-T4 NEW DIAGNOSTICS AND USE OF TESTS
2:30 PM - 4:00 PM

945 DNA-CONFIRMATION OF HIV-1&2 COINFECTIONS AMONG DUALLY-REACTIVE WEST AFRICAN PATIENTS
Research Group: The EDIMARK-2 Study group

946 EVALUATION OF A NOVEL MULTIPLEX IMMUNOASSAY: IMPROVEMENT FOR HTLV-2 DETECTION
Victor A. Folgosi, Pedro L. Junior, Felipe D. Silva, Augusto C. Oliveira, Maan Zrein, Florent Salvador, Jorge Casseb
**Poster Session-U3 SARS-CoV-2 DIAGNOSTICS**

**2:30 PM - 4:00 PM**

- **947** HIV DETECTION IN WASTEWATER AS A NEW EPIDEMIOLOGICAL TOOL  
  Austen Terwilliger, Justin Clark, Visanthi Avadhanula, Karen Feliz, Eric Murphy, Loren Hopkins, Pedro Piedra, Anthony Maresso, Thomas P. Giordano

- **961** ANTIBODIES TO SARS-CoV-2 VARY DUE TO ORDER AND FREQUENCY OF VACCINATION OR INFECTION  
  Owen Baker, Evan Beck, Andrew Karaba, Eshan U. Patel, Andrea Cox, Yukari C. Manabe, Zoe Demko, Mira Prabhu, Yu-Hsiang Hsieh, Aaron Millstone, Andrew Redd, Aaron Tobian, Thomas C. Quinn, Joel N. Blankson, Oliver Laeyendecker

- **962** SARS-CoV-2 REPLICON SYSTEM FOR THE PHENOTYPIC EVALUATION OF NSP GENE SUBSTITUTIONS  
  Dong Han, Venice Du Pont, Simin Xu, Arya Vijjaparupu, Jiani Li, Bandita Parhy, Ross Martin, Gregory Camus, Jason K. Perry, Danielle P. Porter, Charlotte Hedskog, John P. Bilello, Tomas Cihlar, Hongmei Mo, Lauren Rodriguez  
  Research Group: Gilead Clinical Virology

- **963** USE OF Ag-RDTs TO REDUCE SARS-CoV-2 INFECTIONS AT RELIGIOUS GATHERINGS IN LICS & MICS  
  Megan A. Hansen, Alvin X. Han, Joshua M. Chevalier, Ethan Klock, Hiromi Pandithakoralage, Tom Ockhuisen, Sarah Girdwood, Nkgomeleng Lekodeba, Alexandra de Nooy, Helen E. Jenkins, Colin A. Russell, Brooke Nichols

- **964** Ag-RDT MASS TESTING IN LARGE GATHERINGS TO IDENTIFY SARS-CoV-2 INFECTIONS IN KENYA  
  Rose Masaba, Lise Denoeud, Stephen Siamba, Heather J. Hoffman, Mario Songane, Edyth Osire, Njoki Kimani, Magoma Kwasa

- **965** SARS-CoV-2 WASTEWATER SURVEILLANCE IN A US JAIL: CORRELATION, FEASIBILITY, NEXT STEPS  
  Lindsay Saber, Anne Spaudling, Matthew J. Akiyama, Stephen Hilton, Shanika Kennedy, Christine Moe, Victoria Phillips  
  Research Group: SWANSS Study Group

- **966** DISABILITY AND COVID-19 TESTING: A CROSS-SECTIONAL RADx-UP STUDY  
  Haley R. Martin, Wensong Wu, Sabrina Sales Martinez, Jose A. Bastida Rodriguez, Angelique Johnson, Marianna K. Baum

**Poster Session-V4 PrEP USE IN SPECIAL POPULATIONS**

**2:30 PM - 4:00 PM**

- **982** ASSOCIATION OF METH USE AMONG GBMSM ON HIV PRE-EXPOSURE PROPHYLAXIS CARE ENGAGEMENT  
  Alexander Moran, Marjan Javanbakht, Matthew Mimiaga, Steven Shoptaw, Famina M. Gorbach

- **983** NO IMPROVEMENT IN PREEXPOSURE PROPHYLAXIS USE AMONG PWID: SAN FRANCISCO, 2018-2022  
  Bow Suprasert, Moranda Tate, Danyion Reagan, Raul Ruiz, Katherine Gao, Katherine McNaughton, Kassandra Miller, Alexander Marr, Kelly D. Taylor, Willi McFarland, Erin C. Wilson

- **984** EFFECT OF INTIMATE PARTNER VIOLENCE ON ART & PREP ADHERENCE IN SERODIFFERENT COUPLES  
  Dorothy Thomas, Lylianne Nakabugo, Florence Nambi, Joseph Kibuuka, Timothy Mwuonge, Erika Feutz, Katherine Thomas, Jane Simoni, Elizabeth Montgomery, Norma Ware, Monique Wyatt, Ingrid Katz, Herbert Kadama, Andrew Muyugira, Renee Heffron
985  **DETERMINANTS OF PREEXPOSURE PROPHYLAXIS RETENTION AMONG TRANSGENDER WOMEN**  
Jack Andrzejewski, Heather A. Pines, Sheldon Moris, Robert Bolan, David J. Moore, Leah B. Burke, Jill Blumenthal

986  **PrEP PRESCRIPTIONS AMONG PERSONS WITH MEDICAID BY RACE AND ETHNICITY: UNITED STATES**  
Karen Hoover, Weiming Zhu, Duygu Islek Yaras, Dawn Smith, Ya-Lin A. Huang

987  **BONE DENSITY CHANGES WITH CAB-LA OR TDF/FTC PrEP IN MSM AND TGW IN HPTN 083**  
**Research Group:** HPTN 083 Study Team

---

**Poster Session-V5 EARLY STUDIES OF NEW PREVENTION AGENTS**  
2:30 PM - 4:00 PM

988  **PHASE 1 TRIAL OF CAP256V2LS AND VRC07-523LS ANTIBODIES AMONG WOMEN IN SOUTH AFRICA**  
Sharana Mahomed, Nigel Garrett, Edmund Capparelli, Farzana Osman, Nonhlanhla N. Mkhize, Derseree Archary, Leonid Serebryannyy, Mike Castro, Adrian B. McDermott, Kevin Carlton, Penny L. Moore, Lynn Morris, Quarraisha Abdool Karim, John R. Mascola, Salim S. Abdool Karim

989  **VAGINAL PrEP EFFICACY OF BIODEGRADABLE ISLATRAVIR IMPLANTS IN MACAQUES**  
Michele B. Daly, Daniel Kim, Linying Li, Archana Krovi, Chasity Norton, Catalina Forero, Marie Brake, Chuong Dinh, Tianchong Edwards, Mackenzie Cottrell, Walid Heneine, Gerardo Garcia-Lerma, Charles Dobard, James Mitchell, Leah Johnson

990  **EXTENDED POST-EXPOSURE PROTECTION AGAINST SHIV VAGINAL INFECTION WITH TAF/EVG INSERTS**  
Natalia Makarova, Tyana Singletary, Missy Peet, James Mitchell, Angela Holder, Chuong Dinh, Yi Pan, Maria Corazon Bueno Mendoza, Meredith Clark, Walid Heneine, James Smith, Gerardo Garcia-Lerma, Gustavo F. Doncel

991  **PHARMACOKINETICS AND XRAY IMAGING OF LONG-ACTING CABOTEGRAVIR IN SITU FORMING IMPLANT**  
Isabella Young, Panita Maturavongsadit, Alka Prasher, Roopali Shrivastava, Craig Sykes, Mackenzie Cottrell, Angela DM. Kashuba, S. Rahima Benhabbour

992  **LENACAPAVIR PROTECTS AGAINST RECTAL SHIV ACQUISITION IN MACAQUE MODEL**  
Elena Bekerman, Stephen Yant, Laurie A. Vanderveen, Derek Hansen, Bing Lu, William Rowe, Kelly Wang, Christian Callebaut

---

**Poster Session-X3 NEW PERSPECTIVES ON HUMAN PAPILLOMAVIRUS AND HIV**  
2:30 PM - 4:00 PM

1029  **INCREASED BURDEN OF ANAL HPV-RELATED POTENTIALLY PRECANCEROUS LESIONS IN HIV+ WOMEN**  
Eugenio Nelson Cavallari, Letizia Santinelli, Motta Eleonora, Federica Tanzi, Luca Maddaloni, Ilaria Cuccu, Giancarlo Ceccellari, Carolina Scagnolari, Alessandra Pierangeli, Innocenza Palaia, Claudio M. Mastroianni, Gabriella D’Ettorre
Poster Sessions

1030 EFFICACY OF LATE HPV VACCINATION IN YOUNG HIV+ MSM
Eugenio Nelson Cavallari, Letizia Santinelli, Luca Maddaloni, Motta Eleonora, Mirko Scordio, Federica Frasca, Giancarlo Ceccarelli, Carolina Scagnolari, Stefano Arcieri, Alessandra Pierangeli, Claudio M. Mastroianni, Gabriella D’Ettorre

1031 HIGH PREVALENCE OF HPV, OTHER STIs, AND ANAL LESIONS AMONG MSM IN TOGO

1032 METHYLATION MARKERS ON ANAL SMEARS ARE ASSOCIATED WITH HIGHER ANAL CANCER RISK

Poster Session-Y08 HIV CARE CASCADE

2:30 PM - 4:00 PM

1064 NEW HIV DIAGNOSES IN THE SETTING OF PUBLICLY FUNDED PrEP IN BRITISH COLUMBIA, CANADA
K. Junine Toy, Raquel M. Espinoza, Jason Trigg, Erin Ready, Cora L. Keeney, Wendy W. Zhang, Chanson J. Brumme, Paul Sereda, Rolando Barrios, Julio Montaner

1065 ESTIMATING THE EPIDEMIOLOGICAL IMPACT OF FLORIDA’S INTEGRATED HIV CARE PLAN IN MIAMI
Lia Humphrey, Benjamin Enns, Micah Piske, Xiao Zang, Bohdan Nosyk, Emma Spencer, Mara Michniewicz, Daniel Feaster, Hansel Tookes Research Group: Centre for Health Evaluation & Outcome Sciences (CHEOS)

1066 AN RCT OF HOME-BASED CARE TO REDUCE POSTHOSPITAL MORTALITY IN SOUTH AFRICA: HOMELINK
Christopher Hoffmann, Kate Shearer, Boitumelo Kekana, Tumelo Molonatoa, Maxine Nunu, Jonathan Golub, Ekrahim Varajia, Neil Martinon

1067 IMPROVING REINITIATION IN CARE AMONG MEN WITH HIV IN MALAWI: TWO RANDOMIZED TRIALS
Kathryn Dovel, Kelvin Balakasi, Julie Hubbard, Mischek Mphande, Isabella Robson, Elijah Chikuse, Morna Cornell, Risa Hoffman, Sam Phiri, Joep J Van Oosterhout, Agnes Moses, Thomas J. Coates, Augustine Choko

1068 REENGAGING PERSONS WITH HIV OUT OF CARE: RADICAL CHANGE IS NEEDED
Thomas Martin, Laramie Smith, Susan R. Little, Christy Anderson, Kari Abulhosn

1069 THE IMPACT OF FINANCIAL INCENTIVES AND A DECISION-SUPPORT APP ON THE HIV CARE CASCADE
Maxime Inghels, Hae-Young Kim, Thulile Mathenjwa, Maryam Shahmanesh, Janet Seeley, Adrian Dobra, Manisha H. Yapa, Sally Wyke, Nuala McGrath, Till Baernighausen, Frank Tanser

1070 THE HIV CARE CONTINUUM AMONG TRANSGENDER WOMEN IN 2010-2020 IN THE NETHERLANDS
Vita Jongen, Ceranza Daans, Ard van Sighem, Maarten Schim Van Der Loeff, Kris Hage, Camiel Welling, Alex Von Vaupel-Klein, Martin Den Heijer, Edgar Peters, Marc van Der Valk, Peter Reiss, Maria Prins, Elske Hoornenborg Research Group: ATHENA observational HIV cohort
1071 PROJECTED IMPACT OF IMPROVING HIV CARE ON LIFE EXPECTANCY AMONG BLACK AND WHITE MSM


Poster Session-Y09 THE PrEP CASCADE

2:30 PM - 4:00 PM

1071.5 RETENTION IN CARE AMONG PERUVIAN MSM AND TGW IN A REAL-WORLD HIV PrEP PROGRAM

Pamela Ramirez, Alexander J. Lankowski, Jorge A. Gallardo-Cartagena, Javier Valencia, Pedro Gonzalez, Javier Lama, Javier Salvatierra, Hugo Sanchez, Robinson Cabello, Martin Casapia, Jorge L. Sanchez

1072 PrEP KNOWLEDGE, EVER USE, AND DISCONTINUATION AMONG LAKE VICTORIA FISHERFOLK IN UGANDA


1073 STRUCTURAL INFLUENCES ON PrEP CASCADE AMONG YOUNG WOMEN IN POST-ABORTAL CARE IN KENYA

Poster Session-Y10 RESPONSE DURING CRISIS

2:30 PM - 4:00 PM

1076 CONDUCTING RESEARCH IN A SETTING OF SEVERE POLITICAL INSTABILITY: THE GHESKIO MODEL


1077 A MODEL OF SUCCESSFUL ART INITIATION IN THE CONTEXT OF MASSIVE CIVIL UNREST IN HAITI

Jean Bernard Marc, Samuel Pierre, Vanessa Rivera, Zion Abigail, David Montreuil, Fabienne Houses, David Andre, Carl Frederic Duchatellier, Elizabeth Fox, Vanessa Rouzier, Bernard Liautaud, Patrice Severe, Collette Guiteau, Jean William Pape, Serena Koenig

1078 EMERGENCY RESPONSE TO RESTORE HIV TREATMENT SERVICES IN AMHARA REGION, ETHIOPIA: 2022


Research Group: National and Amhara Regional Emergency Response Team
Poster Session-Y11 RETENTION IN HIV CARE

1079  8-YEAR CARE TRAJECTORIES IN AN URBAN COHORT OF PWH RECEIVING CARE: WASHINGTON, DC
Amanda D. Castel, Elisabeth Andersen, Shannon Barth, Michael A. Horberg, Anne Monroe

1080  PREDICTORS OF RETENTION IN THE WOMEN'S INTERAGENCY HIV STUDY: 2011-2019
Caitlin A. Moran, Brittany W. Jacob, Cyra C. Mehta, Anandi N. Sheth, Sarah Krier, Zenoria Causey-Pruitt, Deborah Jones Weiss, Andrew Edmonds, Gypsamber D'Souza, Kathleen Weber, Jennifer Cohen, Lakshmi Goparajju, Susan Holman, Adebola Adedimeji, Cecile D. Lahiri

1081  RETENTION IN OPIOID AGONIST THERAPY AMONG PEOPLE LIVING WITH HIV IN BRITISH COLUMBIA
Kniana Yazdani, Kate Salters, Katerina Dolguikh, Monica Ye, Jason Trigg, Ronald Joe, David Moore, Julio Montaner, Rolando Barrios, K. Junine Toy

1082  A RANDOMIZED CONTROL TRIAL OF AN HIV CARE INTERVENTION BUNDLE FOR PEOPLE WITH HIV
Joseph D. Perazzo, Tamilyn Bakas, Qutaibah Oudat, Joshua Lambert, Carl J. Fichtenbaum

1083  LONG-TERM OUTCOMES OF RAPID ANTIRETROVIRAL THERAPY IN AN INTEGRATED HEALTH SYSTEM
Avani Dalal, Earl Clark, Christian Lee-Rodriguez, Zahra Samiezade-Yazd, Jennifer O. Lam, Mitchell N. Loo

1084  MODELLING OF CARE ENGAGEMENT PATTERNS IN A LONGITUDINAL COHORT OF PWH: WASHINGTON, DC
Amanda D. Castel, Elisabeth Andersen, Shannon Barth, Michael A. Horberg, Anne Monroe

Poster Session-Y15 TREATMENT OF COVID-19 AND MPOX

1101  COST EFFECTIVENESS OF NIRMATRELVIR/RITONAVIR FOR MILD-MODERATE COVID-19 IN SPAIN
Philip E. Wikman-Jorgensen, Miriam Navarro, Jose Maria Ibarra, Carlos Devesa, Jose Miguel Segui-Ripoll, Jorge Peris-Garcia, Vicente Giner-Galvan, Jara Llenas-Garcia

1102  OUTCOMES OF A TELEHEALTH VISIT MODEL TO DELIVER TECOVIRIMAT FOR MPOX IN NYC
Ofole Mgbako, David Ditullio, Patricia Pagan-Pirallo, Dana Mazo, Robert Pitts, Dorothy Knutsen, Andrew Wallach, Angelica C. Kottkamp, Isaac Holmes, Justin Chan
POSTER SESSIONS BY CATEGORY

All poster sessions will be held from 2:30 PM to 4:00 PM on the scheduled day (listed in parenthesis below). Posters should be displayed for the duration of the conference and are located in the Exhibit Hall.

A. VIROLOGY OF HIV, SARS-CoV-2, OR MPOX VIRUS
P-A1 HIV-1 ENTRY (Monday)
P-A2 IFN AND ANTIVIRAL FACTORS (Tuesday)
P-A3 VIRUS REPRODUCTION (Wednesday)
P-A4 VIRUS DIVERSITY IN POPULATIONS (Wednesday)

B. PATHOGENESIS OF HIV, SARS-CoV-2, OR MPOX VIRUS: HUMAN STUDIES AND ANIMAL MODELS
P-B1 GENETICS, EARLY HIV INFECTION, NATURAL CONTROL (Monday)
P-B2 HIV AND THE MICROBIOME (Wednesday)
P-B3 HIV NON IMMUNO PATHOGENESIS, COINFECTION (Tuesday)
P-B4 HIV AND AGING (Wednesday)
P-B5 HIV IMMUNOPATHOGENESIS (Tuesday)
P-B6 SARS-CoV-2 PATHOGENESIS (Monday)
P-B7 LONG COVID (Tuesday)
P-B8 MPOX PATHOGENESIS (Wednesday)

C. HIV-ASSOCIATED TUMOR VIRUSES
P-C1 BASIC SCIENCE OF TUMOR VIRUSES: HTLV, HBV, EBV, AND ENDOGENOUS RETROVIRUSES (Tuesday)

D. HOST IMMUNE RESPONSES, VACCINES, AND IMMUNOTHERAPIES: HIV, SARS-CoV-2, OR MPOX VIRUS
P-D1 ANTIBODY AND BROADLY NEUTRALIZING RESPONSES (Monday)
P-D2 ELITE CONTROLLERS (Monday)
P-D3 IMMUNE MODULATION AND VACCINES (Tuesday)
P-D4 LYMPH NODES (Wednesday)
P-D5 NK CELLS, NEUTROPHILS, AND B CELL (Monday)
P-D6 SARS-CoV-2 IMMUNOPATHOGENESIS (Monday)
P-D7 SARS-CoV-2 VACCINES AND PREVENTION (Tuesday)
P-D8 MPOX VACCINES AND IMMUNOPATHOGENESIS (Wednesday)

E. HIV RESERVOIRS, LATENCY, AND CURATIVE STRATEGIES INCLUDING THERAPEUTIC VACCINES AND GENE THERAPY
P-E01 CONTROLLERS AND POSTTREATMENT CONTROLLERS (Monday)
P-E02 DYNAMICS OF THE HIV RESERVOIR (Monday)
P-E03 IMMUNE PRESSURE ON THE RESERVOIR (Wednesday)
P-E04 HIV RESERVOIRS IN CELLS AND TISSUES (Tuesday)
P-E05 INNOVATIVE APPROACHES TO TARGET THE RESERVOIR (Wednesday)
P-E06 INTERVENTIONS TO TARGET THE VIRAL RESERVOIR AND DELAY VIRAL REBOUND (Tuesday)
P-E07 MECHANISMS OF HIV LATENCY (Monday)
P-E08 DYNAMICS OF PROVIRAL INTEGRATION SITES (Tuesday)
P-E09 HIV RESERVOIRS IN CHILDREN AND YOUTH (Tuesday)

F. NEUROPATHOGENESIS AND NEUROLOGIC COMPLICATIONS OF HIV AND SARS-COV-2 INFECTION AND NEUROLOGIC COMPLICATIONS OF HIV IN ADULTS
P-F1 CLINICAL AND BIOMARKER ASSOCIATIONS WITH COGNITION IN PEOPLE WITH HIV (Monday)
P-F2 INTERPLAY BETWEEN VASCULAR AND NERVOUS SYSTEM FUNCTION IN HIV (Monday)
P-F3 ANTIRETROVIRAL EFFECTS ON CENTRAL NERVOUS SYSTEM OUTCOMES (Monday)
P-F4 PSYCHIATRIC SYMPTOMS, SLEEP DISTURBANCE, AND ASSOCIATED BIOMARKERS IN PEOPLE WITH HIV (Tuesday)
P-F5 CNS HIV INFECTION, PERSISTENCE, AND CURE STUDIES (Tuesday)
P-F6 MECHANISMS OF HIV NEUROPATHOGENESIS (Wednesday)
P-F7 COINFECTIONS AND THE NERVOUS SYSTEM IN PEOPLE WITH HIV (Wednesday)
P-F8 POST-ACUTE NERVOUS SYSTEM SEQUELAE OF COVID-19 IN PEOPLE WITH AND WITHOUT HIV (Monday)

G. CLINICAL PHARMACOLOGY IN ADULTS
P-G1 CLINICAL AND BIOMARKER ASSOCIATIONS WITH COGNITION IN PEOPLE WITH HIV (Monday)
P-G2 DRUG-DRUG INTERACTIONS: A FOCUS ON TB, EFAVIRENZ SWITCHING (Tuesday)
P-G3 PHARACOKINETICS/PHARMACODYNAMICS OF SARS-CoV-2 THERAPEUTICS (Wednesday)

H. ANTIVIRAL THERAPY: PRE-CLINICAL DATA, RANDOMIZED TRIALS, EFFICACY, AND EFFECTIVENESS STUDIES IN HIV OR SARS-CoV-2 OR MPXV VIRUS IN ADULTS
P-H1 LAI CAB/RPV: WHERE ARE WE NOW AND WHERE ARE WE GOING? (Tuesday)
P-H2 ANTIRETROVIRAL THERAPY: PROSPECTIVE CLINICAL TRIALS (Wednesday)
P-H3 ANTIRETROVIRAL THERAPY: OBSERVATIONS FROM COUNTRIES, CLINICS, AND PWH (Monday)
P-H4 ANTIRETROVIRAL THERAPY: COMPARTMENTS, HIV-2, AND NANOFORMULATIONS (Wednesday)
P-H5 NEW AGENTS FOR TREATMENT OF SARS-CoV-2 AND RELATED VIRUSES (Monday)
P-H6 CAN ANTIVIRAL AGENTS PREVENT SARS-CoV-2 TRANSMISSION? (Monday)
P-H7 SARS-CoV-2 TREATMENT: THE IMPACT OF REMDESVIR (Tuesday)
P-H8 SARS-CoV-2 TREATMENT: CLINICAL AND ANTIVIRAL ACTIVITY (OR NOT) (Wednesday)

I. RESISTANCE OF HIV OR SARS-CoV-2 TO SMALL MOLECULES AND ANTIBODIES IN ADULTS
P-I1 HIV RESISTANCE EMERGENCE AND OUTCOMES (Tuesday)
P-I2 HIV RESISTANCE TO NEUTRALIZING ANTIBODIES (Monday)
P-I3 PRETREATMENT HIV DRUG RESISTANCE (Wednesday)

J. HEPATITIS VIRUSES AND LIVER COMPLICATIONS IN ADULTS
P-J1 HBV PREVENTION AND TREATMENT (Tuesday)
P-J2 NEW DEVELOPMENTS IN HCV EPIDEMIOLOGY AND TREATMENT (Tuesday)
P-J3 VIRAL HEPATITIS IN SUB-SAHARAN AFRICA (Wednesday)
P-J4 LIFE AFTER SVR (Wednesday)
P-J5 STEATOSIS AND STEATOHEPATITIS (Monday)
P-J6 PATHOGENESIS AND NATURAL HISTORY (Wednesday)

K. AIDS-RELATED MALIGNANCIES
P-K1 NON-AIDS DEFINING CANCERS: PATHOGENESIS (Wednesday)
P-K2 CANCER (GENERAL): RISK AND MORTALITY (Wednesday)
P-K3 KAPOSI SARCOMA AND KHSV-RELATED DISEASES: PATHOGENESIS AND TREATMENT (Monday)
Poster Sessions by Category

CROI 2023

P-K4  CERVICAL CANCER: SCREENING AND TREATMENT (Monday)
P-K5  ANAL CANCER: PATHOGENESIS, PREVENTION, AND SCREENING (Wednesday)

L. CARDIOVASCULAR COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY
P-L1  PLAQUE (Monday)
P-L2  LIPID METABOLISM (Monday)
P-L3  HYPERTENSION, VASCULAR DISEASE, AND PLATELET FUNCTION (Tuesday)
P-L4  INFLAMMATION AND CARDIOVASCULAR DISEASE (Wednesday)
P-L5  THE GUT MICROBIOME AND COMORBIDITIES (Wednesday)

M. OTHER COMPLICATIONS OF HIV INFECTION AND ANTIRETROVIRAL THERAPY IN ADULTS
P-M1  DOES WHAT GOES UP ALWAYS COME DOWN? (Wednesday)
P-M2  METABOLIC COMPLICATIONS (Tuesday)
P-M3  BONE, RENAL, PULMONARY, AND HEMATOLOGIC DISEASE (Tuesday)
P-M4  BIOMARKERS OF MORBIDITY AND MORTALITY (Monday)
P-M5  FRAILTY, FUNCTIONAL STATUS, AND HEALTH (Tuesday)
P-M6  WEIGHT GAIN AND ADIPOSE TISSUE (Wednesday)

N. CLINICAL COMPLICATIONS OF EMERGING DISEASES (COVID-19) IN ADULTS
P-N1  PASC (LONG COVID) (Monday)
P-N2  COVID IN THOSE WITH HIV AND IMMUNOCOMPROMISING CONDITIONS (Tuesday)
P-N3  COVID-19: CLINICAL AND PROGNOSTIC FEATURES AND EFFECTS OF THERAPEUTIC INTERVENTIONS (Tuesday)

Q. TUBERCULOSIS AND OTHER OPPORTUNISTIC INFECTIONS, INCLUDING THE IMPACT OF HIV OR SARS-CoV-2 IN ADULTS
P-Q1  OUTCOMES OF HIV-EXPOSED UNINFECTED (Monday)
P-Q2  INFLAMMATION AND IMMUNITY IN CHILDREN (Tuesday)
P-Q3  REAL-WORLD OUTCOMES IN CHILDREN AND YOUTH WITH HIV (Tuesday)
P-Q4  COMORBIDITIES AND COMPLICATIONS AND IN CHILDREN AND YOUTH WITH HIV (Wednesday)
P-Q5  ARVs AND bNAbs FOR CHILDREN AND ADOLESCENTS (Monday)
P-Q6  SARS-CoV-2 INFECTION AND PREVENTION IN INFANTS, CHILDREN, AND ADOLESCENTS (Wednesday)

Q. HIV, SARS-CoV-2, OR MPXV VIRUS, AND OTHER EMERGING INFECTIONS, IN INFANTS, CHILDREN, AND ADOLESCENTS
P-Q7  HIV RESERVOIRS IN CHILDREN AND YOUTH (Tuesday)
P-Q8  OUTCOMES OF HIV-EXPOSED UNINFECTED (Monday)
P-Q9  INFLAMMATION AND IMMUNITY IN CHILDREN (Tuesday)
P-Q10  REAL-WORLD OUTCOMES IN CHILDREN AND YOUTH WITH HIV (Tuesday)
P-Q11  COMORBIDITIES AND COMPLICATIONS AND IN CHILDREN AND YOUTH WITH HIV (Wednesday)
P-Q12  ARVs AND bNAbs FOR CHILDREN AND ADOLESCENTS (Monday)
P-Q13  SARS-CoV-2 INFECTION AND PREVENTION IN INFANTS, CHILDREN, AND ADOLESCENTS (Wednesday)
Poster Sessions by Category

R. EPIDEMIOLOGY OF HIV IN ADULTS
P-R1 MOLECULAR HIV EPIDEMIOLOGY (Monday)
P-R2 RECENT HIV INFECTIONS (Monday)
P-R3 HIV INFECTION CLUSTERS (Monday)
P-R4 SEX, GENDER, AND VIOLENCE AND ASSOCIATION WITH OUTCOMES (Tuesday)
P-R5 RISK FACTORS FOR HIV ACQUISITION AND TRANSMISSION (Tuesday)
P-R6 HIV MORTALITY (Monday)
P-R7 FACTORS AFFECTING OUTCOMES FOR PEOPLE LIVING WITH HIV (Wednesday)

S. EPIDEMIOLOGY OF COVID-19, MPOX, AND OTHER EMERGING INFECTIONS
P-S1 COVID-19 CHARACTERISTICS AND OUTCOMES (Monday)
P-S2 IMPACT OF COVID-19 ON HIV AND MALARIA SERVICES AND OUTCOMES (Monday)
P-S3 MPOX EPIDEMIOLOGY, IMPACT ON SEXUAL BEHAVIORS, AND STIGMA (Tuesday)
P-S4 MPOX CHARACTERISTICS AND OUTCOMES (Tuesday)
P-S5 SARS-CoV-2 SEROPREVALENCE AND SURVEILLANCE (Wednesday)
P-S6 MODELLING MPOX AND COVID-19 (Wednesday)

T. HIV TESTING IN ADULTS: NEW TESTS, POPULATION STUDIES, AND SCALE-UP
P-T1 HIV SELF-TESTING (Monday)
P-T2 DISPARITIES AND SOCIAL CONTEXT FOR HIV TESTING (Tuesday)
P-T3 HIV TESTING IN CLINICAL SETTINGS (Wednesday)
P-T4 NEW DIAGNOSTICS AND USE OF TESTS (Wednesday)

U. TESTING FOR COVID-19, MPOX, AND OTHER EMERGING INFECTIONS: DIAGNOSTIC TESTS, POPULATION STUDIES, AND SCALE-UP
P-U1 MPOX TESTING (Monday)
P-U2 SARS-CoV-2 SELF-TESTING (Tuesday)
P-U3 SARS-CoV-2 DIAGNOSTICS (Wednesday)

V. HIV PREVENTION INTERVENTIONS IN ADULTS
P-V1 COST EFFECTIVENESS OF PEP AND PrEP (Monday)
P-V2 PrEP AND PEP: ADHERENCE MEASURES AND STIs (Monday)
P-V3 OPTIMIZING PrEP ROLLOUT (Tuesday)
P-V4 PrEP USE IN SPECIAL POPULATIONS (Wednesday)
P-V5 EARLY STUDIES OF NEW PREVENTION AGENTS (Wednesday)
P-V6 PrEP PRODUCT UPDATE AND EFFECTIVENESS (Tuesday)

W. PREVENTION OF COVID-19, MPOX, AND OTHER EMERGING INFECTIONS
P-W1 MPOX PREVENTION (Monday)
P-W2 SARS-CoV-2 VACCINE STRATEGIES (Tuesday)

X. CONTRACEPTION, SEXUALLY TRANSMITTED INFECTIONS, AND REPRODUCTIVE HEALTH IN ADULTS
P-X1 SPECIAL TOPICS IN SRH AND HIV (Monday)
P-X2 STI EPIDEMIOLOGY IN POPULATIONS AFFECTED BY HIV (Tuesday)
P-X3 NEW PERSPECTIVES ON HUMAN PAPILLOMAVIRUS AND HIV (Wednesday)
P-X4  INTERTWINED: MPOX AND STI EPIDEMIOLOGY (Tuesday)

Y. IMPLEMENTATION AND SCALE-UP OF PREVENTION AND TREATMENT FOR HIV AND IMPACT OF COVID-19 AND OTHER EMERGING INFECTIONS ON HIV-RELATED PROGRAMS

P-Y01  ACCESS TO ART (Monday)
P-Y02  MODELS TO ACHIEVE VIRAL LOAD SUPPRESSION (Monday)
P-Y03  ACHIEVING TARGETS (Monday)
P-Y04  HIV TESTING (Monday)
P-Y05  PRESENTATION FOR CARE (Tuesday)
P-Y06  LONG-ACTING ART (Tuesday)
P-Y07  ART REGIMENS (Tuesday)
P-Y08  HIV CARE CASCADE (Wednesday)
P-Y09  PrEP CASCADE (Wednesday)
P-Y10  RESPONSE DURING CRISIS (Wednesday)
P-Y11  RETENTION IN HIV CARE (Wednesday)
P-Y12  ADVANCED HIV DISEASE (Tuesday)
P-Y13  PREVENTION AND PrEP MODELS (Tuesday)
P-Y14  COVID-19 EFFECT ON HIV SERVICES AND OUTCOMES (Tuesday)
P-Y15  TREATMENT OF COVID-19 AND MPOX (Wednesday)
The following index lists CROI presenters as of January 24, 2023. Changes to presenting authors after that date are not reflected. A complete list of all abstract authors can be found in the Abstract eBook on the CROI website.

<table>
<thead>
<tr>
<th>Name</th>
<th>Abstract Number(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abassi, Mahsa</td>
<td>749</td>
</tr>
<tr>
<td>Abela, Irene A.</td>
<td>352, 353</td>
</tr>
<tr>
<td>Abelman, Rebecca A</td>
<td>679</td>
</tr>
<tr>
<td>Abu-Raddad, L.</td>
<td>1005</td>
</tr>
<tr>
<td>Agathis, Nickolas T</td>
<td>811</td>
</tr>
<tr>
<td>Aguemang, Nana</td>
<td>505</td>
</tr>
<tr>
<td>Ake, Julie A</td>
<td>430</td>
</tr>
<tr>
<td>Al-Sherif, Sabri</td>
<td>1084</td>
</tr>
<tr>
<td>Andersen, Elisabeth</td>
<td>560</td>
</tr>
<tr>
<td>Anderson, Albert</td>
<td>485</td>
</tr>
<tr>
<td>Anderson, Kim</td>
<td>778</td>
</tr>
<tr>
<td>Anderson, Peter L</td>
<td>20</td>
</tr>
<tr>
<td>Andrezejewski, Jack</td>
<td>985</td>
</tr>
<tr>
<td>Antar, Anuskka A R</td>
<td>722</td>
</tr>
<tr>
<td>Armstrong-Hough, Mari</td>
<td>1050</td>
</tr>
<tr>
<td>Arumugam, Viswanathan</td>
<td>1043</td>
</tr>
<tr>
<td>Ashipala, Laimi</td>
<td>1075</td>
</tr>
<tr>
<td>Ashokkumar, Swetha</td>
<td>916</td>
</tr>
<tr>
<td>Atkins, Kaitlyn</td>
<td>951, 1025</td>
</tr>
<tr>
<td>Atkinson, Andrew</td>
<td>1021</td>
</tr>
<tr>
<td>Augello, Matteo</td>
<td>344</td>
</tr>
<tr>
<td>Augustin, Max</td>
<td>720</td>
</tr>
<tr>
<td>Aung, Sai W</td>
<td>862</td>
</tr>
<tr>
<td>Aung, Su</td>
<td>583</td>
</tr>
<tr>
<td>Avihingsanon, Anchalee</td>
<td>116</td>
</tr>
<tr>
<td>Ayieko, James</td>
<td>200</td>
</tr>
<tr>
<td>Bachina, Preetham</td>
<td>1054</td>
</tr>
<tr>
<td>Baill, Samuel S</td>
<td>508</td>
</tr>
<tr>
<td>Baker, Owen</td>
<td>961</td>
</tr>
<tr>
<td>Baker, Pieter</td>
<td>1016</td>
</tr>
<tr>
<td>Balachandran, Harikrishnan</td>
<td>340</td>
</tr>
<tr>
<td>Balkus, Jennifer</td>
<td>785</td>
</tr>
<tr>
<td>Bardon, Ashley R</td>
<td>977</td>
</tr>
<tr>
<td>Barr, Elizabeth</td>
<td>1023</td>
</tr>
<tr>
<td>Bassett, Ingrid</td>
<td>999, 1039</td>
</tr>
<tr>
<td>Bassler, John R</td>
<td>877</td>
</tr>
<tr>
<td>Batista, Facundo</td>
<td>44</td>
</tr>
<tr>
<td>Bayer, Cara</td>
<td>855</td>
</tr>
<tr>
<td>Baylieh, Chanie</td>
<td>1084</td>
</tr>
<tr>
<td>Bayon-Gil, Angel</td>
<td>46</td>
</tr>
<tr>
<td>Bazzi, Angela R</td>
<td>212</td>
</tr>
<tr>
<td>Bean, David</td>
<td>351</td>
</tr>
<tr>
<td>Bedimo, Roger</td>
<td>709</td>
</tr>
<tr>
<td>Begré, Lorin</td>
<td>586</td>
</tr>
<tr>
<td>Béguelin, Charles</td>
<td>8</td>
</tr>
<tr>
<td>Behrens, Georg</td>
<td>45</td>
</tr>
<tr>
<td>Bekerma, Elena</td>
<td>992</td>
</tr>
<tr>
<td>Bender Ignacio, Rachel A</td>
<td>571</td>
</tr>
<tr>
<td>Benet, Susana</td>
<td>378</td>
</tr>
<tr>
<td>Benito, José M</td>
<td>245</td>
</tr>
<tr>
<td>Berenguer, Juan</td>
<td>608, 703</td>
</tr>
<tr>
<td>Bernardi, Stefania</td>
<td>834</td>
</tr>
<tr>
<td>Berry, Mark</td>
<td>718</td>
</tr>
<tr>
<td>Berton, Mattia</td>
<td>506</td>
</tr>
<tr>
<td>Bettonne, Sara</td>
<td>508</td>
</tr>
<tr>
<td>Betts, Michael R</td>
<td>3</td>
</tr>
<tr>
<td>Bhatt, Niles</td>
<td>213</td>
</tr>
<tr>
<td>Bhattacharya, Romit</td>
<td>660</td>
</tr>
<tr>
<td>Bieniasz, Paul D</td>
<td>107</td>
</tr>
<tr>
<td>Birnbaum, Michael</td>
<td>5</td>
</tr>
<tr>
<td>Bishop, Marley D</td>
<td>779</td>
</tr>
<tr>
<td>Black, Danae</td>
<td>825</td>
</tr>
<tr>
<td>Blair, Jessica</td>
<td>657</td>
</tr>
<tr>
<td>Blázquez Bondia, Carlos</td>
<td>670</td>
</tr>
<tr>
<td>Blower, Sally</td>
<td>1037</td>
</tr>
<tr>
<td>Board, Nathan L</td>
<td>401</td>
</tr>
<tr>
<td>Boltz, Valerie F</td>
<td>240</td>
</tr>
<tr>
<td>Bone, Benjamin R</td>
<td>450</td>
</tr>
<tr>
<td>Borgielli, Alberto</td>
<td>574</td>
</tr>
<tr>
<td>Borgognone, Alessandria</td>
<td>481</td>
</tr>
<tr>
<td>Bosch, Bronwyn E</td>
<td>671</td>
</tr>
<tr>
<td>Boswel, Kristin L</td>
<td>180</td>
</tr>
<tr>
<td>Bouba, Yagai</td>
<td>928</td>
</tr>
<tr>
<td>Bouhaddou, Mehdi</td>
<td>108</td>
</tr>
<tr>
<td>Bouqdayr, Meryem</td>
<td>241</td>
</tr>
<tr>
<td>Bourgi, Kassem</td>
<td>674</td>
</tr>
<tr>
<td>Bramante, Carolyn</td>
<td>170</td>
</tr>
<tr>
<td>Brañas, Fátima</td>
<td>701</td>
</tr>
<tr>
<td>Brew, Bruce</td>
<td>715</td>
</tr>
<tr>
<td>Bricker, Katherine M</td>
<td>252</td>
</tr>
<tr>
<td>Brooks, John</td>
<td>89</td>
</tr>
<tr>
<td>Brooks, Kelsey</td>
<td>279</td>
</tr>
<tr>
<td>Brown, Erin E.</td>
<td>1027</td>
</tr>
<tr>
<td>Brown, Todd T</td>
<td>987</td>
</tr>
<tr>
<td>Brumme, Zabrina</td>
<td>366</td>
</tr>
<tr>
<td>Buck, Amanda M</td>
<td>424</td>
</tr>
<tr>
<td>Bunge, Katherine E</td>
<td>127</td>
</tr>
<tr>
<td>Burdorf, Rachel M</td>
<td>577</td>
</tr>
<tr>
<td>Butt, Adeel</td>
<td>559</td>
</tr>
<tr>
<td>Butt, Adeel</td>
<td>569, 570, 618, 729</td>
</tr>
<tr>
<td>Byakwagw, Helen</td>
<td>150</td>
</tr>
<tr>
<td>Cabrera, Cecilia</td>
<td>222</td>
</tr>
<tr>
<td>cachay, Edward</td>
<td>644</td>
</tr>
<tr>
<td>Cai, Chenrongrong</td>
<td>342</td>
</tr>
<tr>
<td>Cai, Renying</td>
<td>695</td>
</tr>
<tr>
<td>Cameron, Cheryl</td>
<td>269</td>
</tr>
<tr>
<td>Cannon, Chase</td>
<td>948</td>
</tr>
<tr>
<td>Caporferri, Adam A</td>
<td>106</td>
</tr>
<tr>
<td>Carlin, Aaron</td>
<td>543</td>
</tr>
<tr>
<td>Carlson, Jesse E</td>
<td>1033</td>
</tr>
<tr>
<td>Cappino, Thomas</td>
<td>900</td>
</tr>
<tr>
<td>Carson, Joanne M</td>
<td>603</td>
</tr>
<tr>
<td>Cartwright, Emily J</td>
<td>1014</td>
</tr>
<tr>
<td>Castagna, Antonella</td>
<td>293</td>
</tr>
<tr>
<td>Castel, Amanda D</td>
<td>1004</td>
</tr>
<tr>
<td>Castel, Amanda D</td>
<td>1079</td>
</tr>
<tr>
<td>Cavallan, Eugenio</td>
<td>1029, 1030</td>
</tr>
<tr>
<td>Cerian, Cristina</td>
<td>444</td>
</tr>
<tr>
<td>Cevik, Muge</td>
<td>109</td>
</tr>
<tr>
<td>Chabala, Chishala</td>
<td>824</td>
</tr>
<tr>
<td>Chagantti, Joga</td>
<td>492</td>
</tr>
<tr>
<td>Chalroudi, Ann</td>
<td>29</td>
</tr>
<tr>
<td>Chalra, Davide D</td>
<td>126</td>
</tr>
<tr>
<td>Chamy, Gabriel</td>
<td>112</td>
</tr>
<tr>
<td>Chan, Justin</td>
<td>1102</td>
</tr>
<tr>
<td>Chan, Phillip</td>
<td>464</td>
</tr>
<tr>
<td>Chandasana, Hardik</td>
<td>832</td>
</tr>
<tr>
<td>Chang, Michelle</td>
<td>101</td>
</tr>
<tr>
<td>Chappell, Catherine</td>
<td>597</td>
</tr>
<tr>
<td>Charalambous, Salome</td>
<td>745</td>
</tr>
<tr>
<td>Charpentier, Charlotte</td>
<td>1031</td>
</tr>
<tr>
<td>Chaturvedi, Sonali</td>
<td>235</td>
</tr>
<tr>
<td>Chemaitelly, Hiam</td>
<td>842</td>
</tr>
<tr>
<td>Chen, Wanyi</td>
<td>517</td>
</tr>
<tr>
<td>Chen, Yuexuan</td>
<td>234</td>
</tr>
<tr>
<td>Chen, Yufen</td>
<td>484</td>
</tr>
<tr>
<td>Cherkos, Ashenafi S</td>
<td>800, 801</td>
</tr>
<tr>
<td>Chevalier, Joshua M</td>
<td>958</td>
</tr>
<tr>
<td>Chew, Kara W</td>
<td>31</td>
</tr>
<tr>
<td>Chew, Kara W</td>
<td>428</td>
</tr>
<tr>
<td>Cholli, Preetam A</td>
<td>912</td>
</tr>
<tr>
<td>Chomont, Nicolas</td>
<td>1, 247</td>
</tr>
</tbody>
</table>
CROI 2023

Index of Presenters

Choudhary, Manish C 168
Chow, Felicia C 183
Christ, Frauke 216
Clark, Kolin 447
Clement, Meredith E 994
Coburn, Sally B 628
Coghill, Sarah 468, 487
Collercandy, Nived 853
Collura, Randall 157
Contreras, German A 886
Cooley, Sarah 468, 487
Corley, Michael 383
Corley, Michael 480
Corrigan, Angela 423
Corrigan, Angela 423
Costa, Alvaro 915
Dabral, Prerna 448
DC  567, 607, 904
Dad, Lili 521
Dalal, Avani 1083
Daly, Michele B 1007
Cox, Sarah N 1051
Craig, Cosette 974
Cressey, Tim R. 826
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Dallas, José 461
Crabtree-Ramirez, Brenda E 727
Craig, Cosette 974
Cressey, Tim R. 826
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
Corma-Gómez, Anaïs 606, 607, 904
Corrigan, Angela 423
Costa, Alvaro 915
Cotugno, Nicola 843
Coutinho, Carolina 915
Cowan, Frances M 123
Cowden, Jessica J 1007
Cox, Sarah N 1051
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gisslen, Magnus</td>
<td>184</td>
</tr>
<tr>
<td>Glenn, Jeffrey S</td>
<td>167</td>
</tr>
<tr>
<td>Godot, Veronique</td>
<td>362</td>
</tr>
<tr>
<td>Gómez, Laurén A</td>
<td>766</td>
</tr>
<tr>
<td>González-Hernández</td>
<td>682</td>
</tr>
<tr>
<td>Horta, Bhavana</td>
<td>304</td>
</tr>
<tr>
<td>Ho, Ya-Chi</td>
<td>4</td>
</tr>
<tr>
<td>Hodcroft, Emma B</td>
<td>19</td>
</tr>
<tr>
<td>Hoffman, Lisa</td>
<td>20</td>
</tr>
<tr>
<td>Hoffmann, Christopher</td>
<td>411</td>
</tr>
<tr>
<td>Hiransuthikul, Akarin</td>
<td>996</td>
</tr>
<tr>
<td>Ho, Rehana V</td>
<td>645</td>
</tr>
<tr>
<td>Hightow-Weidman, Lisa</td>
<td>21</td>
</tr>
<tr>
<td>Hikichi, Yuta</td>
<td>103</td>
</tr>
<tr>
<td>Hileman, Corrilyn O</td>
<td>712</td>
</tr>
<tr>
<td>Hiner, Christopher</td>
<td>2</td>
</tr>
<tr>
<td>Hirsan, Chris</td>
<td>1066</td>
</tr>
<tr>
<td>Hogan, Joseph W</td>
<td>707</td>
</tr>
<tr>
<td>Hoornenborg, Elke</td>
<td>897, 911, 1070</td>
</tr>
<tr>
<td>Hoover, Karen</td>
<td>986</td>
</tr>
<tr>
<td>Hosek, Sybil</td>
<td>162</td>
</tr>
<tr>
<td>Hsieh, Evelyn</td>
<td>686</td>
</tr>
<tr>
<td>Huang, Ya-Lin A</td>
<td>997</td>
</tr>
<tr>
<td>Hughes, Michael D</td>
<td>9</td>
</tr>
<tr>
<td>Hume, Rulian</td>
<td>165</td>
</tr>
<tr>
<td>Huang, Lyn</td>
<td>165</td>
</tr>
<tr>
<td>Hyn,宥</td>
<td>165</td>
</tr>
<tr>
<td>Hye, Emily P</td>
<td>145</td>
</tr>
<tr>
<td>Ichihashi, Genki</td>
<td>166</td>
</tr>
<tr>
<td>Ignacio, Caroline</td>
<td>387</td>
</tr>
<tr>
<td>Imaz, Arkaitz</td>
<td>537, 677</td>
</tr>
<tr>
<td>Inghels, Maxime</td>
<td>1069</td>
</tr>
<tr>
<td>Isaacs, Stuart N</td>
<td>40</td>
</tr>
<tr>
<td>Ishii, Hiroshi</td>
<td>177</td>
</tr>
<tr>
<td>Isard, Stephane</td>
<td>276</td>
</tr>
<tr>
<td>Itell, Hannah L</td>
<td>105</td>
</tr>
<tr>
<td>Izquierdo-Pujol, Jon</td>
<td>838</td>
</tr>
<tr>
<td>Jackson, Charlotte</td>
<td>134</td>
</tr>
<tr>
<td>Jacobs, Tom G</td>
<td>831</td>
</tr>
<tr>
<td>Jacobson, Denise L</td>
<td>799</td>
</tr>
<tr>
<td>Jain, Mamta K</td>
<td>728</td>
</tr>
<tr>
<td>Jalho, Sallieu</td>
<td>267</td>
</tr>
<tr>
<td>Jamieson, Denise J</td>
<td>27</td>
</tr>
<tr>
<td>Jang, Hyukjin</td>
<td>258</td>
</tr>
<tr>
<td>Jao, Jennifer</td>
<td>775</td>
</tr>
<tr>
<td>Jassat, Waasila</td>
<td>885</td>
</tr>
<tr>
<td>Javanbakt, Manjari</td>
<td>982</td>
</tr>
<tr>
<td>Jeger-Madiot, Raphael</td>
<td>332</td>
</tr>
<tr>
<td>Jeong, Dahn</td>
<td>620</td>
</tr>
<tr>
<td>Jiang, Danting</td>
<td>251</td>
</tr>
<tr>
<td>Jilg, Nikolaus</td>
<td>283</td>
</tr>
<tr>
<td>Johansson, Emil</td>
<td>335</td>
</tr>
<tr>
<td>Johnson, Shacara</td>
<td>878</td>
</tr>
<tr>
<td>Johnson, Kell Y</td>
<td>204</td>
</tr>
<tr>
<td>Johnson, Joly</td>
<td>204</td>
</tr>
<tr>
<td>Jonnalagadda, Sasi</td>
<td>1049</td>
</tr>
<tr>
<td>Jordans, Carla</td>
<td>943</td>
</tr>
<tr>
<td>Joseph Davey</td>
<td>786</td>
</tr>
<tr>
<td>Joseph, Fokam</td>
<td>239</td>
</tr>
<tr>
<td>Joy, Jaimy</td>
<td>326</td>
</tr>
<tr>
<td>Kabami, Jane</td>
<td>130</td>
</tr>
<tr>
<td>Kablawi, Dana</td>
<td>611</td>
</tr>
<tr>
<td>Kaften, David</td>
<td>924</td>
</tr>
<tr>
<td>Kagan, Ron M</td>
<td>955</td>
</tr>
<tr>
<td>Kaielmo, Alexander</td>
<td>757</td>
</tr>
<tr>
<td>Kailemo, Alexander</td>
<td>936</td>
</tr>
<tr>
<td>Kakande, Elijah</td>
<td>124</td>
</tr>
<tr>
<td>Kalata, Newton L</td>
<td>872</td>
</tr>
<tr>
<td>Kalata, Newton L</td>
<td>872</td>
</tr>
<tr>
<td>Kamori, Doreen D</td>
<td>578</td>
</tr>
<tr>
<td>Kamya, Moses</td>
<td>128</td>
</tr>
<tr>
<td>Kane, Melissa</td>
<td>104</td>
</tr>
<tr>
<td>Kang, C. Yong</td>
<td>357</td>
</tr>
<tr>
<td>Kangethe, James</td>
<td>635</td>
</tr>
<tr>
<td>Kankasa, Chipeto</td>
<td>131</td>
</tr>
<tr>
<td>Kapombe, Priscilla</td>
<td>923</td>
</tr>
<tr>
<td>Katsiimie, Mary</td>
<td>807</td>
</tr>
<tr>
<td>Keele, Brandon F</td>
<td>391</td>
</tr>
<tr>
<td>Kelley, Colleen</td>
<td>34</td>
</tr>
<tr>
<td>Kelly, Sherrie L</td>
<td>927</td>
</tr>
<tr>
<td>Kengni Ngeko, Aurelie</td>
<td>387</td>
</tr>
<tr>
<td>Keniyopoulos, Roso</td>
<td>658</td>
</tr>
<tr>
<td>Kennedy, Brooke D</td>
<td>386</td>
</tr>
<tr>
<td>Kennedy, Caitlin E</td>
<td>206</td>
</tr>
<tr>
<td>Kenney, Stephanie</td>
<td>516</td>
</tr>
<tr>
<td>Kenny, Grace</td>
<td>272</td>
</tr>
<tr>
<td>Kiarie, James</td>
<td>35</td>
</tr>
<tr>
<td>Kilee, Emma</td>
<td>706</td>
</tr>
<tr>
<td>Kim, Eun Hye Grace</td>
<td>477</td>
</tr>
<tr>
<td>Kim, H. Nina</td>
<td>7</td>
</tr>
<tr>
<td>Kim, Sangwon</td>
<td>147</td>
</tr>
<tr>
<td>Kim, Sung-Han</td>
<td>726</td>
</tr>
<tr>
<td>Kincher, Laura P</td>
<td>478</td>
</tr>
<tr>
<td>Kistou, Konstantia</td>
<td>297</td>
</tr>
<tr>
<td>Kizito, Samuel</td>
<td>814</td>
</tr>
<tr>
<td>Klock, Ethan</td>
<td>959</td>
</tr>
<tr>
<td>Knudsen, Andreas D</td>
<td>655</td>
</tr>
<tr>
<td>Knudsen, Andreas D</td>
<td>667</td>
</tr>
<tr>
<td>Kolossvary, Marton</td>
<td>274</td>
</tr>
<tr>
<td>Koss, Catherine</td>
<td>975</td>
</tr>
<tr>
<td>Koss, Catherine</td>
<td>975</td>
</tr>
<tr>
<td>Kroidl, Arne</td>
<td>132</td>
</tr>
<tr>
<td>Kroidl, Inge</td>
<td>869</td>
</tr>
<tr>
<td>Krolowski, Kristyn</td>
<td>1034</td>
</tr>
<tr>
<td>Krolowski, Kristyn</td>
<td>908</td>
</tr>
<tr>
<td>Kuchel, George A</td>
<td>38</td>
</tr>
<tr>
<td>Kufera, Joshua T</td>
<td>455</td>
</tr>
<tr>
<td>Kuhn, Louise</td>
<td>815</td>
</tr>
<tr>
<td>Kulkarni, Smita</td>
<td>225</td>
</tr>
<tr>
<td>Kulkarni, Vandana P</td>
<td>760</td>
</tr>
<tr>
<td>Kulsuptrakul, Jessie</td>
<td>228</td>
</tr>
<tr>
<td>Kuo, Alexandra</td>
<td>1090</td>
</tr>
</tbody>
</table>
### New Investigator Scholarship
- Kupritz, Jonah
- Kuriakose, Sofia
- Kuzmichev, Yury

### International Investigator Scholarship
- Lacourse, Sylvia
- Lahiri, Cecile
- Lanini, Simone
- Lang, Raynell
- Lacourse, Sylvia M
- Laeyendecker, Oliver
- Lahiri, Cecile D
- Lake, Jordan E
- Lang, Raynell
- Lanini, Simone
- Lankowski, Alexander J
- Laouénan, Cédric
- Lapadula, Giuseppe
- Larson, Heidi J
- Laverdure, Sylvian
- Lebouché, Bertrand
- Lee, Cheng-Yi
- Lee, Guinevere Q
- Lee, Jane J
- Lehner, Paul J
- Leone, Peter
- Leskov, Konstantin
- Levy, Yves
- Lewis, Lara
- Li, Chenglei
- Li, Jonathan Z
- Li, Jun
- Li, Yifan
- Li, Yijia
- Li, Zichong
- Liang, Chen
- Linden, Noemi L
- Liu, Jerry
- Li, Yijia
- Li, Zichong
- Li, Yijia
- Li, Zichong
- Lim, Viviane D
- Loosli, Tom
- Lopez, Brianna
- Loubet, Paul
- Loutfy, Mona
- Lovato, Taguma Allen
- Lombardi, Francesca

### Nonauthor Presenter
- Kuprictz, Jonah
- Kuriakose, Sofia
- Kuzmichev, Yury
- Kvaratskhelia, Mamuka
- Lacourse, Sylvia M
- Lahiri, Cecile D
- Lanini, Simone
- Lang, Raynell
- Lanini, Simone
- Lankowski, Alexander J
- Laouénan, Cédric
- Lapadula, Giuseppe
- Larson, Heidi J
- Laverdure, Sylvian
- Lebouché, Bertrand
- Lee, Cheng-Yi
- Lee, Guinevere Q
- Lee, Jane J
- Lehner, Paul J
- Leone, Peter
- Leskov, Konstantin
- Levy, Yves
- Lewis, Lara
- Li, Chenglei
- Li, Jonathan Z
- Li, Jun
- Li, Yifan
- Li, Yijia
- Li, Zichong
- Liang, Chen
- Linden, Noemi L
- Liu, Jerry
- Li, Yijia
- Li, Zichong
- Lim, Viviane D
- Loosli, Tom
- Lopez, Brianna
- Loubet, Paul
- Loutfy, Mona
- Lovato, Taguma Allen
- Lombardi, Francesca

### Nonauthor Presenter
- Kuprictz, Jonah
- Kuriakose, Sofia
- Kuzmichev, Yury
- Kvaratskhelia, Mamuka
- Lacourse, Sylvia M
- Lahiri, Cecile D
- Lanini, Simone
- Lang, Raynell
- Lanini, Simone
- Lankowski, Alexander J
- Laouénan, Cédric
- Lapadula, Giuseppe
- Larson, Heidi J
- Laverdure, Sylvian
- Lebouché, Bertrand
- Lee, Cheng-Yi
- Lee, Guinevere Q
- Lee, Jane J
- Lehner, Paul J
- Leone, Peter
- Leskov, Konstantin
- Levy, Yves
- Lewis, Lara
- Li, Chenglei
- Li, Jonathan Z
- Li, Jun
- Li, Yifan
- Li, Yijia
- Li, Zichong
- Liang, Chen
- Linden, Noemi L
- Liu, Jerry
- Li, Yijia
- Li, Zichong
- Lim, Viviane D
- Loosli, Tom
- Lopez, Brianna
- Loubet, Paul
- Loutfy, Mona
- Lovato, Taguma Allen
- Lombardi, Francesca
<table>
<thead>
<tr>
<th>Index of Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nabeemeha, Firdaus 746</td>
</tr>
<tr>
<td>Nabeta, Henry W 554</td>
</tr>
<tr>
<td>Naggi, Susanna 572</td>
</tr>
<tr>
<td>Naggiyirinya, Agnes Bwanka 202</td>
</tr>
<tr>
<td>Naidoo, Anushka 827</td>
</tr>
<tr>
<td>Namayanja, Grace 528</td>
</tr>
<tr>
<td>Nanubuya, Annet 1024</td>
</tr>
<tr>
<td>Nasser, Tanner B 1100</td>
</tr>
<tr>
<td>Nayan, Mohammad Ullah 540</td>
</tr>
<tr>
<td>Naggirinya, Agnes Bwanika 202</td>
</tr>
<tr>
<td>Naggie, Susanna 572</td>
</tr>
<tr>
<td>Naggirinya, Agnes Bwanika 202</td>
</tr>
<tr>
<td>Naidoo, Anushka 827</td>
</tr>
<tr>
<td>Namayanja, Grace 528</td>
</tr>
<tr>
<td>Ogale, Yasmin 950</td>
</tr>
<tr>
<td>Ogbaru, Onyema 523</td>
</tr>
<tr>
<td>Okoye, Afam A 264</td>
</tr>
<tr>
<td>Okrut, Samuel 489</td>
</tr>
<tr>
<td>Olivera, Kristen M 330</td>
</tr>
<tr>
<td>Ollerton, Matthew 265</td>
</tr>
<tr>
<td>Omo-Emmanuel, Ugherghoghe 1097, 1098</td>
</tr>
<tr>
<td>Onovo, Amobi A 847</td>
</tr>
<tr>
<td>Oom, Aaron 1001</td>
</tr>
<tr>
<td>Opsteen, Sky 350, 683</td>
</tr>
<tr>
<td>Orentas, Rimas 399</td>
</tr>
<tr>
<td>Orkin, Chloe 173</td>
</tr>
<tr>
<td>Orrell, Catherine 22, 205</td>
</tr>
<tr>
<td>Ortblad, Katrina F 929</td>
</tr>
<tr>
<td>Ortiz, Alexandra 322</td>
</tr>
<tr>
<td>Otten, Twan JW 371</td>
</tr>
<tr>
<td>Ouk, Vichea 848</td>
</tr>
<tr>
<td>Paiardini, Mirko 329</td>
</tr>
<tr>
<td>Palmer, Clovis C 289</td>
</tr>
<tr>
<td>Pampena, M.Betina 319</td>
</tr>
<tr>
<td>Pang, Alina 443</td>
</tr>
<tr>
<td>Panigrahi, Soumya 255</td>
</tr>
<tr>
<td>Panovska-Griffiths, Jasmina 925</td>
</tr>
<tr>
<td>Parcewski, Miłosz 731</td>
</tr>
<tr>
<td>Pardons, Marion 397</td>
</tr>
<tr>
<td>Parisi, Christina E 536</td>
</tr>
<tr>
<td>Park, Jiwon 286, 339</td>
</tr>
<tr>
<td>Parkes-Ratanshi, Rosalind 1038</td>
</tr>
<tr>
<td>Parra-Rodriguez, Luis 469</td>
</tr>
<tr>
<td>Pascom, Ana Roberta 1058</td>
</tr>
<tr>
<td>Pasin, Chloe 300, 301, 1022</td>
</tr>
<tr>
<td>Passanduca, Alfredo 810</td>
</tr>
<tr>
<td>Patel, Deesha 935</td>
</tr>
<tr>
<td>Patel, Eshan U 920</td>
</tr>
<tr>
<td>Patel, Robert 188</td>
</tr>
<tr>
<td>Peluso, Michael J 33, 273, 282, 435</td>
</tr>
<tr>
<td>Pepper, Marion 43</td>
</tr>
<tr>
<td>Perazzo, Hugo 592</td>
</tr>
<tr>
<td>Perazzo, Joseph D. 1082</td>
</tr>
<tr>
<td>Perea, David 338</td>
</tr>
<tr>
<td>Pereira Ribeiro, Susan 143</td>
</tr>
<tr>
<td>Pereles, Michael J 33, 273, 282, 435</td>
</tr>
<tr>
<td>Perez-Caballero, Raúl 345</td>
</tr>
<tr>
<td>Perez-Pizot, Daniel 548</td>
</tr>
<tr>
<td>Permar, Sallie R 328</td>
</tr>
<tr>
<td>Petersen, Kajen J 186, 475</td>
</tr>
<tr>
<td>Petrarca, Maria Raffaella 819</td>
</tr>
<tr>
<td>Phillips, Andrew 968</td>
</tr>
<tr>
<td>Phillips, Gregory 898</td>
</tr>
<tr>
<td>Philpott, David CE 903</td>
</tr>
<tr>
<td>Pickering, Suzanne 231</td>
</tr>
<tr>
<td>Piers, Daan KJ 325, 361</td>
</tr>
<tr>
<td>Pierre, Samuel 1076</td>
</tr>
<tr>
<td>Piñeirúa-Menéndez, Alicia 1059</td>
</tr>
<tr>
<td>Pines, Heather A 932</td>
</tr>
<tr>
<td>Pinto, Tara 1045</td>
</tr>
<tr>
<td>Pinto-Cardoso, Sandra 248</td>
</tr>
<tr>
<td>Pintye, Jillian 771</td>
</tr>
<tr>
<td>Plaza-Jennings, Amara 187</td>
</tr>
<tr>
<td>Poel, Eugenie 940</td>
</tr>
<tr>
<td>Polk, Christopher 944</td>
</tr>
<tr>
<td>Poloni, Chad 363</td>
</tr>
<tr>
<td>Poopola, Victor O 857</td>
</tr>
<tr>
<td>Post, Frank 1095</td>
</tr>
<tr>
<td>Post, Frank 739</td>
</tr>
<tr>
<td>Powis, Kathleen M. 783, 793, 803</td>
</tr>
<tr>
<td>Prates, Gabriela S 294</td>
</tr>
<tr>
<td>Premeaux, Thomas 691</td>
</tr>
<tr>
<td>Pry, Jake M 1052</td>
</tr>
<tr>
<td>Pryke, Luke 680</td>
</tr>
<tr>
<td>Puray-Chavez, Manzita 224</td>
</tr>
<tr>
<td>Puryear, Sarah 883</td>
</tr>
<tr>
<td>Rallón, Norma 441, 627</td>
</tr>
<tr>
<td>Ramaswami, Ramya 632</td>
</tr>
<tr>
<td>Ramgopal, Moti N. 191</td>
</tr>
<tr>
<td>Ramos-Martín, Fernando 320</td>
</tr>
<tr>
<td>Raphael, Yvette A 14</td>
</tr>
<tr>
<td>Rappaport, Amy 323</td>
</tr>
<tr>
<td>Ratzan, Scott C 46</td>
</tr>
<tr>
<td>Rava, Marta 871</td>
</tr>
<tr>
<td>Rebelo, Peter F 875</td>
</tr>
<tr>
<td>Reddy, Kavitha 395</td>
</tr>
<tr>
<td>Reeves, R. Keith 479</td>
</tr>
<tr>
<td>Reimer Jensen, Anne Marie 651</td>
</tr>
<tr>
<td>Reis, Karl 756</td>
</tr>
<tr>
<td>Rich, Katherine M 1071</td>
</tr>
<tr>
<td>Riddler, Sharon A 164</td>
</tr>
<tr>
<td>Ridolfi, Felipe 741</td>
</tr>
<tr>
<td>Riebensahm, Carlotta 602, 616</td>
</tr>
<tr>
<td>Riggs, Patricia K 491</td>
</tr>
<tr>
<td>Rist, Michael 139</td>
</tr>
<tr>
<td>Roan, Nadia R 2</td>
</tr>
<tr>
<td>Robinson, Jake A 663</td>
</tr>
<tr>
<td>Rocco, Joseph 367, 631</td>
</tr>
<tr>
<td>Roche, Stephanie 978</td>
</tr>
<tr>
<td>Rodriguez, Lauren 561</td>
</tr>
<tr>
<td>Rodriguez-Centeno, Javier 692</td>
</tr>
<tr>
<td>Roon, Ashley 623</td>
</tr>
<tr>
<td>Romero, Elena V 226</td>
</tr>
<tr>
<td>Romo, Matthew L 533</td>
</tr>
<tr>
<td>Rosen, Joseph G 1041, 1047</td>
</tr>
<tr>
<td>Roseto, Isabelle C 453</td>
</tr>
<tr>
<td>Rossotti, Roberto 899</td>
</tr>
<tr>
<td>Rothemeijer, Frederik H 403</td>
</tr>
<tr>
<td>Routhy, Jean-Pierre 856</td>
</tr>
<tr>
<td>Rouzier, Vanessa 813</td>
</tr>
<tr>
<td>Name</td>
</tr>
<tr>
<td>-----------------------------</td>
</tr>
<tr>
<td>Roy, Upal</td>
</tr>
<tr>
<td>Royston, Léna</td>
</tr>
<tr>
<td>Rubenstein, Emma</td>
</tr>
<tr>
<td>Rubinstein, Paul</td>
</tr>
<tr>
<td>Ruderman, Stephanie</td>
</tr>
<tr>
<td>Rudolph, Jacqueline E</td>
</tr>
<tr>
<td>Ruiz, Felicitas</td>
</tr>
<tr>
<td>Saber, Lindsay</td>
</tr>
<tr>
<td>Sabin, Caroline</td>
</tr>
<tr>
<td>Sachdev, Daphna</td>
</tr>
<tr>
<td>Sahu, Maitreyi</td>
</tr>
<tr>
<td>Saini, Pratima</td>
</tr>
<tr>
<td>Sainz, Talia</td>
</tr>
<tr>
<td>Saito, Suzue</td>
</tr>
<tr>
<td>Saldi, Pia</td>
</tr>
<tr>
<td>Sabina, Caroline</td>
</tr>
<tr>
<td>Sahu, Maitreyi</td>
</tr>
<tr>
<td>Saini, Pratima</td>
</tr>
<tr>
<td>Sainz, Talia</td>
</tr>
<tr>
<td>Saito, Suzue</td>
</tr>
<tr>
<td>Sardi, Luca</td>
</tr>
<tr>
<td>Savinelli, Stefano</td>
</tr>
<tr>
<td>Sax, Paul</td>
</tr>
<tr>
<td>Schuetz, Alexandra</td>
</tr>
<tr>
<td>Schwarczmueller, Magdalena</td>
</tr>
<tr>
<td>Scott, Hyman</td>
</tr>
<tr>
<td>Scully, Eileen</td>
</tr>
<tr>
<td>Sebasti, Giada</td>
</tr>
<tr>
<td>Selzer, Lisa</td>
</tr>
<tr>
<td>Sereti, Irini</td>
</tr>
<tr>
<td>Serghides, Lena</td>
</tr>
<tr>
<td>Serrano-Villar, Sergio</td>
</tr>
<tr>
<td>Serwin, Karol</td>
</tr>
<tr>
<td>Shah, N. Sarita</td>
</tr>
<tr>
<td>Shahnemanesh, Maryam</td>
</tr>
<tr>
<td>Shaik, Naveed A</td>
</tr>
<tr>
<td>Shaikh, Simran</td>
</tr>
<tr>
<td>Shabir, Shadil</td>
</tr>
<tr>
<td>Shankwitz, Kimberly</td>
</tr>
<tr>
<td>Shapiro, Adrienne E</td>
</tr>
<tr>
<td>Shapiro, Roger</td>
</tr>
<tr>
<td>Sharma, Ashish</td>
</tr>
<tr>
<td>Shen, Yanhan</td>
</tr>
<tr>
<td>Shi, Guoli</td>
</tr>
<tr>
<td>Shi, Yuhang</td>
</tr>
<tr>
<td>Shih, Teichiro</td>
</tr>
<tr>
<td>Shmakova, Anna</td>
</tr>
<tr>
<td>Sikombe, Kombatende</td>
</tr>
<tr>
<td>Siliciano, Janet M</td>
</tr>
<tr>
<td>Silva, Mayara S. T.</td>
</tr>
<tr>
<td>silvera, Richard J</td>
</tr>
<tr>
<td>Silverberg, Michael J</td>
</tr>
<tr>
<td>Simpson, Jennifer</td>
</tr>
<tr>
<td>Singh, Meera</td>
</tr>
<tr>
<td>Singh, Sonia</td>
</tr>
<tr>
<td>Singogo, Emmanuel</td>
</tr>
<tr>
<td>Siribelli, Alessia</td>
</tr>
<tr>
<td>Sivile, Sujata</td>
</tr>
<tr>
<td>Smith, Amanda J</td>
</tr>
<tr>
<td>Smith, Lauren N</td>
</tr>
<tr>
<td>Smith, Robert A</td>
</tr>
<tr>
<td>Sodeke, Olutomi</td>
</tr>
<tr>
<td>Sogaard, Ole S</td>
</tr>
<tr>
<td>Solis-Leal, Antonio</td>
</tr>
<tr>
<td>Solomona, Sunil S</td>
</tr>
<tr>
<td>Songane, Mario</td>
</tr>
<tr>
<td>Sousa, Ana E</td>
</tr>
<tr>
<td>Spagnuolo, Vincenzo</td>
</tr>
<tr>
<td>Spinelli, Matthew A</td>
</tr>
<tr>
<td>Sponaugle, Alexis</td>
</tr>
<tr>
<td>Spudich, Serena</td>
</tr>
<tr>
<td>Squires, Kathleen E</td>
</tr>
<tr>
<td>Srinivasa, Suman</td>
</tr>
<tr>
<td>Stanfseld, Sarah E</td>
</tr>
<tr>
<td>Stephens, Reno</td>
</tr>
<tr>
<td>Stewart, Jenell</td>
</tr>
<tr>
<td>Stone, Julie</td>
</tr>
<tr>
<td>Storti, Samuele</td>
</tr>
<tr>
<td>Struyve, Tine</td>
</tr>
<tr>
<td>Stuart, Robyn</td>
</tr>
<tr>
<td>Stumpf, Julia</td>
</tr>
<tr>
<td>Su, Hang</td>
</tr>
<tr>
<td>Sudderruddin, Hanwei</td>
</tr>
<tr>
<td>Sudsila, Pupe</td>
</tr>
<tr>
<td>Sun, Hsin-Yun</td>
</tr>
<tr>
<td>Sun, Jing</td>
</tr>
<tr>
<td>Sun, Jing</td>
</tr>
<tr>
<td>Sun, Weiwei</td>
</tr>
<tr>
<td>Suprasert, Bow</td>
</tr>
<tr>
<td>Surial, Bernard</td>
</tr>
<tr>
<td>Surial, Bernard</td>
</tr>
<tr>
<td>Suryawanshi, Rahul K</td>
</tr>
<tr>
<td>Suthar, Amitabh B.</td>
</tr>
<tr>
<td>Szojka, Zsofia F</td>
</tr>
<tr>
<td>Taddese, Maraake</td>
</tr>
<tr>
<td>Tagarro, Alfredo</td>
</tr>
<tr>
<td>Taha, Taha Y</td>
</tr>
<tr>
<td>Taiwo, Babafemi</td>
</tr>
<tr>
<td>Takaori-Kondo, AkiKumi</td>
</tr>
<tr>
<td>Tambe, Lisa Arrah</td>
</tr>
<tr>
<td>Tan, Darrell H. S</td>
</tr>
<tr>
<td>Tang, Weiming</td>
</tr>
<tr>
<td>Tapley, Asa</td>
</tr>
<tr>
<td>Tate, Moranda</td>
</tr>
<tr>
<td>Tatham, Lee</td>
</tr>
<tr>
<td>Thongua, Boris K</td>
</tr>
<tr>
<td>Teeraananchai, Sirinya</td>
</tr>
<tr>
<td>Tefera, Fana</td>
</tr>
<tr>
<td>Teysou, Elisa</td>
</tr>
<tr>
<td>Thiebaut, Rodolphe</td>
</tr>
<tr>
<td>Thomas, Dorothy</td>
</tr>
<tr>
<td>Thomson, Michael M</td>
</tr>
<tr>
<td>Tiendrebeego, Thierry</td>
</tr>
<tr>
<td>Tindle, Hilary A</td>
</tr>
<tr>
<td>Titania, Boghuma K</td>
</tr>
<tr>
<td>Tobin, Nicole H</td>
</tr>
<tr>
<td>Tomalka, Jeffrey A</td>
</tr>
<tr>
<td>Tong, Xiao</td>
</tr>
<tr>
<td>Torgeres, Jessie</td>
</tr>
<tr>
<td>Torres, Thiago S</td>
</tr>
<tr>
<td>Townsley, Samantha</td>
</tr>
<tr>
<td>Toy, K. Junine</td>
</tr>
<tr>
<td>Toy, K. Junine</td>
</tr>
<tr>
<td>Traeger, Michael W</td>
</tr>
<tr>
<td>Tram, Khai Hoan</td>
</tr>
<tr>
<td>Treurnicht, Florette K</td>
</tr>
<tr>
<td>Trickey, Adam</td>
</tr>
<tr>
<td>Trigueiros, Macedonia</td>
</tr>
<tr>
<td>Trunfo, Mattia</td>
</tr>
<tr>
<td>Truong, Hong-Ma H</td>
</tr>
<tr>
<td>Tsima, Billy M</td>
</tr>
<tr>
<td>Tucker, Emma</td>
</tr>
<tr>
<td>Tusch, Erich</td>
</tr>
<tr>
<td>Tuyishime, Simeon</td>
</tr>
<tr>
<td>Twentyman, Joy</td>
</tr>
<tr>
<td>Umutesi, Grace</td>
</tr>
<tr>
<td>Underwood, Mark</td>
</tr>
<tr>
<td>Vaidya, Akanksha</td>
</tr>
<tr>
<td>van den Elshout, Mark</td>
</tr>
<tr>
<td>van Eekeren, Louise E</td>
</tr>
<tr>
<td>van Rooyen, Heidi</td>
</tr>
<tr>
<td>van Wijk, Rob</td>
</tr>
<tr>
<td>Vandekeerckhove, Linos</td>
</tr>
<tr>
<td>Varo, Ryan</td>
</tr>
<tr>
<td>Vasireddy, Yamsi</td>
</tr>
<tr>
<td>Veenhuish, Rebecca</td>
</tr>
<tr>
<td>Vekslar, Veronica</td>
</tr>
<tr>
<td>Velu, Vijayakumar</td>
</tr>
<tr>
<td>Venkatesh, Sreenidhi</td>
</tr>
<tr>
<td>Vera, Jaime</td>
</tr>
<tr>
<td>Verburch, Myrthe L</td>
</tr>
<tr>
<td>Vieira, Vinicius</td>
</tr>
<tr>
<td>Viguerie, Alex</td>
</tr>
<tr>
<td>Vioz, Elise</td>
</tr>
<tr>
<td>Vissieux, Benoit</td>
</tr>
<tr>
<td>Vö, Christophlet A</td>
</tr>
<tr>
<td>Vos, Wilhelm A. W.</td>
</tr>
</tbody>
</table>
Vraga, Emily 47
Vyas, Kartavya 881

-W-
Waheed, Abdul 101
Wallace, Michael S 621
Wandeler, Gilles 587
* Wang, Qiankun 229
Wang, Zheng 669
Wanjalla, Celestine N 650
* Ward, Adam R 398
Wei, Yulong 142
* Weissman, Sam 456
Wells, Alan B 261
Whitehead, Hannah 1018
Whitehill, Greg 305
Whitesell, Veronika 530
Whitney, Bridget 882
Wikman-Jorgensen, Philip E 1101
* Winchester, Nicole 662
Winston, Alan 463
Wise, Jenni 1096
Woodhouse, Edwin Wilbur 1003
Worobey, Michael 17
* Wu, Fengting 138
Wu, Jinzi J. 550
* Wu, Linxuan 770, 998
Wu, Richard 499
Wu, Vincent 390
* Wu, Xinshe 1036
Wu, Yiquan 630
Wynberg, Elke 710

-X-
Xing, Enming 547

-Y-
* Yaffe, Zak A 781
Yagnik, Bhrugu 140
Yendewa, George A 724
Yin, Anna 358
Yin, Kaillin 346
Yin, Li 797
Yoshida, Takeshi 220
* Young, Isabella 991
Young, Kyria C 343
Yu, Yifan 782
Yuan, Zhe 394

-Z-
Zafilaza, Karen 281
Zalla, Lauren 876
Zang, Xiao 1065
Zaniewski, Elizabeth 1062
Zechner, Steven 280
Zemelko, Lily 408
Zhang, Liao 437
Zhang, Weiying 259
* Zhao, Ying 525
Zhou, Shuntai 846
Zhou, Xiao-Jian 512, 513
Zhu, Weiming 980
* Zhu, Xianming 880
Zia, Yasaman 1073
Zisis, Sokratis N 713
Zisis, Sokratis N 714
Zou, Roger S 652
Zucker, Jason 738
* Zuze, Boitumelo J L 584

164 CROI 2023 ✓ New Investigator Scholarship ✓ International Investigator Scholarship ✓ Nonauthor Presenter
SCHOLARSHIP AWARDEE INFORMATION

CROI is committed to supporting new and early-career investigators, as well as international investigators and community educators working in resource-limited countries who would otherwise be unable to attend CROI. New Investigator and International Investigator Scholarship Awardees have completed the scholarship application and are presenting authors on abstracts. Community Educator Scholarship Awardees have shown through their applications and letters of recommendation that they will greatly benefit from the opportunity to participate in CROI. Presenting authors who are New Investigator Scholarship Awardees are indicated throughout the program using the corresponding Icons.

ACTIVITIES FOR NEW INVESTIGATOR SCHOLARSHIP AWARDEES

Scott M. Hammer Workshop for New Investigators and Trainees  
Widely considered the most informative and comprehensive session at CROI, this workshop highlights advances in HIV and SARS-CoV-2 molecular virology and immunology; advances in HIV treatment strategies, biomedical prevention, and cure; and community perspectives. Scholarship recipients are required to attend the entire workshop.

Meet the Luminary Sessions  
Small-group sessions (up to 25 New Investigators) during Monday and Tuesday lunchtimes at CROI host a leader in the field, generally a named lecturer or plenary speaker at CROI. These sessions provide the unique opportunity to meet and network with a leading scientific expert, and to ask one-on-one questions in an intimate setting. Each New Investigator can sign up for 1 session. **Note:** Sign up in advance is required.

Poster Walks (New for CROI 2023)  
Daily Poster Walks take place during poster sessions on Monday, Tuesday, and Wednesday, with 6 concurrent Poster Walks per day in the areas of clinical research, basic science, and epidemiology/public health. Each 30- to 40-minute Poster Walk is led by a CROI Program Committee member (Poster Walk Leader) with up to 8 New Investigators though a selection of posters curated by the Poster Walk Leader. Each New Investigator can sign up for 1 Poster Walk. **Note:** Sign up in advance is required.

ACTIVITIES FOR COMMUNITY EDUCATOR SCHOLARSHIP AWARDEES

Community Educator Scholarship Awardees Networking Area  
A designated area for Community Educator Scholarship Awardees and other HIV community representatives and advocates in the Ballroom 3 Lobby Area provides a central meeting point for community attendees.
# General Information

## Conference Services

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Badge and Conference Materials Pickup</td>
<td>Summit Lobby Level 1</td>
<td>Saturday 3:00 PM – 6:00 PM</td>
</tr>
<tr>
<td>Attendee Services</td>
<td></td>
<td>Sunday 7:00 AM – 7:00 PM</td>
</tr>
<tr>
<td>Housing Information</td>
<td></td>
<td>Monday to Wednesday 7:30 AM – 6:00PM</td>
</tr>
<tr>
<td>Continental Breakfast</td>
<td>Flex Foyer Level 2</td>
<td>Monday to Wednesday 7:30 AM – 8:30 AM</td>
</tr>
</tbody>
</table>
| Bag & Coat Check                   | Summit Lobby Level 1      | Sunday 8:00 AM – 9:30 PM
|                                   |                           | Monday to Wednesday 10:00 AM – 6:00 PM |
| Cyber Café                         | Ballroom 1 Lobby Level 5  | Sunday - Wednesday 7:00 AM – 6:00 PM |

**Note:** Computers with internet are available.

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Media Center</td>
<td>Meeting Rooms 421 and 422 Level 4</td>
<td>Sunday 10:00 AM – 7:30 PM Monday and Tuesday 8:00 AM – 6:00 PM Wednesday 7:00 AM – 6:00 PM</td>
</tr>
</tbody>
</table>

**Note:** Open exclusively to registered, accredited media, the Media Center is a workspace with WiFi and the location of the daily press conference.

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Office</td>
<td>Terrace 1 Level 4</td>
<td>Saturday 3:00 PM – 6:00 PM   Sunday to Wednesday 7:00 AM – 6:00 PM</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker Ready Room</td>
<td>Meeting Rooms 431 and 432 Level 4</td>
<td>Saturday 3:00 PM – 6:00 PM Sunday to Wednesday 6:00 AM – 6:00 PM</td>
</tr>
</tbody>
</table>

**Note:** Oral abstract, themed discussion, and special/invited session speakers must drop off PowerPoint slides here at least 24 hours prior to their presentation.

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personal Considerations and Lactation Room</td>
<td>Near Room 341 (Level 3); Near Room 441 (Level 4)</td>
<td>Saturday 3:00 PM – 6:00 PM Sunday 9:00 AM – 7:00 PM Monday to Wednesday 8:00 AM – 6:00 PM</td>
</tr>
</tbody>
</table>

**Note:** The Personal Considerations and Lactation room is set aside for those who require a short-term private space for personal health needs. This room is available on a first-come, first-served basis.

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Investigator Networking Lounge</td>
<td>Signature Room Level 5</td>
<td>Sunday 1:30 PM – 7:00 PM     Monday to Wednesday 8:00 AM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td>Signature Room Level 5</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seattle Visitors Information Booth</td>
<td>Summit Lobby Level 1</td>
<td>Saturday 2:30 PM – 6:30 PM   Sunday 2:00 PM – 9:00 PM Monday to Wednesday 10:00 AM – 6:00 PM</td>
</tr>
</tbody>
</table>

**Note:** Local information and reservations assistance.

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Convention Center Emergency Medical Services</td>
<td>Near Flex C Level 2</td>
<td>Sunday 8:30 AM – 9:00 PM Monday to Wednesday 8:30 AM – 6:00 PM</td>
</tr>
<tr>
<td>TIME</td>
<td>SUNDAY, FEBRUARY 19, 2023</td>
<td>MONDAY, FEBRUARY 20, 2023</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>7:30am</td>
<td>Continental Breakfast 7:30 am–8:30 am</td>
<td>Continental Breakfast 7:30 am–8:30 am</td>
</tr>
<tr>
<td>8:30am</td>
<td>Scott M. Hammer Workshop for New Investigators and Trainees 9:00 am–12:30 pm Flex A (Level 2)</td>
<td>Plenary Session 8:30 am - 9:30 am</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The Path to Hepatitis B Cure Flex C (Level 2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00am</td>
<td>Concurrent Oral Abstract Sessions 10:00 AM – 12:00 PM</td>
<td>Concurrent Oral Abstract Sessions 10:00 AM – 12:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0-01 Virology/Pathogenesis Ballroom 2 (Level 5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0-02 TB and Hepatitis Ballroom 1 (Level 5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0-01 HIV and STI Prevention: New Tools and Approaches Flex C (Level 2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0-04 Insights into Prevention and Treatment of HIV in Women and Children Flex A (Level 2)</td>
</tr>
<tr>
<td>12:00pm</td>
<td>Lunch 12:00 PM – 1:30 PM</td>
<td>Lunch 12:00 PM – 1:30 PM</td>
</tr>
<tr>
<td></td>
<td>** Meet the Luminaries 12:15 PM – 1:15 PM</td>
<td>** Meet the Luminaries 12:15 PM – 1:15 PM</td>
</tr>
<tr>
<td>2:30pm</td>
<td>Poster Sessions 2:30 PM – 4:00 PM</td>
<td>Poster Sessions 2:30 PM – 4:00 PM</td>
</tr>
<tr>
<td></td>
<td>** Poster Walks</td>
<td>** Poster Walks</td>
</tr>
<tr>
<td>4:00pm</td>
<td>Concurrent Symposia 4:00 PM – 5:30 PM</td>
<td>Concurrent Symposia 4:00 PM – 5:30 PM</td>
</tr>
<tr>
<td></td>
<td>S-01 Viral Origins and Evolution of HIV and SARS-CoV-2 Ballroom 2 (Level 5)</td>
<td>S-01 Pediatric HIV Cure Ballroom 2 (Level 5)</td>
</tr>
<tr>
<td></td>
<td>S-02 From Rocket Science to Reality: Monitoring Antiretrovirals and Adherence Flex A (Level 2)</td>
<td>S-05 COVID-19: Where Are We Now? Flex A (Level 2)</td>
</tr>
<tr>
<td></td>
<td>S-03 Delivering on the Success of Injectable PrEP Ballroom 1 (Level 5)</td>
<td>S-06 Consternation About Complications Flex A (Level 2)</td>
</tr>
<tr>
<td>5:00pm</td>
<td>Opening Session 5:00 PM – 7:20 PM</td>
<td>Special Session 5:40 PM – 6:00 PM</td>
</tr>
<tr>
<td></td>
<td>Reception – 7:20 PM – 9:30 PM Garden Terrace (Level 3)</td>
<td>Results from the MOSAICO HIV Vaccine Trial and Future Directions for HIV Vaccines Flex A (Level 2)</td>
</tr>
<tr>
<td></td>
<td>Bernard Fields Lecture</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N’Galy-Mann Lecture</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Martin Delaney Presentation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CROI at 30: Progress in HIV Through the Lens of CROI</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Special Recognition of Dr Anthony Fauci</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Flex C (Level 2)</td>
<td></td>
</tr>
</tbody>
</table>

*Please note: Poster Walks and Meet the Luminaries sessions are limited to New Investigator Scholarship Awardees. Sign up in advance is required.*